U.S. patent application number 14/474362 was filed with the patent office on 2016-06-09 for pesticidal compositions and processes related thereto.
This patent application is currently assigned to Dow AgroSciences LLC. The applicant listed for this patent is Dow AgroSciences LLC. Invention is credited to Peter Borromeo, Ann M. Buysse, Carl DeAmicis, David A. Demeter, Negar Garizi, Ricky Hunter, Daniel I. Knueppel, Asako Kubota, Paul Renee LePlae, JR., Christian T. Lowe, Noormohamed M. Niyaz, Akshay Patny, Ronald Ross, JR., Tony K. Trullinger, Martin J. Walsh, Frank J. Wessels, Yu Zhang.
Application Number | 20160159766 14/474362 |
Document ID | / |
Family ID | 55401717 |
Filed Date | 2016-06-09 |
United States Patent
Application |
20160159766 |
Kind Code |
A9 |
Buysse; Ann M. ; et
al. |
June 9, 2016 |
PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO
Abstract
This document discloses molecules having the following formula
("Formula One"): ##STR00001## and processes related thereto.
Inventors: |
Buysse; Ann M.; (Carmel,
IN) ; Niyaz; Noormohamed M.; (Indianapolis, IN)
; Demeter; David A.; (Fishers, IN) ; Zhang;
Yu; (Carmel, IN) ; Walsh; Martin J.; (Carmel,
IN) ; Kubota; Asako; (Indianapolis, IN) ;
Hunter; Ricky; (Westfield, IN) ; Trullinger; Tony
K.; (Westfield, IN) ; Lowe; Christian T.;
(Westfield, IN) ; Knueppel; Daniel I.;
(Zionsville, IN) ; Patny; Akshay; (Waltham,
MA) ; Garizi; Negar; (Westfield, IN) ; LePlae,
JR.; Paul Renee; (Brownsburg, IN) ; Wessels; Frank
J.; (Indianapolis, IN) ; Ross, JR.; Ronald;
(Zionsville, IN) ; DeAmicis; Carl; (Indianapolis,
IN) ; Borromeo; Peter; (Fishers, IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Dow AgroSciences LLC |
Indianapolis |
IN |
US |
|
|
Assignee: |
Dow AgroSciences LLC
Indianapolis
IN
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20160060245 A1 |
March 3, 2016 |
|
|
Family ID: |
55401717 |
Appl. No.: |
14/474362 |
Filed: |
September 2, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13788850 |
Mar 7, 2013 |
8901153 |
|
|
14474362 |
|
|
|
|
61639274 |
Apr 27, 2012 |
|
|
|
Current U.S.
Class: |
504/100 ;
424/408; 504/103; 504/116.1; 504/118; 514/236.5; 514/256; 514/274;
514/333; 514/341; 544/131; 544/316; 544/327; 546/256; 546/269.7;
546/271.1; 546/271.4; 546/272.4; 546/274.4; 546/275.4 |
Current CPC
Class: |
A01N 43/653 20130101;
C07D 401/14 20130101; C07D 417/14 20130101; C07D 405/14 20130101;
A01N 47/18 20130101; C07D 413/14 20130101; A01N 47/36 20130101;
A01N 43/56 20130101; C07D 409/14 20130101; A01N 43/80 20130101;
C07D 403/04 20130101; A01N 43/78 20130101; A01N 43/84 20130101;
C07D 401/04 20130101; A01N 43/76 20130101 |
International
Class: |
C07D 401/04 20060101
C07D401/04; A01N 47/36 20060101 A01N047/36; A01N 47/18 20060101
A01N047/18; C07D 405/14 20060101 C07D405/14; C07D 401/14 20060101
C07D401/14; A01N 43/653 20060101 A01N043/653; C07D 417/14 20060101
C07D417/14; A01N 43/78 20060101 A01N043/78; C07D 413/14 20060101
C07D413/14; A01N 43/76 20060101 A01N043/76; A01N 43/80 20060101
A01N043/80; C07D 409/14 20060101 C07D409/14; C07D 403/04 20060101
C07D403/04; A01N 43/84 20060101 A01N043/84; A01N 43/56 20060101
A01N043/56 |
Claims
1. A composition comprising a molecule according to ##STR00273##
wherein (a) A is either ##STR00274## (b) R1 is H, F, Cl, Br, I, CN,
NO.sub.2, substituted or unsubstituted C.sub.1-C.sub.6 alkyl,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyl, substituted
or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, S(O).sub.nR9,
S(O).sub.nOR9, S(O).sub.nN(R9).sub.2, or R9S(O).sub.nR9, wherein
each said R1, which is substituted, has one or more substituents
selected from F, Cl, Br, I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6
haloalkenyl, C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6
haloalkenyloxy, C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10
cycloalkenyl, C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10
halocycloalkenyl, OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or
C.sub.1-C.sub.20 heterocyclyl, (each of which that can be
substituted, may optionally be substituted with R9); (c) R2 is H,
F, Cl, Br, I, CN, NO.sub.2, substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.2-C.sub.6
alkenyl, substituted or unsubstituted C.sub.1-C.sub.6 alkoxy,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyloxy,
substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl,
substituted or unsubstituted C.sub.3-C.sub.10 cycloalkenyl,
substituted or unsubstituted C.sub.6-C.sub.20 aryl, substituted or
unsubstituted C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9,
C(=X1)OR9, C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9,
S(O).sub.nOR9, or R9S(O).sub.nR9, wherein each said R2, which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9); (d) R3 is H, F, Cl, Br, I, CN,
NO.sub.2, substituted or unsubstituted C.sub.1-C.sub.6 alkyl,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyl, substituted
or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
or R9S(O).sub.nR9, wherein each said R3, which is substituted, has
one or more substituents selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OR9,
S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9); (e) when A is (1) A1 then A1 is
either (a) A11 ##STR00275## where R4 is H, NO.sub.2, substituted or
u8nsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, S(O).sub.nOR9, or
R9S(O).sub.nR9, wherein each said R4, which is substituted, has one
or more substituents selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OR9,
S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9), or (b) A12 ##STR00276## where
R4 is a C.sub.1-C.sub.6 alkyl, (2) A2 then R4 is H, F, Cl, Br, I,
CN, NO.sub.2, substituted or unsubstituted C.sub.1-C.sub.6 alkyl,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyl, substituted
or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
or R9S(O).sub.nR9, wherein each said R4, which is substituted, has
one or more substituents selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OR9,
S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9); (f) R5 is H, F, Cl, Br, I, CN,
NO.sub.2, substituted or unsubstituted C.sub.1-C.sub.6 alkyl,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyl, substituted
or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
or R9S(O).sub.nR9, wherein each said R5, which is substituted, has
one or more substituents selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OR9,
S(O).sub.nOR9, or C.sub.6-C.sub.20 aryl, (each of which that can be
substituted, may optionally be substituted with R9); (g) (1) when A
is A1 then R6 is R11, substituted or unsubstituted C.sub.1-C.sub.6
alkyl, substituted or unsubstituted C.sub.2-C.sub.6 alkenyl,
substituted or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
R9S(O).sub.nR9, C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.20 aryl
(wherein the alkyl and aryl can independently be substituted or
unsubstituted), C(=X2)R9, C(=X1)X2R9, R9X2C(=X1)R9, R9X2R9,
C(.dbd.O)(C.sub.1-C.sub.6 alkyl)S(O).sub.n(C.sub.1-C.sub.6 alkyl),
C(.dbd.O)(C.sub.1-C.sub.6 alkyl)C(.dbd.O)O(C.sub.1-C.sub.6 alkyl),
(C.sub.1-C.sub.6 alkyl)OC(.dbd.O)(C.sub.6-C.sub.20 aryl),
(C.sub.1-C.sub.6 alkyl)OC(.dbd.O)(C.sub.1-C.sub.6 alkyl),
C.sub.1-C.sub.6 alkyl-(C.sub.3-C.sub.10 cyclohaloalkyl), or
(C.sub.1-C.sub.6 alkenyl)C(.dbd.O)O(C.sub.1-C.sub.6 alkyl), or
R9X2C(=X1)X2R9, wherein each said R6 (except R11), which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, R9aryl, (each of which that can be substituted, may
optionally be substituted with R9), optionally R6 (except R11) and
R8 can be connected in a cyclic arrangement, where optionally such
arrangement can have one or more heteroatoms selected from O, S,
or, N, in the cyclic structure connecting R6 and R8, and (2) when A
is A2 then R6 is R11, H, substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.2-C.sub.6
alkenyl, substituted or unsubstituted C.sub.1-C.sub.6 alkoxy,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyloxy,
substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl,
substituted or unsubstituted C.sub.3-C.sub.10 cycloalkenyl,
substituted or unsubstituted C.sub.6-C.sub.20 aryl, substituted or
unsubstituted C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9,
C(=X1)OR9, C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9,
S(O).sub.nOR9, R9S(O).sub.nR9, C.sub.1-C.sub.6 alkyl
C.sub.6-C.sub.20 aryl (wherein the alkyl and aryl can independently
be substituted or unsubstituted), C(=X2)R9, C(=X1)X2R9,
R9X2C(=X1)R9, R9X2R9, C(.dbd.O)(C.sub.1-C.sub.6
alkyl)S(O).sub.n(C.sub.1-C.sub.6 alkyl), C(.dbd.O)(C.sub.1-C.sub.6
alkyl)C(.dbd.O)O(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.6
alkyl)OC(.dbd.O)(C.sub.6-C.sub.20 aryl), (C.sub.1-C.sub.6
alkyl)OC(.dbd.O)(C.sub.1-C.sub.6 alkyl), C.sub.1-C.sub.6
alkyl-(C.sub.3-C.sub.10 cyclohaloalkyl), or (C.sub.1-C.sub.6
alkenyl)C(.dbd.O)O(C.sub.1-C.sub.6 alkyl), or R9X2C(=X1)X2R9,
wherein each said R6 (except R11), which is substituted, has one or
more substituents selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OR9,
S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, R9aryl, (each of which that can be substituted, may
optionally be substituted with R9), optionally R6 (except R11) and
R8 can be connected in a cyclic arrangement, where optionally such
arrangement can have one or more heteroatoms selected from O, S, or
N, in the cyclic structure connecting R6 and R8; (h) R7 is O, S,
NR9, or NOR9; (i) R8 is R13-S(O).sub.n--R13 wherein each R13 is
independently selected from substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.2-C.sub.6
alkenyl, substituted or unsubstituted C.sub.1-C.sub.6 alkoxy,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyloxy,
substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl,
substituted or unsubstituted C.sub.3-C.sub.10 cycloalkenyl,
substituted or unsubstituted C.sub.6-C.sub.20 aryl, substituted or
unsubstituted C.sub.1-C.sub.20 heterocyclyl, substituted or
unsubstituted S(O).sub.nC.sub.1-C.sub.6 alkyl, substituted or
unsubstituted N(C.sub.1-C.sub.6alkyl).sub.2, wherein each said
substituted alkyl, substituted alkenyl, substituted alkoxy,
substituted alkenyloxy, substituted cycloalkyl, substituted
cycloalkenyl, substituted aryl, substituted heterocyclyl, has one
or more substituents independently selected from F, Cl, Br, I, CN,
NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OC.sub.1-C.sub.6 alkyl, OC.sub.1-C.sub.6 haloalkyl,
S(O).sub.nC.sub.1-C.sub.6alkyl, S(O).sub.nOC.sub.1-C.sub.6 alkyl,
C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20 heterocyclyl,
C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 alkoxy, N(R9)S(O).sub.nR9,
OR9, N(R9).sub.2, R9OR9, R9N(R9).sub.2, R9C(=X1)R9,
R9C(=X1)N(R9).sub.2, N(R9)C(=X1)R9, R9N(R9)C(=X1)R9, S(O).sub.nOR9,
R9C(=X1)OR9, R9OC(=X1)R9, R9S(O).sub.nR9, S(O).sub.nR9, oxo, (each
of which that can be substituted, may optionally be substituted
with R9); (j) R9 is (each independently) H, CN, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, substituted or unsubstituted
S(O).sub.nC.sub.1-C.sub.6 alkyl, substituted or unsubstituted
N(C.sub.1-C.sub.6alkyl).sub.2, wherein each said R9, which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OC.sub.1-C.sub.6 alkyl, OC.sub.1-C.sub.6 haloalkyl,
S(O).sub.nC.sub.1-C.sub.6alkyl, S(O).sub.nOC.sub.1-C.sub.6 alkyl,
C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20 heterocyclyl; (k) n is
0, 1, or 2; (l) X is N or CR.sub.n1 where R.sub.n1 is H, F, Cl, Br,
I, CN, NO.sub.2, substituted or unsubstituted C.sub.1-C.sub.6
alkyl, substituted or unsubstituted C.sub.2-C.sub.6 alkenyl,
substituted or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nR9,
S(O).sub.nOR9, or R9S(O).sub.nR9, wherein each said R.sub.n1 which
is substituted, has one or more substituents selected from F, Cl,
Br, I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10
halocycloalkenyl, OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or
C.sub.1-C.sub.20 heterocyclyl, (each of which that can be
substituted, may optionally be substituted with R9); (m) X1 is
(each independently) O or S; (n) X2 is (each independently) 0, S,
=NR9, or =NOR9; (o) Z is CN, NO.sub.2, C.sub.1-C.sub.6 alkyl(R9),
C(=X1)N(R9).sub.2; (p) R11 is Q.sub.1(C.ident.C)R12, wherein
Q.sub.1 is a bond, substituted or unsubstituted C.sub.1-C.sub.6
alkyl, substituted or unsubstituted C.sub.2-C.sub.6 alkenyl,
substituted or unsubstituted C.sub.2-C.sub.6 alkynyl, substituted
or unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.2-C.sub.10 cycloalkoxy, substituted or
unsubstituted C.sub.1-C.sub.6 alkylOR9, substituted or
unsubstituted C.sub.1-C.sub.6 alkylS(O).sub.nR9, substituted or
unsubstituted C.sub.1-C.sub.6 alkylS(O).sub.n(=NR9), substituted or
unsubstituted C.sub.1-C.sub.6 alkylN(R9) (where (C.ident.C) is
attached directly to the N by a bond), substituted or unsubstituted
C.sub.1-C.sub.6 alkylN(R9).sub.2, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkylC(=R7)C.sub.0-C.sub.6 alkylR9, substituted or
unsubstituted C.sub.2-C.sub.6 alkylC(=R7)OR9, substituted or
unsubstituted C.sub.1-C.sub.6 alkylOC.sub.0-C.sub.6 alkylC(=R7)R9,
substituted or unsubstituted C.sub.1-C.sub.6 alkylN(R9)(C(=R7)R9),
substituted or unsubstituted C.sub.1-C.sub.6 alkylN(R9)(C(=R7)OR9),
substituted or unsubstituted C.sub.2-C.sub.6 alkyl
C(=R7)C.sub.0-C.sub.6 alkylN(R9) (where (C.ident.C) is attached
directly to the N by a bond), substituted or unsubstituted
C.sub.2-C.sub.6alkylC(=R7)C.sub.0-C.sub.6 alkylN(R9).sub.2, OR9,
S(O).sub.nR9, N(R9)R9, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, wherein each said Q.sub.1, which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6
haloalkenyl, C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6
haloalkenyloxy, C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10
cycloalkenyl, C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10
halocycloalkenyl, OR9, SR9, S(O).sub.nR9, S(O).sub.nOR9,
C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20 heterocyclyl, R9aryl,
C.sub.1-C.sub.6alkylOR9, C.sub.1-C.sub.6alkylS(O).sub.nR9, (each of
which that can be substituted, may optionally be substituted with
R9) optionally Q.sub.1 and R8 can be connected in a cyclic
arrangement, where optionally such arrangement can have one or more
heteroatoms selected from O, S, or N, in the cyclic structure
connecting Q.sub.1 and R8; (q) R12 is Q.sub.1 (except where Q.sub.1
is a bond), F, Cl, Br, I, Si(R9).sub.3 (where each R9 is
independently selected), or R9.
2. A composition according to claim 1 wherein said molecule said A
is A1.
3. A composition according to claim 1 wherein said molecule said A
is A2.
4. A composition according to claim 1 wherein said molecule said R1
is H.
5. A composition according to claim 1 wherein said molecule said R2
is H.
6. A composition according to claim 1 wherein said molecule said R3
is selected from H, or substituted or unsubstituted C.sub.1-C.sub.6
alkyl.
7. A composition according to claim 1 wherein said molecule said R3
is selected from H or CH.sub.3.
8. A composition according to claim 1 wherein said molecule when
said A is A1 then A1 is A11.
9. A composition according to claim 1 wherein said molecule when
said A is A1, and A1 is A11, then R4 is selected from H, or
substituted or unsubstituted C.sub.1-C.sub.6 alkyl, or substituted
or unsubstituted C.sub.6-C.sub.20 aryl.
10. A composition according to claim 1 wherein said molecule when
said A is A1, and A1 is A11 then R4 is selected from CH.sub.3,
CH(CH.sub.3).sub.2, or phenyl.
11. A composition according to claim 1 wherein said molecule when
said A is A1, and A1 is A12, then R4 is CH.sub.3.
12. A composition according to claim 1 wherein said molecule when
said A is A2 then R4 is selected from H, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, wherein each said R4, which is substituted,
has one or more substituents selected from F, Cl, Br, or I.
13. A composition according to claim 1 wherein said molecule when
said A is A2 then R4 is H or C.sub.1-C.sub.6 alkyl.
14. A composition according to claim 1 wherein said molecule when
said A is A2 then R4 is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.dbd.CH.sub.2, cyclopropyl, CH.sub.2Cl, CF.sub.3, or phenyl.
15. A composition according to claim 1 wherein said molecule when
said A is A2 then R4 is Br or Cl.
16. A composition according to claim 1 wherein said molecule said
R5 is selected from H, F, Cl, Br, I, substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.1-C.sub.6
alkoxy.
17. A composition according to claim 1 wherein said molecule said
R5 is selected from H, OCH.sub.2CH.sub.3, F, Cl, Br, or
CH.sub.3.
18. A composition according to claim 1 wherein said molecule said
R11 is substituted or unsubstituted C.sub.1-C.sub.6
alkylC.ident.CR12.
19. A composition according to claim 1 wherein said molecule said
R11 is substituted or unsubstituted C.sub.1-C.sub.6
alkylC.ident.CH.
20. A composition according to claim 1 wherein said molecule said
R11 is substituted or unsubstituted C.sub.1-C.sub.4
alkylC.ident.CH.
21. A composition according to claim 1 wherein said molecule said
R11 is substituted or unsubstituted C.sub.1-C.sub.2
alkylC.ident.CH.
22. A composition according to claim 1 wherein said molecule said
R11 is substituted or unsubstituted CH.sub.2C.ident.CH.
23. A composition according to claim 1 wherein said molecule said
R7 is O or S.
24. A composition according to claim 1 wherein said molecule said
R8 is selected from CH(CH.sub.3)SCH.sub.2CF.sub.3,
CH.sub.2CH.sub.2SCH.sub.2CF.sub.3, CH.sub.2SCH.sub.2CF.sub.3,
CH.sub.2SCHClCF.sub.3, CH(CH.sub.2CH.sub.3)SCH.sub.2CF.sub.3,
CH(CH.sub.3)SCH.sub.2CHF.sub.2, CH(CH.sub.3)SCH.sub.2CH.sub.2F,
CH.sub.2CH.sub.2SCH.sub.2CH.sub.2F,
CH(CH.sub.3)S(.dbd.O).sub.2CH.sub.2CF.sub.3,
CH(CH.sub.3)S(.dbd.O)CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2S(.dbd.O)CH.sub.2CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2S(.dbd.O).sub.2CH.sub.2CH.sub.2CF.sub.3,
CH(CH.sub.3)CH.sub.2SCF.sub.3,
CH(CH.sub.3)SCH.sub.2CH.sub.2CF.sub.3, and
CH.sub.2CH.sub.2SCH.sub.2CH.sub.2CF.sub.3.
25. A composition according to claim 1 wherein said molecule said
R8 is selected from
CH(CH.sub.3)CH.sub.2SCH.sub.2(2,2-difluorocyclopropyl),
CH.sub.2CH.sub.2SCH.sub.2(2,2-difluorocyclopropyl),
CH.sub.2CH.sub.2S(.dbd.O)CH.sub.2(2,2-difluorocyclopropyl),
CH.sub.2CH.sub.2S(.dbd.O).sub.2CH.sub.2(2,2-difluorocyclopropyl),
and CH.sub.2CH(CF.sub.3)SCH.sub.2(2,2-difluorocyclopropyl).
26. A composition according to claim 1 wherein said molecule said
R8 is selected from CH.sub.2CH.sub.2SCH.sub.2CH.dbd.CCl.sub.2,
CH.sub.2SCH.sub.2CH.dbd.CCl.sub.2,
CH(CH.sub.3)SCH.sub.2CH.dbd.CCl.sub.2, and
CH(CH.sub.3)SCH.dbd.CHF.CH.sub.2CH.sub.2SCH.sub.2CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2S(.dbd.O)CH.sub.2CH.sub.2CF.sub.3 and
CH.sub.2CH.sub.2S(.dbd.O).sub.2CH.sub.2CH.sub.2CF.sub.3.
27. A composition according to claim 1 wherein said molecule said
R8 is selected from (substituted or unsubstituted C.sub.1-C.sub.6
alkyl)-S(O).sub.n-(substituted or unsubstituted C.sub.1-C.sub.6
alkyl) wherein said substituents on said substituted alkyls are
selected from F, Cl, Br, I, CN, NO.sub.2, N(R9)S(O).sub.nR9, OR9,
S(O).sub.nOR9, R9S(O).sub.nR9, S(O).sub.nR9, C.sub.6-C.sub.20 aryl,
or C.sub.1-C.sub.20 heterocyclyl, (each of which that can be
substituted, may optionally be substituted with R9).
28. A composition according to claim 1 wherein said molecule said X
is CR.sub.n1 where R.sub.n1 is H or halo.
29. A composition according to claim 1 wherein said molecule said X
is CR.sub.n1 where R.sub.n1 is H or F.
30. A composition according to claim 1 wherein said molecule said
X1 or X2 or both are O.
31. A composition according to claim 1 wherein said molecule has
one of the following structures ##STR00277## ##STR00278##
32. A composition according to claim 1 further comprising: (a) one
or more compounds having acaricidal, algicidal, avicidal,
bactericidal, fungicidal, herbicidal, insecticidal, molluscicidal,
nematicidal, rodenticidal, or virucidal properties; or (b) one or
more compounds that are antifeedants, bird repellents,
chemosterilants, herbicide safeners, insect attractants, insect
repellents, mammal repellents, mating disrupters, plant activators,
plant growth regulators, or synergists; or (c) both (a) and
(b).
33. A composition according to claim 1 wherein further comprising
one or more compounds selected from: (3-ethoxypropyl)mercury
bromide, 1,2-dichloropropane, 1,3-dichloropropene,
1-methylcyclopropene, 1-naphthol, 2-(octylthio)ethanol,
2,3,5-tri-iodobenzoic acid, 2,3,6-TBA, 2,3,6-TBA-dimethylammonium,
2,3,6-TBA-lithium, 2,3,6-TBA-potassium, 2,3,6-TBA-sodium, 2,4,5-T,
2,4,5-T-2-butoxypropyl, 2,4,5-T-2-ethylhexyl,
2,4,5-T-3-butoxypropyl, 2,4,5-TB, 2,4,5-T-butometyl,
2,4,5-T-butotyl, 2,4,5-T-butyl, 2,4,5-T-isobutyl, 2,4,5-T-isoctyl,
2,4,5-T-isopropyl, 2,4,5-T-methyl, 2,4,5-T-pentyl, 2,4,5-T-sodium,
2,4,5-T-triethylammonium, 2,4,5-T-trolamine, 2,4-D,
2,4-D-2-butoxypropyl, 2,4-D-2-ethylhexyl, 2,4-D-3-butoxypropyl,
2,4-D-ammonium, 2,4-DB, 2,4-DB-butyl, 2,4-DB-dimethylammonium,
2,4-DB-isoctyl, 2,4-DB-potassium, 2,4-DB-sodium, 2,4-D-butotyl,
2,4-D-butyl, 2,4-D-diethylammonium, 2,4-D-dimethylammonium,
2,4-D-diolamine, 2,4-D-dodecylammonium, 2,4-DEB, 2,4-DEP,
2,4-D-ethyl, 2,4-D-heptylammonium, 2,4-D-isobutyl, 2,4-D-isoctyl,
2,4-D-isopropyl, 2,4-D-isopropylammonium, 2,4-D-lithium,
2,4-D-meptyl, 2,4-D-methyl, 2,4-D-octyl, 2,4-D-pentyl,
2,4-D-potassium, 2,4-D-propyl, 2,4-D-sodium, 2,4-D-tefuryl,
2,4-D-tetradecylammonium, 2,4-D-triethylammonium,
2,4-D-tris(2-hydroxypropyl)ammonium, 2,4-D-trolamine, 2iP,
2-methoxyethylmercury chloride, 2-phenylphenol, 3,4-DA, 3,4-DB,
3,4-DP, 4-aminopyridine, 4-CPA, 4-CPA-potassium, 4-CPA-sodium,
4-CPB, 4-CPP, 4-hydroxyphenethyl alcohol, 8-hydroxyquinoline
sulfate, 8-phenylmercurioxyquinoline, abamectin, abscisic acid,
ACC, acephate, acequinocyl, acetamiprid, acethion, acetochlor,
acetophos, acetoprole, acibenzolar, acibenzolar-S-methyl,
acifluorfen, acifluorfen-methyl, acifluorfen-sodium, aclonifen,
acrep, acrinathrin, acrolein, acrylonitrile, acypetacs,
acypetacs-copper, acypetacs-zinc, alachlor, alanycarb, albendazole,
aldicarb, aldimorph, aldoxycarb, aldrin, allethrin, allicin,
allidochlor, allosamidin, alloxydim, alloxydim-sodium, allyl
alcohol, allyxycarb, alorac, alpha-cypermethrin, alpha-endosulfan,
ametoctradin, ametridione, ametryn, amibuzin, amicarbazone,
amicarthiazol, amidithion, amidoflumet, amidosulfuron, aminocarb,
aminocyclopyrachlor, aminocyclopyrachlor-methyl,
aminocyclopyrachlor-potassium, aminopyralid,
aminopyralid-potassium, aminopyralid-tris(2-hydroxypropyl)ammonium,
amiprofos-methyl, amiprophos, amisulbrom, amiton, amiton oxalate,
amitraz, amitrole, ammonium sulfamate, ammonium
.alpha.-naphthaleneacetate, amobam, ampropylfos, anabasine,
ancymidol, anilazine, anilofos, anisuron, anthraquinone, antu,
apholate, aramite, arsenous oxide, asomate, aspirin, asulam,
asulam-potassium, asulam-sodium, athidathion, atraton, atrazine,
aureofungin, aviglycine, aviglycine hydrochloride, azaconazole,
azadirachtin, azafenidin, azamethiphos, azimsulfuron,
azinphos-ethyl, azinphos-methyl, aziprotryne, azithiram,
azobenzene, azocyclotin, azothoate, azoxystrobin, bachmedesh,
barban, barium hexafluorosilicate, barium polysulfide, barthrin,
BCPC, beflubutamid, benalaxyl, benalaxyl-M, benazolin,
benazolin-dimethylammonium, benazolin-ethyl, benazolin-potassium,
bencarbazone, benclothiaz, bendiocarb, benfluralin, benfuracarb,
benfuresate, benodanil, benomyl, benoxacor, benoxafos, benquinox,
bensulfuron, bensulfuron-methyl, bensulide, bensultap, bentaluron,
bentazone, bentazone-sodium, benthiavalicarb,
benthiavalicarb-isopropyl, benthiazole, bentranil, benzadox,
benzadox-ammonium, benzalkonium chloride, benzamacril,
benzamacril-isobutyl, benzamorf, benzfendizone, benzipram,
benzobicyclon, benzofenap, benzofluor, benzohydroxamic acid,
benzoximate, benzoylprop, benzoylprop-ethyl, benzthiazuron, benzyl
benzoate, benzyladenine, berberine, berberine chloride,
beta-cyfluthrin, beta-cypermethrin, bethoxazin, bicyclopyrone,
bifenazate, bifenox, bifenthrin, bifujunzhi, bilanafos,
bilanafos-sodium, binapacryl, bingqingxiao, bioallethrin,
bioethanomethrin, biopermethrin, bioresmethrin, biphenyl, bisazir,
bismerthiazol, bispyribac, bispyribac-sodium, bistrifluron,
bitertanol, bithionol, bixafen, blasticidin-S, borax, Bordeaux
mixture, boric acid, boscalid, brassinolide, brassinolide-ethyl,
brevicomin, brodifacoum, brofenvalerate, brofluthrinate, bromacil,
bromacil-lithium, bromacil-sodium, bromadiolone, bromethalin,
bromethrin, bromfenvinfos, bromoacetamide, bromobonil, bromobutide,
bromocyclen, bromo-DDT, bromofenoxim, bromophos, bromophos-ethyl,
bromopropylate, bromothalonil, bromoxynil, bromoxynil butyrate,
bromoxynil heptanoate, bromoxynil octanoate, bromoxynil-potassium,
brompyrazon, bromuconazole, bronopol, bucarpolate, bufencarb,
buminafos, bupirimate, buprofezin, Burgundy mixture, busulfan,
butacarb, butachlor, butafenacil, butamifos, butathiofos,
butenachlor, butethrin, buthidazole, buthiobate, buthiuron,
butocarboxim, butonate, butopyronoxyl, butoxycarboxim, butralin,
butroxydim, buturon, butylamine, butylate, cacodylic acid,
cadusafos, cafenstrole, calcium arsenate, calcium chlorate, calcium
cyanamide, calcium polysulfide, calvinphos, cambendichlor,
camphechlor, camphor, captafol, captan, carbamorph, carbanolate,
carbaryl, carbasulam, carbendazim, carbendazim benzenesulfonate,
carbendazim sulfite, carbetamide, carbofuran, carbon disulfide,
carbon tetrachloride, carbophenothion, carbosulfan, carboxazole,
carboxide, carboxin, carfentrazone, carfentrazone-ethyl,
carpropamid, cartap, cartap hydrochloride, carvacrol, carvone,
CDEA, cellocidin, CEPC, ceralure, Cheshunt mixture, chinomethionat,
chitosan, chlobenthiazone, chlomethoxyfen, chloralose, chloramben,
chloramben-ammonium, chloramben-diolamine, chloramben-methyl,
chloramben-methylammonium, chloramben-sodium, chloramine
phosphorus, chloramphenicol, chloraniformethan, chloranil,
chloranocryl, chlorantraniliprole, chlorazifop,
chlorazifop-propargyl, chlorazine, chlorbenside, chlorbenzuron,
chlorbicyclen, chlorbromuron, chlorbufam, chlordane, chlordecone,
chlordimeform, chlordimeform hydrochloride, chlorempenthrin,
chlorethoxyfos, chloreturon, chlorfenac, chlorfenac-ammonium,
chlorfenac-sodium, chlorfenapyr, chlorfenazole, chlorfenethol,
chlorfenprop, chlorfenson, chlorfensulphide, chlorfenvinphos,
chlorfluazuron, chlorflurazole, chlorfluren, chlorfluren-methyl,
chlorflurenol, chlorflurenol-methyl, chloridazon, chlorimuron,
chlorimuron-ethyl, chlormephos, chlormequat, chlormequat chloride,
chlornidine, chlornitrofen, chlorobenzilate,
chlorodinitronaphthalenes, chloroform, chloromebuform,
chloromethiuron, chloroneb, chlorophacinone,
chlorophacinone-sodium, chloropicrin, chloropon, chloropropylate,
chlorothalonil, chlorotoluron, chloroxuron, chloroxynil,
chlorphonium, chlorphonium chloride, chlorphoxim, chlorprazophos,
chlorprocarb, chlorpropham, chlorpyrifos, chlorpyrifos-methyl,
chlorquinox, chlorsulfuron, chlorthal, chlorthal-dimethyl,
chlorthal-monomethyl, chlorthiamid, chlorthiophos, chlozolinate,
choline chloride, chromafenozide, cinerin I, cinerin II, cinerins,
cinidon-ethyl, cinmethylin, cinosulfuron, ciobutide, cisanilide,
cismethrin, clethodim, climbazole, cliodinate, clodinafop,
clodinafop-propargyl, cloethocarb, clofencet, clofencet-potassium,
clofentezine, clofibric acid, clofop, clofop-isobutyl, clomazone,
clomeprop, cloprop, cloproxydim, clopyralid, clopyralid-methyl,
clopyralid-olamine, clopyralid-potassium,
clopyralid-tris(2-hydroxypropyl)ammonium, cloquintocet,
cloquintocet-mexyl, cloransulam, cloransulam-methyl, closantel,
clothianidin, clotrimazole, cloxyfonac, cloxyfonac-sodium, CMA,
codlelure, colophonate, copper acetate, copper acetoarsenite,
copper arsenate, copper carbonate, basic, copper hydroxide, copper
naphthenate, copper oleate, copper oxychloride, copper silicate,
copper sulfate, copper zinc chromate, coumachlor, coumafuryl,
coumaphos, coumatetralyl, coumithoate, coumoxystrobin, CPMC, CPMF,
CPPC, credazine, cresol, crimidine, crotamiton, crotoxyphos,
crufomate, cryolite, cue-lure, cufraneb, cumyluron, cuprobam,
cuprous oxide, curcumenol, cyanamide, cyanatryn, cyanazine,
cyanofenphos, cyanophos, cyanthoate, cyantraniliprole, cyazofamid,
cybutryne, cyclafuramid, cyclanilide, cyclethrin, cycloate,
cycloheximide, cycloprate, cycloprothrin, cyclosulfamuron,
cycloxydim, cycluron, cyenopyrafen, cyflufenamid, cyflumetofen,
cyfluthrin, cyhalofop, cyhalofop-butyl, cyhalothrin, cyhexatin,
cymiazole, cymiazole hydrochloride, cymoxanil, cyometrinil,
cypendazole, cypermethrin, cyperquat, cyperquat chloride,
cyphenothrin, cyprazine, cyprazole, cyproconazole, cyprodinil,
cyprofuram, cypromid, cyprosulfamide, cyromazine, cythioate,
daimuron, dalapon, dalapon-calcium, dalapon-magnesium,
dalapon-sodium, daminozide, dayoutong, dazomet, dazomet-sodium,
DBCP, d-camphor, DCIP, DCPTA, DDT, debacarb, decafentin,
decarbofuran, dehydroacetic acid, delachlor, deltamethrin,
demephion, demephion-O, demephion-S, demeton, demeton-methyl,
demeton-O, demeton-O-methyl, demeton-S, demeton-S-methyl,
demeton-S-methylsulphon, desmedipham, desmetryn,
d-fanshiluquebingjuzhi, diafenthiuron, dialifos, di-allate,
diamidafos, diatomaceous earth, diazinon, dibutyl phthalate,
dibutyl succinate, dicamba, dicamba-diglycolamine,
dicamba-dimethylammonium, dicamba-diolamine,
dicamba-isopropylammonium, dicamba-methyl, dicamba-olamine,
dicamba-potassium, dicamba-sodium, dicamba-trolamine, dicapthon,
dichlobenil, dichlofenthion, dichlofluanid, dichlone,
dichloralurea, dichlorbenzuron, dichlorflurenol,
dichlorflurenol-methyl, dichlormate, dichlormid, dichlorophen,
dichlorprop, dichlorprop-2-ethylhexyl, dichlorprop-butotyl,
dichlorprop-dimethylammonium, dichlorprop-ethylammonium,
dichlorprop-isoctyl, dichlorprop-methyl, dichlorprop-P,
dichlorprop-P-2-ethylhexyl, dichlorprop-P-dimethylammonium,
dichlorprop-potassium, dichlorprop-sodium, dichlorvos,
dichlozoline, diclobutrazol, diclocymet, diclofop, diclofop-methyl,
diclomezine, diclomezine-sodium, dicloran, diclosulam, dicofol,
dicoumarol, dicresyl, dicrotophos, dicyclanil, dicyclonon,
dieldrin, dienochlor, diethamquat, diethamquat dichloride,
diethatyl, diethatyl-ethyl, diethofencarb, dietholate, diethyl
pyrocarbonate, diethyltoluamide, difenacoum, difenoconazole,
difenopenten, difenopenten-ethyl, difenoxuron, difenzoquat,
difenzoquat metilsulfate, difethialone, diflovidazin,
diflubenzuron, diflufenican, diflufenzopyr, diflufenzopyr-sodium,
diflumetorim, dikegulac, dikegulac-sodium, dilor, dimatif,
dimefluthrin, dimefox, dimefuron, dimepiperate, dimetachlone,
dimetan, dimethacarb, dimethachlor, dimethametryn, dimethenamid,
dimethenamid-P, dimethipin, dimethirimol, dimethoate, dimethomorph,
dimethrin, dimethyl carbate, dimethyl phthalate, dimethylvinphos,
dimetilan, dimexano, dimidazon, dimoxystrobin, dinex,
dinex-diclexine, dingjunezuo, diniconazole, diniconazole-M,
dinitramine, dinobuton, dinocap, dinocap-4, dinocap-6, dinocton,
dinofenate, dinopenton, dinoprop, dinosam, dinoseb, dinoseb
acetate, dinoseb-ammonium, dinoseb-diolamine, dinoseb-sodium,
dinoseb-trolamine, dinosulfon, dinotefuran, dinoterb, dinoterb
acetate, dinoterbon, diofenolan, dioxabenzofos, dioxacarb,
dioxathion, diphacinone, diphacinone-sodium, diphenamid, diphenyl
sulfone, diphenylamine, dipropalin, dipropetryn, dipyrithione,
diquat, diquat dibromide, disparlure, disul, disulfiram,
disulfoton, disul-sodium, ditalimfos, dithianon, dithicrofos,
dithioether, dithiopyr, diuron, d-limonene, DMPA, DNOC,
DNOC-ammonium, DNOC-potassium, DNOC-sodium, dodemorph, dodemorph
acetate, dodemorph benzoate, dodicin, dodicin hydrochloride,
dodicin-sodium, dodine, dofenapyn, dominicalure, doramectin,
drazoxolon, DSMA, dufulin, EBEP, EBP, ecdysterone, edifenphos,
eglinazine, eglinazine-ethyl, emamectin, emamectin benzoate, EMPC,
empenthrin, endosulfan, endothal, endothal-diammonium,
endothal-dipotassium, endothal-disodium, endothion, endrin,
enestroburin, EPN, epocholeone, epofenonane, epoxiconazole,
eprinomectin, epronaz, EPTC, erbon, ergocalciferol,
erlujixiancaoan, esdepallethrine, esfenvalerate, esprocarb,
etacelasil, etaconazole, etaphos, etem, ethaboxam, ethachlor,
ethalfluralin, ethametsulfuron, ethametsulfuron-methyl,
ethaprochlor, ethephon, ethidimuron, ethiofencarb, ethiolate,
ethion, ethiozin, ethiprole, ethirimol, ethoate-methyl,
ethofumesate, ethohexadiol, ethoprophos, ethoxyfen,
ethoxyfen-ethyl, ethoxyquin, ethoxysulfuron, ethychlozate, ethyl
formate, ethyl .alpha.-naphthaleneacetate, ethyl-DDD, ethylene,
ethylene dibromide, ethylene dichloride, ethylene oxide, ethylicin,
ethylmercury 2,3-dihydroxypropyl mercaptide, ethylmercury acetate,
ethylmercury bromide, ethylmercury chloride, ethylmercury
phosphate, etinofen, etnipromid, etobenzanid, etofenprox,
etoxazole, etridiazole, etrimfos, eugenol, EXD, famoxadone,
famphur, fenamidone, fenaminosulf, fenamiphos, fenapanil,
fenarimol, fenasulam, fenazaflor, fenazaquin, fenbuconazole,
fenbutatin oxide, fenchlorazole, fenchlorazole-ethyl, fenchlorphos,
fenclorim, fenethacarb, fenfluthrin, fenfuram, fenhexamid,
fenitropan, fenitrothion, fenjuntong, fenobucarb, fenoprop,
fenoprop-3-butoxypropyl, fenoprop-butometyl, fenoprop-butotyl,
fenoprop-butyl, fenoprop-isoctyl, fenoprop-methyl,
fenoprop-potassium, fenothiocarb, fenoxacrim, fenoxanil,
fenoxaprop, fenoxaprop-ethyl, fenoxaprop-P, fenoxaprop-P-ethyl,
fenoxasulfone, fenoxycarb, fenpiclonil, fenpirithrin,
fenpropathrin, fenpropidin, fenpropimorph, fenpyrazamine,
fenpyroximate, fenridazon, fenridazon-potassium, fenridazon-propyl,
fenson, fensulfothion, fenteracol, fenthiaprop, fenthiaprop-ethyl,
fenthion, fenthion-ethyl, fentin, fentin acetate, fentin chloride,
fentin hydroxide, fentrazamide, fentrifanil, fenuron, fenuron TCA,
fenvalerate, ferbam, ferimzone, ferrous sulfate, fipronil,
flamprop, flamprop-isopropyl, flamprop-M, flamprop-methyl,
flamprop-M-isopropyl, flamprop-M-methyl, flazasulfuron,
flocoumafen, flometoquin, flonicamid, florasulam, fluacrypyrim,
fluazifop, fluazifop-butyl, fluazifop-methyl, fluazifop-P,
fluazifop-P-butyl, fluazinam, fluazolate, fluazuron, flubendiamide,
flubenzimine, flucarbazone, flucarbazone-sodium, flucetosulfuron,
fluchloralin, flucofuron, flucycloxuron, flucythrinate,
fludioxonil, fluenetil, fluensulfone, flufenacet, flufenerim,
flufenican, flufenoxuron, flufenprox, flufenpyr, flufenpyr-ethyl,
flufiprole, flumethrin, flumetover, flumetralin, flumetsulam,
flumezin, flumiclorac, flumiclorac-pentyl, flumioxazin,
flumipropyn, flumorph, fluometuron, fluopicolide, fluopyram,
fluorbenside, fluoridamid, fluoroacetamide, fluorodifen,
fluoroglycofen, fluoroglycofen-ethyl, fluoroimide, fluoromidine,
fluoronitrofen, fluothiuron, fluotrimazole, fluoxastrobin,
flupoxam, flupropacil, flupropadine, flupropanate,
flupropanate-sodium, flupyradifurone, flupyrsulfuron,
flupyrsulfuron-methyl, flupyrsulfuron-methyl-sodium,
fluquinconazole, flurazole, flurenol, flurenol-butyl,
flurenol-methyl, fluridone, flurochloridone, fluroxypyr,
fluroxypyr-butometyl, fluroxypyr-meptyl, flurprimidol, flursulamid,
flurtamone, flusilazole, flusulfamide, fluthiacet,
fluthiacet-methyl, flutianil, flutolanil, flutriafol, fluvalinate,
fluxapyroxad, fluxofenim, folpet, fomesafen, fomesafen-sodium,
fonofos, foramsulfuron, forchlorfenuron, formaldehyde, formetanate,
formetanate hydrochloride, formothion, formparanate, formparanate
hydrochloride, fosamine, fosamine-ammonium, fosetyl,
fosetyl-aluminium, fosmethilan, fospirate, fosthiazate, fosthietan,
frontalin, fuberidazole, fucaojing, fucaomi, funaihecaoling,
fuphenthiourea, furalane, furalaxyl, furamethrin, furametpyr,
furathiocarb, furcarbanil, furconazole, furconazole-cis, furethrin,
furfural, furilazole, furmecyclox, furophanate, furyloxyfen,
gamma-cyhalothrin, gamma-HCH, genit, gibberellic acid,
gibberellins, gliftor, glufosinate, glufosinate-ammonium,
glufosinate-P, glufosinate-P-ammonium, glufosinate-P-sodium,
glyodin, glyoxime, glyphosate, glyphosate-diammonium,
glyphosate-dimethylammonium, glyphosate-isopropylammonium,
glyphosate-monoammonium, glyphosate-potassium,
glyphosate-sesquisodium, glyphosate-trimesium, glyphosine,
gossyplure, grandlure, griseofulvin, guazatine, guazatine acetates,
halacrinate, halfenprox, halofenozide, halosafen, halosulfuron,
halosulfuron-methyl, haloxydine, haloxyfop, haloxyfop-etotyl,
haloxyfop-methyl, haloxyfop-P, haloxyfop-P-etotyl,
haloxyfop-P-methyl, haloxyfop-sodium, HCH, hemel, hempa, HEOD,
heptachlor, heptenophos, heptopargil, heterophos,
hexachloroacetone, hexachlorobenzene, hexachlorobutadiene,
hexachlorophene, hexaconazole, hexaflumuron, hexaflurate, hexalure,
hexamide, hexazinone, hexylthiofos, hexythiazox, HHDN, holosulf,
huancaiwo, huangcaoling, huanjunzuo, hydramethylnon, hydrargaphen,
hydrated lime, hydrogen cyanide, hydroprene, hymexazol, hyquincarb,
IAA, IBA, icaridin, imazalil, imazalil nitrate, imazalil
sulfate, imazamethabenz, imazamethabenz-methyl, imazamox,
imazamox-ammonium, imazapic, imazapic-ammonium, imazapyr,
imazapyr-isopropylammonium, imazaquin, imazaquin-ammonium,
imazaquin-methyl, imazaquin-sodium, imazethapyr,
imazethapyr-ammonium, imazosulfuron, imibenconazole, imicyafos,
imidacloprid, imidaclothiz, iminoctadine, iminoctadine triacetate,
iminoctadine trialbesilate, imiprothrin, inabenfide, indanofan,
indaziflam, indoxacarb, inezin, iodobonil, iodocarb, iodomethane,
iodosulfuron, iodosulfuron-methyl, iodosulfuron-methyl-sodium,
iofensulfuron, iofensulfuron-sodium, ioxynil, ioxynil octanoate,
ioxynil-lithium, ioxynil-sodium, ipazine, ipconazole,
ipfencarbazone, iprobenfos, iprodione, iprovalicarb, iprymidam,
ipsdienol, ipsenol, IPSP, isamidofos, isazofos, isobenzan,
isocarbamid, isocarbophos, isocil, isodrin, isofenphos,
isofenphos-methyl, isolan, isomethiozin, isonoruron, isopolinate,
isoprocarb, isopropalin, isoprothiolane, isoproturon, isopyrazam,
isopyrimol, isothioate, isotianil, isouron, isovaledione, isoxaben,
isoxachlortole, isoxadifen, isoxadifen-ethyl, isoxaflutole,
isoxapyrifop, isoxathion, ivermectin, izopamfos, japonilure,
japothrins, jasmolin I, jasmolin II, jasmonic acid,
jiahuangchongzong, jiajizengxiaolin, jiaxiangjunzhi, jiecaowan,
jiecaoxi, jodfenphos, juvenile hormone I, juvenile hormone II,
juvenile hormone III, kadethrin, karbutilate, karetazan,
karetazan-potassium, kasugamycin, kasugamycin hydrochloride,
kejunlin, kelevan, ketospiradox, ketospiradox-potassium, kinetin,
kinoprene, kresoxim-methyl, kuicaoxi, lactofen, lambda-cyhalothrin,
latilure, lead arsenate, lenacil, lepimectin, leptophos, lindane,
lineatin, linuron, lirimfos, litlure, looplure, lufenuron,
lvdingjunzhi, lvxiancaolin, lythidathion, MAA, malathion, maleic
hydrazide, malonoben, maltodextrin, MAMA, mancopper, mancozeb,
mandipropamid, maneb, matrine, mazidox, MCPA, MCPA-2-ethylhexyl,
MCPA-butotyl, MCPA-butyl, MCPA-dimethylammonium, MCPA-diolamine,
MCPA-ethyl, MCPA-isobutyl, MCPA-isoctyl, MCPA-isopropyl,
MCPA-methyl, MCPA-olamine, MCPA-potassium, MCPA-sodium,
MCPA-thioethyl, MCPA-trolamine, MCPB, MCPB-ethyl, MCPB-methyl,
MCPB-sodium, mebenil, mecarbam, mecarbinzid, mecarphon, mecoprop,
mecoprop-2-ethylhexyl, mecoprop-dimethylammonium,
mecoprop-diolamine, mecoprop-ethadyl, mecoprop-isoctyl,
mecoprop-methyl, mecoprop-P, mecoprop-P-2-ethylhexyl,
mecoprop-P-dimethylammonium, mecoprop-P-isobutyl,
mecoprop-potassium, mecoprop-P-potassium, mecoprop-sodium,
mecoprop-trolamine, medimeform, medinoterb, medinoterb acetate,
medlure, mefenacet, mefenpyr, mefenpyr-diethyl, mefluidide,
mefluidide-diolamine, mefluidide-potassium, megatomoic acid,
menazon, mepanipyrim, meperfluthrin, mephenate, mephosfolan,
mepiquat, mepiquat chloride, mepiquat pentaborate, mepronil,
meptyldinocap, mercuric chloride, mercuric oxide, mercurous
chloride, merphos, mesoprazine, mesosulfuron, mesosulfuron-methyl,
mesotrione, mesulfen, mesulfenfos, metaflumizone, metalaxyl,
metalaxyl-M, metaldehyde, metam, metam-ammonium, metamifop,
metamitron, metam-potassium, metam-sodium, metazachlor,
metazosulfuron, metazoxolon, metconazole, metepa, metflurazon,
methabenzthiazuron, methacrifos, methalpropalin, methamidophos,
methasulfocarb, methazole, methfuroxam, methidathion,
methiobencarb, methiocarb, methiopyrisulfuron, methiotepa,
methiozolin, methiuron, methocrotophos, methometon, methomyl,
methoprene, methoprotryne, methoquin-butyl, methothrin,
methoxychlor, methoxyfenozide, methoxyphenone, methyl apholate,
methyl bromide, methyl eugenol, methyl iodide, methyl
isothiocyanate, methylacetophos, methylchloroform, methyldymron,
methylene chloride, methylmercury benzoate, methylmercury
dicyandiamide, methylmercury pentachlorophenoxide,
methylneodecanamide, metiram, metobenzuron, metobromuron,
metofluthrin, metolachlor, metolcarb, metominostrobin, metosulam,
metoxadiazone, metoxuron, metrafenone, metribuzin, metsulfovax,
metsulfuron, metsulfuron-methyl, mevinphos, mexacarbate, mieshuan,
milbemectin, milbemycin oxime, milneb, mipafox, mirex, MNAF,
moguchun, molinate, molosultap, monalide, monisouron,
monochloroacetic acid, monocrotophos, monolinuron, monosulfuron,
monosulfuron-ester, monuron, monuron TCA, morfamquat, morfamquat
dichloride, moroxydine, moroxydine hydrochloride, morphothion,
morzid, moxidectin, MSMA, muscalure, myclobutanil, myclozolin,
N-(ethylmercury)-p-toluenesulphonanilide, nabam, naftalofos, naled,
naphthalene, naphthaleneacetamide, naphthalic anhydride,
naphthoxyacetic acids, naproanilide, napropamide, naptalam,
naptalam-sodium, natamycin, neburon, niclosamide,
niclosamide-olamine, nicosulfuron, nicotine, nifluridide,
nipyraclofen, nitenpyram, nithiazine, nitralin, nitrapyrin,
nitrilacarb, nitrofen, nitrofluorfen, nitrostyrene,
nitrothal-isopropyl, norbormide, norflurazon, nornicotine, noruron,
novaluron, noviflumuron, nuarimol, OCH, octachlorodipropyl ether,
octhilinone, ofurace, omethoate, orbencarb, orfralure,
ortho-dichlorobenzene, orthosulfamuron, oryctalure, orysastrobin,
oryzalin, osthol, ostramone, oxabetrinil, oxadiargyl, oxadiazon,
oxadixyl, oxamate, oxamyl, oxapyrazon, oxapyrazon-dimolamine,
oxapyrazon-sodium, oxasulfuron, oxaziclomefone, oxine-copper,
oxolinic acid, oxpoconazole, oxpoconazole fumarate, oxycarboxin,
oxydemeton-methyl, oxydeprofos, oxydisulfoton, oxyfluorfen,
oxymatrine, oxytetracycline, oxytetracycline hydrochloride,
paclobutrazol, paichongding, para-dichlorobenzene, parafluron,
paraquat, paraquat dichloride, paraquat dimetilsulfate, parathion,
parathion-methyl, parinol, pebulate, pefurazoate, pelargonic acid,
penconazole, pencycuron, pendimethalin, penflufen, penfluron,
penoxsulam, pentachlorophenol, pentanochlor, penthiopyrad,
pentmethrin, pentoxazone, perfluidone, permethrin, pethoxamid,
phenamacril, phenazine oxide, phenisopham, phenkapton,
phenmedipham, phenmedipham-ethyl, phenobenzuron, phenothrin,
phenproxide, phenthoate, phenylmercuriurea, phenylmercury acetate,
phenylmercury chloride, phenylmercury derivative of pyrocatechol,
phenylmercury nitrate, phenylmercury salicylate, phorate,
phosacetim, phosalone, phosdiphen, phosfolan, phosfolan-methyl,
phosglycin, phosmet, phosnichlor, phosphamidon, phosphine,
phosphocarb, phosphorus, phostin, phoxim, phoxim-methyl, phthalide,
picloram, picloram-2-ethylhexyl, picloram-isoctyl, picloram-methyl,
picloram-olamine, picloram-potassium, picloram-triethylammonium,
picloram-tris(2-hydroxypropyl)ammonium, picolinafen, picoxystrobin,
pindone, pindone-sodium, pinoxaden, piperalin, piperonyl butoxide,
piperonyl cyclonene, piperophos, piproctanyl, piproctanyl bromide,
piprotal, pirimetaphos, pirimicarb, pirimioxyphos,
pirimiphos-ethyl, pirimiphos-methyl, plifenate, polycarbamate,
polyoxins, polyoxorim, polyoxorim-zinc, polythialan, potassium
arsenite, potassium azide, potassium cyanate, potassium
gibberellate, potassium naphthenate, potassium polysulfide,
potassium thiocyanate, potassium .alpha.-naphthaleneacetate,
pp'-DDT, prallethrin, precocene I, precocene II, precocene III,
pretilachlor, primidophos, primisulfuron, primisulfuron-methyl,
probenazole, prochloraz, prochloraz-manganese, proclonol,
procyazine, procymidone, prodiamine, profenofos, profluazol,
profluralin, profluthrin, profoxydim, proglinazine,
proglinazine-ethyl, prohexadione, prohexadione-calcium,
prohydrojasmon, promacyl, promecarb, prometon, prometryn, promurit,
propachlor, propamidine, propamidine dihydrochloride, propamocarb,
propamocarb hydrochloride, propanil, propaphos, propaquizafop,
propargite, proparthrin, propazine, propetamphos, propham,
propiconazole, propineb, propisochlor, propoxur, propoxycarbazone,
propoxycarbazone-sodium, propyl isome, propyrisulfuron,
propyzamide, proquinazid, prosuler, prosulfalin, prosulfocarb,
prosulfuron, prothidathion, prothiocarb, prothiocarb hydrochloride,
prothioconazole, prothiofos, prothoate, protrifenbute, proxan,
proxan-sodium, prynachlor, pydanon, pymetrozine, pyracarbolid,
pyraclofos, pyraclonil, pyraclostrobin, pyraflufen,
pyraflufen-ethyl, pyrafluprole, pyramat, pyrametostrobin,
pyraoxystrobin, pyrasulfotole, pyrazolynate, pyrazophos,
pyrazosulfuron, pyrazosulfuron-ethyl, pyrazothion, pyrazoxyfen,
pyresmethrin, pyrethrin I, pyrethrin II, pyrethrins,
pyribambenz-isopropyl, pyribambenz-propyl, pyribencarb,
pyribenzoxim, pyributicarb, pyriclor, pyridaben, pyridafol,
pyridalyl, pyridaphenthion, pyridate, pyridinitril, pyrifenox,
pyrifluquinazon, pyriftalid, pyrimethanil, pyrimidifen,
pyriminobac, pyriminobac-methyl, pyrimisulfan, pyrimitate,
pyrinuron, pyriofenone, pyriprole, pyripropanol, pyriproxyfen,
pyrithiobac, pyrithiobac-sodium, pyrolan, pyroquilon,
pyroxasulfone, pyroxsulam, pyroxychlor, pyroxyfur, quassia,
quinacetol, quinacetol sulfate, quinalphos, quinalphos-methyl,
quinazamid, quinclorac, quinconazole, quinmerac, quinoclamine,
quinonamid, quinothion, quinoxyfen, quintiofos, quintozene,
quizalofop, quizalofop-ethyl, quizalofop-P, quizalofop-P-ethyl,
quizalofop-P-tefuryl, quwenzhi, quyingding, rabenzazole,
rafoxanide, rebemide, resmethrin, rhodethanil, rhodojaponin-III,
ribavirin, rimsulfuron, rotenone, ryania, saflufenacil, saijunmao,
saisentong, salicylanilide, sanguinarine, santonin, schradan,
scilliroside, sebuthylazine, secbumeton, sedaxane, selamectin,
semiamitraz, semiamitraz chloride, sesamex, sesamolin, sethoxydim,
shuangjiaancaolin, siduron, siglure, silafluofen, silatrane, silica
gel, silthiofam, simazine, simeconazole, simeton, simetryn,
sintofen, SMA, S-metolachlor, sodium arsenite, sodium azide, sodium
chlorate, sodium fluoride, sodium fluoroacetate, sodium
hexafluorosilicate, sodium naphthenate, sodium
orthophenylphenoxide, sodium pentachlorophenoxide, sodium
polysulfide, sodium thiocyanate, sodium .alpha.-naphthaleneacetate,
sophamide, spinetoram, spinosad, spirodiclofen, spiromesifen,
spirotetramat, spiroxamine, streptomycin, streptomycin
sesquisulfate, strychnine, sulcatol, sulcofuron, sulcofuron-sodium,
sulcotrione, sulfallate, sulfentrazone, sulfiram, sulfluramid,
sulfometuron, sulfometuron-methyl, sulfosulfuron, sulfotep,
sulfoxaflor, sulfoxide, sulfoxime, sulfur, sulfuric acid, sulfuryl
fluoride, sulglycapin, sulprofos, sultropen, swep, tau-fluvalinate,
tavron, tazimcarb, TCA, TCA-ammonium, TCA-calcium, TCA-ethadyl,
TCA-magnesium, TCA-sodium, TDE, tebuconazole, tebufenozide,
tebufenpyrad, tebufloquin, tebupirimfos, tebutam, tebuthiuron,
tecloftalam, tecnazene, tecoram, teflubenzuron, tefluthrin,
tefuryltrione, tembotrione, temephos, tepa, TEPP, tepraloxydim,
terallethrin, terbacil, terbucarb, terbuchlor, terbufos,
terbumeton, terbuthylazine, terbutryn, tetcyclacis,
tetrachloroethane, tetrachlorvinphos, tetraconazole, tetradifon,
tetrafluron, tetramethrin, tetramethylfluthrin, tetramine,
tetranactin, tetrasul, thallium sulfate, thenylchlor,
theta-cypermethrin, thiabendazole, thiacloprid, thiadifluor,
thiamethoxam, thiapronil, thiazafluron, thiazopyr, thicrofos,
thicyofen, thidiazimin, thidiazuron, thiencarbazone,
thiencarbazone-methyl, thifensulfuron, thifensulfuron-methyl,
thifluzamide, thiobencarb, thiocarboxime, thiochlorfenphim,
thiocyclam, thiocyclam hydrochloride, thiocyclam oxalate,
thiodiazole-copper, thiodicarb, thiofanox, thiofluoximate,
thiohempa, thiomersal, thiometon, thionazin, thiophanate,
thiophanate-methyl, thioquinox, thiosemicarbazide, thiosultap,
thiosultap-diammonium, thiosultap-disodium, thiosultap-monosodium,
thiotepa, thiram, thuringiensin, tiadinil, tiaojiean, tiocarbazil,
tioclorim, tioxymid, tirpate, tolclofos-methyl, tolfenpyrad,
tolylfluanid, tolylmercury acetate, topramezone, tralkoxydim,
tralocythrin, tralomethrin, tralopyril, transfluthrin,
transpermethrin, tretamine, triacontanol, triadimefon, triadimenol,
triafamone, tri-allate, triamiphos, triapenthenol, triarathene,
triarimol, triasulfuron, triazamate, triazbutil, triaziflam,
triazophos, triazoxide, tribenuron, tribenuron-methyl, tribufos,
tributyltin oxide, tricamba, trichlamide, trichlorfon,
trichlormetaphos-3, trichloronat, triclopyr, triclopyr-butotyl,
triclopyr-ethyl, triclopyr-triethylammonium, tricyclazole,
tridemorph, tridiphane, trietazine, trifenmorph, trifenofos,
trifloxystrobin, trifloxysulfuron, trifloxysulfuron-sodium,
triflumizole, triflumuron, trifluralin, triflusulfuron,
triflusulfuron-methyl, trifop, trifop-methyl, trifopsime,
triforine, trihydroxytriazine, trimedlure, trimethacarb,
trimeturon, trinexapac, trinexapac-ethyl, triprene, tripropindan,
triptolide, tritac, triticonazole, tritosulfuron, trunc-call,
uniconazole, uniconazole-P, urbacide, uredepa, valerate,
validamycin, valifenalate, valone, vamidothion, vangard,
vaniliprole, vernolate, vinclozolin, warfarin, warfarin-potassium,
warfarin-sodium, xiaochongliulin, xinjunan, xiwojunan, XMC,
xylachlor, xylenols, xylylcarb, yishijing, zarilamid, zeatin,
zengxiaoan, zeta-cypermethrin, zinc naphthenate, zinc phosphide,
zinc thiazole, zineb, ziram, zolaprofos, zoxamide, zuomihuanglong,
.alpha.-chlorohydrin, .alpha.-ecdysone, .alpha.-multistriatin, and
.alpha.-naphthaleneacetic acid.
34. A composition according to claim 1 further comprising an
agriculturally acceptable carrier.
35. A composition according to claim 1 wherein said molecule is in
the form of a pesticidally acceptable acid addition salt.
36. A composition according to claim 1 wherein said molecule is in
the form of a salt derivative.
37. A composition according to claim 1 wherein said molecule is in
the form a hydrate.
38. A composition according to claim 1 wherein said molecule is a
resolved stereoisomer.
39. A composition according to claim 1 wherein said molecule is in
the form a crystal polymorph.
40. A composition according to claim 1 wherein said molecule has a
.sup.2H in place of .sup.1H.
41. A composition according to claim 1 wherein said molecule has a
.sup.13C in place of a .sup.12C.
42. A composition according to claim 1 further comprising a
biopesticide.
43. A composition according to claim 1 further comprising one or
more of the following compounds: (a)
3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-oxa-1-azaspiro[4,5]dec-3-en-2-
-one; (b)
3-(4'-chloro-2,4-dimethyl[1,1'-biphenyl]-3-yl)-4-hydroxy-8-oxa-1-
-azaspiro[4,5]dec-3-en-2-one; (c)
4-[[(6-chloro-3-pyridinyl)methyl]methylamino]-2(5H)-furanone; (d)
4-[[(6-chloro-3-pyridinyl)methyl]cyclopropylamino]-2(5H)-furanone;
(e)
3-chloro-N2-[(1S)-1-methyl-2-(methylsulfonyl)ethyl]-N1-[2-methyl-4-[1,2,2-
,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]-1,2-benzenedicarboxamide;
(f) 2-cyano-N-ethyl-4-fluoro-3-methoxy-benenesulfonamide; (g)
2-cyano-N-ethyl-3-methoxy-benzenesulfonamide; (h)
2-cyano-3-difluoromethoxy-N-ethyl-4-fluoro-benzenesulfonamide; (i)
2-cyano-3-fluoromethoxy-N-ethyl-benzenesulfonamide; (j)
2-cyano-6-fluoro-3-methoxy-N,N-dimethyl-benzenesulfonamide; (k)
2-cyano-N-ethyl-6-fluoro-3-methoxy-N-methyl-benzenesulfonamide; (l)
2-cyano-3-difluoromethoxy-N,N-dimethylbenzenesulfon-amide; (m)
3-(difluoromethyl)-N-[2-(3,3-dimethylbutyl)phenyl]-1-methyl-1H-pyrazole-4-
-carboxamide; (n)
N-ethyl-2,2-dimethylpropionamide-2-(2,6-dichloro-.alpha.,.alpha.,.alpha.--
trifluoro-p-tolyl) hydrazone; (o)
N-ethyl-2,2-dichloro-1-methylcyclopropane-carboxamide-2-(2,6-dichloro-.al-
pha.,.alpha.,.alpha.-trifluoro-p-tolyl) hydrazone nicotine; (p)
O-{(E-)-[2-(4-chloro-phenyl)-2-cyano-1-(2-trifluoromethylphenyl)-vinyl]}S-
-methyl thiocarbonate; (q)
(E)-N1-[(2-chloro-1,3-thiazol-5-ylmethyl)]-N2-cyano-N1-methylacetamidine;
(r)
1-(6-chloropyridin-3-ylmethyl)-7-methyl-8-nitro-1,2,3,5,6,7-hexahydro-
-imidazo[1,2-a]pyridin-5-ol; (s)
4-[4-chlorophenyl-(2-butylidine-hydrazono)methyl)]phenyl mesylate;
and (t)
N-Ethyl-2,2-dichloro-1-methylcyclopropanecarboxamide-2-(2,6-dichloro--
alpha,alpha,alpha-trifluoro-p-tolyl)hydrazone.
44. A composition according to claim 1 further comprising a
compound having one or more of the following modes of action:
acetylcholinesterase inhibitor; sodium channel modulator; chitin
biosynthesis inhibitor; GABA and glutamate-gated chloride channel
antagonist; GABA and glutamate-gated chloride channel agonist;
acetylcholine receptor agonist; acetylcholine receptor antagonist;
MET I inhibitor; Mg-stimulated ATPase inhibitor; nicotinic
acetylcholine receptor; Midgut membrane disrupter; oxidative
phosphorylation disrupter, and ryanodine receptor (RyRs).
45. A composition according to claim 1 further comprising a
seed.
46. A composition according to claim 1 further comprising a seed
that has been genetically modified to express one or more
specialized traits.
47. A composition according to claim 1 wherein said composition is
encapsulated inside, or placed on the surface of, a capsule.
48. A composition according to claim 1 wherein said composition is
encapsulated inside, or placed on the surface of, a capsule,
wherein said capsule has a diameter of about 100-900 nanometers or
about 10-900 microns.
49. A process comprising applying a composition according to claim
1, to an area to control a pest, in an amount sufficient to control
such pest.
50. A process according to claim 49 wherein said pest is selected
from beetles, earwigs, cockroaches, flies. aphids, scales,
whiteflies, leafhoppers, ants, wasps, termites, moths, butterflies,
lice, grasshoppers, locusts, crickets, fleas, thrips, bristletails,
mites, ticks, nematodes, and symphylans.
51. A process according to claim 49 wherein said pest is from the
Phyla Nematoda or Arthropoda.
52. A process according to claim 49 wherein said pest is from the
Subphyla Chelicerata, Myriapoda, or Hexapoda.
53. A process according to claim 49 wherein said pest is from the
Class of Arachnida, Symphyla, or Insecta.
54. A process according to claim 49 wherein said pest is from the
Order Anoplura, Order Coleoptera, Order Dermaptera, Order
Blattaria, Order Diptera, Order Hemiptera, Order Hymenoptera, Order
Isoptera, Order Lepidoptera, Order Mallophaga, Order Orthoptera,
Order Siphonaptera, Order Thysanoptera, Order Thysanura, Order
Acarina, or Order Symphyla.
55. A process according to claim 49 wherein said pest is MYZUPE or
BEMITA.
56. A process according to claim 49 wherein said amount is from
about 0.01 grams per hectare to about 5000 grams per hectare.
57. A process according to claim 49 wherein said amount is from
about 0.1 grams per hectare to about 500 grams per hectare.
58. A process according to claim 49 wherein said amount is from
about 1 gram per hectare to about 50 grams per hectare.
59. A process according to claim 49 wherein said area is an area
where apples, corn, cotton, soybeans, canola, wheat, rice, sorghum,
barley, oats, potatoes, oranges, alfalfa, lettuce, strawberries,
tomatoes, peppers, crucifers, pears, tobacco, almonds, sugar beets,
or beans, are growing, or the seeds thereof are going to be
planted.
60. A process according to claim 49 further comprising applying
said composition to a genetically modified plant that has been
genetically modified to express one or more specialized traits.
61. A process according to claim 49 where said composition further
comprise ammonium sulfate.
62. A process comprising: orally administering; or topically
applying; a composition according to claim 1, to a non-human
animal, to control endoparasites, ectoparasites, or both.
63. A process comprising applying a composition according to claim
1 to a plant to enhance the plant's health, yield, vigor, quality,
or tolerance, at a time when pest activity is low.
64. A process comprising reacting a compound of Formula 33.1 with a
compound of Formula 33.2 to produce a compound of Formula 33.3
wherein said R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6,
and R.sub.8 are as defined in claim 1 ##STR00279##
65. A process comprising reacting a compound of Formula XXX with a
compound of ##STR00280##
Description
CROSS REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. non-provisional
application Ser. No. 13/788,850, which was filed on Mar. 7, 2013,
which claims priority from, and benefit of, U.S. provisional
application Ser. No. 61/639,274, which was filed on Apr. 27, 2012.
The entire contents of these applications is hereby incorporated by
reference into this application.
FIELD OF THE DISCLOSURE
[0002] This disclosure is related to the field of processes to
produce molecules that are useful as pesticides (e.g., acaricides,
insecticides, molluscicides, and nematicides), such molecules, and
processes of using such molecules to control pests.
BACKGROUND
[0003] Pests cause millions of human deaths around the world each
year. Furthermore, there are more than ten thousand species of
pests that cause losses in agriculture. The world-wide agricultural
losses amount to billions of U.S. dollars each year.
[0004] Termites cause damage to all kinds of private and public
structures. The world-wide termite damage losses amount to billions
of U.S. dollars each year.
[0005] Stored food pests eat and adulterate stored food. The
world-wide stored food losses amount to billions of U.S. dollars
each year, but more importantly, deprive people of needed food.
[0006] There is an acute need for new pesticides. Certain pests are
developing resistance to pesticides in current use. Hundreds of
pest species are resistant to one or more pesticides. The
development of resistance to some of the older pesticides, such as
DDT, the carbamates, and the organophosphates, is well known. But
resistance has even developed to some of the newer pesticides.
[0007] Therefore, for many reasons, including the above reasons, a
need exists for new pesticides.
DEFINITIONS
[0008] The examples given in the definitions are generally
non-exhaustive and must not be construed as limiting the invention
disclosed in this document. It is understood that a substituent
should comply with chemical bonding rules and steric compatibility
constraints in relation to the particular molecule to which it is
attached.
[0009] "Alkenyl" means an acyclic, unsaturated (at least one
carbon-carbon double bond), branched or unbranched, substituent
consisting of carbon and hydrogen, for example, vinyl, allyl,
butenyl, pentenyl, and hexenyl.
[0010] "Alkenyloxy" means an alkenyl further consisting of a
carbon-oxygen single bond, for example, allyloxy, butenyloxy,
pentenyloxy, hexenyloxy.
[0011] "Alkoxy" means an alkyl further consisting of a
carbon-oxygen single bond, for example, methoxy, ethoxy, propoxy,
isopropoxy, butoxy, isobutoxy, and tert-butoxy.
[0012] "Alkyl" means an acyclic, saturated, branched or unbranched,
substituent consisting of carbon and hydrogen, for example, methyl,
ethyl, (C.sub.3)alkyl which represents n-propyl and isopropyl),
(C.sub.4)alkyl which represents n-butyl, sec-butyl, isobutyl, and
tert-butyl.
[0013] "Alkynyl" means an acyclic, unsaturated (at least one
carbon-carbon triple bond), branched or unbranched, substituent
consisting of carbon and hydrogen, for example, ethynyl, propargyl,
butynyl, and pentynyl.
[0014] "Alkynyloxy" means an alkynyl further consisting of a
carbon-oxygen single bond, for example, pentynyloxy, hexynyloxy,
heptynyloxy, and octynyloxy.
[0015] "Aryl" means a cyclic, aromatic substituent consisting of
hydrogen and carbon, for example, phenyl, naphthyl, and
biphenyl.
[0016] "(C.sub.x-C.sub.y)" where the subscripts "x" and "y" are
integers such as 1, 2, or 3, means the range of carbon atoms for a
substituent--for example, (C.sub.1-C.sub.4)alkyl means methyl,
ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and
tert-butyl, each individually.
[0017] "Cycloalkenyl" means a monocyclic or polycyclic, unsaturated
(at least one carbon-carbon double bond) substituent consisting of
carbon and hydrogen, for example, cyclobutenyl, cyclopentenyl,
cyclohexenyl, norbornenyl, bicyclo[2.2.2]octenyl,
tetrahydronaphthyl, hexahydronaphthyl, and octahydronaphthyl.
[0018] "Cycloalkenyloxy" means a cycloalkenyl further consisting of
a carbon-oxygen single bond, for example, cyclobutenyloxy,
cyclopentenyloxy, norbornenyloxy, and bicyclo[2.2.2]octenyloxy.
[0019] "Cycloalkyl" means a monocyclic or polycyclic, saturated
substituent consisting of carbon and hydrogen, for example,
cyclopropyl, cyclobutyl, cyclopentyl, norbornyl,
bicyclo[2.2.2]octyl, and decahydronaphthyl.
[0020] "Cycloalkoxy" means a cycloalkyl further consisting of a
carbon-oxygen single bond, for example, cyclopropyloxy,
cyclobutyloxy, cyclopentyloxy, norbornyloxy, and
bicyclo[2.2.2]octyloxy.
[0021] "Halo" means fluoro, chloro, bromo, and iodo.
[0022] "Haloalkoxy" means an alkoxy further consisting of, from one
to the maximum possible number of identical or different, halos,
for example, fluoromethoxy, trifluoromethoxy, 2,2-difluoropropoxy,
chloromethoxy, trichloromethoxy, 1,1,2,2-tetrafluoroethoxy, and
pentafluoroethoxy.
[0023] "Haloalkyl" means an alkyl further consisting of, from one
to the maximum possible number of, identical or different, halos,
for example, fluoromethyl, trifluoromethyl, 2,2-difluoropropyl,
chloromethyl, trichloromethyl, and 1,1,2,2-tetrafluoroethyl.
[0024] "Heterocyclyl" means a cyclic substituent that may be fully
saturated, partially unsaturated, or fully unsaturated, where the
cyclic structure contains at least one carbon and at least one
heteroatom, where said heteroatom is nitrogen, sulfur, or oxygen.
In the case of sulfur, that atom can be in other oxidation states
such as a sulfoxide and sulfone. Examples of aromatic heterocyclyls
include, but are not limited to, benzofuranyl, benzoisothiazolyl,
benzoisoxazolyl, benzoxazolyl, benzothienyl, benzothiazolyl,
cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoindolyl,
isoquinolinyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolinyl,
oxazolyl, phthalazinyl, pyrazinyl, pyrazolinyl, pyrazolyl,
pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl,
quinolinyl, quinoxalinyl, tetrazolyl, thiazolinyl, thiazolyl,
thienyl, triazinyl, and triazolyl. Examples of fully saturated
heterocyclyls include, but are not limited to, piperazinyl,
piperidinyl, morpholinyl, pyrrolidinyl, oxetanyl,
tetrahydrofuranyl, tetrahydrothienyl and tetrahydropyranyl.
Examples of partially unsaturated heterocyclyls include, but are
not limited to, 1,2,3,4-tetrahydroquinolinyl, 4,5-dihydro-oxazolyl,
4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-isoxazolyl, and
2,3-dihydro-[1,3,4]-oxadiazolyl. Additional examples include the
following
##STR00002##
DETAILED DESCRIPTION
[0025] This document discloses molecules having the following
formula ("Formula One"):
##STR00003##
[0026] wherein
[0027] (a) A is either
##STR00004##
[0028] (b) R1 is H, F, Cl, Br, I, CN, NO.sub.2, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, S(O).sub.nR9,
S(O).sub.nOR9, S(O).sub.nN(R9).sub.2, or R9S(O).sub.nR9, [0029]
wherein each said R1, which is substituted, has one or more
substituents selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OR9,
S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9);
[0030] (c) R2 is H, F, Cl, Br, I, CN, NO.sub.2, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
or R9S(O).sub.nR9, [0031] wherein each said R2, which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9);
[0032] (d) R3 is H, F, Cl, Br, I, CN, NO.sub.2, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
or R9S(O).sub.nR9, [0033] wherein each said R3, which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9);
[0034] (e) when A is [0035] (1) A1 then A1 is either [0036] (a)
A11
[0036] ##STR00005## [0037] where R4 is H, NO.sub.2, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, S(O).sub.nOR9, or
R9S(O).sub.nR9, [0038] wherein each said R4, which is substituted,
has one or more substituents selected from F, Cl, Br, I, CN,
NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9), or [0039] (b) A12
[0039] ##STR00006## [0040] where R4 is a C.sub.1-C.sub.6 alkyl,
[0041] (2) A2 then R4 is H, F, Cl, Br, I, CN, NO.sub.2, substituted
or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
or R9S(O).sub.nR9, [0042] wherein each said R4, which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9);
[0043] (f) R5 is H, F, Cl, Br, I, CN, NO.sub.2, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, OR9, C(=X1)R9, C(=X1)OR9, C(=X1)N(R9).sub.2,
N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9, or R9S(O).sub.nR9,
[0044] wherein each said R5, which is substituted, has one or more
substituents selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OR9,
S(O).sub.nOR9, or C.sub.6-C.sub.20 aryl, (each of which that can be
substituted, may optionally be substituted with R9);
[0045] (g) [0046] (1) when A is A1 then R6 is R11, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
R9S(O).sub.nR9, C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.20 aryl
(wherein the alkyl and aryl can independently be substituted or
unsubstituted), C(=X2)R9, C(=X1)X2R9, R9X2C(=X1)R9, R9X2R9,
C(.dbd.O)(C.sub.1-C.sub.6 alkyl)S(O).sub.n(C.sub.1-C.sub.6 alkyl),
C(.dbd.O)(C.sub.1-C.sub.6 alkyl)C(.dbd.O)O(C.sub.1-C.sub.6 alkyl),
(C.sub.1-C.sub.6 alkyl)OC(.dbd.O)(C.sub.6-C.sub.20 aryl),
(C.sub.1-C.sub.6 alkyl)OC(.dbd.O)(C.sub.1-C.sub.6 alkyl),
C.sub.1-C.sub.6 alkyl-(C.sub.3-C.sub.10 cyclohaloalkyl), or
(C.sub.1-C.sub.6 alkenyl)C(.dbd.O)O(C.sub.1-C.sub.6 alkyl), or
R9X2C(=X1)X2R9, [0047] wherein each said R6 (except R11), which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, R9aryl, (each of which that can be substituted, may
optionally be substituted with R9), [0048] optionally R6 (except
R11) and R8 can be connected in a cyclic arrangement, where
optionally such arrangement can have one or more heteroatoms
selected from O, S, or, N, in the cyclic structure connecting R6
and R8, and [0049] (2) when A is A2 then R6 is R11, H, substituted
or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nOR9,
R9S(O).sub.nR9, C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.20 aryl
(wherein the alkyl and aryl can independently be substituted or
unsubstituted), C(=X2)R9, C(=X1)X2R9, R9X2C(=X1)R9, R9X2R9,
C(.dbd.O)(C.sub.1-C.sub.6 alkyl)S(O).sub.n(C.sub.1-C.sub.6 alkyl),
C(.dbd.O)(C.sub.1-C.sub.6 alkyl)C(.dbd.O)O(C.sub.1-C.sub.6 alkyl),
(C.sub.1-C.sub.6 alkyl)OC(.dbd.O)(C.sub.6-C.sub.20 aryl),
(C.sub.1-C.sub.6 alkyl)OC(.dbd.O)(C.sub.1-C.sub.6 alkyl),
C.sub.1-C.sub.6 alkyl-(C.sub.3-C.sub.10 cyclohaloalkyl), or
(C.sub.1-C.sub.6 alkenyl)C(.dbd.O)O(C.sub.1-C.sub.6 alkyl), or
R9X2C(=X1)X2R9, [0050] wherein each said R6 (except R11), which is
substituted, has one or more substituents selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, R9aryl, (each of which that can be substituted, may
optionally be substituted with R9), [0051] optionally R6 (except
R11) and R8 can be connected in a cyclic arrangement, where
optionally such arrangement can have one or more heteroatoms
selected from O, S, or N, in the cyclic structure connecting R6 and
R8;
[0052] (h) R7 is O, S, NR9, or NOR9;
[0053] (i) R8 is substituted or unsubstituted C.sub.1-C.sub.6
alkyl, substituted or unsubstituted C.sub.2-C.sub.6 alkenyl,
substituted or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, OR9S(O).sub.nR9, C(=X1)R9,
C(=X1)OR9, R9C(=X1)OR9, R9X2C(=X1)R9X2R9, C(=X1)N(R9).sub.2,
N(R9).sub.2, N(R9)(R9S(O).sub.nR9), N(R9)C(=X1)R9, SR9,
S(O).sub.nOR9, R9S(O).sub.nR9, or R9S(O).sub.n(NZ)R9, [0054]
wherein each said R8, which is substituted, has one or more
substituents selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
N(R9)S(O).sub.nR9, oxo, OR9, S(O).sub.nOR9, R9S(O).sub.nR9,
S(O).sub.nR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9) [0055] alternatively R8 is
R13-S(O).sub.n--R13 wherein each R13 is independently selected from
substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, substituted or unsubstituted
S(O).sub.nC.sub.1-C.sub.6 alkyl, substituted or unsubstituted
N(C.sub.1-C.sub.6alkyl).sub.2, wherein each said substituted alkyl,
substituted alkenyl, substituted alkoxy, substituted alkenyloxy,
substituted cycloalkyl, substituted cycloalkenyl, substituted aryl,
substituted heterocyclyl, has one or more substituents
independently selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OC.sub.1-C.sub.6
alkyl, OC.sub.1-C.sub.6 haloalkyl, S(O).sub.nC.sub.1-C.sub.6alkyl,
S(O).sub.nOC.sub.1-C.sub.6 alkyl, C.sub.6-C.sub.20 aryl, or
C.sub.1-C.sub.20 heterocyclyl, C.sub.2-C.sub.6 alkynyl,
C.sub.1-C.sub.6 alkoxy, N(R9)S(O).sub.nR9, OR9, N(R9).sub.2, R9OR9,
R9N(R9).sub.2, R9C(=X1)R9, R9C(=X1)N(R9).sub.2, N(R9)C(=X1)R9,
R9N(R9)C(=X1)R9, S(O).sub.nOR9, R9C(=X1)OR9, R9OC(=X1)R9,
R9S(O).sub.nR9, S(O).sub.nR9, oxo, (each of which that can be
substituted, may optionally be substituted with R9);
[0056] (j) R9 is (each independently) H, CN, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.1-C.sub.6 alkoxy, substituted or unsubstituted
C.sub.2-C.sub.6 alkenyloxy, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkenyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, substituted or unsubstituted
S(O).sub.nC.sub.1-C.sub.6 alkyl, substituted or unsubstituted
N(C.sub.1-C.sub.6alkyl).sub.2, [0057] wherein each said R9, which
is substituted, has one or more substituents selected from F, Cl,
Br, I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OC.sub.1-C.sub.6 alkyl, OC.sub.1-C.sub.6 haloalkyl,
S(O).sub.nC.sub.1-C.sub.6alkyl, S(O).sub.nOC.sub.1-C.sub.6 alkyl,
C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20 heterocyclyl;
[0058] (k) n is 0, 1, or 2;
[0059] (l) X is N or CR.sub.n1 where R.sub.n1 is H, F, Cl, Br, I,
CN, NO.sub.2, substituted or unsubstituted C.sub.1-C.sub.6 alkyl,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyl, substituted
or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, OR9, C(=X1)R9, C(=X1)OR9,
C(=X1)N(R9).sub.2, N(R9).sub.2, N(R9)C(=X1)R9, SR9, S(O).sub.nR9,
S(O).sub.nOR9, or R9S(O).sub.nR9, [0060] wherein each said R.sub.n1
which is substituted, has one or more substituents selected from F,
Cl, Br, I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OR9, S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, (each of which that can be substituted, may
optionally be substituted with R9);
[0061] (m) X1 is (each independently) O or S;
[0062] (n) X2 is (each independently) O, S, =NR9, or =NOR9;
[0063] (o) Z is CN, NO.sub.2, C.sub.1-C.sub.6 alkyl(R9),
C(=X1)N(R9).sub.2;
[0064] (p) R11 is Q.sub.1(C.ident.C)R12, wherein Q.sub.1 is a bond,
substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.2-C.sub.6 alkynyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.2-C.sub.10 cycloalkoxy, substituted or unsubstituted
C.sub.1-C.sub.6 alkylOR9, substituted or unsubstituted
C.sub.1-C.sub.6 alkylS(O).sub.nR9, substituted or unsubstituted
C.sub.1-C.sub.6 alkylS(O).sub.n(=NR9), substituted or unsubstituted
C.sub.1-C.sub.6 alkylN(R9) (where (C.ident.C) is attached directly
to the N by a bond), substituted or unsubstituted C.sub.1-C.sub.6
alkylN(R9).sub.2, substituted or unsubstituted C.sub.2-C.sub.6
alkenyloxy, substituted or unsubstituted C.sub.3-C.sub.10
cycloalkenyl, substituted or unsubstituted C.sub.0-C.sub.6
alkylC(=R7)C.sub.0-C.sub.6 alkylR9, substituted or unsubstituted
C.sub.0-C.sub.6 alkylC(=R7)OR9, substituted or unsubstituted
C.sub.1-C.sub.6 alkylOC.sub.0-C.sub.6 alkylC(=R7)R9, substituted or
unsubstituted C.sub.1-C.sub.6 alkylN(R9)(C(=R7)R9), substituted or
unsubstituted C.sub.1-C.sub.6 alkylN(R9)(C(=R7)OR9), substituted or
unsubstituted C.sub.0-C.sub.6 alkyl C(=R7)C.sub.0-C.sub.6
alkylN(R9) (where (C.ident.C) is attached directly to the N by a
bond), substituted or unsubstituted
C.sub.0-C.sub.6alkylC(=R7)C.sub.0-C.sub.6 alkylN(R9).sub.2, OR9,
S(O).sub.nR9, N(R9)R9, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, [0065] wherein each said Q.sub.1,
which is substituted, has one or more substituents selected from F,
Cl, Br, I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6 haloalkyloxy,
C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10 cycloalkyl,
C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10 halocycloalkyl,
C.sub.3-C.sub.10 halocycloalkenyl, OR9, SR9, S(O).sub.nR9,
S(O).sub.nOR9, C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20
heterocyclyl, R9aryl, C.sub.1-C.sub.6alkylOR9,
C.sub.1-C.sub.6alkylS(O).sub.nR9, (each of which that can be
substituted, may optionally be substituted with R9) [0066]
optionally Q.sub.1 and R8 can be connected in a cyclic arrangement,
where optionally such arrangement can have one or more heteroatoms
selected from O, S, or N, in the cyclic structure connecting
Q.sub.1 and R8;
[0067] (q) R12 is Q.sub.1 (except where Q.sub.1 is a bond), F, Cl,
Br, I, Si(R9).sub.3 (where each R9 is independently selected), or
R9; and
[0068] (r) with the following provisos [0069] (1) that R6 and R8
cannot both be C(.dbd.O)CH.sub.3, [0070] (2) that when A1 is A11
then R6 and R8 together do not form fused ring systems, [0071] (3)
that R6 and R8 are not linked in a cyclic arrangement with only
--CH.sub.2--, [0072] (4) that when A is A2 then R5 is not
C(.dbd.O)OH, [0073] (5) that when A is A2 and R6 is H then R8 is
not a --(C.sub.1-C.sub.6 alkyl)-O--(substituted aryl), and [0074]
(6) that when A is A2 then R6 is not --(C.sub.1alkyl)(substituted
aryl).
[0075] In another embodiment of this invention A is A1.
[0076] In another embodiment of this invention A is A2.
[0077] In another embodiment of this invention R1 is H.
[0078] In another embodiment of this invention R2 is H.
[0079] In another embodiment of this invention R3 is selected from
H, or substituted or unsubstituted C.sub.1-C.sub.6 alkyl.
[0080] In another embodiment of this invention R3 is selected from
H or CH.sub.3.
[0081] In another embodiment of the invention when A is A1 then A1
is A11.
[0082] In another embodiment of the invention when A is A1, and A1
is A11, then R4 is selected from H, or substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, or substituted or unsubstituted
C.sub.6-C.sub.20 aryl.
[0083] In another embodiment of the invention when A is A1, and A1
is A11 then R4 is selected from CH.sub.3, CH(CH.sub.3).sub.2, or
phenyl.
[0084] In another embodiment of the invention when A is A1, and A1
is A12, then R4 is CH.sub.3.
[0085] In another embodiment of this invention when A is A2 then R4
is selected from H, or substituted or unsubstituted C.sub.1-C.sub.6
alkyl, substituted or unsubstituted C.sub.2-C.sub.6 alkenyl,
substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl,
substituted or unsubstituted C.sub.6-C.sub.20 aryl, wherein each
said R4, which is substituted, has one or more substituents
selected from F, Cl, Br, or I.
[0086] In another embodiment of this invention when A is A2 then R4
is H or C.sub.1-C.sub.6 alkyl.
[0087] In another embodiment of this invention when A is A2 then R4
is H, CH.sub.3, CH.sub.2CH.sub.3, CH.dbd.CH.sub.2, cyclopropyl,
CH.sub.2Cl, CF.sub.3, or phenyl.
[0088] In another embodiment of this invention when A is A2 then R4
is Br or Cl.
[0089] In another embodiment of this invention R5 is H, F, Cl, Br,
I, or substituted or unsubstituted C.sub.1-C.sub.6 alkyl,
substituted or unsubstituted C.sub.1-C.sub.6 alkoxy.
[0090] In another embodiment of this invention R5 is H,
OCH.sub.2CH.sub.3, F, Cl, Br, or CH.sub.3.
[0091] In another embodiment of this invention, when A is A1 then
R6 is substituted or unsubstituted C.sub.1-C.sub.6 alkyl.
[0092] In another embodiment of this invention when A is A2 then R6
is selected from is substituted or unsubstituted C.sub.1-C.sub.6
alkyl, substituted or unsubstituted C.sub.2-C.sub.6 alkenyl,
substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl, C(=X1)R9,
C(=X1)X2R9, R9X2R9, C(.dbd.O)(C.sub.1-C.sub.6
alkyl)S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.6
alkyl)OC(.dbd.O)(C.sub.6-C.sub.20 aryl), (C.sub.1-C.sub.6
alkyl)OC(.dbd.O)(C.sub.1-C.sub.6 alkyl), or R9X2C(=X1)X2R9.
[0093] In another embodiment of this invention when A is A2 then R6
and R8 are connected in a cyclic arrangement, where optionally such
arrangement can have one or more heteroatoms selected from O, S,
or, N, in the cyclic structure connecting R6 and R8.
[0094] In another embodiment of this invention R6 is
C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 alkyl-phenyl.
[0095] In another embodiment of this invention R6 is H, CH.sub.3,
CH.sub.2CH.sub.3, CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2,
CH.sub.2phenyl, CH.sub.2CH(CH.sub.3).sub.2, CH.sub.2cyclopropyl,
C(.dbd.O)CH.sub.2CH.sub.2SCH.sub.3, C(.dbd.O)OC(CH.sub.3).sub.3,
CH.sub.2CH.dbd.CH.sub.2, C(.dbd.O)OCH.sub.2CH.sub.3,
C(.dbd.O)CH(CH.sub.3)CH.sub.2SCH.sub.3, cyclopropyl, CD.sub.3,
CH.sub.2OC(.dbd.O)phenyl, C(.dbd.O)CH.sub.3,
C(.dbd.O)CH(CH.sub.3).sub.2, CH.sub.2OC(.dbd.O)CH(CH.sub.3).sub.2,
CH.sub.2OC(.dbd.O)CH.sub.3, C(.dbd.O)phenyl, CH.sub.2OCH.sub.3,
CH.sub.2OC(.dbd.O)CH.sub.2OCH.sub.2CH.sub.3,
CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2OC(.dbd.O)OCH(CH.sub.3).sub.2,
CH.sub.2CH.sub.2OCH.sub.2OCH.sub.3, CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OC(.dbd.O)CH.sub.3, CH.sub.2CN.
[0096] In another embodiment of this invention R6 is methyl or
ethyl.
[0097] In another embodiment of this invention R7 is O or S.
[0098] In another embodiment of this invention R8 is selected from
substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted
C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, R9C(=X1)OR9, SR9, S(O).sub.nOR9,
R9S(O).sub.nR9, or R9S(O).sub.n(NZ)R9.
[0099] In another embodiment of this invention R8 is
CH(CH.sub.3)CH.sub.2SCH.sub.3, CH(CH.sub.3).sub.2,
C(CH.sub.3).sub.2CH.sub.2SCH.sub.3, CH.sub.2CH.sub.2SCH.sub.3,
CH.sub.2CF.sub.3, CH.sub.2CH.sub.2C(.dbd.O)OCH.sub.3,
N(H)(CH.sub.2CH.sub.2SCH.sub.3), OCH.sub.2CH.sub.2SCH.sub.3,
CH(CH.sub.2SCH.sub.3)(CH.sub.2phenyl), thiazolyl, oxazolyl,
isothiazolyl, substituted-furanyl, CH.sub.3, C(CH.sub.3).sub.3,
phenyl, CH.sub.2CH.sub.2OCH.sub.3, pyridyl,
CH.sub.2CH(CH.sub.3)SCH.sub.3, OC(CH.sub.3).sub.3,
C(CH.sub.3).sub.2CH.sub.2SCH.sub.3,
CH(CH.sub.3)CH(CH.sub.3)SCH.sub.3, CH(CH.sub.3)CF.sub.3,
CH.sub.2CH.sub.2-thienyl, CH(CH.sub.3)SCF.sub.3,
CH.sub.2CH.sub.2Cl, CH.sub.2CH.sub.2CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2S(.dbd.O)CH.sub.3,
CH(CH.sub.3)CH.sub.2S(.dbd.O)CH.sub.3,
CH.sub.2CH.sub.2S(.dbd.O).sub.2CH.sub.3,
CH(CH.sub.3)CH.sub.2S(.dbd.O).sub.2CH.sub.3, NCH.sub.2CH.sub.3,
N(H)(CH.sub.2CH.sub.2CH.sub.3), C(CH.sub.3).dbd.C(H)(CH.sub.3),
N(H)(CH.sub.2CH.dbd.CH.sub.2), CH.sub.2CH(CF.sub.3)SCH.sub.3,
CH(CF.sub.3)CH.sub.2SCH.sub.3, thietanyl,
CH.sub.2CH(CF.sub.3).sub.2, CH.sub.2CH.sub.2CF(OCF.sub.3)CF.sub.3,
CH.sub.2CH.sub.2CF(CF.sub.3)CF.sub.3, CF(CH.sub.3).sub.2,
CH(CH.sub.3)phenyl-Cl, CH(CH.sub.3)phenyl-F,
CH(CH.sub.3)phenyl-OCF.sub.3,
CH.sub.2N(CH.sub.3)(S(.dbd.O).sub.2N(CH.sub.3).sub.2,
CH(CH.sub.3)OCH.sub.2CH.sub.2SCH.sub.3,
CH(CH.sub.3)OCH.sub.2CH.sub.2OCH.sub.3, OCH.sub.3,
CH(CH.sub.3)SCH.sub.3, CH.sub.2SCH.sub.3, N(H)CH.sub.3,
CH(Br)CH.sub.2Br, or CH(CH.sub.3)CH.sub.2SCD.sub.3.
[0100] In another more preferred embodiment of this invention R8 is
preferably R13-S(O).sub.n--R13 wherein each R13 is independently
selected from substituted or unsubstituted C.sub.1-C.sub.6 alkyl,
substituted or unsubstituted C.sub.2-C.sub.6 alkenyl, substituted
or unsubstituted C.sub.1-C.sub.6 alkoxy, substituted or
unsubstituted C.sub.2-C.sub.6 alkenyloxy, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkenyl, substituted or
unsubstituted C.sub.6-C.sub.20 aryl, substituted or unsubstituted
C.sub.1-C.sub.20 heterocyclyl, substituted or unsubstituted
S(O).sub.nC.sub.1-C.sub.6 alkyl, substituted or unsubstituted
N(C.sub.1-C.sub.6alkyl).sub.2, wherein each said substituted alkyl,
substituted alkenyl, substituted alkoxy, substituted alkenyloxy,
substituted cycloalkyl, substituted cycloalkenyl, substituted aryl,
substituted heterocyclyl, has one or more substituents
independently selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OC.sub.1-C.sub.6
alkyl, OC.sub.1-C.sub.6 haloalkyl, S(O).sub.nC.sub.1-C.sub.6alkyl,
S(O).sub.nOC.sub.1-C.sub.6 alkyl, C.sub.6-C.sub.20 aryl, or
C.sub.1-C.sub.20 heterocyclyl, C.sub.2-C.sub.6 alkynyl,
C.sub.1-C.sub.6 alkoxy, N(R9)S(O).sub.nR9, OR9, N(R9).sub.2, R9OR9,
R9N(R9).sub.2, R9C(=X1)R9, R9C(=X1)N(R9).sub.2, N(R9)C(=X1)R9,
R9N(R9)C(=X1)R9, S(O).sub.nOR9, R9C(=X1)OR9, R9OC(=X1)R9,
R9S(O).sub.nR9, S(O).sub.nR9, oxo, (each of which that can be
substituted, may optionally be substituted with R9).
[0101] In another embodiment of this invention R8 is (substituted
or unsubstituted C.sub.1-C.sub.6 alkyl)-S(O).sub.n-(substituted or
unsubstituted C.sub.1-C.sub.6 alkyl) wherein said substituents on
said substituted alkyls are independently selected from F, Cl, Br,
I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 haloalkenyl,
C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy,
C.sub.3-C.sub.10cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl,
C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl,
OC.sub.1-C.sub.6 alkyl, OC.sub.1-C.sub.6 haloalkyl,
S(O).sub.nC.sub.1-C.sub.6alkyl, S(O).sub.nOC.sub.1-C.sub.6 alkyl,
C.sub.6-C.sub.20 aryl, or C.sub.1-C.sub.20 heterocyclyl,
C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 alkoxy, N(R9)S(O).sub.nR9,
OR9, N(R9).sub.2, R9OR9, R9N(R9).sub.2, R9C(=X1)R9,
R9C(=X1)N(R9).sub.2, N(R9)C(=X1)R9, R9N(R9)C(=X1)R9, S(O).sub.nOR9,
R9C(=X1)OR9, R9OC(=X1)R9, R9S(O).sub.nR9, S(O).sub.nR9, oxo, (each
of which that can be substituted, may optionally be substituted
with R9).
[0102] In another embodiment of this invention R8 is selected from
CH(CH.sub.3)SCH.sub.2CF.sub.3, CH.sub.2CH.sub.2SCH.sub.2CF.sub.3,
CH.sub.2SCH.sub.2CF.sub.3, CH.sub.2SCHClCF.sub.3,
CH(CH.sub.2CH.sub.3)SCH.sub.2CF.sub.3,
CH(CH.sub.3)SCH.sub.2CHF.sub.2, CH(CH.sub.3)SCH.sub.2CH.sub.2F,
CH.sub.2CH.sub.2SCH.sub.2CH.sub.2F,
CH(CH.sub.3)S(.dbd.O).sub.2CH.sub.2CF.sub.3,
CH(CH.sub.3)S(.dbd.O)CH.sub.2CF.sub.3,
CH(CH.sub.3)CH.sub.2SCF.sub.3, CH(CH.sub.3)CH.sub.2SCF.sub.3,
CH(CH.sub.3)SCH.sub.2CH.sub.2CF.sub.3, and
CH.sub.2CH.sub.2SCH.sub.2CH.sub.2CF.sub.3.
[0103] In another embodiment of this invention R8 is (substituted
or unsubstituted C.sub.1-C.sub.6 alkyl)-S(O).sub.n-(substituted or
unsubstituted C.sub.1-C.sub.6 alkyl)-(substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl) wherein said substituents on said
substituted alkyls and said substituted cycloalkyls are
independently selected from F, Cl, Br, I, CN, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6
haloalkyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6
haloalkyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.3-C.sub.10
cycloalkyl, C.sub.3-C.sub.10 cycloalkenyl, C.sub.3-C.sub.10
halocycloalkyl, C.sub.3-C.sub.10 halocycloalkenyl, OC.sub.1-C.sub.6
alkyl, OC.sub.1-C.sub.6 haloalkyl, S(O).sub.nC.sub.1-C.sub.6alkyl,
S(O).sub.nOC.sub.1-C.sub.6 alkyl, C.sub.6-C.sub.20 aryl, or
C.sub.1-C.sub.20 heterocyclyl, C.sub.2-C.sub.6 alkynyl,
C.sub.1-C.sub.6 alkoxy, N(R9)S(O).sub.nR9, OR9, N(R9).sub.2, R9OR9,
R9N(R9).sub.2, R9C(=X1)R9, R9C(=X1)N(R9).sub.2, N(R9)C(=X1)R9,
R9N(R9)C(=X1)R9, S(O).sub.nOR9, R9C(=X1)OR9, R9OC(=X1)R9,
R9S(O).sub.nR9, S(O).sub.nR9, oxo, (each of which that can be
substituted, may optionally be substituted with R9).
[0104] In another embodiment of this invention R8 is selected from
CH(CH.sub.3)CH.sub.2SCH.sub.2(2,2 difluorocyclopropyl),
CH.sub.2CH.sub.2SCH.sub.2(2,2 difluorocyclopropyl),
CH.sub.2CH.sub.2S(.dbd.O)CH.sub.2(2,2 difluorocyclopropyl),
CH.sub.2CH.sub.2S(.dbd.O).sub.2 CH.sub.2CH.sub.2(2,2
difluorocyclopropyl), and CH.sub.2CH(CF.sub.3)SCH.sub.2(2,2
difluorocyclopropyl).
[0105] In another embodiment of this invention R8 is (substituted
or unsubstituted C.sub.1-C.sub.6 alkyl)-S(O).sub.n-(substituted or
unsubstituted C.sub.2-C.sub.6 alkenyl) wherein said substituents on
said substituted alkyls and substituted alkenyls are independently
selected from F, Cl, Br, I, CN, NO.sub.2, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6
haloalkenyl, C.sub.1-C.sub.6 haloalkyloxy, C.sub.2-C.sub.6
haloalkenyloxy, C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10
cycloalkenyl, C.sub.3-C.sub.10 halocycloalkyl, C.sub.3-C.sub.10
halocycloalkenyl, OC.sub.1-C.sub.6 alkyl, OC.sub.1-C.sub.6
haloalkyl, S(O).sub.nC.sub.1-C.sub.6alkyl,
S(O).sub.nOC.sub.1-C.sub.6 alkyl, C.sub.6-C.sub.20 aryl, or
C.sub.1-C.sub.20 heterocyclyl, C.sub.2-C.sub.6 alkynyl,
C.sub.1-C.sub.6 alkoxy, N(R9)S(O).sub.nR9, OR9, N(R9).sub.2, R9OR9,
R9N(R9).sub.2, R9C(=X1)R9, R9C(=X1)N(R9).sub.2, N(R9)C(=X1)R9,
R9N(R9)C(=X1)R9, S(O).sub.nOR9, R9C(=X1)OR9, R9OC(=X1)R9,
R9S(O).sub.nR9, S(O).sub.nR9, oxo, (each of which that can be
substituted, may optionally be substituted with R9).
[0106] In another embodiment of this invention R8 is selected from
CH.sub.2CH.sub.2SCH.sub.2CH.dbd.CCl.sub.2, CH2SCH2CH.dbd.CCl.sub.2,
CH(CH3)SCH2CH.dbd.CCl.sub.2, CH(CH3)SCH.dbd.CHF,
CH.sub.2CH.sub.2S(.dbd.O)CH.sub.2CH.sub.2CF.sub.3, and
CH.sub.2CH.sub.2S(.dbd.O).sub.2CH.sub.2CH.sub.2CF.sub.3.
[0107] In another embodiment of this invention X is CR.sub.n1 where
R.sub.n1 is H or halo.
[0108] In another embodiment of this invention X is CR.sub.n1 where
R.sub.n1 is H or F.
[0109] In another embodiment of this invention X1 is O.
[0110] In another embodiment of this invention X2 is O.
[0111] In another embodiment of this invention R11 is substituted
or unsubstituted C.sub.1-C.sub.6 alkylC.ident.CR12.
[0112] In another embodiment of this invention R11 is
CH.sub.2C.ident.CH.
[0113] The molecules of Formula One will generally have a molecular
mass of about 100 Daltons to about 1200 Daltons. However, it is
generally preferred if the molecular mass is from about 120 Daltons
to about 900 Daltons, and it is even more generally preferred if
the molecular mass is from about 140 Daltons to about 600
Daltons.
[0114] The following schemes illustrate approaches to generating
aminopyrazoles. In step a of Scheme I, treatment of a
3-acetopyridine or a 5-acetopyrimidine of Formula II, wherein R1,
R2, R3 and X are as previously defined, with carbon disulfide and
iodomethane in the presence of a base such as sodium hydride and in
a solvent such as dimethyl sulfoxide provides the compound of
Formula III. In step b of Scheme I, the compound of Formula III can
be treated with an amine or amine hydrochloride, in the presence of
a base, such as triethylamine, in a solvent such as ethyl alcohol
to afford the compound of Formula IV, wherein R1, R2, R3, R6 and X
are as previously defined. The compound of Formula IV can be
transformed into the aminopyrazole of Formula Va where R5=H as in
step c of Scheme I and as in Peruncheralathan, S. et al. J. Org.
Chem. 2005, 70, 9644-9647, by reaction with a hydrazine, such as
methylhydrazine, in a polar protic solvent such as ethyl
alcohol.
##STR00007##
[0115] Another approach to aminopyrazoles is illustrated in Scheme
II. In step a, the nitrile of Formula VI wherein X, R1, R2 and R3
are as previously defined and R5 is hydrogen, is condensed as in
Dhananjay, B. Kendre et al. J. Het Chem 2008, 45, (5), 1281-86 with
hydrazine of Formula VII, such as methylhydrazine to give a mixture
of aminopyrazoles of Formula Vb, wherein R5 and R6=H, both of whose
components were isolated.
##STR00008##
[0116] Preparation of aminopyrazoles such as those of Formula XIIa
is demonstrated in Scheme III. The compound of Formula X in step a
and as in Cristau, Henri-Jean et al. Eur. J. Org. Chem. 2004,
695-709 can be prepared through the N-arylation of a pyrazole of
Formula IX with an appropriate aryl halide of Formula VIIIa where Q
is bromo in the presence of a base such as cesium carbonate, a
copper catalyst such as copper (II) oxide and a ligand such as
salicylaldoxime in a polar aprotic solvent such as acetonitrile.
Compounds of Formula IX, as shown in Scheme III, wherein R4=Cl and
R5=H, can be prepared as in Pelcman, B. et al WO 2007/045868 A1.
Nitration of the pyridylpyrazole of Formula X as in step b of
Scheme III and as in Khan, Misbanul Ain et al. J. Heterocyclic
Chem. 1981, 18, 9-14 by reaction with nitric acid and sulfuric acid
gave compounds of Formula XIa. Reduction of the nitro functionality
of compounds of Formula XIa in the presence of hydrogen with a
catalyst such as 5% Pd/C in a polar aprotic solvent such as
tetrahydrofuran gave the amine of Formula XIIa, as shown in step c
in Scheme III. Reduction of the nitro functionality of compounds of
Formula XIa, wherein R1, R2, R3, R4 and X are as previously defined
and R5=H, in the presence of hydrogen with a catalyst such as 10%
Pd/C in a polar protic solvent such as ethanol gave the amine of
Formula XIIa, wherein R5=H, as well as the amine of Formula XIIa,
wherein R5=OEt, as shown in step d of Scheme III. Compounds of
Formula XIa, wherein R1, R2, R3, R5 and X are as previously defined
and R4=Cl, can be reduced in the presence of a reducing agent such
as iron in a mixture of polar protic solvents such as acetic acid,
water, and ethanol to give amines of Formula XIIa, wherein R1, R2,
R3, R5 and X are as previously defined R4=Cl, as shown in step e of
Scheme III. Compounds of Formula XIa, wherein R1, R2, R3, R5 and X
are as previously defined and R4=Cl, can be allowed to react under
Suzuki coupling conditions with a boronic acid such as
phenylboronic acid in the presence of a catalyst such as palladium
tetrakis, a base such as 2M aqueous potassium carbonate, and in a
mixed solvent system such as ethanol and toluene to provide
cross-coupled pyrazoles of Formula XIb, as shown in step f of
Scheme III.
##STR00009##
[0117] In step a of Scheme IV, the compounds of Formula XIIb can be
treated with triethylorthoformate and an acid such as
trifluoroacetic acid. Subsequent addition of a reducing agent such
as sodium borohydride in a polar protic solvent such as ethanol
gave a compound of Formula XIIIa, wherein R6=methyl.
[0118] In step b of Scheme IV, the compound of Formula XIIb can be
treated with acetone in a solvent such as isopropyl acetate, an
acid such as trifluoroacetic acid and sodium triacetoxyborohydride
to give compounds of Formula XIIIa, wherein R6=isopropyl.
[0119] In step c of Scheme IV, the compounds of Formula XIIb can be
acylated with an acid chloride such as acetyl chloride in a polar
aprotic solvent such as dichloromethane using the conditions
described in Scheme V. Reduction of the amide with a reducing agent
such as lithium aluminum hydride in a polar aprotic solvent such
tetrahydrofuran gives compounds of Formula XIIIa, wherein
R6=ethyl.
[0120] Alternatively, in step d of Scheme IV, the compounds of
Formula XIIb can be treated with benzotriazole and an aldehyde in
ethanol followed by reduction using, for example, sodium
borohydride, to afford compounds of Formula XIIIa. In step e of
Scheme IV, the compounds of Formula XIIb can be treated with an
aldehyde such as propionaldehyde and sodium triacetoxyborohydride
in a polar aprotic solvent such as dichloromethane to give
compounds of Formula XIIIa, wherein R6=propyl. As in step f,
acylation of compounds of Formula XIIIa in Scheme IV using the
conditions described in Scheme IX affords compounds of Formula Ia,
wherein R1, R2, R3, R4, R5, R6, R8 and X are as previously
defined.
##STR00010##
[0121] In step a of Scheme V, the compounds of Formula Vc, wherein
R1, R2, R3, R4, R5 and R6 and X are as previously defined, can be
treated with an acid chloride of Formula XIV, in the presence of a
base such as triethylamine or N,N-dimethylaminopyridine in a polar
aprotic solvent such as dichloroethane (DCE) to yield compounds of
Formula Ib, wherein R8 is as previously defined. Additionally, when
R6=H the 2.degree. amide may be subsequently alkylated in step b of
Scheme V with an alkyl halide such as iodoethane, in the presence
of a base such as sodium hydride and a polar aprotic solvent such
as N,N-dimethylformamide (DMF) to yield the desired compounds of
Formula Ib. The acid chlorides used in the acylation reactions
herein are either commercially available or can be synthesized by
those skilled in the art.
##STR00011##
[0122] In step a of Scheme VI and as in Sammelson et al. Bioorg.
Med. Chem. 2004, 12, 3345-3355, the aminopyrazoles of Formula Vd,
wherein R1, R2, R3, R4, R6 and X are as previously defined and
R5=H, can be halogenated with a halogen source such as
N-chlorosuccinimide or N-bromosuccinimide in a polar aprotic
solvent such as acetonitrile to provide the R5-substituted
pyrazole. In step b, acylation of this compound using the
conditions described in Scheme V affords the compound of Formula
Ic, wherein R1, R2, R3, R4, R5, R6, R8 and X are as previously
defined.
##STR00012##
[0123] In step a of Scheme VII, ureas and carbamates are made from
the aminopyrazoles of Formula Ve. Compounds of Formula Ve, wherein
X, R1, R2, R3, R4, R5 and R6 are as previously defined are allowed
to react with phosgene to provide the intermediate carbamoyl
chloride which is subsequently treated with an amine, as shown in
step b, or alcohol, as shown in step c, respectively, to generate a
urea of Formula Id or a carbamate of Formula Ie, respectively,
wherein R9 is as previously defined.
##STR00013##
[0124] In step a of Scheme VIII, compounds of Formula XIIc, wherein
X, R1, R2, R3, R4 and R5 are as previously defined, can be treated
with di-tert-butyl dicarbonate (Boc.sub.2O) and a base such as
triethylamine in a polar aprotic solvent such as dichloromethane
(DCM) to yield compounds of Formula XVIa. Treatment of the
carbamate functionality with an alkyl halide such as iodomethane or
Boc-anhydride in the presence of a base such as sodium hydride and
in a polar aprotic solvent such as DMF yields carbamates of Formula
XVII, as shown in step b of Scheme VIII, wherein R6 is as
previously defined, except where R6 is hydrogen. The Boc-group can
be removed under conditions that are well-known in the art, such as
under acidic conditions such as trifluoroacetic acid (TFA) in a
polar aprotic solvent like dichloromethane to give compounds of
Formula XIIIb as in step c.
##STR00014##
[0125] In steps a, b and c of Scheme IX, compounds of Formula
XIIIc, wherein X, R1, R2, R3, R4, R5 and R6 are as previously
defined, can be treated with a compound of Formula XVIII, wherein
R8 is as previously defined and R10 is either OH, OR9 or
O(C.dbd.O)OR9, to yield compounds of Formula Id. When R10=OH,
compounds of Formula XIIIc can be converted to compounds of Formula
Id in the presence of a coupling reagent such as
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDC.HCl) and a base such as N,N-dimethylaminopyridine (DMAP) in a
polar aprotic solvent such as dichloroethane (DCE), as shown in
step a. When R10=OR9, compounds of Formula XIIIc can be converted
to compounds of Formula Id in the presence of
2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine in a polar
aprotic solvent such as 1,4-dioxane under elevated temperature, as
shown in step b. When R10=O(C.dbd.O)OR9, compounds of Formula XIIIc
can be converted to compounds of Formula Id in a polar aprotic
solvent such as dichloromethane (DCM), as shown in step c.
Acylation of amides of Formula Id, when R6=H, with an acid chloride
in the presence of a base such as diisopropyl ethylamine in a polar
aprotic solvent such as dichloroethane (DCE) yields imides of
Formula Ie, as shown in step d. Furthermore, alkylation of amides
of Formula Id, when R6=H, with an alkyl halide or alkyl sulfonate
in the presence of a base such as sodium hydride in a polar aprotic
solvent such as N,N-dimethylformamide (DMF) yields alkylated amides
of Formula Ie, as shown in step e. Halogenation of compounds of
Formula Id, wherein R1, R2, R3, R4, R6, R8 and X are as previously
defined and R5=H, with a halogen source such as N-bromosuccinimide
in a polar aprotic solvent such as DCE or a halogen source such as
N-chlorosuccinimide in a polar aprotic solvent such as DCE or
acetonitrile or a halogen source such as Selectfluor.RTM. in a
mixture of polar aprotic solvents such as acetonitrile and DMF give
halogenated pyrazoles of Formula Ie, wherein R5=halogen, as shown
in step f of Scheme IX. Amides of Formula Id can be converted to
thioamides of Formula If in the presence of a thionating agent such
as Lawesson's reagent in a polar aprotic solvent such as
dichloroethane (DCE), as shown in step g.
##STR00015##
[0126] In step a of Scheme X, compounds of Formula XIIId, wherein
X, R1, R2, R3, R4, R5 and R6 are as previously defined, can be
treated with compounds of Formula XIX, wherein R8 is as previously
defined, in a polar aprotic solvent such as dichloroethane (DCE) to
yield compounds of Formula XX. Additionally, when R6=H and R8
contains a halogen, compounds of Formula XX can be treated with a
base, such as sodium hydride, in a polar aprotic solvent, such as
THF, to yield compounds of Formula XXI, where m is an integer
selected from 1, 2, 3, 4, 5, or 6, as shown in step b of Scheme
X.
##STR00016##
[0127] Oxidation of the sulfide to the sulfoxide or sulfone is
accomplished as in Scheme XI where (.about.S.about.) can be any
sulfide previously defined within the scope of R8 of this
invention. The sulfide of Formula XXIIa, wherein X, R1, R2, R3, R4,
R5 and R6 are as previously defined, is treated with an oxidant
such as sodium perborate tetrahydrate in a polar protic solvent
such as glacial acetic acid to give the sulfoxide of Formula XXIII
as in step a of Scheme XI. Alternatively, the sulfide of Formula
XXIIa can be oxidized with an oxidant such as hydrogen peroxide in
a polar protic solvent such as hexafluoroisopropanol to give the
sulfoxide of Formula XXIII as in step d of Scheme XI. The sulfoxide
of Formula XXIII can be further oxidized to the sulfone of Formula
XXIV by sodium perborate tetrahydrate in a polar protic solvent
such as glacial acetic acid as in step c of Scheme XI.
Alternatively, the sulfone of Formula XXIV can be generated in a
one-step procedure from the sulfide of Formula XXIIa by using the
aforementioned conditions with >2 equivalents of sodium
perborate tetrahydrate, as in step b of Scheme XI.
##STR00017##
[0128] Oxidation of the sulfide to the sulfoximine is accomplished
as in Scheme XII where (.about.S.about.) can be any sulfide
previously defined within the scope of R8 of this invention. The
sulfide of Formula XXIIb, wherein X, R1, R2, R3, R4, R5 and R6 are
as previously defined, is oxidized as in step a with iodobenzene
diacetate in the presence of cyanamide in a polar aprotic solvent
such as methylene chloride (DCM) to give the sulfilimine of the
Formula XXV. The sulfilimine of Formula XXV may be further oxidized
to the sulfoximine of Formula XXVI with an oxidant such as
meta-Chloroperoxybenzoic acid ("mCPBA") in the presence of a base
such as potassium carbonate in a protic polar solvent system such
as ethanol and water as in step b of Scheme XII.
##STR00018##
[0129] Iodination of the pyrazole of Formula Xb as in step a of
Scheme XIII and as in Potapov, A. et al. Russ. J. Org. Chem. 2006,
42, 1368-1373 was accomplished by reaction with an iodinating agent
such as iodine in the presence of acids such as iodic acid and
sulfuric acid in a polar protic solvent such as acetic acid gives
compounds of Formula XXVII. In step b of Scheme XIII and as in
Wang, D. et al. Adv. Synth. Catal. 2009, 351, 1722-1726,
aminopyrazoles of Formula XIIIe can be prepared from iodopyrazoles
of Formula XXVII through cross coupling reactions with an
appropriate amine in the presence of a base such as cesium
carbonate, a copper catalyst such as copper (I) bromide, and a
ligand such as 1-(5,6,7,8-tetrahydroquinolin-8-yl)ethanone in a
polar aprotic solvent such as DMSO.
##STR00019##
[0130] In step a of the Scheme XIV, compounds of the formula XXIX,
wherein R4 is Cl, R5 is H and X.sup.- represents Cl.sup.-, can be
prepared according to the methods described in Acta. Pharm. Suec.
22, 147-156 (1985) by Tolf, Bo-Ragnar and Dahlbom, R. In a similar
manner, compounds of the Formula XXIX, wherein R4 is Br, X.sup.-
represents Br and R5 is as defined previously, can be prepared by
treating compounds of the Formula XXVIII with hydrogen gas in the
presence of a metal catalyst such as 5% Pd on alumina and a
solution of 50% aqueous HBr in a solvent such as ethanol.
Alternatively, in step a of Scheme XIV, compounds of the Formula
XXIX, wherein R4 is Cl or Br, X.sup.- represents Cl.sup.- or Br and
R5 is as defined previously, can be prepared by treating compounds
of the Formula XXVIII, wherein R5 is as defined previously, with a
hydrosilane such as triethyl silane in the presence of a metal
catalyst such as 5% Pd on alumina and an acid such as HCl or HBr,
respectively, in a solvent such as ethanol.
[0131] In step b of the Scheme XIV, compounds of the Formula XXX,
wherein R4 is Cl or Br and R5 is as defined previously, can be
prepared by treating the compounds of the Formula XXIX, wherein R4
is Cl or Br, X.sup.- represents Cl.sup.- or Br and R5 is as defined
previously, with di-tert-butyl dicarbonate (Boc.sub.2O) in the
presence of a mixture of solvents such as THF and water and a base
such as sodium bicarbonate.
[0132] In step c of the Scheme XIV, compounds of the Formula XVIa,
wherein X, R1, R2, R3 and R5 are as defined previously and R4 is Cl
or Br, preferably Cl can be obtained by treating compounds of the
Formula XXX, wherein R4 is Cl or Br and R5 is as defined
previously, preferably H, with compounds of the Formula VIIIb,
wherein X, R1, R2 and R3 are as defined previously and Q is iodo,
in the presence of a catalytic amount of copper salt such as
CuCl.sub.2, a ligand such as an ethane-1,2-diamine derivative such
as N.sup.1,N.sup.2-dimethylethane-1,2-diamine and a base such as
K.sub.3PO.sub.4 in a polar aprotic solvent such as acetonitrile at
a suitable temperature.
[0133] In step c pyrazoles of Formula XXX are coupled with
compounds of the Formula VIIIb, preferably 3-iodo pyridine, in the
presence of a metal catalyst, such as CuCl.sub.2, and a diamine
ligand such as N.sup.1,N.sup.2-dimethylethane-1,2-diamine, and an
inorganic base, such as K.sub.3PO.sub.4. The reaction is carried
out in a polar aprotic solvent such as acetonitrile. The reaction
is conducted at a temperature from about 60.degree. C. to about
82.degree. C. and preferably from about 75.degree. C. to 82.degree.
C. Approximately, a 1:1.2 molar ratio of pyrazoles of Formula XXX
to heterocyclyl iodide of Formula VIIIb may be used, however, a
molar ratios of about 5:1 to about 1:5 may also be used. The
reaction is conducted at about atmospheric pressure, however,
higher or lower pressures can be used.
[0134] The Boc-group of compounds of Formula XVIa can be removed
under conditions that are well-known in the art such as under
acidic conditions such as TFA in a polar aprotic solvent such as
dichloromethane to give compounds of Formula XIId, as shown in step
d of Scheme XIV.
##STR00020##
[0135] Bromopyrazoles of Formula XXXI, wherein R1, R2, R3, R5, R8
and X are as previously defined, can be allowed to react under
Suzuki coupling conditions with a boronic ester such as
vinylboronic acid pinacol ester or cyclopropylboronic acid pinacol
ester in the presence of a catalyst such as palladium tetrakis, a
base such as 2 M aqueous potassium carbonate, and in a mixed
solvent system such as ethanol and toluene to provide compounds of
Formula XXXII, as shown in step a of Scheme XV.
##STR00021##
[0136] The vinyl group of compounds of Formula XXXIII, wherein R1,
R2, R3, R5, R6, R8 and X are as previously defined, can be reduced
in the presence of hydrogen with a catalyst such as 10% Pd/C in a
polar protic solvent such methanol to give compounds of Formula
XXXIV, as shown in step a of Scheme XVI. Oxidation of the vinyl
group of compounds of Formula XXXIII using an oxidant such as
osmium tetroxide in the presence of sodium periodate in mixture of
a polar protic solvent such as water and a polar aprotic solvent
such as THF gave compounds of Formula XXXV, as shown in step b of
Scheme XVI. Reduction of the aldehyde of compounds of Formula XXXV,
as shown in step c of Scheme XVI, with a reducing agent such as
sodium borohydride in a polar protic solvent such as methanol gave
the corresponding alcohol of Formula XXXVI. Treatment of compounds
of Formula XXXVI with a chlorinating agent such as thionyl chloride
in a polar aprotic solvent such as dichloromethane gave compounds
of Formula XXXVII, as shown in step d of Scheme XVI.
##STR00022##
[0137] In step a of Scheme XVII, an .alpha.,.beta.-unsaturated acid
XXXVIII can be treated with a nucleophile such as sodium
thiomethoxide in a polar protic solvent such as methanol to give
acid XXXIX.
##STR00023##
[0138] In Step a of the Scheme XVIII, treatment of the compounds of
Formula Ig, where A is A2, R7 is O and R8 is tert-butoxy with a
reagent such as propargyl bromide in the presence of a base such as
sodium hydride and in a polar aprotic solvent such as DMF yields
compounds of Formula Ih, wherein R6=R11.
##STR00024##
[0139] In step a of Scheme XIX, compounds of Formula XL, wherein X,
R1, R2, R3, R4, R5 and R6 are as previously defined, can be treated
with an acid of Formula XLI, wherein R8 is as previously defined,
in the presence of a coupling reagent, such as
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDC.HCl), and a base, such as N,N-dimethylaminopyridine (DMAP), in
a polar aprotic solvent, such as dichloromethane (DCM), to yield
compounds of Formula XLII. In step b, compounds of the Formula XLII
can be treated with a base, such as sodium methoxide, in a polar
solvent such as THF, followed by an alkyl halide R9-Hal to give the
compounds of the Formula XLIII.
##STR00025##
[0140] Alternatively, in step a of Scheme XX, compounds of the
Formula XL or the corresponding HCl salt, wherein X, R1, R2, R3,
R4, R5, and R6 are as previously defined, can be coupled to acids
of the formula XLIV, wherein R8 is as previously defined, in the
presence of a coupling reagent, such as
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDC.HCl), and a base, such as N,N-dimethylaminopyridine, in a
polar aprotic solvent, such as dichloromethane, to yield compounds
of the Formula XLV, wherein X, R1, R2, R3, R4, R5, R6 and R8 are as
previously defined. In step b of Scheme XX, compounds of the
Formula XLV, wherein X, R1, R2, R3, R4, R5, R6 and R8 are as
previously defined and Tr represents trityl (triphenylmethyl), can
be treated with an acid, such as 2,2,2-trifluoroacetic acid, in the
presence of a trialkyl silane, such as triethyl silane, in a polar
aprotic solvent, such as methylene chloride, to remove the trityl
group to give thiols of the Formula XLVI, wherein X, R1, R2, R3,
R4, R5, R6 and R8 are as previously defined. In step c of Scheme
XX, thiols of the Formula XLVI, wherein X, R1, R2, R3, R4, R5, R6
and R8 are as previously defined, can be treated with a base, such
as sodium hydride, in a polar aprotic solvent such as
tetrahydrofuran, or cesium carbonate in acetonitrile, or DBU in
dimethylformamide, and an electrophile (R9-Hal), such as
2-(bromomethyl)-1,1-difluorocyclopropane, in tetrahydrofuran, to
give compounds of the Formula XLVII. Alternatively, the modified
conditions described by Pustovit and coworkers (Synthesis 2010, 7,
1159-1165) could be employed in the transformation of XLVI to
XLVII.
##STR00026##
[0141] Alternatively, in step a of the Scheme XXI, compounds of the
Formula XL or the corresponding HCl salt, wherein X, R1, R2, R3,
R4, R5, and R6 are as previously defined, can be coupled to acids
of the Formula XLVIII, wherein R9 is as previously defined, in the
presence of a coupling reagent such as EDC.HCl and a base such as
DMAP in a polar aprotic solvent such as DMF to yield compounds of
Formula XLIX, where in X, R1, R2, R3, R4, R5, R6 and R9 are as
previously defined. In step b of the Scheme XXI, compounds of the
Formula XLIX, wherein X, R1, R2, R3, R4, R5, R6 and R9 are as
previously defined, can be treated with a thio acid salt, such as
potassium thioacetate, at an elevated temperature (about 50.degree.
C.) in a solvent, such as DMSO, to give compounds of the Formula L,
wherein X, R1, R2, R3, R4, R5, R6 and R9 are as previously defined.
In step c of the Scheme XXI, compounds of the Formula L, wherein X,
R1, R2, R3, R4, R5, R6 and R9 are as previously defined, can be
treated with an equimolar amount of a base, such as sodium
methoxide, prepared from mixing sodium hydride, and methanol,
followed by an electrophile (R9-Halo), such as
2-(bromomethyl)-1,1-difluorocyclopropane, in a solvent, such as
tetrahydrofuran, to give compounds of the Formula LI.
##STR00027##
[0142] In step a of Scheme XXII, compounds of the Formula XL,
wherein X, R1, R2, R3, R4, R5, R6, and halo are as previously
defined, can be treated with an acid chloride of Formula LII in the
presence of a base, such as triethylamine or diisopropylethylamine
in a polar aprotic solvent, such as DCE, to yield compounds of the
Formula LIII, wherein R8 is either a substituted or unsubstituted
alkyl chain. In step b, compounds of the Formula LIII can be
treated with potassium thioacetate to provide compounds of Formula
LIV after heating (about 60.degree. C.) in a polar aprotic solvent,
such as acetone. As indicated in step c, a one-pot
methanolysis/alkylation sequence can be achieved via treatment of
compounds of the Formula LIV with one equivalent of a base, such as
sodium methoxide (NaOMe) in a polar aprotic solvent, such as
tetrahydrofuran (THF). An alkyl sulfonate or alkyl halide, such as
2-iodo-1,1,1-trifluoroethane, can then be added to the reaction
mixture to deliver compounds of the Formula LV, wherein R9 is as
previously defined. In step d compounds of the Formula LV may be
obtained from compounds of the Formula LIII via treatment with an
alkyl thiol such as 2,2,2-trifluoroethanethiol at elevated
temperatures (about 50.degree. C.) in a polar aprotic solvent, such
as THF, in the presence of sodium iodide and a base, such as
diisopropylethylamine. Alternatively, in step f treating compounds
of Formula LIII with an alkyl thiol, such as sodium
methanethiolate, in a polar aprotic solvent, such as DMSO, at
elevated temperatures (about 50.degree. C.) will afford compounds
of Formula LV. As demonstrated in step e, when compounds of the
Formula LIV are treated with two or more equivalents of a base,
such as NaOMe, followed by a 1,2,2-trihaloalkyl compound, such as
2-bromo-1,1-difluoroethane, compounds of Formula LVI are
obtained.
##STR00028##
[0143] In step a of Scheme 23, compounds of Formula 23.1, wherein
X, R1, R2, R3, R4, R5, R6 and R8 are as previously defined, can be
treated with a base, such as aqueous 2M lithium hydroxide, in a
polar protic solvent, such as methanol, to give compounds of
Formula 23.2. Then in step b, compounds of Formula 23.2 can be
treated with a base, such as sodium hydride in a polar aprotic
solvent, such as tetrahydrofuran, followed by an electrophile, such
as an alkyl halide or sulfonyl halide, to afford compounds of
Formula 23.3.
##STR00029##
[0144] In step a of Scheme 24, compounds of Formula 24.1, where X,
R1, R2, R3, R4, R5, R8 and halo are as previously defined, and
R6=H, can be treated with a base such as sodium hydride, in a polar
aprotic solvent, such as tetrahydrofuran (THF), to yield compounds
of Formula 24.2 where m is an integer selected from 0,1,2,3,4,5, or
6. In step b of Scheme 24, compounds of Formula 24.2 can be treated
with a base, such as triethylamine, and silylation reagents, such
as trimethylsilyl trifluoromethanesulfonate and
dimethylmethylideneammonium iodide (Eschenmoser's salt) in a polar
aprotic solvent, such as dichloromethane (DCM), to yield compounds
of Formula 24.3. In step c of Scheme 24, compounds of Formula 24.3
can be treated with a base, such as potassium hydroxide, and a
nucleophile, such as S,S-dimethyl carbonodithioate, in water and a
polar aprotic solvent such as tetrahydrofuran (THF) to yield
compounds of Formula 24.4, wherein X, R1, R2, R3, R4, R5, R9 and m
are as previously defined.
##STR00030##
[0145] A route to compounds of Formula 25.2 is described in Scheme
25. As demonstrated in step a, when compounds of the Formula 25.1,
wherein X, R1, R2, R3, R4, R5, R6 and R8 are as previously defined,
are treated with two or more equivalents of a base, such as sodium
methoxide, followed by a 1,2-dihaloalkyl compound, such as
1-fluoro-2-iodoethane, in a solvent, such as tetrahydrofuran (THF),
compounds of Formula 25.2, wherein R9 is as previously defined, are
obtained.
##STR00031##
[0146] An alternative route to vinyl sulfides is described in step
a of Scheme 26. This route utilizes conditions developed by Kao and
Lee (Org. Lett. 2011, 13, 5204-5207) in which thiols of the Formula
26.1, wherein X, R1, R2, R3, R4, R5, R6 and R8 are as previously
defined, are coupled with a vinyl halide, such as
(E)-1-bromo-3,3,3-trifluoroprop-1-ene, in the presence of a
catalyst, such as copper(I) oxide, a base, such as potassium
hydroxide, and a solvent, such as dioxane, at elevated temperatures
to afford products of Formula 26.2, wherein R9 is as previously
defined.
##STR00032##
[0147] In step a of Scheme 27, an acrylamide of Formula 27.1,
wherein X, R1, R2, R3, R4, R5, and R6 are as previously defined, is
reacted with a sulfonamide of Formula 27.2, wherein R9 is as
previously defined, in the presence of a base, such as potassium
carbonate, at elevated temperatures in a polar aprotic solvent,
such as dimethylformamide (DMF), to deliver compounds of Formula
27.3. This product can then be treated with a base, such as sodium
hydride, and an alkyl halide, such as 2-bromoacetonitrile, in a
polar aprotic solvent, such as tetrahydrofuran (THF), to provide
compounds of the Formula 27.4, as demonstrated in step b.
##STR00033##
[0148] When compounds of the Formula 28.1, wherein X, R1, R2, R3,
R4, R5, R6, R8 and halo are as previously defined, are treated with
amines of the Formula 28.2, wherein R9 is as previously defined, at
elevated temperatures in a polar protic solvent, such as methanol,
compounds of the Formula 28.3 can be obtained, as demonstrated in
step a of Scheme 28. Compounds of the Formula 28.3 may be treated
with a sulfonyl chloride, such as methanesulfonyl chloride, in the
presence of a base, such as diisopropylethylamine, and a polar
aprotic solvent, such as dichloromethane (DCM), to afford products
of the Formula 28.4, as shown in step b. As demonstrated in step c,
when compounds of the Formula 28.3 are treated with an alkyl
halide, such as 3-bromo-1,1,1-trifluoropropane, at elevated
temperatures and in the presence of a base, such as potassium
carbonate, and a polar aprotic solvent, such as dimethylformamide
(DMF), compounds of the Formula 28.5 may be obtained.
Alternatively, compounds of Formula 28.3 may be prepared via a two
step process as described in steps d and e of Scheme 28. Compounds
of Formula 28.6 can be converted to compounds of Formula 28.8 when
treated with compounds of Formula 28.7 in the presence of a
coupling reagent such as
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDC.HCl) and a base such as N,N-dimethylaminopyridine (DMAP) in a
polar aprotic solvent such as dichloroethane (DCE), as shown in
step d. The Boc-group can be removed under conditions that are
well-known in the art, such as under acidic conditions such as
trifluoroacetic acid (TFA) in a polar aprotic solvent like
dichloromethane to give compounds of Formula 28.3 as in step e.
##STR00034##
[0149] In step a of Scheme 29, compounds of Formula 29.1, wherein
X, R1, R2, R3, R4, R5, R6 and R8 are as previously defined, can be
reacted with either a cyclic or acyclic enone, such as
but-3-ene-2-one, under the conditions described by Chakraborti
(Org. Lett. 2006, 8, 2433-2436) to deliver compounds of the Formula
29.2, wherein R9 is as previously defined. These products may then
be subjected to a fluorinating reagent, such as Deoxo-Fluor, and an
initiator, such as ethanol, in a polar aprotic solvent, such as
dichloromethane (DCM), to deliver compounds of the Formula 29.3, as
described in step b.
##STR00035##
[0150] Step a of Scheme 30 depicts the hydrolysis of compounds of
the Formula 30.1, wherein X, R1, R2, R3, R4, R5, R6, R8, and R9 are
as previously defined, via treatment with an acid, such as aqueous
hydrochloric acid, in a solvent, such as THF, to afford an
intermediate aldehyde of the Formula 30.2. Compounds of the Formula
30.2 can be immediately reacted with a fluorinating reagent, such
as Deoxo-Fluor, in the presence of an initiator, such as ethanol,
and a solvent, such as tetrahydrofuran (THF), to provide products
of the Formula 30.3.
##STR00036##
[0151] In Scheme 31, compounds of the Formula 31.1, wherein R9 is
as previously defined, are converted to compounds of the Formula
31.2 via the procedure described in Dmowski (J. Fluor. Chem., 2007,
128, 997-1006), as shown in step a. Compounds of Formula 31.2 may
then be subjected to conditions described in step b, in which a
reaction with a thioate salt in a solvent, such as
dimethylformamide (DMF), provides compounds of the Formula 31.3,
wherein W is aryl or alkyl. As indicated in step c, a one-pot
deprotection/alkylation sequence can be achieved via treatment of
compounds of the Formula 31.3 with one equivalent of a base, such
as sodium methoxide (NaOMe), in a polar aprotic solvent, such as
tetrahydrofuran (THF). A compound of the Formula 31.4, wherein X,
R1, R2, R3, R4, R5, R6, R8 and halo are as previously defined, may
then be added to the reaction mixture to afford compounds of the
Formula 31.5.
##STR00037##
[0152] In Scheme 32, a neat mixture of an olefin of the Formula
32.1, where n is an integer selected from 0, 1, 2, 3, 4, or 5, and
trimethylsilyl 2,2-difluoro-2-(fluorosulfonyl)acetate can be heated
in the presence of sodium fluoride to deliver a substituted
difluorocyclopropane of the Formula 32.2, as indicated in step a.
In step b, this product was treated with tetrabutylammonium
fluoride (TBAF) in tetrahydrofuran (THF) to afford an intermediate
homoallylic alcohol of the Formula 32.3. This alcohol was not
isolated, but rather immediately treated with p-toluenesulfonyl
chloride in the presence of pyridine and dichloromethane to afford
a tosylate of the Formula 32.4, as shown in step c.
##STR00038##
[0153] Compounds of the Formula 33.1, wherein X, R1, R2, R3, R4,
R5, and R6 are as previously defined, where X is preferably carbon,
R1, R2, R3, and R5 are hydrogen and R4 is chloro, may be coupled
with an acid chloride of the Formula 33.2, wherein R8 is as
previously defined, in the presence of a base, such as pyridine,
diisopropylethylamine, or N,N-dimethylaminopyridine (DMAP), and a
solvent, such as 1,2-dichloroethane or methylene choride, to afford
products of the Formula 33.3, as depicted in step a of Scheme
33.
[0154] In step a of Scheme 33 amines of Formula 33.1 are coupled
with acid chlorides of Formula 33.2 in the presence of a base, or
combination of bases such as pyridine, N,N-dimethylaminopyridine,
or diisopropylethylamine. The reaction is carried out in a
halogenated solvent such as 1,2-dichloroethane or methylene
chloride. The reaction is conducted at a temperature from 0.degree.
C. to 80.degree. C. and preferably from about 0.degree. C. to
23.degree. C. Approximately, a 1:1 molar ratio of the amine of
formula 33.1 to acid chloride of Formula 33.2 may be used, however,
molar ratios of about 5:1 to about 1:5 may also be used. The
reaction is conducted at about atmospheric pressure, however,
higher or lower pressures can be used.
##STR00039##
[0155] In step a of Scheme 34, the compounds of Formula 34.1,
wherein R1, R2, R3, R4, R5 and R6 and X are as previously defined,
can be treated with an acid of Formula 34.2, wherein R8 is as
previously defined, in the presence of
N,N'-dicyclohexylcarbodiimide (DCC), and a base, such as
N,N-dimethylaminopyridine (DMAP), in a solvent, such as diethyl
ether (Et.sub.2O), to yield compounds of Formula 34.3.
##STR00040##
[0156] In step a of Scheme 35, aminopyrazoles of Formula 35.1,
wherein X, R1, R2, R3, R4, R5 and R6 are as previously defined, can
be treated with phosgene and N,N-dimethylaminopyridine (DMAP) at
about 80.degree. C. in a polar aprotic solvent such as
dichloroethane (DCE). Subsequently, treatment with an amine, as
shown in step b, or an alcohol, as shown in step c, or a thiol, as
shown in step d, generates a urea of Formula 35.2, a carbamate of
Formula 35.3, or a carbamothioate of Formula 35.4, wherein R9 is as
previously defined, respectively.
##STR00041##
[0157] In step a of Scheme 36, compounds of Formula 36.1, wherein
X, R1, R2 and R3 are as previously defined, can be treated with a
base such as triethylamine, carbon disulfide and a sulfonyl
chloride such as 4-methylbenzene-1-sulfonyl chloride in a polar
aprotic solvent such as tetrahydrofuran (THF) to yield compounds of
Formula 36.2. In step b of Scheme 36, oxazolidin-2-one can be
treated with an equimolar amount of a base, such as sodium hydride
followed by compounds of Formula 36.2, in a polar aprotic solvent
such as dimethylformamide (DMF) to give compounds of the Formula
36.3. Additionally, the product of step b, (previous to work-up)
can be treated with an electrophile such as iodomethane to give
compounds of Formula 36.4 as demonstrated in step c of Scheme
36.
##STR00042##
[0158] In step a of Scheme 37, ureas of Formula 37.1, wherein R1,
R2, R3, R4, R5, R6, R8, and X are as previously defined, can be
reacted with a base such as lithium bis(trimethylsilyl)amide in a
polar aprotic solvent such as THF followed by an acyl chloride such
as pivaloyl chloride to yield acylated ureas of Formula 37.2,
wherein R1, R2, R3, R4, R5, R6, R8, and X are as previously
defined. In step b of Scheme 37, ureas of Formula 37.1, wherein R1,
R2, R3, R4, R5, R6, R8, and X are as previously defined, can be
reacted with a base such as lithium bis(trimethylsilyl)amide in a
polar aprotic solvent such as THF followed by an alkyl halide such
as (chloromethyl)(methyl)sulfane to yield alkylated ureas of
Formula 37.2, wherein R1, R2, R3, R4, R5, R6, R8, and X are as
previously defined. In step c of Scheme 37, ureas of Formula 37.1,
wherein R1, R2, R3, R4, R5, R6, R8, and X are as previously
defined, can be reacted with a base such as lithium
bis(trimethylsilyl)amide in a polar aprotic solvent such as THF
followed by a sulfonyl chloride such as methanesulfonyl chloride to
yield sulfonylated ureas of Formula 37.3, wherein R1, R2, R3, R4,
R5, R6, R8, and X are as previously defined.
##STR00043##
[0159] In step a of Scheme 38, amines of Formula 38.1, wherein R6
is H or Me, can be reacted with an electrophile of Formula 38.2,
wherein R8 and R9 are as previously defined, such as
naphthalen-2-ylmethyl 3-(methylthio)propanimidothioate hydrobromide
in a polar protic solvent such as ethanol followed by exposure to a
base such as MP-Carbonate in a polar protic solvent such as
methanol to give amidines of Formula 38.3, wherein R6 is H or Me,
and R8 and R9 are as previously defined.
##STR00044##
[0160] In step a of the Scheme 39, compounds of the Formula 39.1,
wherein X, R1, R2, R3, R4, R5, R6 and R8 are as previously defined,
can be treated with alcohols of the Formula 39.2, wherein R9 is as
previously defined, in the presence of a base such as sodium
hydride or potassium tert-butoxide in a polar aprotic solvent such
as THF at appropriate temperatures, to give the corresponding
ethers of the Formula 39.3. Alternatively, in step b of Scheme 39,
thioethers of the Formula 39.5 can be obtained by treating
compounds of the Formula 39.1, wherein X, R1, R2, R3, R4, R5, R6
and R8 are as previously defined, with thiols of the Formula 39.4,
wherein R9 is as previously defined, in the presence of a base such
as sodium hydride in an aprotic solvent such as THF.
##STR00045##
[0161] In Scheme 40, compounds of the Formula 40.1, wherein X, R1,
R2, R3, R4, R5, R6 and R8 are as previously defined, can be treated
according to the conditions of Estrada et. al. (Synlett, 2011,
2387-2891), to give the corresponding sulfonamides of the Formula
40.2, wherein R9 is as previously defined with the proviso that at
least one of the R9 is not H.
##STR00046##
[0162] In step a of Scheme 41, compounds of the Formula 41.1,
wherein X, R1, R2, R3, R4, R5 and R6 are as previously defined, can
be coupled to acids of the Formula 41.2, wherein R8 and R9 are as
previously defined, in the presence of a coupling reagent such as
EDC.HCl and a base such as DMAP in an aprotic solvent such as
dichloromethane to give phosphonates of the Formula 41.3. In step b
of Scheme 41, phosphonates of the Formula 41.3, wherein X, R1, R2,
R3, R4, R5, R6, R8 and R9 are as previously defined, can be treated
with carbonyl compounds of the Formula 41.4, where R9 is as
previously defined in the presence of a base such as sodium hydride
in an aprotic solvent such as THF to give the corresponding alkenes
of the Formula 41.5.
##STR00047##
[0163] In step a of the Scheme 42, compounds of the Formula 42.1,
wherein X, R1, R2, R3, R4, and R5, are as previously defined, can
be treated with trifluoroacetic anhydride in the presence of a base
such as triethylamine in an aprotic solvent such as dichloromethane
to give amides of the Formula 42.2, where X, R1, R2, R3, R4, and
R5, are as previously defined. In step b of Scheme 42, amides of
the Formula 42.2, wherein X, R1, R2, R3, R4, and R5, are as
previously defined, can be treated with an alkylating agent such as
iodomethane in the presence of a base such as potassium
tert-butoxide in a solvent such as THF to afford compounds of the
Formula 42.3. In step c of the Scheme 42 amides of the Formula
42.3, wherein X, R1, R2, R3, R4, and R5, are as previously defined
can be treated under basic conditions such as potassium carbonate
and methanol to give the corresponding amines of the Formula
42.4.
##STR00048##
EXAMPLES
[0164] The examples are for illustration purposes and are not to be
construed as limiting the invention disclosed in this document to
only the embodiments disclosed in these examples.
[0165] Starting materials, reagents, and solvents that were
obtained from commercial sources were used without further
purification. Anhydrous solvents were purchased as Sure/Seal.TM.
from Aldrich and were used as received. Melting points were
obtained on a Thomas Hoover Unimelt capillary melting point
apparatus or an OptiMelt Automated Melting Point System from
Stanford Research Systems and are uncorrected. Molecules are given
their known names, named according to naming programs within ISIS
Draw, ChemDraw or ACD Name Pro. If such programs are unable to name
a molecule, the molecule is named using conventional naming rules.
All NMR shifts are in ppm (6) and were recorded at 300, 400 or 600
MHz unless otherwise stated. Examples using "room temperature" were
conducted in climate controlled laboratories with temperatures
ranging from about 20.degree. C. to about 24.degree. C.
Example 1
Step 1: Preparation of
3,3-bis-methylsulfanyl-1-pyridin-3-yl-propenone
##STR00049##
[0167] To a room-temperature suspension of sodium hydride (NaH, 60%
suspension in mineral oil; 4.13 g, 86 mmol) in dry dimethyl
sulfoxide (DMSO, 60 mL) under an atmosphere of nitrogen (N.sub.2)
was added 3-acetylpyridine (5.00 g, 41.3 mmol) dropwise over 30
minutes (min). The mixture was stirred for an additional 30 minutes
at the same temperature. Carbon disulfide (CS.sub.2; 3.27 g, 43
mmol) was added dropwise with vigorous stirring followed by
iodomethane (12.21 g, 86 mmol) dropwise over a period of 45 min.
Stirring was continued for an additional 18 hours (h) under
N.sub.2. The reaction was quenched with cold water (H.sub.2O, 50
mL). The dark solid was filtered and washed with ice-cold ethyl
alcohol (EtOH) until the washings were colorless. The off-white
solid product was dried under vacuum at 60.degree. C. to provide
3,3-bis-methylsulfanyl-1-pyridin-3-yl-propenone as a brown solid
(4.8 g, 51%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 9.13 (d,
J=1.8 Hz, 1H), 8.72 (dd, J=4.8, 1.6 Hz, 1H), 8.23 (ddd, J=7.9, 2, 2
Hz, 1H), 7.40 (dd, J=7.9, 4.8 Hz, 1H), 6.73 (s, 1H), 2.58 (d, J=9.4
Hz, 6H); MS m/z 226.2 (M+1).
[0168] 1-(5-fluoropyridin-3-yl)-3,3-bis(methylthio)prop-2-en-1-one
was prepared as described in Example 1, Step 1: mp 150-152.degree.
C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.93 (t, J=1.6 Hz,
1H), 8.58 (d, J=2.8 Hz, 1H), 7.94 (ddd, J=8.9, 2.8, 1.7 Hz, 1H),
6.69 (s, 1H), 2.60 (s, 3H), 2.57 (s, 3H).
Example 1
Step 2: Preparation of
(Z)-3-methylamino-3-methylsulfanyl-1-pyridin-3-yl-propenone
##STR00050##
[0170] A solution of
3,3-bis-methylsulfanyl-1-pyridin-3-yl-propenone (18.6 g, 82.5 mmol)
in absolute alcohol (400 mL) under N.sub.2 was treated with
methylamine hydrochloride (27.86 g, 412 mmol) followed by
triethylamine (Et.sub.3N; 58.5 mL, 412 mmol). The mixture was
heated to reflux for 3 h, cooled to room temperature and
concentrated under reduced pressure. The solid residue was
dissolved in ethyl acetate (EtOAc; 150 mL). The solution was washed
with H.sub.2O (2.times.50 mL) and brine (50 mL), dried over
Na.sub.2SO.sub.4, concentrated under reduced pressure and purified
by silica gel chromatography eluting with 10% EtOAc in petroleum
ether to yield
(Z)-3-methylamino-3-methylsulfanyl-1-pyridin-3-yl-propenone as a
pale yellow solid (8.6 g, 50%): .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 11.8 (br s, 1H), 9.06 (s, 1H); 8.67 (d, J=3.9 Hz, 1H), 8.26
(d, J=8.0 Hz 1H), 7.46 (dd, J=7.6, 4.9 Hz 1H), 5.62 (s, 1H), 3.10
(d, J=5.2 Hz, 3H), 2.52 (s, 3H); MS (m/z) 209.2 [M+1].
[0171]
(Z)-3-(ethylamino)-3(methylthio)-1-(pyridin-3-yl)prop-2-en-1-one
was prepared as described in Example 1, Step 2: .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 11.81 (bs, 1H), 9.04 (dd, J=2.2, 0.7 Hz,
1H), 8.64 (dd, J=4.8, 1.7 Hz, 1H), 8.29-7.98 (m, 1H), 7.35 (ddd,
J=7.9, 4.8, 0.9 Hz, 1H), 3.45 (q, J=7.2, 5.6 Hz, 2H), 2.50 (s, 3H),
1.35 (t, J=7.2 Hz, 3H).
[0172]
(Z)-3-(cyclopropylmethyl)amino-3(methylthio)-1-(pyridin-3-yl)prop-2-
-en-1-one was prepared as described in Example 1, Step 2: .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 9.00 (s, 1H), 9.05 (dd, J=2.2,
0.7 Hz, 1H), 8.64 (dd, J=4.8, 1.7 Hz, 1H), 8.16 (dt, J=7.9, 2.0 Hz,
1H), 7.35 (ddd, J=7.9, 4.8, 0.8 Hz, 1H), 5.62 (s, 1H), 3.27 (dd,
J=7.0, 5.5 Hz, 2H), 2.50 (s, 3H), 1.20-1.07 (m, 1H), 0.73-0.49 (m,
2H), 0.41-0.17 (m, 2H).
Example 1
Step 3: Preparation of
methyl-(2-methyl-5-pyridin-3-pyrazol-3-yl)-amine
##STR00051##
[0174] A solution of
(Z)-3-methylamino-3-methylsulfanyl-1-pyridin-3-yl-propenone (3.00
g, 14 mmol) and methylhydrazine (729 mg, 15.4 mmol) in absolute
EtOH (64 mL) was stirred at reflux for 18 h under N.sub.2, cooled
to room temperature and evaporated under reduced pressure. The
residue was dissolved in EtOAc (50 mL), and the organic layer was
washed with H.sub.2O (2.times.30 mL) and brine (30 mL), dried over
Na.sub.2SO.sub.4, concentrated under reduced pressure and purified
using silica gel chromatography eluting with a gradient of 0-1%
EtOH in EtOAc to yield two regioisomers in a 1:2 ratio, with the
major regioisomer as a brown solid (1.0 g, 27%): .sup.1H NMR (300
MHz, CDCl.sub.3) .delta. 8.97 (d, J=1.3 Hz, 1H), 8.51 (dd, J=3.6,
1.0 Hz, 1H), 8.07 (ddd, J=5.9, 1.4, 1.4 Hz, 1H), 7.30 (dd, J=5.9,
3.6 Hz, 1H), 5.82 (s, 1H), 3.69 (s, 3H), 2.93 (s, 3H); MS (m/z)
188.6 [M+1].
[0175] 1-Ethyl-N-methyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine was
prepared as described in Example 1, Step 3: ESIMS m/z 204
([M+2H]).
[0176] N-ethyl-1-methyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine was
prepared as described in Example 1, Step 3: ESIMS m/z 203
([M+H]).
[0177] N-methyl-1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine was
prepared as described in Example 1, Step 3: ESIMS m/z 252
([M+2H]).
[0178]
N-(cyclopropylmethyl)-1-methyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine
was prepared as described in Example 1, Step 3: ESIMS m/z 230
([M+2H]).
[0179] 1-Isopropyl-N-methyl-3-pyridin-3-yl)-1H-pyrazol-5-amine was
prepared as described in Example 1, Step 3: .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.53 (s, 1H), 8.06-7.90 (m, J=7.2 Hz, 2H), 7.13
(dd, J=7.9, 5.6 Hz, 1H), 5.33 (s, 1H), 3.70 (bs, 1H), 3.65 (dt,
J=13.2, 6.6 Hz, 1H), 2.31 (s, 3H), 0.88 (d, J=6.6 Hz, 6H); ESIMS
m/z 217 ([M+H]). 3-(5-Fluoropyridin-3-yl)-N,
1-dimethyl-1H-pyrazol-5-amine was prepared as described in Example
1, Step 3: .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.28 (s, 1H),
7.87 (t, J=1.3 Hz, 1H), 7.60 (m, 1H), 6.66 (s, 1H), 5.28 (bs, 2H),
3.12 (s, 3H), 2.34 (s, 3H); ESIMS m/z 206 ([M+H])
Example 2
Preparation of
(4-chloro-2-methyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-methyl-amine
##STR00052##
[0181] A mixture of
methyl-(2-methyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-amine (0.35 g, 1.8
mmol) and N-chlorosuccinimide (0.273 g, 2 mmol) was combined in
acetonitrile (3 mL), stirred at room temperature for 30 minutes,
concentrated under reduced pressure and purified using silica gel
chromatography eluting with a gradient of EtOAc in hexanes to yield
the title compound as a yellow oil (0.096 g, 23%): IR (thin film)
1581.6 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 9.12 (d,
J=1.5 Hz, 1H), 8.57 (dd, J=4.8, 1.3 Hz, 1H), 8.15 (ddd, J=7.8, 2.0,
2.0 Hz, 1H), 7.33 (dd, J=8.1, 5.1 Hz, 1H), 3.80 (s, 3H), 2.91 (d,
J=5.8 Hz, 3H); ESIMS (m/z) 225.6 [M+2].
[0182] The reaction also gave
4-chloro-2-methyl-5-pyridin-3-yl-2H-pyrazol-3-ylamine as a green
gum (0.046 g, 13%): IR (thin film) 1720.5 cm.sup.-1; .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 9.13 (br s, 1H), 8.57 (br s, 1H),
8.16 (dt, J=8.0, 2.0 Hz, 1H), 7.33 (dd, J=7.8, 4.8 Hz, 1H), 3.76
(s, 3H); ESIMS (m/z) 207.0 [M-1].
Example 3
Preparation of
2,N-dimethyl-N-(2-methyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-3-methylsulfanyl-
-propionamide (Compound 1)
##STR00053##
[0184] To a solution of
methyl-(2-methyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-amine (150 mg, 0.8
mmol) under N.sub.2 in ice-cold dichloroethane (DCE; 2 mL) was
added dropwise via pipette a solution of
2-methyl-3-methylsulfanyl-propionylchloride (146 mg, 0.9 mmol) in
DCE (1.5 mL). After stirring for 10 minutes (min), a solution of
4-N,N-dimethylaminopyridine (DMAP; 107 mg, 0.9 mmol) in DCE (2 mL)
was added dropwise. The ice bath was removed after 30 min, and the
mixture was stirred at room temperature for 90 min and then at
reflux for 14 h. The mixture was concentrated under reduced
pressure and was purified by silica gel chromatography eluting with
a gradient of EtOAc in hexane. The product,
2,N-dimethyl-N-(2-methyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-3-methylsulfanyl-
-propionamide, was isolated as a yellow semi-solid (44 mg, 24%):
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.00 (s, 1H), 8.58 (s,
1H), 8.08 (br d, J=7.0 Hz, 1H), 7.35 (br dd, J=7.3, 4.8 Hz, 1H),
6.58 (br s, 0.5H), 6.49 (br s, 0.5H), 3.89-3.79 (m, 3H), 3.25 (s,
3H), 2.96-2.80 (m, 1H), 2.42-2.40 (m, 1H), 2.02-1.99 (m, 3H), 2.62
(m, 1H), 1.15 (d, J=6.0 Hz, 3H); MS (m/z) 305.0 [M+1].
[0185] Compounds 2-6, 9-10, 12, 18-21, 24-33, 477, 487, 509, 520,
556-557, 562-568 were made from the appropriate amines in
accordance with the procedures disclosed in Example 3.
Example 4
Preparation of
1-methyl-1-(2-methyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-3-(2-methylsulfanyl--
ethyl)-urea (Compound 7)
##STR00054##
[0187] To a solution of
methyl-(2-methyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-amine (150 mg, 0.8
mmol) in ice-cold DCE (2 mL) under N.sub.2 was added a solution of
phosgene in toluene (20%, 0.43 mL, 0.88 mmol). The ice bath was
removed after 30 min, and the mixture was stirred at room
temperature for 1 h and at reflux for 2 h. The mixture was cooled
to room temperature and then more phosgene (0.86 mL, 1.76 mmol) was
added. The mixture was stirred at reflux for 90 min and then cooled
in an ice bath. To this was added a solution of
2-methylthioethylamine (80 mg, 0.88 mmol) in DCE (2 mL). The ice
bath was removed after 10 min, and the reaction mixture was stirred
at reflux for 14 h, cooled, and diluted with DCE (30 mL). The
diluted reaction mixture was washed with saturated NaHCO.sub.3 (20
mL), dried over MgSO.sub.4, adsorbed onto silica gel and purified
using silica gel chromatography eluting with a gradient of methanol
in dichloromethane to afford
1-methyl-1-(2-methyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-3-(2-methylsulfanyl--
ethyl)-urea as a yellow gum (14 mg, 6%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.99 (d, J=1.5 Hz, 1H), 8.57 (dd, J=4.8, 1.5
Hz, 1H), 8.08 (ddd, J=8.1, 2.1, 2.1 Hz, 1H), 7.34 (dd, J=7.9, 4.8
Hz, 1H), 6.52 (s, 1H), 4.88 (br t, J=5.5 Hz, 1H), 3.80 (s, 3H),
3.41 (q, J=6.3 Hz, 2H), 3.24 (s, 3H), 2.61 (t, J=6.3, 2H), 2.06 (s,
3H); ESIMS (m/z) 292.2 [M+2].
[0188] Compound 8 was made in accordance with the procedures
disclosed in Example 4 using 2-(methylthio)ethanol in place of
2-methylthioethylamine.
Example 5
Preparation of 1-methyl-5-(pyridin-3-yl)-1H-pyrazol-3-amine and
1-methyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine
##STR00055##
[0190] To ethanol (8.53 mL) was added
3-oxo-3-(pyridin-3-yl)propanenitrile (0.82 g, 5.61 mmol) and
methylhydrazine (0.25 g, 5.61 mmol) and stirred at reflux for 2
hours. The reaction was cooled to room temperature and concentrated
to dryness. The crude material was purified by silica gel
chromatography by eluting with 0-20% MeOH/dichloromethane to yield
two products--1-methyl-5-(pyridin-3-yl)-1H-pyrazol-3-amine (0.060
g; 6.14%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.72 (s, 1H),
8.53 (d, 1H), 7.76-7.63 (m, 1H), 7.43-7.33 (m, 1H), 5.75 (s, 1H),
3.76-3.57 (m, 5H) and 1-methyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine
(0.150 g, 15.35%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.88
(s, 1H), 8.48 (d, 1H), 7.99 (d, 1H), 7.38-7.07 (m, 1H), 585 (s,
1H), 3.80-3.59 (m, 5H).
Example 6
Step 1: Preparation of 3-pyrazol-1-yl-pyridine
##STR00056##
[0192] To a solution of 3-bromopyridine (5 g, 0.031 mol) in 50 ml
of acetonitrile were added pyrazole (2.6 g, 0.038 mol),
Cs.sub.2CO.sub.3 (16.5 g, 0.050 mol), Cu.sub.2O (0.226 g, 0.0016
mol), and salicylaldoxime (0.867 g, 0.006 mol) under N.sub.2
atmosphere. The reaction mass was refluxed for 24 hrs at 80.degree.
C. The reaction mass was concentrated and the crude was purified by
column chromatography using ethyl acetate and hexane (1:1) to
afford the pyrazolyl pyridine as a dark brown liquid (2 g, 43%):
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.99 (d, J=2.8 Hz, 1H),
8.48 (dd, J=4.8, 1.2 Hz, 1H), 8.11-8.08 (m, 1H), 7.99 (d, J=1.2 Hz,
1H), 7.78 (d, J=1.2 Hz, 1H), 7.38-7.35 (m, 1H), 6.53 (t, J=1.2 Hz,
1H); MS (m/z) 146 [M+1].
[0193] 3-(3-chloro-1H-pyrazol-1-yl)pyridine was prepared as in
Example 6, Step 1: mp 98-106.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.93 (d, J=2.6 Hz, 1H), 8.57 (dd, J=4.8, 1.4
Hz, 1H), 8.03 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.90 (d, J=2.5 Hz,
1H), 7.42 (ddd, J=8.3, 4.8, 0.7 Hz, 1H), 6.46 (d, J=2.5 Hz, 1H);
.sup.13C (DMSO-d.sub.6) 148, 142, 140, 136, 131, 126, 125, 108.
[0194] 2-methyl-3-(3-methyl-1H-pyrazol-1-yl)pyridine was prepared
as in Example 6, Step 1: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.53 (d, J=4.7 Hz, 1H), 7.67 (d, J=7.9 Hz, 1H), 7.54 (t, J=8.0 Hz,
1H), 7.27-7.19 (m, 1H), 6.27 (d, J=1.4 Hz, 1H), 2.53 (s, 3H), 2.38
(s, 3H).
[0195] 3-(3-(Trifluoromethyl)-1H-pyrazol-1-yl)pyridine was prepared
from the appropriate starting materials as described in Example 6,
Step 1: mp 59.0-61.0.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.00 (s, 1H), 8.70-8.59 (m, 1H), 8.11 (ddd, J=8.3, 2.7, 1.5
Hz, 1H), 8.05-7.98 (m, 1H), 7.46 (dd, J=8.3, 4.8 Hz, 1H), 6.79 (d,
J=2.4 Hz, 1H); EIMS m/z 213.
[0196] 3-Fluoro-5-(3-methyl-1H-pyrazol-1-yl)pyridine was prepared
from the appropriate starting materials as described in Example 6,
Step 1: mp 70.0-72.0.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.76-8.73 (m, 1H), 8.37-8.33 (m, 1H), 7.88-7.85 (m, 1H),
7.84-7.79 (m, 1H), 6.34-6.29 (m, 1H), 2.37 (s, 3H); EIMS m/z
177.
[0197] 3-(3-Chloro-1H-pyrazol-1-yl)-5-fluoropyridine was prepared
from the appropriate starting materials as described in Example 6,
Step 1: mp 77.0-82.0.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.75 (d, J=1.8 Hz, 1H), 8.43 (d, J=2.3 Hz, 1H), 7.92 (d,
J=2.6 Hz, 1H), 7.84 (dt, J=9.3, 2.4 Hz, 1H), 6.48 (d, J=2.6 Hz,
1H); EIMS m/z 198.
[0198] 3-(3-methyl-1H-pyrazol-1-yl)pyridine was prepared as
described in Example 6, Step 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.94 (bs, 1H), 8.51 (d, J=3.9 Hz, 1H), 8.02 (ddd, J=8.3,
2.6, 1.5 Hz, 1H), 7.90-7.79 (m, 1H), 7.39 (dd, J=8.2, 5.1 Hz, 1H),
6.30 (d, J=2.4 Hz, 1H), 2.39 (s, 3H).
[0199] 3-(5-methyl-1H-pyrazol-1-yl)pyridine was prepared as in
Example 6, Step 1: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.77
(d, J=2.5 Hz, 1H), 8.65 (dd, J=4.8, 1.5 Hz, 1H), 7.84 (ddd, J=8.2,
2.5, 1.5 Hz, 1H), 7.63 (d, J=1.6 Hz, 1H), 7.44 (ddd, J=8.2, 4.8,
0.7 Hz, 1H), 6.225 (dd, J=1.6, 0.7 Hz, 1H), 2.40 (s, 3H).
Example 6
Step 2: Preparation of 3-(4-nitro-pyrazol-1-yl)-pyridine
##STR00057##
[0201] 3-Pyrazol-1-yl-pyridine (2 g, 0.032 mol) was dissolved in
concentrated H.sub.2SO.sub.4 (32 mL 0.598 mmol) and cooled at
-5.degree. C. using an ice bath. To the reaction mass, a 1:1
mixture of concentrated HNO.sub.3 (30 mL, 0.673 mmol) and
concentrated H.sub.2SO.sub.4 (30 ml, 15 Vol.) was added dropwise
over a period of 30 min. Cooling was discontinued and the reaction
mixture was stirred at room temperature overnight. After the
reaction was complete, the mixture was poured over crushed ice and
neutralized with saturated NaHCO.sub.3, filtered, washed with water
and dried to furnish the nitro pyrazole as pale yellow solid (1.8
g, 68%): .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.03 (d, J=2.8
Hz, 1H); 8.70 (dd, J=4.8, 1.6 Hz, 1H), 8.69 (s, 1H), 8.33 (s, 1H),
8.11-8.08 (m, 1H), 7.51 (dd, J=8.4, 4.8 Hz, 1H); MS (m/z) 191
[M+1].
[0202] 3-(3-chloro-4-nitro-1H-pyrazol-1-yl)pyridine was prepared as
in Example 6, Step 2: mp 139-142.degree. C., .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.01 (d, J=2.0 Hz, 1H), 8.73 (d, J=4.9 Hz, 2H),
8.08 (ddd, J=8.3, 2.5, 1.3 Hz, 1H), 7.52 (dd, J=8.3, 4.8 Hz, 1H),
EIMS m/z 224.
[0203] 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)pyridine was prepared as
in Example 6, Step 2: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.81-8.71 (m, 2H), 8.32 (s, 1H), 7.83 (ddd, J=8.2, 2.5, 1.6 Hz,
1H), 7.54 (dd, J=8.2, 4.8 Hz, 1H), 2.72 (s, 3H).
[0204] 2-methyl-3-(3-methyl-4-nitro-1H-pyrazol-1-yl)pyridine was
prepared as in Example 6, Step 2: .sup.1H NMR (400 MHz,
d.sub.6-DMSO) .delta. 14.01 (s, 1H), 9.37 (d, J=4.0 Hz, 1H), 8.69
(t, J=17.3 Hz, 1H), 8.21 (dd, J=7.7, 4.8 Hz, 1H), 2.29 (s, 3H),
2.20 (s, 3H); .sup.13C 154, 150, 146, 135, 134.9, 134.8, 134.3,
122, 21, 14; EIMS m/z 218.
[0205] 3-(3-methyl-4-nitro-1H-pyrazol-1-yl)pyridine was prepared as
in Example 6, Step 2: mp 122-124.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.01 (d, J=2.5 Hz, 1H), 8.77-8.56 (m, 2H), 8.07
(ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.56-7.37 (m, 1H), 2.66 (s, 3H);
EIMS m/z 208.
[0206] 3-Fluoro-5-(3-methyl-4-nitro-1H-pyrazol-1-yl)pyridine was
prepared from the appropriate starting material as described in
Example 6, Step 2: mp 90.0-92.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.82 (d, J=2.0 Hz, 1H), 8.69 (s, 1H), 8.54 (d,
J=2.5 Hz, 1H), 7.89 (dt, J=8.9, 2.4 Hz, 1H), 2.66 (s, 3H); EIMS m/z
222.
[0207] 3-(4-Nitro-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine was
prepared from the appropriate starting material as described in
Example 6, Step 2: mp 121.0-123.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.04 (d, J=2.5 Hz, 1H), 8.79 (s, 1H), 8.77 (d,
J=0.9 Hz, 1H), 8.13 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.55 (dt,
J=10.8, 5.4 Hz, 1H); EIMS m/z 258.
[0208] 3-(3-Chloro-4-nitro-1H-pyrazol-1-yl)-5-fluoropyridine was
prepared from the appropriate starting material as described in
Example 6, Step 2: mp 109.5-111.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.83 (d, J=2.1 Hz, 1H), 8.75 (s, 1H), 8.60 (d,
J=2.4 Hz, 1H), 7.89 (dt, J=8.6, 2.4 Hz, 1H); EIMS m/z 242.
[0209] 3-(3-Bromo-4-nitro-1H-pyrazol-1-yl)pyridine was prepared
from the appropriate starting material as described in Example 6,
Step 2: mp 139.0-141.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.01 (d, J=2.5 Hz, 1H), 8.73 (dd, J=4.7, 1.1
Hz, 1H), 8.71 (s, 1H), 8.15-8.00 (m, 1H), 7.52 (dd, J=8.3, 4.8 Hz,
1H); ESIMS m/z 271 ([M+2].sup.+).
Example 6
Step 3: Preparation of 1-pyridin-3-yl-1H-pyrazol-4-ylamine
##STR00058##
[0211] To a solution of 3-(4-nitro-pyrazol-1-yl)-pyridine (1.8 g,
0.009 mol) in dry THF (18 mL) was added 5% Pd/C (180 mg) under
nitrogen atmosphere. The mixture was then stirred under hydrogen
atmosphere until the reaction was complete. The reaction mixture
was filtered through a pad of celite, and concentrated to dryness
to give an impure dark brown solid (1.76 g): .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.89 (dd, J=2.8. 0.4 Hz, 1H); 8.48 (dd,
J=4.8, 1.2 Hz, 1H), 7.99-7.96 (m, 1H), 7.54 (d, J=1.2 Hz, 1H), 7.45
(d, J=0.4 Hz, 1H), 7.38-7.35 (m, 1H), 4.81 (bs 1H); ESIMS (m/z) 161
[M+1].
[0212] 5-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was prepared as
in Example 6, Step 3: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.74 (d, J=2.3 Hz, 1H), 8.63-8.50 (m, 1H), 7.81 (ddd, J=8.2, 2.5,
1.5 Hz, 1H), 7.46-7.33 (m, 2H), 2.64 (bs, 1H), 2.29 (s, 3H);
.sup.13C (DMSO-d.sub.6) 147, 144, 137, 133, 130, 129, 124, 123, 10;
EIMS m/z 174
[0213] 3-methyl-1-(pyrimidin-5-yl)-1H-pyrazol-4-amine was prepared
as in Example 6, Step 3: mp 211-215.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 9.10-8.87 (m, 3H), 7.51 (s, 1H), 3.24 (bs,
2H), 2.29 (s, 3H); ESIMS m/z 176 ([M+H]).
[0214] 3-chloro-1-(pyrimidin-5-yl)-1H-pyrazol-4-amine was prepared
as in Example 6, Step 3: mp 146-148.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 9.07 (s, 1H), 9.02 (s, 2H), 7.52 (s, 1H),
3.45 (s, 2H); ESIMS m/z 196 ([M+H]).
Example 7
Preparation of methyl-(1-pyridin-3-yl-1H-pyrazol-4-yl)-amine
##STR00059##
[0216] To a 25 ml round bottom flask containing
1-pyridin-3-yl-1H-pyrazol-4-ylamine (1.76 g, 0.011 mol) in ethanol
(26.4 mL) was added benzotriazole (1.31 g, 0.011 mol). The reaction
was cooled at 0.degree. C.-10.degree. C. and formaldehyde (0.36 mL,
0.0121 mol) was added slowly and kept for 30 min at this
temperature. The reaction was filtered and concentrated to dryness.
The crude material (2.56 g, 0.009 mol) was dissolved in dry
tetrahydrofuran (25.6 mL), cooled to 0.degree. C. and sodium
borohydride (0.326 g, 0.00882 mol.) was added over 15 min. The
reaction was warmed to room temperature and stirred for 2 hours.
The reaction was poured into water and extracted using
dichloromethane, the organic layer was dried over anhydrous
Na.sub.2SO.sub.4 and concentrated to dryness. Purified the crude
material by silica gel chromatography eluting with 20%
methanol/chloroform to afford the desired product as a brown solid
(0.610 g, 32%): .sup.1H NMR (400 MHz, d.sub.6-DMSO) .delta. 8.92
(d, J=2.4 Hz, 1H), 8.47 (dd, J=4.8, 1.6 Hz, 1H), 8.01-7.98 (m, 1H),
7.45 (s, 1H), 7.30 (s, 1H), 7.37 (dd, J=8.0, 4.4 Hz, 1H), 2.84 (s,
3H); ESIMS m/z 175 ([M+1]).
Method B:
[0217] 1-pyridin-3-yl-1H-pyrazol-4-ylamine (1.0 g, 6.2 mmol) was
dissolved in triethyl orthoformate (5 mL, 30 mmol) and to that was
added trifluoroacetic acid (3-4 drops). The reaction mixture was
refluxed at 120.degree. C. for 3 hours and was then concentrated.
The crude was dissolved in ethanol (5 ml), cooled to 0.degree. C.
and treated with sodium borohydride (0.6 g, 15.7 mmol). After
warming to room temperature, the mixture was refluxed for 3 hours.
The mixture was concentrated and the residue was suspended between
water and diethyl ether. The diethyl ether layer was separated and
concentrated to dryness. The crude material was purified by silica
gel chromatography, eluting with 5% methanol/chloroform to afford
the desired product as a pale yellow solid (0.3 g, 27%): mp
65-67.degree. C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.91
(bs, 1H), 8.46 (d, J=4.5 Hz, 1H), 7.99 (d, J=8.3 Hz, 1H), 7.43 (s,
1H), 7.41 (s, 1H), 7.36 (dd, J=8.3, 4.7 Hz, 1H), 2.86 (d, J=12.4
Hz, 3H); ESIMS m/z 175 ([M+1]).
Example 8
Preparation of ethyl-(1-pyridin-3-yl-1H-pyrazol-4-yl)-amine
##STR00060##
[0218] Method A:
[0219] To 1-pyridin-3-yl-1H-pyrazol-4-ylamine (0.5 g, 3.12 mmol) in
dichloromethane (5 mL) was added acetyl chloride (0.28 g, 3.75
mmol) followed by DMAP (0.57 g, 4.68 mmol) and stirred at room
temperature for 3 hours. The reaction mixture was concentrated and
purified by silica gel column chromatography. The recovered
material was dissolved in tetrahydrofuran (5 mL) and lithium
aluminum hydride (0.23 g, 6.25 mmol) was added and stirred at room
temperature for 12 hours. The reaction was quenched with saturated
Na.sub.2SO.sub.4 and filtered through celite. The filtrate was
collected and concentrated to dryness. The crude material was
purified by silica gel column chromatography eluting with 0-5%
methanol/chloroform and resubjected to silica gel chromatography,
eluting with 0-100% ethyl acetate/hexanes) to give the desired
product (0.080 g, 14%): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.90 (d, J=2.7 Hz, 1H), 8.46 (dd, J=4.7, 1.3 Hz, 1H), 7.98 (ddd,
J=8.3, 2.6, 1.5 Hz, 1H), 7.41 (dt, J=13.3, 6.6 Hz, 2H), 7.36 (ddd,
J=8.3, 4.7, 0.7 Hz, 1H), 3.10 (q, J=7.1 Hz, 2H), 1.27 (t, 3H).
Method B:
[0220] To a solution of tert-butyl
ethyl(1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (3.4 g, 11.79
mmol) in dichloromethane (4.54 mL) was added trifluoroacetic acid
(9 mL), and the reaction mixture was stirred for 1 hour at room
temperature. Toluene was added and the reaction was concentrated to
near dryness. The reaction was poured into a separatory funnel and
carefully quenched with saturated aqueous NaHCO.sub.3 and extracted
with dichloroethane.
[0221] The organic layer was dried (MgSO.sub.4), filtered and
concentrated to dryness. The crude product was purified by silica
gel chromatography (0-10% MeOH/dichloromethane) to give the desired
product as a pale yellow oil (2.10 g, 95%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.90 (dd, J=1.8, 0.8 Hz, 1H), 8.51-8.39 (m,
1H), 7.97 (ddt, J=8.3, 2.7, 1.3 Hz, 1H), 7.41 (d, J=0.8 Hz, 2H),
7.38-7.30 (m, 1H), 3.21-2.93 (m, 2H), 1.34-1.19 (m, 3H).
[0222] 3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared as described in Example 8, Method B: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.87 (d, J=2.5 Hz, 1H), 8.47 (dd, J=4.7, 1.2
Hz, 1H), 7.96 (ddd, J=8.4, 2.6, 1.4 Hz, 1H), 7.38-7.32 (m, 2H),
3.11 (q, J=7.1 Hz, 2H), 2.97 (bs, 1H), 1.31 (t, J=7.1 Hz, 3H).
[0223] 3-chloro-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared as in Example 8, Method B: mp 108-118 C; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.88 (d, J=2.4 Hz, 1H), 8.48 (dd, J=4.7,
1.4 Hz, 1H), 7.96 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.41-7.29 (m, 2H),
2.87 (s, 3H); EIMS m/z 208.
[0224] N,3-dimethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared as in Example 8, Method B: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.03-8.73 (m, 1H), 8.41 (dd, J=4.7, 1.4 Hz,
1H), 7.95 (ddd, J=8.4, 2.7, 1.4 Hz, 1H), 7.42-7.27 (m, 2H), 2.85
(s, 4H), 2.25 (s, 3H); EIMS m/z 189
[0225]
3-chloro-N-(cylopropylmethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine
was prepared as in Example 8, Method B: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.5 Hz, 1H), 8.47 (dd, J=4.7, 1.4
Hz, 1H), 8.03-7.89 (m, 1H), 7.40-7.29 (m, 2H), 3.21 (s, 1H), 2.91
(d, J=4.4 Hz, 2H), 1.18-1.02 (m, 1H), 0.65-0.45 (m, 2H), 0.41-0.12
(m, 2H).
[0226] 3-chloro-N-propyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared as in Example 8, Method B: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.6 Hz, 1H), 8.47 (dd, J=4.7, 1.4
Hz, 1H), 8.01-7.89 (m, 1H), 7.42-7.27 (m, 2H), 3.23-2.84 (m, 3H),
1.77-1.59 (m, 2H), 1.03 (t, J=7.4 Hz, 3H).
[0227] 1-(5-Fluoropyridin-3-yl)-N, 3-dimethyl-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: mp 142.0-143.5.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.67 (s, 1H), 8.26 (d, J=2.3 Hz, 1H), 7.73 (dt,
J=10.0, 2.4 Hz, 1H), 7.27 (s, 1H), 2.92-2.81 (m, 4H), 2.24 (s, 3H);
ESIMS m/z 207 ([M+H].sup.+).
[0228] N-ethyl-1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: mp 85.0-86.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.66 (s, 1H), 8.25 (d, J=2.5 Hz, 1H), 7.72 (dt,
J=10.0, 2.3 Hz, 1H), 7.27 (s, 1H), 3.07 (q, J=7.1 Hz, 2H), 2.71 (s,
1H), 2.25 (s, 3H), 1.30 (t, J=7.1 Hz, 3H); ESIMS m/z 221
([M+H].sup.+).
[0229] 3-Methyl-N-propyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: mp 65.0-67.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.4 Hz, 1H), 8.40 (dd, J=4.7, 1.4
Hz, 1H), 7.94 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.35-7.28 (m, 2H),
3.00 (t, J=7.1 Hz, 2H), 2.26 (s, 3H), 1.76-1.58 (m, 2H), 1.03 (t,
J=7.4 Hz, 3H); ESIMS m/z 217 ([M+H].sup.+).
[0230]
N-(cyclopropylmethyl)-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: mp 73.0-75.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.4 Hz, 1H), 8.40 (dd, J=4.7, 1.3
Hz, 1H), 7.94 (ddd, J=8.3, 2.6, 1.5 Hz, 1H), 7.35-7.28 (m, 2H),
2.87 (d, J=6.9 Hz, 2H), 2.75 (s, 1H), 2.28 (s, 3H), 1.22-1.05 (m,
1H), 0.63-0.56 (m, 2H), 0.26 (q, J=4.7 Hz, 2H); ESIMS m/z 229
([M+H].sup.+).
[0231] N-isopropyl-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: IR (thin film) 3303 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.3 Hz, 1H), 8.41 (dd, J=4.7, 1.4
Hz, 1H), 7.94 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.36-7.28 (m, 2H),
3.30 (hept, J=6.3 Hz, 1H), 2.25 (s, 3H), 1.24 (d, J=6.3 Hz, 6H);
EIMS m/z 216.
[0232]
5-Ethoxy-1-(5-fluoropyridin-3-yl)-N,3-dimethyl-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: IR (thin film) 3340 cm.sup.-1; H NMR (400 MHz,
CDCl.sub.3) .delta. 8.91 (s, 1H), 8.31 (d, J=2.5 Hz, 1H), 7.88-7.80
(m, 1H), 4.24 (q, J=7.1 Hz, 2H), 2.79 (s, 3H), 2.24 (s, 3H), 1.36
(t, J=7.1 Hz, 3H); EIMS m/z 250.
[0233] 5-Bromo-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: mp 77.0-79.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.90 (d, J=2.0 Hz, 1H), 8.63 (d, J=3.9 Hz, 1H),
7.93 (ddd, J=8.2, 2.4, 1.5 Hz, 1H), 7.51 (s, 1H), 7.43 (dd, J=8.2,
4.8 Hz, 1H), 4.49 (s, 1H), 2.91 (s, 3H); ESIMS m/z 255
([M+2].sup.+).
[0234] 5-Fluoro-N, 3-dimethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.91 (t,
J=2.1 Hz, 1H), 8.50 (dd, J=4.8, 1.5 Hz, 1H), 7.93 (ddt, J=8.3, 2.8,
1.5 Hz, 1H), 7.37 (ddd, J=8.3, 4.8, 0.7 Hz, 1H), 2.86 (d, J=1.6 Hz,
3H), 2.43 (s, 2H), 2.24 (s, 3H); EIMS m/z 206.
[0235] 5-Bromo-N, 3-dimethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.86 (dd,
J=2.5, 0.5 Hz, 1H), 8.59 (dd, J=4.8, 1.5 Hz, 1H), 7.88 (ddd, J=8.2,
2.6, 1.5 Hz, 1H), 7.40 (ddd, J=8.2, 4.8, 0.7 Hz, 1H), 2.85 (s, 3H),
2.69 (s, 1H), 2.35 (s, 3H); ESIMS m/z 268 ([M+H].sup.+).
[0236] 5-Chloro-N, 3-dimethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.87 (d,
J=2.3 Hz, 1H), 8.59 (dd, J=4.8, 1.3 Hz, 1H), 7.90 (ddd, J=8.2, 2.6,
1.5 Hz, 1H), 7.40 (ddd, J=8.2, 4.8, 0.6 Hz, 1H), 2.87 (s, 3H),
2.45-2.19 (m, 4H); EIMS m/z 223.
[0237]
3-Chloro-1-(5-fluoropyridin-3-yl)-N-methyl-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: mp 117.5-119.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.68 (d, J=1.1 Hz, 1H), 8.33 (d, J=2.5 Hz, 1H),
7.75 (dt, J=9.6, 2.4 Hz, 1H), 7.31 (s, 1H), 3.14 (s, 1H), 2.87 (s,
3H); ESIMS m/z 227 ([M].sup.+).
[0238] 3-Chloro-N-ethyl-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-amine
amine was prepared from the appropriate Boc-amine as described in
Example 8, Method B: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.70-8.63 (m, 1H), 8.32 (d, J=2.4 Hz, 1H), 7.74 (dt, J=9.7, 2.4 Hz,
1H), 7.31 (s, 1H), 3.11 (q, J=7.2 Hz, 2H), 1.31 (t, J=7.1 Hz,
3H).
[0239] 1-(5-Fluoropyridin-3-yl)-N-methyl-3-vinyl-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: 105.0-107.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.72 (s, 1H), 8.31 (d, J=2.5 Hz, 1H), 7.81 (dt,
J=9.8, 2.4 Hz, 1H), 7.33 (s, 1H), 6.75 (dd, J=18.0, 11.6 Hz, 1H),
5.83 (dd, J=18.0, 1.1 Hz, 1H), 5.46 (dd, J=11.6, 1.1 Hz, 1H), 2.86
(s, 3H); ESIMS m/z 219 ([M+H].sup.+).
[0240]
3-Cyclopropyl-1-(5-fluoropyridin-3-yl)-N-methyl-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: mp 118.0-119.5.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.66-8.58 (m, 1H), 8.23 (d, J=2.5 Hz, 1H),
7.75-7.68 (m, 1H), 7.25 (s, 1H), 3.09 (s, 1H), 2.86 (s, 3H),
1.78-1.63 (m, 1H), 0.99-0.90 (m, 4H); ESIMS m/z 233
([M+H].sup.+).
[0241] 3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine was prepared
from the appropriate Boc-amine as described in Example 8, Method B:
mp 137.9-139.9; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.84 (d,
J=2.4 Hz, 1H), 8.50 (dd, J=4.7, 1.4 Hz, 1H), 7.95 (ddd, J=8.3, 2.7,
1.5 Hz, 1H), 7.52 (s, 1H), 7.37 (ddd, J=8.4, 4.7, 0.7 Hz, 1H), 3.18
(s, 2H); ESIMS m/z 196 ([M+H].sup.+).
[0242]
2-((3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)acetonitrile
was prepared from
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(cyanomethyl)carbama-
te as in Example 8, Method B: mp 141-143.degree. C.; .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 8.91 (d, J=2.7 Hz, 1H), 8.54 (dd,
J=5.1, 1.8 Hz, 1H), 7.97 (m, 1H), 7.62 (s, 1H), 7.38 (dd, J=12.0,
7.5 Hz, 1H), 4.97 (d, J=6.9 Hz, 2H), 3.52 (m, 1H); EIMS m/z 235
([M+1].sup.+).
[0243] N-3-dimethyl-1-(pyrimidin-5-yl)-1H-pyrazol-4-amine was
prepared as in Example 8, Method B: mp 139-143.degree. C.; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 9.02 (s, 2H), 9.00 (s, 1H), 7.30
(s, 1H), 2.87 (d, J=11.5 Hz, 3H), 2.27 (s, 3H); ESIMS m/z 190
([M+H]).
[0244] 3-chloro-N-methyl-1-(pyrimidin-5-yl)1-1H-pyrazol-4-amine was
prepared as in Example 8, Method B: mp 111-114.degree. C.; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 9.09-9.04 (m, 1H), 9.02 (s, 2H),
7.30 (s, 1H), 3.14 (bs, 1H), 2.88 (s, 3H); ESIMS m/z 196
([M+H]).
[0245]
1-(5-Fluoro-3-pyridyl)-3-methyl-N-(trideuteriomethyl)pyrazol-4-amin-
e was prepared from compound 380 using the procedure as described
in Example 8, method B: mp 146-148.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.67 (s, 1H), 8.25 (d, J=2.5 Hz, 1H), 7.73
(dt, J=10.0, 2.3 Hz, 1H), 7.27 (s, 1H), 2.87 (s, 1H), 2.24 (s, 3H);
ESIMS m/z 210 ([M+H].sup.+); IR (Thin film) 1599 cm.sup.-1.
[0246] 3-Chloro-1-(3-pyridyl)-N-(trideuteriomethyl)pyrazol-4-amine
was prepared from compound 381 using the procedure as described in
Example 8, method B: mp 104-106.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.87 (d, J=1.9 Hz, 1H), 8.47 (d, J=4.7 Hz, 1H),
8.00-7.90 (m, 1H), 7.40-7.30 (m, 2H), 3.10 (s, 1H); ESIMS m/z 212
([M+H].sup.+); IR (Thin film) 1579 cm.sup.-1.
[0247]
3-Chloro-N-(cyclopropylmethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine
was prepared from compound 361 using the procedure as described in
Example 8, method B: mp 82-83.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.5 Hz, 1H), 8.47 (dd, J=4.7, 1.3
Hz, 1H), 7.95 (ddd, J=8.4, 2.7, 1.5 Hz, 1H), 7.38-7.32 (m, 2H),
3.22 (s, 1H), 2.90 (d, J=6.9 Hz, 2H), 1.23-1.06 (m, 1H), 0.65-0.53
(m, 2H), 0.31-0.19 (m, 2H).; ESIMS m/z 249 ([M+H].sup.+);
[0248] 3-Chloro-N-propyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from compound 360 using the procedure as described in
Example 8, method B: mp 92-94.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.6 Hz, 1H), 8.47 (dd, J=4.7, 1.4
Hz, 1H), 7.95 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.35 (ddd, J=8.4, 4.7,
0.6 Hz, 1H), 7.33 (s, 1H), 3.22-2.94 (m, 3H), 1.75-1.52 (m, 2H),
1.02 (t, J=7.4 Hz, 3H); ESIMS m/z 237 ([M+H].sup.+).
[0249]
3-Chloro-1-(pyridin-3-yl)-N-(4,4,4-trifluorobutyl)-1H-pyrazol-4-ami-
ne was prepared from the appropriate Boc-amine as described in
Example 8, Method B: IR (thin film) 3416, 3089 cm.sup.-1; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.86 (d, J=2.5 Hz, 1H), 8.48 (dd,
J=4.7, 1.3 Hz, 1H), 7.95 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.42-7.31
(multiple peaks, 2H), 3.16 (dd, J=13.0, 6.5 Hz, 2H), 3.08 (d, J=5.6
Hz, 1H), 2.35-2.18 (m, 2H), 2.00-1.86 (m, 2H); ESIMS m/z 307
([M+2H].sup.+).
[0250]
3-Chloro-1-(pyridin-3-yl)-N-(5,5,5-trifluoropentyl)-1H-pyrazol-4-am-
ine was prepared from the appropriate Boc-amine as described in
Example 8, Method B: IR (thin film) 3087 cm.sup.-1; .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.86 (d, J=2.5 Hz, 1H), 8.48 (dd,
J=4.7, 1.4 Hz, 1H), 7.96 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.36 (ddd,
J=8.3, 4.8, 0.6 Hz, 1H), 7.34 (s, 1H), 3.10 (s, 2H), 3.04 (s, 1H),
2.30-1.98 (m, 2H), 1.84-1.69 (multiple peaks, 4H); .sup.19F NMR
(376 MHz, CDCl.sub.3) .delta.-66.28; ESIMS m/z 320
([M+2H].sup.+).
[0251]
3-Chloro-N-(4-fluorobutyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: mp 82-83.degree. C.; IR (thin film) 3348, 3086 cm.sup.-1;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.86 (d, J=2.5 Hz, 1H),
8.47 (dd, J=4.7, 1.4 Hz, 1H), 7.95 (ddd, J=8.3, 2.7, 1.5 Hz, 1H),
7.38-7.33 (multiple peaks, 2H), 4.58 (t, J=5.7 Hz, 1H), 4.50-4.42
(m, 1H), 3.11 (multiple peaks, 3H), 1.90-1.76 (multiple peaks, 4H);
ESIMS m/z 269 ([M+H].sup.+).
[0252] 3-Chloro-N-isopropyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: IR (thin film) 3318, 1583 cm.sup.-1; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.86 (d, J=2.7 Hz, 1H), 8.47 (dd, J=4.7,
1.4 Hz, 1H), 7.96 (ddd, J=8.4, 2.7, 1.5 Hz, 1H), 7.36 (ddd, J=8.3,
4.8, 0.7 Hz, 1H), 7.31 (s, 1H), 2.87 (d, J=6.8 Hz, 2H), 1.92 (dq,
J=13.4, 6.7 Hz, 1H), 1.02 (d, J=6.7 Hz, 6H); ESIMS m/z 251
([M+H].sup.+).
[0253]
3-Chloro-N-(2-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: IR (thin film) 3364, 1485 cm.sup.-1; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.86 (dd, J=2.7, 0.7 Hz, 1H), 8.48 (dd,
J=4.7, 1.5 Hz, 1H), 7.96 (ddd, J=8.4, 2.7, 1.5 Hz, 1H), 7.38 (s,
1H), 7.38-7.34 (m, 1H), 3.68-3.59 (m, 2H), 3.49 (s, 1H), 3.42 (s,
3H), 3.24 (d, J=7.3 Hz, 2H); ESIMS m/z 253 ([M+H].sup.+).
[0254]
3-Chloro-N-((2,2-difluorocyclopropyl)methyl)-1-(pyridin-3-yl)-1H-py-
razol-4-amine was prepared from the appropriate Boc-amine as
described in Example 8, Method B: H NMR (400 MHz, CDCl.sub.3)
.delta. 8.87 (d, J=2.6 Hz, 1H), 8.49 (dd, J=4.7, 1.5 Hz, 1H), 7.96
(ddd, J=8.4, 2.7, 1.4 Hz, 1H), 7.41 (s, 1H), 7.37 (ddd, J=8.3, 4.7,
0.7 Hz, 1H), 3.19 (td, J=15.5, 13.0, 6.8 Hz, 2H), 2.00-1.84 (m,
1H), 1.55 (m, 1H), 1.26 (s, 1H), 1.23-1.11 (m, 1H); .sup.19F NMR
(376 MHz, CDCl.sub.3) .delta.-128.61 (d, J=159.5 Hz), -143.58 (d,
J=160.0 Hz); ESIMS m/z 285 ([M+H].sup.+).
[0255]
3-Chloro-N-(3-fluoropropyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: IR (thin film) 3359 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.87 (d, J=2.7 Hz, 1H), 8.48 (dd, J=4.7, 1.4
Hz, 1H), 7.95 (ddd, J=8.3, 2.6, 1.4 Hz, 1H), 7.39-7.34 (multiple
peaks, 2H), 4.63 (dt, J=47.2, 5.6 Hz, 2H), 3.25 (t, J=6.7 Hz, 2H),
3.18 (br s, 1H), 2.17-1.92 (m, 2H); ESIMS m/z 255
([M+H].sup.+).
[0256] N-allyl-3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: IR (thin film) 3291 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.85 (d, J=2.6 Hz, 1H), 8.48 (dd, J=4.8, 1.5
Hz, 1H), 7.95 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.38-7.35 (m, 1H),
7.34 (s, 1H), 5.97 (ddt, J=17.3, 10.6, 5.5 Hz, 1H), 5.34 (dq,
J=17.2, 1.6 Hz, 1H), 5.23 (dq, J=10.3, 1.5 Hz, 1H), 3.73 (dt,
J=5.5, 1.6 Hz, 2H), 3.25 (s, 1H); ESIMS m/z 235 ([M+H].sup.+).
[0257] 2-((3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)ethyl
acetate was prepared from the appropriate Boc-amine as described in
Example 8, Method B: IR (thin film) 3361, 1733 cm.sup.-1; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.87 (s, 1H), 8.49 (d, J=4.7 Hz,
1H), 7.96 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.43 (s, 1H), 7.37 (dd,
J=8.4, 4.7 Hz, 1H), 4.30 (dd, J=5.9, 4.8 Hz, 2H), 3.34 (t, J=5.5
Hz, 2H), 2.12 (s, 3H), 1.59 (s, 1H); ESIMS m/z 281
([M+H].sup.+).
[0258]
3-Chloro-N-(2-fluoroethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: IR (thin film) 3369 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.7 Hz, 1H), 8.49 (dd, J=4.7, 1.4
Hz, 1H), 7.96 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.40 (s, 1H), 7.37
(dd, J=8.3, 4.7 Hz, 1H), 4.82-4.53 (m, 2H), 3.54-3.27 (multiple
peaks, 3H); ESIMS m/z 241 ([M+H].sup.+).
[0259]
3-Chloro-1-(pyridin-3-yl)-N-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrazol-4-
-amine was prepared from the appropriate Boc-amine as described in
Example 8, Method B: ESIMS m/z 292 ([M+H].sup.+).
[0260]
3-Chloro-N-(2,2-difluoroethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine
was prepared from the appropriate Boc-amine as described in Example
8, Method B: IR (thin film) 3295 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.87 (dd, J=2.8, 0.7 Hz, 1H), 8.51 (dd, J=4.7,
1.4 Hz, 1H), 7.95 (ddd, J=8.4, 2.7, 1.5 Hz, 1H), 7.45 (s, 1H), 7.37
(ddd, J=8.5, 4.7, 0.8 Hz, 1H), 5.96 (tt, J=55.9, 4.1 Hz, 1H),
3.69-3.26 (multiple peaks, 3H); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta.-122.15; ESIMS m/z 259 ([M+H].sup.+).
[0261]
3-Chloro-1-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazol-4-ami-
ne was prepared from the appropriate Boc-amine as described in
Example 8, Method B: IR (thin film) 3309 cm.sup.-1; .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.92-8.85 (m, 1H), 8.52 (dd, J=4.8,
1.4 Hz, 1H), 7.98 (ddd, J=8.4, 2.7, 1.5 Hz, 1H), 7.47 (s, 1H), 7.40
(ddd, J=8.4, 4.8, 0.7 Hz, 1H), 3.68 (q, J=8.9 Hz, 2H), 3.49 (s,
1H); .sup.19F NMR (376 MHz, CDCl.sub.3) .delta.-72.29; ESIMS m/z
277 ([M+H].sup.+).
[0262]
3-Chloro-N-(2-chloroethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: IR (thin film) 3354 cm.sup.-1; H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (dd, J=2.7, 0.7 Hz, 1H), 8.50 (dd, J=4.8,
1.5 Hz, 1H), 7.96 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.40 (s, 1H), 7.37
(ddd, J=8.5, 4.8, 0.8 Hz, 1H), 3.76 (dd, J=6.0, 5.4 Hz, 2H), 3.54
(s, 1H), 3.43 (t, J=5.7 Hz, 2H); ESIMS m/z 257 ([M+H].sup.+).
[0263]
3-Chloro-1-(pyridin-3-yl)-N-(3,3,3-trifluoropropyl)-1H-pyrazol-4-am-
ine was prepared from the appropriate Boc-amine as described in
Example 8, Method B: IR (thin film) 3366, 3081 cm.sup.-1; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.87 (dd, J=2.6, 0.7 Hz, 1H),
8.50 (dd, J=4.7, 1.4 Hz, 1H), 7.96 (ddd, J=8.3, 2.7, 1.4 Hz, 1H),
7.40-7.35 (multiple peaks, 2H), 3.38 (q, J=6.8 Hz, 2H), 3.22 (t,
J=6.7 Hz, 1H), 2.48 (qt, J=10.7, 7.0 Hz, 2H); .sup.19F NMR (376
MHz, CDCl.sub.3) .delta.-64.99; ESIMS m/z 291 ([M+H].sup.+).
[0264]
N-(but-2-yn-1-yl)-3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate Boc-amine as described in Example 8,
Method B: IR (thin film) 3249, 3122 cm.sup.-1; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.89 (dd, J=2.7, 0.7 Hz, 1H), 8.49 (dd,
J=4.8, 1.5 Hz, 1H), 7.98 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.50 (s,
1H), 7.37 (ddd, J=8.4, 4.8, 0.8 Hz, 1H), 3.93-3.68 (m, 2H), 3.33
(s, 1H), 1.83 (t, J=2.4 Hz, 3H); ESIMS m/z 247 ([M+H].sup.+).
[0265] 3-Chloro-N-isobutyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was
prepared as in Example 8, Method B: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.5 Hz, 1H), 8.47 (dd, J=4.7, 1.3
Hz, 1H), 7.95 (ddd, J=8.4, 2.7, 1.5 Hz, 1H), 7.35 (ddd, J=8.3, 4.7,
0.6 Hz, 1H), 7.31 (s, 1H), 3.11 (bs, 1H), 2.87 (t, J=6.5 Hz, 2H),
1.93 (dp, J=13.4, 6.7 Hz, 1H), 1.01 (d, J=6.7 Hz, 6H).
Example 9
Preparation of isopropyl-(1-pyridin-3-yl-1H-pyrazol-4-yl)-amine
##STR00061##
[0267] 1-pyridin-3-yl-1H-pyrazol-4-ylamine (0.6 g, 3.7 mmol) was
dissolved in isopropyl acetate (8.5 mL). To the mixture, acetone
(0.261 g, 4.5 mmol), trifluoroacetic acid (0.855 g, 7.5 mmol) and
sodium triacetoxyborohydride (0.945 g, 4.5 mmol) were added. The
reaction was stirred under nitrogen at room temperature for 4.5
hours and then quenched with 10% sodium hydroxide solution until
the pH reached .about.9. The layers were separated, and the aqueous
phase was extracted with ethyl acetate. The organic extracts were
combined, dried over sodium sulfate and concentrated to dryness.
The crude material was purified by silica gel chromatography
(gradient elution of 5% methanol/dichloromethane) to give the title
compound as an off white solid (0.35 g, 46%): mp 105-107.degree.
C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.82 (d, J=2.2 Hz,
1H), 8.63 (dd, J=4.8, 1.5 Hz, 1H), 8.13 (d, J=1.8 Hz, 1H), 8.03 (d,
J=2.7 Hz, 1H), 7.94-7.77 (m, 1H), 7.38 (dt, J=15.2, 7.6 Hz, 1H),
6.99 (t, 1H), 3.72 (m, 1H), 1.30 (t, J=10.0 Hz, 6H). ESIMS 214 m/z
(M+1).
Example 10
Preparation of propyl-(1-pyridin-3-yl-1H-pyrazol-4-yl-amine
##STR00062##
[0269] To 1-pyridin-3-yl-1H-pyrazol-4-ylamine (0.5 g, 3.12 mmol) in
dichloromethane (5 mL) was added propionaldehyde (0.18 g, 3.12
mmol) and sodium triacetoxy borohydride (0.99 g, 4.68 mmol) and
stirred at room temperature for 16 hours. The reaction was taken up
in dichloromethane and was washed with water and brine. The organic
layer was dried (MgSO.sub.4), filtered and concentrated to dryness.
The crude material was purified by silica gel chromatography
eluting with 0-5% MeOH/Dichloromethane and resubjected in 0-100%
ethylacetate/hexanes) to give the title compound as a dark oil
(0.05 g, 7%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.92 (d,
J=2.6 Hz, 1H), 8.48 (dd, J=4.7, 1.4 Hz, 1H), 8.00 (ddd, J=8.3, 2.7,
1.5 Hz, 1H), 7.47-7.40 (m, 2H), 7.37 (dd, J=8.3, 4.7 Hz, 1H), 3.04
(t, J=7.1 Hz, 3H), 1.92-1.46 (m, 2H), 1.03 (t, J=7.4 Hz, 3H).
Example 11
Preparation of
N-methyl-N-(1-pyridin-3-yl-1H-pyrazol-4-yl)-isobutyramide (Compound
42)
##STR00063##
[0271] A solution of isobutyryl chloride (0.138 g, 1.3 mmol) in
dichloroethane (1 mL) was pipetted at a dropwise rate into an
ice-cold suspension of
methyl-(1-pyridin-3-yl-1H-pyrazol-4-yl)-amine (0.15 g, 0.86 mmol)
in dichloroethane (5 mL), stirred for 10 minutes and then treated
at a dropwise rate with a solution of 4-N,N-dimethylaminopyridine
(0.11 g, 0.9 mmol) in dichloroethane (1.5 mL). The cooling bath was
removed after 30 minutes, stirred under nitrogen at room
temperature for 14 hours, diluted with dichloroethane (40 mL),
washed with water (30 mL), brine (10 mL), dried over MgSO.sub.4 and
purified by reversed phase column chromatography to give a
yellowish gum (0.114 g, 54%) .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 9.01-8.93 (m, 1H), 8.67 (s, 0.4H), 8.61 (d, J=4.2 Hz,
0.6H), 8.54 (d, 0.4H), 8.08-8.02 (m, 1H), 7.96 (s, 0.6H), 7.80 (s,
0.4H), 7.70 (s, 0.6H), 7.47-7.37 (m, 1H), 3.49 (s, 1.2H), 3.26 (s,
2.8H), 3.06-2.98 (m, 0.4H), 2.86-2.70 (m, 0.6H), 1.25 (d, J=6.1 Hz,
2.4H), 1.09 (d, J=6.6 Hz, 3.6H). ESIMS m/z 245 ([M+1]).
[0272] Compounds 32-41, 43-52, 54-56, 59-61, 66, 73-75, 77-79,
82-85, 93-100, 113, 117-129, 131-134, 139-140, 142-144, 148, 160,
163, 173-175, 184-186, 197-198, 202, 208, 215-217, 252-253, 277,
282-285, 287-290, 314-316, 347, 350-351, 353-355, 365-367, 370,
388, 395, 399-403, 407, 409, 415-418, 444-449, 452-454, 462-463,
465, 467-469, 496-498, 506-507, 512, 525-527, 569, 577, 581, 591
and 592 were made from the appropriate amines in accordance with
the procedures disclosed in Example 11.
Example 12
Preparation of
4,4,4-trifluoro-2-methyl-N-(1-(pyridin-3-yl)-1H-pyrazol-4-yl)butanamide
(Compound 65)
##STR00064##
[0274] To a solution of 1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.150
g, 0.93 mmol) in dichloroethane (1.8 mL) was added
4,4,4-trifluoro-2-methylbutanoic acid (0.14 g, 0.93 mmol) and
4-N,N-dimethylaminopyridine (0.23 g, 1.87 mmol) followed by
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.36
g, 1.87 mmol). The reaction stirred at room temperature overnight.
The reaction mixture was concentrated and the crude product was
purified by silica gel chromatography eluting with 0-5%
MeOH/dichloromethane to give a white solid (0.15 g, 55%); mp
140-145.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.00
(d, J=2.4 Hz, 1H), 8.62-8.47 (m, 2H), 8.01 (ddd, J=8.3, 2.7, 1.5
Hz, 1H), 7.68 (s, 1H), 7.53 (bs, 1H), 7.40 (ddd, J=8.3, 4.8, 0.6
Hz, 1H), 2.92-2.61 (m, 2H), 2.32-2.05 (m, 1H), 1.38 (d, J=6.6 Hz,
3H); ESIMS m/z 300 ([M+2]).
[0275] Compounds 53, 58, 62-63, 72, 76, 80-81, 107-108, 136-138,
147, 151-159, 164-168, 176-179, 187-196, 201, 203-207, 209-214,
220, 224-249, 251, 259-275, 286, 292-296, 303-313, 323-326,
341-344, 356-359, 371, 378-379, 382, 384, 419-426, 439-443, 455,
458-461, 464, 466, 476, 486, 490-493, 505, 508, 517, 528-529,
536-537, 539-541, 544-545, 549-554, 572-577, 578, 579 and 580 were
prepared from the appropriate amines in accordance with the
procedures disclosed in Example 12.
Example 13
Preparation of tert-butyl 1-(pyridin-3-yl)-1H-pyrazol-4-ylcarbamate
(Compound 57)
##STR00065##
[0276] Method A:
[0277] To a solution of 1-(pyridin-3-yl)-1H-pyrazol-4-amine (3 g,
18.73 mmol) in dichloromethane (33.4 mL) was added triethylamine
(3.13 mL, 7.68 mmol) and BOC-anhydride (4.5 g, 20.60 mmol). The
resulting solution was stirred at room temperature overnight. The
reaction mixture was partitioned between ethyl acetate and water.
The organic portion was dried (MgSO.sub.4), filtered and
concentrated to dryness. The crude product was purified by silica
gel chromatography eluting with 0-100% ethyl acetate/hexanes to
yield a white solid (2.0 g, 41%); mp 108-112.degree. C.; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 9.02 (d, J=2.2 Hz, 1H), 8.51 (t,
J=8.7 Hz, 1H), 8.37 (s, 1H), 8.30 (s, 1H), 7.98 (ddd, J=8.3, 2.4,
1.3 Hz, 1H), 7.68 (s, 1H), 7.36 (dd, J=8.2, 4.8 Hz, 1H), 1.52 (s,
9H); ESIMS m/z 261 ([M+1]).
[0278] Compounds 64 and 130 were prepared in accordance with the
procedures disclosed in Example 13, Method A.
Method B:
[0279] To a solution of 1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.1 g,
0.624 mmol) and di-tert-butyl dicarbonate (0.161 mL, 0.693 mmol) in
tetrahydrofuran (1.890 mL) and water (0.568 mL) was added dropwise
saturated aqueous sodium bicarbonate (0.572 mL, 0.687 mmol). The
reaction was stirred at room temperature overnight. The reaction
was diluted with water and extracted with ethyl acetate. The
combined organic phases were concentrate to give tert-butyl
1-(pyridin-3-yl)-1H-pyrazol-4-ylcarbamate (135 mg, 0.519 mmol,
83%), for which the analytical data was consistent with that
reported in Example 13, Method A.
[0280] Compounds 150, 172, 223, and 317 were prepared in accordance
with the procedures disclosed in Example 13, Method B. Compound 172
and 317 was also prepared in accordance with the procedures
disclosed in Example 17. These compounds, as well as, certain other
compounds, were made by alternative methods further illustrating
certain embodiments.
Example 14
Preparation of tert-butyl
methyl(1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (Compound 67)
##STR00066##
[0282] To a solution of tert-butyl
1-(pyridin-3-yl)-1H-pyrazol-4-ylcarbamate (1.6 g, 6.15 mmol) in DMF
(30.7 mL) at 0.degree. C. was added sodium hydride (0.34 g, 8.61
mmol, 60% dispersion in mineral oil) in one portion and the
suspension was stirred for 30 minutes. The ice bath was removed and
stirred for an additional 30 minutes. Iodomethane (0.46 mL, 7.38
mmol) was added in one portion and stirred overnight at room
temperature. Water and ethyl acetate were added and the resulting
biphasic mixture was separated. The aqueous layer was extracted one
time with ethyl acetate. The combined organic extracts were washed
with brine, dried (MgSO.sub.4), filtered and concentrated to
dryness. The crude product was purified by silica gel
chromatography eluting with 0-35% ethyl acetate/hexanes to yield a
light yellow semi-solid (0.85 g, 50%): IR (KBr) 1703 cm.sup.-1; H
NMR (400 MHz, CDCl.sub.3) .delta. 8.98 (s, 1H), 8.52 (d, J=3.8 Hz,
1H), 8.32 (s, 0.5H), 8.13-7.97 (m, 1H), 7.84 (s, 0.5H), 7.74 (s,
1H), 7.39 (dd, J=8.0, 4.8 Hz, 1H), 3.30 (s, 3H), 1.56 (s, 9H);
ESIMS m/z 275 ([M+H]).
[0283] Compounds 68, 86-92, 105-106, 114-116, 141, 149, 161-162,
199-200, 254, 258, 291, 332, 352, 360-361, 380-381, 414, 430-431,
450, 457, 474-475, 485, 488, 510-511, 515, 523, and 590 were
prepared from the appropriate amides in accordance with the
procedures disclosed in Example 14.
[0284] Tert-butyl
methyl(3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate was
prepared as in Example 14: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.91 (d, J=2.5 Hz, 1H), 8.51 (dd, J=4.7, 1.3 Hz, 1H), 8.00
(ddd, J=8.3, 2.4, 1.4 Hz, 1H), 7.83 (s, 1H), 7.38 (dd, J=8.3, 4.7
Hz, 1H), 3.20 (s, 3H), 2.22 (s, 3H), 1.60-1.30 (m, 9H).
Example 15
Preparation of
N-ethyl-N-(1-methyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)isobutyramide
(Compound 23)
##STR00067##
[0286] To a solution of
N-(1-methyl-3-(pyridine-3-yl)-1H-pyrazol-5-yl)isobutyramide (0.08
g, 0.33 mmol) in DMF (0.66 mL) at 0.degree. C. was added sodium
hydride (0.016 g, 0.39 mmol, 60% dispersion in mineral oil) in one
portion and the suspension was stirred for 30 minutes. The ice bath
was removed and stirred for an additional 30 minutes. Iodoethane
(0.06 g, 0.39 mmol) was added in one portion and stirred overnight
at room temperature. Water and ethyl acetate were added and the
resulting biphasic mixture was separated. The aqueous layer was
extracted one time with ethyl acetate. The combined organic
extracts were washed with brine, dried (MgSO.sub.4), filtered and
concentrated to dryness. The crude product was purified by silica
gel chromatography to give the title compound as a clear oil (27.5
mg, 30%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 9.00 (bs, 1H),
8.57 (s, 1H), 8.09 (dd, J=7.9 Hz, 1H), 7.34 (dd, 1H), 6.48 (s, 1H),
4.00 (m, 1H), 3.76 (s, 3H), 3.36 (m, 1H), 2.33 (m, 1H), 1.17 (t,
J=7.1 Hz, 3H), 1.08 (t, J=6.7 Hz, 6H); ESIMS m/z 273 (M+H).
[0287] Compound 22 was prepared in accordance with the procedures
disclosed in Example 15.
Example 16
Preparation of 5-bromo-1H-pyrazol-4-amine, HBr
##STR00068##
[0289] A mixture of 4-nitro-1H-pyrazole (10 g, 88 mmol) and 5%
palladium on Al.sub.2O.sub.3(1 g) in a mixture of ethanol (150 mL)
and 50% aqueous HBr (50 mL) was shaken in a Par apparatus under
hydrogen (10 psi) for 36 h. The mixture was filtered and the
catalyst washed with ethanol. The filtrate was concentrated in
vacuo to give a white solid. This solid was suspended in 10 mL of
ethanol. After swirling the flask for 5 min, diethyl ether was
added to complete the crystallization. The solid was filtered, was
washed with ether and dried under high vacuum to afford
5-bromo-1H-pyrazol-4-amine, HBr (18.1 g, 84% yield) as a white
solid: mp 248.degree. C. dec; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.47 (s, 1H), 10.00 (s, 1H), 7.79 (s, 1H).
Example 17
Preparation of
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(Compound 172)
Example 17
Step 1: Preparation of 3-chloro-1H-pyrazol-4-amine
hydrochloride
##STR00069##
[0291] Into a 2 L three-necked round bottom flask affixed with an
overhead stirrer, a temperature probe, an addition funnel, and a
nitrogen inlet were added ethanol (600 mL) and 4-nitro-1H-pyrazole
(50.6 g, 447 mmol). To this solution was added, in one portion,
conc. HCl (368 mL) (note: rapid exotherm from 15.degree. C. to
39.degree. C.) and the resulting mixture was purged with nitrogen
for 5 minutes. Palladium on alumina (5% w/w) (2.6 g, Alfa, black
solid) was added to the mixture and stirred at room temperature
while triethylsilane (208 g, 1789 mmol) was added drop-wise over 4
h. The reaction, which started to slowly exotherm from 35.degree.
C. to 55.degree. C. over 2.0 h, was stirred for a total of 16 h and
vacuum filtered through a plug of Celite.RTM. to give a biphasic
mixture. The mixture was transferred to a separatory funnel, the
bottom aqueous layer was collected and rotary evaporated
(60.degree. C., 50 mmHg) to dryness with the aid of acetonitrile
(3.times.350 mL). The resulting yellow solid was suspended in
acetonitrile (150 mL) and allowed to stand for 2 h at room
temperature followed by 1 h at 0.degree. C. in the refrigerator.
The solids were filtered and washed with acetonitrile (100 mL) to
afford the titled compound 3-chloro-1H-pyrazol-4-amine
hydrochloride (84 g, 97% yield, 80% purity) as a white solid: mp
190-193.degree. C.; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.46-10.24 (bs, 2H), 8.03 (s, 0.54H), 7.75 (s, 0.46H), 5.95 (bs,
1H)); .sup.13C-NMR (101 MHz, DMSO) .delta. 128.24, 125.97,
116.71.
Example 17
Step 2: Preparation of
tert-butyl(3-chloro-1H-pyrazol-4-yl)carbamate
##STR00070##
[0293] Into a 2 L round bottom flask was added
3-chloro-1H-pyrazol-4-amine hydrochloride (100 g, 649 mmol) and THF
(500 mL). To this mixture were added di-tert-butyldicarbonate (156
g, 714 mmol) followed by sodium bicarbonate (120 g, 1429 mmol) and
water (50.0 ml). The mixture was stirred for 16 h, diluted with
water (500 mL) and ethyl acetate (500 mL) and transferred to a
separatory funnel. This gave three layers; bottom-a white
gelatinous precipitate, middle-light yellow aqueous, top-auburn
organic. The phases were separated collecting the white gelatinous
precipitate and the aqueous layer together. The aqueous was
extracted with ethyl acetate (2.times.200 mL) and the ethyl acetate
extracts were combined, washed with brine (200 mL), dried over
anhydrous sodium sulfate, filtered and rotary evaporated to give an
auburn thick oil (160 g). The thick oil was suspended in hexane
(1000 mL) and stirred at 55.degree. C. for 2 h. This gave a light
brown suspension. The mixture was cooled to 0.degree. C. and the
solid collected by vacuum filtration and rinsed with hexane
(2.times.10 mL). The sample was air dried to constant mass to
afford (3-chloro-1H-pyrazol-4-yl)carbamate (102.97 g, 72% yield,
80% purity) as a light brown solid: mp 137-138.degree. C.; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 10.69 (s, 1H), 7.91 (s, 1H), 1.52
(s, 9H).
Example 17
Step 3: Preparation of
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(Compound 172)
##STR00071##
[0295] To a dry 2 L round bottom flask equipped with mechanical
stirrer, nitrogen inlet, thermometer, and reflux condenser was
charged the 3-iodopyridine (113.0 g, 551 mmol),
(3-chloro-1H-pyrazol-4-yl)carbamate (100 g, 459 mmol), potassium
phosphate (powdered in a mortar and pestle) (195 g, 919 mmol), and
copper chloride (3.09, 22.97 mmol). Acetonitrile (1 L) followed by
N.sup.1,N.sup.2-dimethylethane-1,2-diamine (101 g, 1149 mmol) were
added and the mixture was heated to 81.degree. C. for 4 hours. The
mixture was cooled to room temperature and filtered through a bed
of Celite.RTM.. The filtrate was transferred to a 4 L Erlenmeyer
flask equipped with mechanical stirrer and diluted with water until
the total volume was about 4 L. The mixture was stirred for 30
minutes at room temperature and the resulting solid was collected
by vacuum filtration. The solid was washed with water and washed
with water and oven dried for several days in vacuo at 40.degree.
C. to a constant weight to give
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(117.8 g, 87% yield, 80% purity) as a tan solid: mp 140-143.degree.
C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.96 (s, 1H), 8.53
(dd, J=4.7, 1.2 Hz, 1H), 8.36 (s, 1H), 7.98 (ddd, J=8.3, 2.7, 1.4
Hz, 1H), 7.38 (dd, J=8.3, 4.8 Hz, 1H), 6.37 (s, 1H), 1.54 (s, 9H);
ESIMS (m/z) 338 ([M-t-Bu].sup.+), 220 ([M-O-t-Bu].sup.-).
[0296] Compound 172 was also prepared in accordance with the
procedures disclosed in Example 13. Compound 317 was prepared in
accordance with the procedures disclosed in Example 17 from
tert-butyl(3-bromo-1H-pyrazol-4-yl)carbamate and also in accordance
with the procedures disclosed in Example 13.
Example 18
Preparation of 3-(3-methyl-1H-pyrazol-1-yl)pyridine and
3-(5-methyl-1H-pyrazol-1-yl)pyridine
##STR00072##
[0298] To a solution of 3-methyl-1H-pyrazole (10.99 g, 134 mmol) in
N,N-dimethylformamide (100 ml) at 0.degree. C. was added sodium
hydride (3.71 g, 154 mmol, 60% dispersion). The reaction was
stirred at 0.degree. C. for 2 hours. 3-Fluoropyridine (10.0 g, 103
mmol) was added, and the reaction was stirred at 100.degree. C.
overnight. The reaction was cooled to room temperature and water
was added slowly. The mixture was extracted with dichloromethane
and the combined organic phases were washed with brine,
concentrated and chromatographed (0-100% ethyl acetate/hexanes) to
afford 3-(3-methyl-1H-pyrazol-1-yl)pyridine (8.4 g, 52.77 mmol,
51.2%) and 3-(5-methyl-1H-pyrazol-1-yl)pyridine (1.0 g, 6%).
Analytical data of both products is consistent with that reported
under Example 6, Step 1.
[0299] 3-(3-Bromo-1H-pyrazol-1-yl)pyridine was prepared from
3-fluoropyridine and 3-bromopyrazole, which was made as in
WO2008130021, as described Example 18: mp 89.5-92.5.degree. C.;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.94 (d, J=2.4 Hz, 1H),
8.62-8.49 (m, 1H), 8.03 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.87 (d,
J=2.5 Hz, 1H), 7.42 (dd, J=8.2, 4.7 Hz, 1H), 6.54 (d, J=2.5 Hz,
1H); ESIMS m/z 224 ([M].sup.+).
Example 19
Preparation of
3-chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-amine
##STR00073##
[0301] To a stirred solution of 5-chloro-1H-pyrazol-4-amine, HCl (2
g, 12.99 mmol) and cesium carbonate (8.89 g, 27.3 mmol) in DMF (13
mL) was added 3,5-difluoropyridine (1.794 g, 15.58 mmol) and the
mixture heated at 70.degree. C. for 12 h. The mixture was cooled to
room temperature and filtered. The solids were washed with copious
amount of ethyl acetate. The filtrates was washed with brine, dried
over anhydrous MgSO.sub.4 and concentrated in vacuo to give a brown
solid. This solid was dissolved in ethyl acetate and the resulting
solution was saturated with hexanes to precipitate
3-chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-amine (2.31 g, 10.32
mmol, 79% yield) as a brown solid: .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.89-8.82 (m, 1H), 8.45 (d, J=2.5 Hz, 1H),
8.07 (d, J=10.4 Hz, 1H), 7.94 (s, 1H), 4.51 (s, 2H);
[0302] EIMS (m/z) 213 ([M+1].sup.+).
3-Bromo-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-amine was prepared
from the corresponding pyrazole as described in Example 19: mp
164-165.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.65
(d, J=1.7 Hz, 1H), 8.36 (d, J=2.5 Hz, 1H), 7.76 (dd, J=5.9, 3.6 Hz,
1H), 7.48 (s, 1H), 3.22 (s, 2H). .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 160.87, 158.30, 135.36, 135.13, 134.39, 134.35, 131.16,
123.31, 114.02, 112.77, 112.54; EIMS (m/z) 258 ([M+1].sup.+).
Example 20
Preparation of
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-amine
##STR00074##
[0304] To a solution of
3-fluoro-5-(3-methyl-4-nitro-1H-pyrazol-1-yl)pyridine (3.133 g,
14.10 mmol) in ethanol (28.2 ml) was added ethyl acetate until all
of the starting material went into solution. The solution was
degassed and 10% palladium on carbon (0.750 g, 0.705 mmol) was
added and the reaction was stirred in a parr hydrogenator at 40 psi
for 3 hours. The solution was filtered through celite with ethyl
acetate and concentrated to give
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-amine (2.000 g,
10.41 mmol, 73.8%) as a brown solid: mp 136.0-138.0.degree. C.;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.67-8.59 (m, 1H), 8.27
(d, J=2.5 Hz, 1H), 7.73 (dt, J=9.9, 2.3 Hz, 1H), 7.45 (s, 1H), 3.01
(s, 2H), 2.28 (s, 3H); EIMS m/z 192.
[0305] 1-(Pyridin-3-yl)-3-(trifluoromethyl)-1H-pyrazol-4-amine was
prepared from the appropriate nitropyrazole as described in Example
20: mp 112.5-115.0.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.89 (d, J=2.4 Hz, 1H), 8.57 (dd, J=4.7, 1.4 Hz, 1H), 8.03
(ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.56 (d, J=0.7 Hz, 1H), 7.41 (ddd,
J=8.3, 4.8, 0.7 Hz, 1H), 3.47-3.31 (m, 2H); EIMS m/z 228.
Example 21
Preparation of 3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine
##STR00075##
[0307] To 3-(3-chloro-4-nitro-1H-pyrazol-1-yl)pyridine (0.95 g,
4.23 mmol) in acetic acid (8.46 mL), ethanol (8.46 mL) and water
(4.23 mL) was added iron powder (1.18 g, 21.15 mmol) and the
reaction was stirred at room temperature for 30 minutes. To this
was added carefully 2 M KOH and extracted with ethyl acetate. The
ethyl acetate layers were combined, dried (MgSO.sub.4), filtered
and concentrated to dryness. The crude material was purified by
silica gel chromatography (0-10% methanol/dichloromethane) to give
the desired product as a white solid (0.66 g, 80%): .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.84 (d, J=2.6 Hz, 1H), 8.49 (dd,
J=4.7, 1.4 Hz, 1H), 7.95 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.53 (s,
1H), 7.37 (ddd, J=8.4, 4.7, 0.6 Hz, 1H), 3.17 (bs, 2H).
[0308] 3-methyl-1-(2-methylpyridin-3-yl)-1H-pyrazol-4-amine was
prepared as described in Example 21: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.48 (dd, J=4.8, 1.6 Hz, 1H), 7.62 (dd, J=8.0,
1.6 Hz, 1H), 7.23-7.18 (m, 2H), 2.91 (bs, 2H), 2.55 (s, 3H), 2.28
(s, 3H); EIMS m/z 188.
[0309] 3-Phenyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine was prepared
from the appropriate nitropyrazole as described in Example 21: IR
(thin film) 3324 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta.
8.94 (d, J=2.2 Hz, 1H), 8.47 (dd, J=4.7, 1.4 Hz, 1H), 8.07 (ddd,
J=8.3, 2.7, 1.5 Hz, 1H), 7.87-7.80 (m, 2H), 7.60 (s, 1H), 7.50-7.44
(m, 2H), 7.40-7.34 (m, 2H), 3.86 (s, 2H); EIMS m/z 236.
[0310] 3-Chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-amine was
prepared from the appropriate nitropyrazole as described in Example
21: mp 149.0-151.0.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.65 (d, J=1.6 Hz, 1H), 8.35 (d, J=2.4 Hz, 1H), 7.75 (dt,
J=9.5, 2.4 Hz, 1H), 7.51 (s, 1H), 3.21 (s, 2H); ESIMS m/z 213
([M].sup.+).
[0311] 3-Bromo-1-(pyridin-3-yl)-1H-pyrazol-4-amine was prepared
from the appropriate nitropyrazole as described in Example 21: mp
143.0-146.0.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.85 (d, J=2.4 Hz, 1H), 8.50 (dd, J=4.7, 1.4 Hz, 1H), 7.96 (ddd,
J=8.3, 2.7, 1.5 Hz, 1H), 7.49 (s, 1H), 7.37 (ddd, J=8.4, 4.7, 0.7
Hz, 1H), 3.21 (s, 2H); ESIMS m/z 241 ([M+2].sup.+)
Example 22
Preparation of
tert-butyl(5-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(Compound 281)
##STR00076##
[0313] To a solution of (E)-tert-butyl
1-(dimethylamino)-3-oxobut-1-en-2-ylcarbamate (0.59 g, 2.58 mmol)
in ethanol (2.5 mL) was added 3-hydrazinylpyridine, 2HCl (0.470 g,
2.58 mmol). The reaction mixture was stirred at ambient temperature
for 16 hours. The reaction mixture was concentrated and purified
using silica gel chromatography (0-100% ethyl acetate/hexanes) to
yield the title compound as an orange foam (0.235 g, 30%): IR (thin
film) 3268, 2978 and 1698 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.75 (dd, J=2.5, 0.5 Hz, 1H), 8.62 (dd, J=4.8,
1.5 Hz, 1H), 7.82 (ddd, J=8.2, 2.6, 1.5 Hz, 1H), 7.78 (s, 1H), 7.43
(ddd, J=8.1, 4.8, 0.6 Hz, 1H), 6.04 (s, 1H), 2.29 (s, 3H), 1.52 (s,
9H); ESIMS m/z 275 ([M+H].sup.+), 273 ([M-H].sup.-).
Example 23
Preparation of tert-butyl
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-ylcarbamate
(Compound 111) and tert-butyl
5-ethoxy-1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-ylcarbamate
(Compound 112)
##STR00077##
[0315] To a solution of
3-fluoro-5-(3-methyl-4-nitro-1H-pyrazol-1-yl)pyridine (3.133 g,
14.10 mmol) in ethanol (28.2 ml) was added ethyl acetate until all
of the starting material went into solution. The solution was
degassed and 10% palladium on carbon (0.750 g, 0.705 mmol) was
added and the reaction was stirred in a parr hydrogenator at 40 psi
for 3 hours. The solution was filtered through celite with ethyl
acetate and the solvent was removed under reduced pressure. The
residue was dissolved in tetrahydrofuran (32.0 ml) and water (9.61
ml). Di-tert-butyl dicarbonate (2.52 g, 11.55 mmol) was added
followed by saturated aqueous sodium bicarbonate (9.54 ml, 11.45
mmol). The reaction was stirred at room temperature overnight,
diluted with water and extracted with ethyl acetate. The combined
organic phases were concentrated and chromatographed (0-100% ethyl
acetate/hexanes) to give tert-butyl
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-ylcarbamate (1.673
g, 5.72 mmol, 41.0%) as a yellow solid and the tert-butyl
5-ethoxy-1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-ylcarbamate
(0.250 g, 0.74 mmol, 5.2%) as a brown oil:
[0316] Tert-butyl
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-ylcarbamate
(Compound 111): mp 131.5-133.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.75 (s, 1H), 8.32 (d, J=2.5 Hz, 1H), 8.28 (s,
1H), 7.77 (dt, J=9.7, 2.4 Hz, 1H), 6.15 (s, 1H), 2.29 (s, 3H), 1.54
(s, 9H); ESIMS m/z 293 ([M+H].sup.+).
[0317] Tert-butyl
5-ethoxy-1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-ylcarbamate
(Compound 112): IR (thin film) 1698 cm.sup.-1; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.88 (s, 1H), 8.34 (d, J=2.5 Hz, 1H), 7.83
(d, J=9.9 Hz, 1H), 5.99 (s, 1H), 4.37 (q, J=7.0 Hz, 2H), 2.17 (s,
3H), 1.50 (s, 9H), 1.37 (t, J=7.1 Hz, 3H); ESIMS m/z 337
([M+H].sup.+).
Example 24
Preparation of Bis
tert-t-butyl(1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (Compound
595)
##STR00078##
[0319] To a solution of
tert-butyl(1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (2.00 g, 7.68
mmol) in dry THF (21.95 mL) at 0.degree. C. was added 60% sodium
hydride (0.33 g, 8.45 mmol) in one portion and stirred at that
temperature for 30 minutes. To this was then added Boc-Anhydride
(1.84 g, 8.45 mmol) in one portion and stirred for 5 minutes at
0.degree. C. The water bath was removed and the reaction was warmed
to room temperature and stirred at additional 30 minutes. The
reaction was quenched with water and extracted with ethyl acetate.
The ethyl acetate layers were combined, dried (MgSO.sub.4),
filtered and concentrated to dryness. The crude material was
purified by silica gel chromatography (0-100% ethyl
acetate/hexanes) to give the desired product as a white solid (2.0
g, 72%): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.12-8.86 (m,
1H), 8.55 (dd, J=4.7, 1.4 Hz, 1H), 8.04 (ddd, J=8.3, 2.7, 1.5 Hz,
1H), 8.01 (d, J=0.5 Hz, 1H), 7.84-7.65 (m, 1H), 7.41 (ddd, J=8.3,
4.8, 0.7 Hz, 1H), 1.51 (s, 18H).
Example 25
Preparation of 3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine
(Compound 516)
##STR00079##
[0321] To
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (2
g, 6.79 mmol) in dichloromethane (6.79 ml) was added
trifluoroacetic acid (6.79 ml) and the mixture was left stirring at
room temperature for 2 hours. Toluene (12 mL) was added and the
reaction was concentrated to near dryness. The mixture was poured
into a separatory funnel containing saturated aqueous sodium
bicarbonated and was extracted with dichloromethane. The combined
organic layers were concentrated to give
3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.954 g, 4.90 mmol,
72.2%) as a white solid: mp 137.9-139.9.degree. C.; .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.84 (d, J=2.4 Hz, 1H), 8.50 (dd,
J=4.7, 1.4 Hz, 1H), 7.95 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.52 (s,
1H), 7.37 (ddd, J=8.4, 4.7, 0.7 Hz, 1H), 3.18 (s, 2H); ESIMS m/z
196 ([M+H].sup.+).
Example 26
Preparation of
N-allyl-1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-amine
hydrochloride
##STR00080##
[0323] To a solution of tert-butyl
allyl(1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-yl)carbamate
(908 mg, 2.73 mmol) in dioxane (5 mL) was added HCl (1M in ether)
(13.65 mL, 13.65 mmol) and the mixture stirred at room temperature
for 48 h. The resulting white solid was filtered, washed with ether
and dried under vacuum to give
N-allyl-1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-amine, HCl
(688 mg, 94% yield) as a white solid: mp 189-190.degree. C.;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.79-8.68 (m, 1H),
8.32-8.26 (m, 1H), 8.23 (s, 1H), 7.98-7.86 (m, 1H), 5.86-5.68 (m,
1H), 5.28-5.17 (m, 1H), 5.17-5.03 (m, 1H), 3.59 (d, J=6.2 Hz, 2H),
2.11 (s, 3H); EIMS (m/z) 233 ([M+1].sup.+).
[0324] N-Allyl-3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine, HCl
was prepared as described in Example 26 from tert-butyl
allyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate: mp
172-174.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.20
(d, J=2.5 Hz, 1H), 8.65 (dd, J=5.3, 1.1 Hz, 1H), 8.61 (ddd, J=8.6,
2.5, 1.1 Hz, 1H), 8.24 (s, 1H), 7.93 (dd, J=8.6, 5.3 Hz, 1H), 3.66
(dt, J=5.5, 1.3 Hz, 2H); EIMS (m/z) 235 ([M+1].sup.+).
[0325] N-Allyl-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, HCl
was prepared as described in Example 26 from tert-butyl
allyl(3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl): mp
195-197.degree. C.; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.12 (d, J=2.4 Hz, 1H), 8.58 (dd, J=5.0, 1.2 Hz, 1H), 8.48 (s, 1H),
8.43 (d, J=9.7 Hz, 1H), 7.77 (dd, J=8.4, 5.0 Hz, 1H), 6.04-5.92 (m,
1H), 5.44 (dd, J=17.2, 1.4 Hz, 1H), 5.32 (d, J=9.4 Hz, 1H), 3.81
(d, J=6.2 Hz, 2H); EIMS (m/z) 249 ([M-1].sup.+).
[0326]
3-Bromo-1-(5-fluoropyridin-3-yl)-N-methyl-1H-pyrazol-4-amine, HCl
was prepared as described in Example 26 from tert-butyl
3-bromo-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl(methyl)carbamate:
mp 167-168.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.93 (s, 1H), 8.50 (d, J=2.5 Hz, 1H), 8.23 (s, 1H), 8.14 (dt,
J=10.4, 2.3 Hz, 1H), 2.73 (s, 3H).
[0327] 3-Bromo-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, HCl
was prepared as described in Example 26 from
tert-butyl(3-bromo-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(methyl)carbamate
(160 mg, 0.45 mmol) in dioxane (1 mL) was added 4M HCl: mp.
226-228.degree. C.; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.26-9.06 (d, J=2.6 Hz, 1H), 8.69-8.54 (m, 1H), 8.54-8.39 (d, J=8.0
Hz, 1H), 8.33-8.14 (s, 1H), 7.90-7.72 (m, 1H), 2.82-2.67 (s, 3H);
EIMS (m/z) 253 ([M+1].sup.+), 255 ([M+2H].sup.+).
[0328] 3-Bromo-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, HCl was
prepared as described in Example 26 from
3-bromo-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, HCl: mp
216-217.degree. C.; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.66-10.05 (s, 3H), 9.28-9.20 (d, J=2.5 Hz, 1H), 8.74-8.67 (m,
1H), 8.67-8.56 (m, 3H), 7.96-7.84 (m, 1H), 3.21-3.14 (m, 2H),
1.29-1.22 (m, 3H); EIMS (m/z) 267 ([M+1].sup.+).
[0329]
3-Chloro-N-(2-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine,
HCl was prepared as described in Example 26 from
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(2-methoxyethyl)carb-
amate, HCl: mp 157-158.degree. C.; .sup.1H NMR (400 MHz, DMSO)
.delta. 9.22-9.14 (d, J=2.5 Hz, 1H), 8.70-8.65 (s, 1H), 8.65-8.59
(m, 1H), 8.38-8.33 (m, 1H), 8.00-7.89 (m, 1H), 3.59-3.50 (t, J=5.8
Hz, 2H), 3.32-3.27 (s, 3H), 3.22-3.14 (m, 2H); EIMS (m/z) 253
([M+1].sup.+).
Example 27
Preparation of 3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
hydrochloride
##STR00081##
[0331] Into a 500 mL three-necked round bottom flask equipped with
a magnetic stir bar was added a solution of
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)carbamate
(21 g, 65.1 mmol) in 1,4-dioxane (35 mL). This pale yellow solution
was placed into an ice bath and cooled to 1.degree. C. A solution
of 4M HCl/dioxane (65 mL, 260 mmol) was added in one portion. After
stirring for 20 minutes, the ice bath was removed and the
suspension was stirred further at ambient temperature for 16 hours.
The reaction was diluted with 200 mL of ethyl ether and the solid
was filtered and washed with ether and placed in a vacuum oven at
40.degree. C. for 18 hours. The title compound was isolated as a
pale yellow solid (18.2 g, 95%): .sup.1H NMR (400 MHz, MeOD)
.delta. 9.52 (d, J=2.5 Hz, 1H), 9.17 (s, 1H), 9.14 (ddd, J=8.7,
2.5, 1.1 Hz, 1H), 8.93 (ddd, J=5.7, 1.1, 0.6 Hz, 1H), 8.31 (ddd,
J=8.7, 5.7, 0.5 Hz, 1H), 3.58 (q, J=7.3 Hz, 2H), 1.48 (t, J=7.3 Hz,
3H); ESIMS m/z 223 ([M+H].sup.+).
[0332] 3-Chloro-N-methyl-1-(pyridin-3-yl)-1H-pyrazole-4-amine, 2HCl
was prepared as described in Example 27: .sup.1H NMR (400 MHz,
MeOD) .delta. 9.28 (d, J=2.5 Hz, 1H), 8.86 (ddd, J=8.7, 2.5, 1.2
Hz, 1H), 8.79-8.75 (m, 1H), 8.62 (s, 1H), 8.19 (ddd, J=8.7, 5.6,
0.5 Hz, 1H), 3.06 (s, 3H); .sup.13C NMR (101 MHz, MeOD) .delta.
141.42, 139.58, 137.76, 134.58, 134.11, 129.33, 127.55, 122.14,
35.62); ESIMS m/z 209 ([M+H].sup.+).
Example 28
Preparation of 3-(4-nitro-3-phenyl-1H-pyrazol-1-yl)pyridine
##STR00082##
[0334] To a suspension of phenylboronic acid (0.546 g, 4.47 mmol)
in toluene (6.63 ml) was added
3-(3-chloro-4-nitro-1H-pyrazol-1-yl)pyridine (0.335 g, 1.492 mmol)
followed by ethanol (3.31 ml) and 2 M aqueous potassium carbonate
(1.492 ml, 2.98 mmol). The solution was degassed by applying vacuum
and then purging with nitrogen (3 times). To the reaction mixture
was added palladium tetrakis (0.086 g, 0.075 mmol) and the flask
was heated at 110.degree. C. under nitrogen for 16 hours. The
aqueous layer was removed and the organic layer was concentrated.
The crude product was purified via silica gel chromatography
(0-100% ethyl acetate/hexanes) to give
3-(4-nitro-3-phenyl-1H-pyrazol-1-yl)pyridine (499 mg, 1.874 mmol,
80%) as a yellow solid: mp 144.0-146.0.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 9.09 (d, J=2.3 Hz, 1H), 8.82 (s, 1H), 8.71
(dd, J=4.8, 1.4 Hz, 1H), 8.16 (ddd, J=8.3, 2.7, 1.5 Hz, 1H),
7.82-7.74 (m, 2H), 7.55-7.48 (m, 4H); EIMS m/z 266.
Example 29
Preparation of
5-bromo-1-(pyridin-3-yl)-1H-pyrazol-4-yl(methyl)carbamate (Compound
110)
##STR00083##
[0336] To tert-butyl
methyl(1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (0.200 g, 0.729
mmol) in dichloroethane (3.65 ml) was added
1-bromopyrrolidine-2,5-dione (0.260 g, 1.458 mmol) and the reaction
was stirred overnight at 50.degree. C. The reaction was
concentrated, diluted with dichloromethane, and washed with water
and saturated aqueous sodium thiosulfate. The organic phase was
concentrated to give tert-butyl
5-bromo-1-(pyridin-3-yl)-1H-pyrazol-4-yl(methyl)carbamate (256 mg,
0.725 mmol, 99%) as a brown oil: IR (thin film) 1697 cm.sup.-1;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.89 (s, 1H), 8.68 (d,
J=4.1 Hz, 1H), 7.93 (ddd, J=8.2, 2.5, 1.5 Hz, 1H), 7.69 (s, 1H),
7.46 (dd, J=8.1, 4.8 Hz, 1H), 3.22 (s, 3H), 1.44 (s, 9H); ESIMS m/z
352 ([M-H].sup.-).
Example 30
Preparation of Bis
tert-t-butyl(5-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(Compound 109)
##STR00084##
[0338] To Bis
tert-t-butyl(1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (1.30 g,
3.61 mmol) in acetonitrile (21.22 mL) was added N-chlorosuccinimide
(0.96 g, 7.21 mmol) and the reaction was stirred at 45.degree. C.
for 48 hours. The reaction was cooled to room temperature and
poured into water and extracted with dichloromethane. The
dichloromethane layers were combined, poured through a phase
separator to remove water and concentrated to dryness. The crude
material was purified by silica gel chromatography (0-60% ethyl
acetate/hexanes) to give the desired product as a yellow solid
(0.90 g, 63%): mp 109-115.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.90 (d, J=2.3 Hz, 1H), 8.68 (dd, J=4.8, 1.5
Hz, 1H), 7.94 (ddd, J=8.2, 2.5, 1.5 Hz, 1H), 7.70 (s, 1H), 7.47
(dtd, J=11.0, 5.6, 5.5, 4.8 Hz, 1H), 1.49 (s, 18H); ESIMS m/z 395
([M+H].sup.+).
[0339]
Tert-butyl(5-chloro-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(meth-
yl)carbamate was prepared from the appropriate pyrazole in
dichloroethane as the solvent as described in Example 30: ESIMS m/z
324 ([M+H].sup.+).
[0340] Compounds 110 (see also procedure in Example 29) and 146
were prepared from the appropriate pyrazoles using
N-bromosuccinimide in accordance with the procedures disclosed in
Example 30.
[0341] Tert-butyl
5-bromo-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl(methyl)carbamate
was prepared from the appropriate pyrazole in dichloroethane as
described in Example 30: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.88 (d, J=2.3 Hz, 1H), 8.69-8.60 (m, 1H), 7.96-7.86 (m, 1H),
7.48-7.39 (m, 1H), 3.18 (s, 3H), 2.26 (s, 3H), 1.60-1.36 (m, 9H);
ESIMS m/z 368 ([M+H].sup.+).
Example 31
Preparation of bis
tert-butyl(5-fluoro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(Compound 135)
##STR00085##
[0343] To a solution of bis
tert-t-butyl(1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (0.075 g,
0.208 mmol) in DMF (0.416 ml) and acetonitrile (0.416 ml) was added
Selecfluor.RTM. (0.184 g, 0.520 mmol). The reaction was stirred at
room temperature for one week. The reaction was concentrated,
saturated aqueous ammonium chloride was added and the mixture was
extracted with ethyl acetate. The combined organic phases were
concentrated and chromatographed (0-100% ethyl acetate/hexanes) to
give bis
tert-butyl(5-fluoro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (16
mg, 0.042 mmol, 20.32%) as an off-white solid: .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.97 (t, J=2.0 Hz, 1H), 8.61 (dd, J=4.8,
1.4 Hz, 1H), 7.99 (ddt, J=8.3, 2.6, 1.3 Hz, 1H), 7.57 (d, J=2.5 Hz,
1H), 7.44 (ddd, J=8.3, 4.8, 0.6 Hz, 1H), 1.50 (s, 18H); ESIMS m/z
379 ([M+H].sup.+).
[0344]
Tert-butyl(5-fluoro-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(meth-
yl)carbamate was prepared as described in Example 31: .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.94 (s, 1H), 8.57 (d, J=4.2 Hz, 1H),
7.96 (d, J=7.7 Hz, 1H), 7.41 (dd, J=7.9, 4.7 Hz, 1H), 3.17 (s, 3H),
2.23 (s, 3H), 1.58-1.40 (m, 9H); ESIMS m/z 307 ([M+H].sup.+).
Example 32
Preparation of
N-cyclopropyl-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
Example 32
Step 1: Preparation of
3-(4-iodo-3-methyl-1H-pyrazol-1-yl)pyridine
##STR00086##
[0346] To a mixture of 3-(3-methyl-1H-pyrazol-1-yl)pyridine (6.7 g,
42.1 mmol), iodic acid (2.96 g, 16.84 mmol), and diiodine (8.55 g,
33.7 mmol) in acetic acid (60.1 ml) was added concentrated sulfur
acid (3.74 ml, 21.04 mmol). The reaction mixture heated to
70.degree. C. for 30 minutes. The reaction mixture was poured onto
ice with sodium thiosulfate and was extracted with diethyl ether.
The combined organic phases were washed with saturated aqueous
sodium bicarbonate. The organic phases were then dried with
magnesium sulfate, filtered and concentrated in vacuo. The solid
residue was dissolved in dichloromethane, applied to a 80 g silica
gel column, and eluted with 0-80% acetone in hexanes to afford
3-(4-iodo-3-methyl-1H-pyrazol-1-yl)pyridine (11.3 g, 35.7 mmol,
85%) as a white solid: mp 131.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.95-8.85 (m, 1H), 8.52 (dd, J=4.8, 1.4 Hz,
1H), 8.00-7.94 (m, 1H), 7.91 (s, 1H), 7.38 (ddd, J=8.3, 4.8, 0.7
Hz, 1H), 2.34 (s, 3H); EIMS m/z 285.
Example 32
Step 2: Preparation of
N-cyclopropyl-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
##STR00087##
[0348] To a solution of 3-(4-iodo-3-methyl-1H-pyrazol-1-yl)pyridine
(2.0 g, 7.02 mmol) in dimethylsulfoxide (7.02 ml) was added
1-(5,6,7,8-tetrahydroquinolin-8-yl)ethanone (0.246 g, 1.403 mmol),
cyclopropanamine (0.486 ml, 7.02 mmol), cesium carbonate (6.86 g,
21.05 mmol) and copper(I) bromide (0.101 g, 0.702 mmol). The
reaction mixture was stirred at 35.degree. C. for 2 days. The
reaction mixture was diluted with water and extracted with
dichloromethane. The combined organics were washed with brine,
concentrated and chromatographed (0-100% ethyl acetate/hexanes) to
give N-cyclopropyl-3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
(269 mg, 1.255 mmol, 17.90%) as a yellow solid: mp
104.0-107.0.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.89 (dd, J=2.7, 0.5 Hz, 1H), 8.41 (dd, J=4.7, 1.4 Hz, 1H), 7.96
(ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.51 (s, 1H), 7.33 (ddd, J=8.3, 4.7,
0.7 Hz, 1H), 3.42 (s, 1H), 2.53-2.42 (m, 1H), 2.22 (s, 3H),
0.72-0.65 (m, 2H), 0.60-0.53 (m, 2H); ESIMS m/z 215
([M+H].sup.+).
[0349]
3-Methyl-N-(3-(methylthio)propyl)-1-(pyridin-3-yl)-1H-pyrazol-4-ami-
ne was prepared as described in Example 32: IR (thin film) 3298
cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 8.87 (d, J=2.3 Hz,
1H), 8.40 (dd, J=4.7, 1.4 Hz, 1H), 7.93 (ddd, J=8.3, 2.7, 1.5 Hz,
1H), 7.35 (s, 1H), 7.34-7.29 (m, 1H), 3.16 (t, J=6.8 Hz, 2H), 2.89
(s, 1H), 2.64 (t, J=7.0 Hz, 2H), 2.25 (s, 3H), 2.13 (s, 3H), 1.95
(p, J=6.9 Hz, 2H); ESIMS m/z 263 ([M+H].sup.+).
[0350]
3-Methyl-N-(2-methyl-3-(methylthio)propyl)-1-(pyridin-3-yl)-1H-pyra-
zol-4-amine was prepared as described in Example 32: IR (thin film)
3325 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 8.86 (d, J=2.5
Hz, 1H), 8.40 (dd, J=4.7, 1.2 Hz, 1H), 7.93 (ddd, J=8.3, 2.7, 1.5
Hz, 1H), 7.35 (s, 1H), 7.32 (ddd, J=8.3, 4.7, 0.5 Hz, 1H), 3.12
(dd, J=11.5, 6.1 Hz, 1H), 2.94 (dd, J=11.9, 6.6 Hz, 1H), 2.62 (dd,
J=12.9, 6.9 Hz, 1H), 2.52 (dd, J=12.9, 6.2 Hz, 1H), 2.26 (s, 3H),
2.14 (s, 3H), 2.12-2.02 (m, 1H), 1.11 (d, J=6.8 Hz, 3H); EIMS m/z
276.
Example 33
Preparation of
tert-butyl(3-cyclopropyl-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)carbama-
te (Compound 434) and
tert-butyl(1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(Compound 489)
##STR00088##
[0352] To a suspension of
2-cyclopropyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.087 g,
6.47 mmol) in toluene (13.69 ml) was added
tert-butyl(3-bromo-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(1.1 g, 3.08 mmol) followed by ethanol (6.84 ml) and 2 M aqueous
potassium carbonate (3.08 mL, 6.16 mmol). The solution was degassed
by applying vacuum and then purging with nitrogen (3 times). To the
reaction mixture was added palladium tetrakis (0.178 g, 0.154 mmol)
and the flask was heated at 100.degree. C. under nitrogen for 36
hours. Water (5 mL) was added and the mixture was extracted with
ethyl acetate. The combined organics were concentrated and
chromatographed (0-100% ethyl acetate/hexanes) to give
tert-butyl(3-cyclopropyl-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)carbama-
te (705 mg, 2.215 mmol, 71.9% yield) as a yellow solid and
tert-butyl(1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)carbamate (242
mg, 0.870 mmol, 28.2% yield) as a yellow solid.
tert-Butyl(3-cyclopropyl-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)carbama-
te: mp 156.5-158.0; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.73
(s, 1H), 8.30 (d, J=2.5 Hz, 1H), 8.27 (s, 1H), 7.76 (dt, J=9.8, 2.4
Hz, 1H), 6.43 (s, 1H), 1.55 (s, 9H), 1.01-0.91 (m, 4H); ESIMS m/z
319 ([M+H].sup.+).
[0353] (1-(5-Fluoropyridin-3-yl)-1H-pyrazol-4-yl)carbamate: mp
121.0-123.0.degree. C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
8.78 (s, 1H), 8.37 (s, 1H), 8.28 (s, 1H), 7.81 (d, J=9.6 Hz, 1H),
7.59 (s, 1H), 6.44 (s, 1H), 1.53 (s, 9H). ESIMS m/z 278
([M].sup.+).
[0354] Compounds 340 and 404 were prepared as described in Example
33.
Example 34
Preparation of
tert-butyl(3-ethyl-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)(methyl)carba-
mate (Compound 408)
##STR00089##
[0356] To a N.sub.2-purged solution of
tert-butyl(1-(5-fluoropyridin-3-yl)-3-vinyl-1H-pyrazol-4-yl)(methyl)carba-
mate (0.730 g, 2.293 mmol) in methanol (15.29 ml) was added 10%
palladium on carbon (0.036 g, 0.339 mmol). The reaction was purged
with hydrogen and run under 80 psi of hydrogen at room temperature
for 60 hours. The reaction gave less than 20% conversion. The
reaction mixture was filtered through celite, concentrated, and
redissolved in ethyl acetate (4 mL) and transferred to a bomb. The
reaction was heated at 50.degree. C. at 600 psi of hydrogen for 20
hours. The reaction was only 50% complete. Methanol (1 mL) and 10%
palladium on carbon (36 mg) were added, and the reaction was heated
at 80.degree. C. at 650 psi of hydrogen for 20 hours. The reaction
was filtered through celite and concentrated to give
tert-butyl(3-ethyl-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)(methyl)carba-
mate (616 mg, 1.923 mmol, 84% yield) as yellow oil: IR (thin film)
1692 cm.sup.-1; H NMR (300 MHz, CDCl.sub.3) .delta. 8.71 (t, J=1.4
Hz, 1H), 8.35 (d, J=2.6 Hz, 1H), 7.83 (dt, J=9.5, 2.3 Hz, 2H), 3.18
(s, 3H), 2.65 (q, J=7.5 Hz, 2H), 1.44 (s, 9H), 1.25 (t, J=7.1 Hz,
3H); EIMS m/z 320.
Example 35
Preparation of
N-(1-(5-fluoropyridin-3-yl)-3-formyl-1H-pyrazol-4-yl)isobutyramide
(Compound 560)
##STR00090##
[0358] To a solution of
N-(1-(5-fluoropyridin-3-yl)-3-vinyl-1H-pyrazol-4-yl)isobutyramide
(0.706 g, 2.57 mmol) in tetrahydrofuran (12.87 ml) and water (12.87
ml) was added osmium tetroxide (0.164 ml, 0.026 mmol). After 10
minutes at room temperature, sodium periodate (1.101 g, 5.15 mmol)
was added in portions over 3 minutes and the resulting solution was
stirred at room temperature. After 18 hours, the solution was
poured into 10 mL water and was extracted with 3.times.10 mL
dichloromethane. The combined organic layers were dried,
concentrated and chromatographed (0-100% ethyl acetate/hexanes) to
give
N-(1-(5-fluoropyridin-3-yl)-3-formyl-1H-pyrazol-4-yl)isobutyramide
(626 mg, 2.266 mmol, 88% yield) as a yellow solid: mp
140.0-142.0.degree. C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
10.12 (s, 1H), 9.14 (s, 1H), 8.90 (d, J=2.0 Hz, 1H), 8.82 (s, 1H),
8.51 (d, J=2.5 Hz, 1H), 7.92 (dt, J=9.2, 2.4 Hz, 1H), 2.65 (dt,
J=13.8, 6.9 Hz, 1H), 1.31 (d, J=6.9 Hz, 6H); ESIMS m/z 277
([M+H].sup.+).
[0359] Compound 369 was prepared in accordance with the procedures
disclosed in Example 35.
Example 36
Preparation of
N-(1-(5-fluoropyridin-3-yl)-3-(hydroxymethyl)-1H-pyrazol-4-yl)isobutyrami-
de (Compound 435) and
N-(1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)isobutyramide (Compound
436)
##STR00091##
[0361] To a solution of
N-(1-(5-fluoropyridin-3-yl)-3-formyl-1H-pyrazol-4-yl)isobutyramide
(0.315 g, 1.140 mmol) in methanol (5.70 ml) at 0.degree. C. was
added sodium borohydride (0.086 g, 2.280 mmol). The reaction was
stirred at 0.degree. C. for 2 hours, and room temperature for 20
hours. 0.5 M HCl was added, the reaction was neutralized with
saturated aqueous sodium bicarbonate, and the mixture was extracted
with dichloromethane. The organic phases were concentrated and
chromatographed (0-100% ethyl acetate/hexanes) to give
N-(1-(5-fluoropyridin-3-yl)-3-(hydroxymethyl)-1H-pyrazol-4-yl)isobut-
yramide (180 mg, 0.647 mmol, 56.7%) as a white solid and
N-(1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)isobutyramide (9 mg,
0.036 mmol, 3.18%) as a white solid.
[0362]
N-(1-(5-fluoropyridin-3-yl)-3-(hydroxymethyl)-1H-pyrazol-4-yl)isobu-
tyramide: mp 144.0-146.0.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.74 (d, J=1.1 Hz, 1H), 8.64 (s, 1H), 8.37-8.29
(m, 2H), 7.74 (dt, J=9.5, 2.3 Hz, 1H), 4.95 (d, J=3.0 Hz, 2H),
3.21-3.06 (m, 1H), 2.63-2.48 (m, 1H), 1.26 (d, J=6.9 Hz, 6H); ESIMS
m/z 279 ([M+H].sup.+).
[0363] N-(1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)isobutyramide:
IR (thin film) 1659 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.79 (d, J=1.2 Hz, 1H), 8.60 (s, 1H), 8.38 (d, J=2.5 Hz,
1H), 7.81 (dt, J=9.5, 2.3 Hz, 1H), 7.68 (s, 1H), 7.54 (s, 1H),
2.63-2.51 (m, 1H), 1.28 (d, J=6.9 Hz, 6H); ESIMS m/z 249
([M+H].sup.+).
Example 37
Preparation of
N-(3-(chloromethyl)-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)isobutyramid-
e (Compound 561)
##STR00092##
[0365] To a solution of
N-(1-(5-fluoropyridin-3-yl)-3-(hydroxymethyl)-1H-pyrazol-4-yl)isobutyrami-
de (0.100 g, 0.359 mmol) in dichloromethane (3.59 ml) was added
thionyl chloride (0.157 ml, 2.151 mmol). The reaction was stirred
at room temperature for 2 hours. Saturated aqueous sodium
bicarbonate was added, and the mixture was extracted with
dichloromethane. The combined organic phases were washed with brine
and concentrated to give
N-(3-(chloromethyl)-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)isobutyramid-
e (100 mg, 0.337 mmol, 94% yield) as a white solid: mp
172.0-177.0.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.79 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 7.80 (dt, J=9.4, 2.3 Hz,
1H), 7.42 (s, 1H), 4.77 (s, 2H), 2.63 (hept, J=6.9 Hz, 1H), 1.30
(d, J=6.9 Hz, 6H); ESIMS m/z 298 ([M+H].sup.+).
Example 38
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methoxyacetamide
(Compound 512) (see also Example 11)
##STR00093##
[0367] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, 2HCl (0.130
g, 0.502 mmol) and in DCM (2.508 ml) was added
N-ethyl-N-isopropylpropan-2-amine (0.257 ml, 1.505 mmol) followed
by 2-methoxyacetyl chloride (0.109 g, 1.003 mmol) and the reaction
mixture was stirred at ambient temperature for 16 hours. The
reaction was quenched by the addition of saturated sodium
bicarbonate. The organic layer was extracted with DCM. The organic
layer was dried over sodium sulfate, filtered, concentrated and
purified using silica gel chromatography (0-100% ethyl
acetate/hexanes) to yield the title compound as a pale yellow oil
(0.12 g, 77%): IR (thin film) 3514, 3091, 2978, 1676 cm.sup.-1; H
NMR (400 MHz, CDCl.sub.3) .delta. 8.96 (d, J=2.4 Hz, 1H), 8.63 (d,
J=3.8 Hz, 1H), 8.09-8.03 (m, 1H), 7.99 (s, 1H), 7.47 (dd, J=8.3,
4.8 Hz, 1H), 3.88 (s, 2H), 3.77-3.65 (m, 2H), 3.40 (s, 3H), 1.18
(t, J=7.2 Hz, 3H); ESIMS m/z 295 ([M+H].sup.+).
[0368] Compounds 71, 478, 481, 483-484, and 543 were prepared in
accordance with the procedures disclosed in Example 38.
Example 39
Preparation of
N-(3-chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3--
(methylthio)butanamide (Compound 182) and
(Z)--N-(3-chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-meth-
ylbut-2-enamide (Compound 183)
##STR00094##
[0370] To a solution 2-methyl-3-(methylthio)butanoic acid (0.154 g,
1.039 mmol) in dichloromethane (1 mL) at room temperature was added
1 drop of dimethylformamide. Oxalyl dichloride (0.178 ml, 2.078
mmol) was added dropwise and the reaction was stirred at room
temperature overnight. The solvent was removed under reduced
pressure. The residue was redissolved in dichloromethane (1 mL) and
the solvent was removed under reduced pressure. The residue was
redissolved in dichloromethane (0.5 mL) and the solution was added
to a solution of
3-chloro-N-ethyl-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-amine (0.100
g, 0.416 mmol) and 4-dimethylaminopyridine (0.254 g, 2.078 mmol) in
dichloromethane (1.5 mL) and stirred at room temperature overnight.
The solvent was removed under reduced pressure and the residue was
purify by chromatography (0-100% ethyl acetate/hexanes) to give
N-(3-chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3--
(methylthio)butanamide (34 mg, 0.092 mmol, 22.06%) as a faint
yellow oil and
(Z)--N-(3-chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2--
methylbut-2-enamide (38 mg, 0.118 mmol, 28.3% yield) as a yellow
oil.
[0371]
N-(3-chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-met-
hyl-3-(methylthio)butanamide: IR (thin film) 1633 cm.sup.-1;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.79 (d, J=2.0 Hz,
0.66H), 8.77 (d, J=2.0 Hz, 0.33H), 8.50 (d, J=2.6 Hz, 0.33H), 8.49
(d, J=2.5 Hz, 0.66H), 8.08 (s, 0.66H), 7.95 (s, 0.33H), 7.92-7.81
(m, 1H), 4.03-3.46 (m, 2H), 3.03-2.78 (m, 1H), 2.59-2.33 (m, 1H),
2.04 (s, 2H), 2.02 (s, 1H), 1.32 (d, J=6.7 Hz, 1H), 1.27 (d, J=6.2
Hz, 1H), 1.23 (d, J=6.9 Hz, 2H), 1.18-1.12 (m, 5H); ESIMS m/z 371
([M].sup.+).
[0372]
(Z)--N-(3-chloro-1-(5-fluoropyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl--
2-methylbut-2-enamide: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.73 (d, J=2.0 Hz, 1H), 8.46 (d, J=2.4 Hz, 1H), 7.87 (d, J=4.9 Hz,
1H), 7.84 (dt, J=9.2, 2.4 Hz, 1H), 5.93-5.76 (m, 1H), 3.73 (q,
J=7.1 Hz, 2H), 1.72 (s, 3H), 1.58 (dd, J=6.9, 0.9 Hz, 3H), 1.17 (t,
J=7.1 Hz, 3H); ESIMS m/z 323 ([M].sup.+).
[0373] Compounds 70, 180-181, 389-392, 397-398, 405-406, 427-429,
432, 456, 482, 521-522, 532-534, 555, and 589 were prepared from
the corresponding intermediates and starting materials in
accordance with the procedures disclosed in Example 39.
Example 40
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methyl-2-(methylthio)acet-
amide (Compound 337)
##STR00095##
[0375] To an ice cold solution of 2-(methylthio)acetic acid (0.092
g, 0.863 mmol) in DCM (2 mL) was added
N-ethyl-N-isopropylpropan-2-amine (0.111 g, 0.863 mmol) followed by
isobutyl chloroformate (0.099 ml, 0.767 mmol). Stirring was
continued for 10 minutes. Next, the mixed anhydride was added to a
solution of 3-chloro-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
(0.08 g, 0.383 mmol) in DCM (0.66 mL) and the reaction mixture was
stirred at ambient temperature for 2 hours. The reaction mixture
was concentrated and purified using reverse phase C-18 column
chromatography (0-100% CH.sub.3CN/H.sub.2O) to yield the title
compound as a pale yellow oil (0.075 g, 66%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.95 (d, J=2.5 Hz, 1H), 8.62 (dd, J=4.8, 1.4
Hz, 1H), 8.13 (s, 1H), 8.04 (ddd, J=8.3, 2.7, 1.4 Hz, 1H),
7.50-7.43 (m, 1H), 3.26 (s, 3H), 3.12 (s, 2H), 2.24 (s, 3H);
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 170.00, 148.61, 140.15,
140.03, 135.68, 126.56, 126.42, 125.33, 124.15, 37.16, 34.94,
16.22; ESIMS m/z 297 ([M+H].sup.+).
[0376] Compounds 335, 336, and 542 were prepared in accordance with
the procedures disclosed in Example 40.
Example 41
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3-oxobutan-
amide (Compound 499)
##STR00096##
[0378] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, HCl (259 mg,
1 mmol) and ethyl 2-methyl-3-oxobutanoate (144 mg, 1.000 mmol) in
dioxane (1 mL) was added
2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine (181 mg, 1.30
mmol) and the mixture was heated in a microwave (CEM Discover) at
150.degree. C. for 1.5 h, with external IR-sensor temperature
monitoring from the bottom of the vessel. LCMS (ELSD) indicated a
40% conversion to the desired product. The mixture was diluted with
ethyl acetate (50 ML) and saturated aqueous NH.sub.4Cl (15 mL), and
the organic phase was separated. The aqueous phase was extracted
with ethyl acetate (20 mL) and the combined organic phase was
washed with brine, dried over MgSO.sub.4 and concentrated in vacuo
to give an oily residue. This residue was purified on silica gel
eluting with mixtures of ethyl acetate and hexanes to give
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3-oxobutan-
amide (37 mg, 11% yield, 96% purity) as a colorless oil: .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 9.02-8.92 (dd, J=2.6, 0.8 Hz,
1H), 8.68-8.60 (dd, J=4.8, 1.5 Hz, 1H), 8.09-7.98 (m, 1H),
7.96-7.87 (s, 1H), 3.87-3.58 (d, J=3.0 Hz, 2H), 3.49-3.38 (m, 1H),
2.16-2.08 (s, 3H), 1.39-1.32 (d, J=7.0 Hz, 3H), 1.22-1.13 (m, 3H);
EIMS (m/z) 321 ([M+1].sup.+), 319 ([M-1].sup.-).
Example 42
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylcyclopropanecarboxam-
ide (Compound 538)
##STR00097##
[0380] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
monohydrochloride (0.10 g, 0.0.38 mmol) in dichloroethane (0.75 ml)
was added cyclopropanecarboxylic acid (0.03 g, 0.38 mmol) and
4-N,N-dimethylaminopyridine (0.14 g, 1.15 mmol) followed by
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.14
g, 0.77 mmol). The reaction was stirred at room temperature
overnight. The reaction mixture was concentrated to dryness and the
crude product was purified by reverse phase silica gel
chromatography eluting with 0-50% acetonitrile/water to give a
white solid (0.03 g, 25%); mp 111-119.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.96 (d, J=2.5 Hz, 1H), 8.63-8.59 (m, 1H),
8.06 (ddd, J=8.3, 2.6, 1.4 Hz, 1H), 8.01 (s, 1H), 7.46 (dd, J=8.3,
4.7 Hz, 1H), 3.73 (q, J=7.2 Hz, 2H), 1.46 (ddd, J=12.6, 8.1, 4.7
Hz, 1H), 1.16 (t, J=7.2 Hz, 3H), 1.04 (t, J=3.7 Hz, 2H), 0.71 (dd,
J=7.7, 3.0 Hz, 2H); ESIMS m/z 291 ([M+H]).
[0381] Compounds 69, 516, 524, 546, 558-559, 582-588, 593, and 594
were prepared from the appropriate acids in accordance with the
procedures disclosed in Example 42.
Example 43
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-methyl-3-(methylthio)-N-(-
3-(methylthio)propanoyl)propanamide (Compound 407)
##STR00098##
[0383] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(methylthio)propanamide
(0.216 g, 0.728 mmol) in DCE (2.91 ml) in a 10 mL vial was added
2-methyl-3-(methylthio)propanoyl chloride (0.244 g, 1.601 mmol).
The vial was capped and placed in a Biotage Initiator microwave
reactor for 3 hours at 100.degree. C., with external IR-sensor
temperature monitoring from the side of the vessel. The crude
mixture was concentrated and purified using reverse phase C-18
column chromatography (0-100% acetonitrile/water) to yield the
title compound as a pale yellow oil (67 mg, 22%): IR (thin film)
2916 and 1714 cm.sup.-1; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
8.96-8.92 (d, J=2.7 Hz, 1H), 8.64-8.59 (dd, J=4.9, 1.4 Hz, 1H),
8.07-7.99 (m, 2H), 7.50-7.40 (dd, J=8.4, 4.8 Hz, 1H), 3.39-3.28 (m,
1H), 3.10-2.99 (td, J=7.2, 3.9 Hz, 2H), 2.96-2.86 (dd, J=13.2, 8.7
Hz, 1H), 2.86-2.79 (t, J=7.3 Hz, 2H), 2.58-2.48 (dd, J=13.1, 5.8
Hz, 1H), 2.14-2.12 (s, 3H), 2.09-2.06 (s, 3H), 1.30-1.26 (d, J=6.9
Hz, 3H); ESIMS m/z 413 ([M+H].sup.+).
[0384] Compounds 383, 410, 433, 437, 451, 470, 530 and 531 were
prepared in accordance with the procedures disclosed in Example
43.
Example 44
Preparation of
N-[3-chloro-1-(3-pyridyl)pyrazol-4-yl]-2,2-dideuterio-N-ethyl-3-methylsul-
fanyl-propanamide (Compound 393)
##STR00099##
[0386] To a 7 mL vial was added
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (111 mg, 0.5
mmol), 2,2-dideuterio-3-methylsulfanyl-propanoic acid (58.0 mg,
0.475 mmol) and followed by DCM (Volume: 2 mL). The solution was
stirred at 0.degree. C. Then the solution of DCC (0.500 mL, 0.500
mmol, 1.0 M in DCM) was added. The solution was allowed to warm up
to 25.degree. C. slowly and stirred at 25.degree. C. overnight.
White precipitate formed during the reaction. The crude reaction
mixture was filtered through a cotton plug and purified by silica
gel chromatography (0-100% EtOAc/hexane) to give
N-[3-chloro-1-(3-pyridyl)pyrazol-4-yl]-2,2-dideuterio-N-ethyl-3-methylsul-
fanyl-propanamide (97 mg, 0.297 mmol, 59.4% yield) as a colorless
oil: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.96 (d, J=2.4 Hz,
1H), 8.63 (dd, J=4.6, 0.9 Hz, 1H), 8.06 (ddd, J=8.4, 2.7, 1.4 Hz,
1H), 7.98 (s, 1H), 7.52-7.40 (m, 1H), 3.72 (q, J=7.2 Hz, 2H), 2.78
(s, 2H), 2.06 (s, 3H), 1.17 (t, J=7.2 Hz, 3H); ESIMS m/z 327
([M+H].sup.+); IR (Thin film) 1652 cm.sup.-1.
[0387] Compounds 394, 396, and 471-473 were prepared from the
corresponding intermediates and starting materials in accordance
with the procedures disclosed in Example 44.
Example 45
Preparation of
1-ethyl-3-(3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)urea (Compound
145)
##STR00100##
[0389] To a solution of
3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.1 g, 0.574 mmol) in
DCM (5.74 ml) was added ethyl isocyanate (0.041 g, 0.574 mmol) and
the reaction mixture was stirred at ambient temperature for 40
minutes. The reaction mixture had turned from a clear solution to a
suspension with white solid material. The reaction mixture was
concentrated and purified using silica gel chromatography (0-20%
MeOH/DCM) to yield the title compound as a white solid (0.135 g,
95%): mp 197-200.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.94 (d, J=2.3 Hz, 1H), 8.48-8.37 (m, 1H), 8.32 (s, 1H),
7.94 (d, J=8.3 Hz, 1H), 7.52 (br s, 1H), 7.41-7.25 (m, 1H), 5.79
(br s, 1H), 3.33-3.23 (m, 2H), 2.29 (d, J=2.9 Hz, 3H), 1.16 (dd,
J=8.7, 5.7 Hz, 3H); ESIMS m/z 246 ([M+H].sup.+), 244
([M-H].sup.-).
[0390] Compounds 169-171, 221-222, 255-257, 278-280, 297-302,
318-322, 334, 345, 348, 375-377, 385-387, and 411-413 were prepared
in accordance with the procedures disclosed in Example 45.
[0391]
1-(3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-ethyl-1-methylthiou-
rea (Compound Y2048) was prepared in accordance with the procedure
disclosed in Example 45 using DMAP as a base, dioxane as a solvent,
and heating the reaction in a microwave (CEM Discover.RTM.) with
external IR-sensor temperature monitoring from the bottom of the
vessel at 120.degree. C. for 2 hours: white solid; mp
160.0-162.0.degree. C.; .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
8.94 (d, J=2.6 Hz, 1H), 8.62 (dd, J=4.8, 1.4 Hz, 1H), 8.05-7.98 (m,
2H), 7.46 (dd, J=8.3, 4.7 Hz, 1H), 5.66 (s, 1H), 3.72-3.59 (m, 5H),
1.17 (t, J=7.2 Hz, 3H); ESIMS m/z 297 ([M+H].sup.+).
Example 46
Preparation of
3-butyl-1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-1-ethylurea
(Compound 500)
##STR00101##
[0393] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, 2HCl (0.130
g, 0.502 mmol) in DCE (1.25 ml) was added
N-ethyl-N-isopropylpropane-2-amine (0.21 mL, 1.255 mmol) followed
by 1-isocyanatobutane (0.109 g, 1.104 mmol) and the reaction
mixture was stirred at ambient temperature for 16 hours. The
reaction mixture was concentrated and purified using silica gel
chromatography (0-20% MeOH/DCM) to yield the title compound as a
beige solid (0.131 g, 77%): IR (thin film) 3326, 2959, 2931, 1648
cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.95 (s, 1H),
8.62 (d, J=4.0 Hz, 1H), 8.08-8.01 (m, 1H), 7.97 (s, 1H), 7.46 (dd,
J=8.3, 4.7 Hz, 1H), 4.42-4.32 (m, 1H), 3.74-3.61 (m, 2H), 3.27-3.15
(m, 2H), 1.49-1.37 (m, 2H), 1.37-1.22 (m, 2H), 1.19-1.12 (m, 3H),
0.94-0.84 (m, 3H); ESIMS m/z 322 ([M+H].sup.+).
[0394] Compounds 479-480, 501-504, 513, 518 and 519 were prepared
according to Example 46.
Example 47
Preparation of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)imidazolidin-2-one
(Compound 374)
##STR00102##
[0396] To a solution of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(2-chloroethyl)urea
(0.1 g, 0.333 mmol) in THF (6.66 ml) was added sodium hydride (8.00
mg, 0.333 mmol) and the reaction mixture was stirred at ambient
temperature for 30 minutes. The reaction was quenched by the
addition of a solution of saturated ammonium chloride and the
product was extracted with ethyl acetate (2.times.). The combined
organic layers were dried over sodium sulfate, filtered and
concentrated. The product was a beige solid which was pure and did
not need any further purification (63 mg, 72%): mp 167-170.degree.
C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.96 (d, J=2.2 Hz,
1H), 8.56 (dd, J=4.7, 1.4 Hz, 1H), 8.33 (s, 1H), 7.99 (ddd, J=8.3,
2.7, 1.4 Hz, 1H), 7.40 (ddd, J=8.3, 4.8, 0.7 Hz, 1H), 5.00 (s, 1H),
4.14-4.07 (m, 2H), 3.68-3.58 (m, 2H); ESIMS m/z 264
([M+H].sup.+).
[0397] Compound 349 was prepared in accordance with the procedures
disclosed in Example 47.
Example 48
Preparation of
S-tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)carbamothio-
ate (Compound 514)
##STR00103##
[0399] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, 2HCl (0.13 g,
0.502 mmol) in DCM (2.508 ml) was added
N-ethyl-N-isopropylpropan-2-amine (0.257 ml, 1.505 mmol) followed
by S-tert-butyl carbonochloridothioate (0.153 g, 1.003 mmol). The
reaction mixture was stirred at ambient temperature for 16 hours.
The reaction was quenched by the addition of saturated sodium
bicarbonate. The organic layer was extracted with DCM. The organic
layer was dried over sodium sulfate, filtered, concentrated and
purified using silica gel column chromatography (0-100% ethyl
acetate/hexanes) to yield the title compound as a white solid (132
mg, 78%): mp 91-93.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.96 (d, J=2.5 Hz, 1H), 8.60 (dd, J=4.7, 1.4 Hz, 1H),
8.08-8.03 (m, 1H), 7.97 (s, 1H), 7.47-7.41 (m, 1H), 3.69 (q, J=7.2
Hz, 2H), 1.47 (s, 9H), 1.21-1.13 (m, 3H); ESIMS m/z 339
([M+H].sup.+).
[0400] Compounds 333, 338, 339, 346, 368 and 373 were prepared in
accordance with the procedures disclosed in Example 48.
Example 49
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3-(methio)-
propanethioamide (Compound 364)
##STR00104##
[0402] To a microwave reaction vessel was added
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3-(methio)-
propanamide (0.07 g, 0.22 mmol) in dichloroethane (1.87 mL) and
Lawesson's reagent (0.05 g, 0.12 mmol). The vessel was capped and
heated in a Biotage Initiator microwave reactor for 15 minutes at
130.degree. C., with external IR-sensor temperature monitoring from
the side of the vessel. The reaction was concentrated to dryness
and the crude material was purified by silica gel chromatography
(0-80% acetonitrile/water) to give the desired product as a yellow
oil (0.33 g, 44%): IR (thin film) 1436 cm.sup.-1; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.97 (d, J=2.5 Hz, 1H), 8.77-8.52 (m, 1H),
8.11-7.89 (m, 2H), 7.60-7.38 (m, 1H), 4.62 (bs, 1H), 4.02 (bs, 1H),
3.21-2.46 (m, 3H), 2.01 (s, 3H), 1.35-1.15 (m, 6H); ESIMS m/z 355
([M+H].sup.+).
[0403] Compounds 372, 438 and 548 were prepared in accordance with
the procedures disclosed in Example 49.
[0404] N-methyl-3-(methylthio)propanethioamide was prepared in
accordance with the procedure disclosed in Example 49 and isolated
as a clear oil; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.69 (s,
1H), 3.20 (d, J=4.8 Hz, 3H), 2.99-2.88 (m, 4H), 2.15 (s, 3H); ESIMS
m/z 150 ([M+H].sup.+).
Example 50
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-4,4,4-trifluoro-3-(-
methylsulfinyl)butanamide (Compound 570)
##STR00105##
[0406] To a 20 mL vial was added
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-4,4,4-trifluoro-3-(-
methylthio)butanamide (82 mg, 0.209 mmol) and hexafluoroisopropanol
(1.5 mL). Hydrogen peroxide (0.054 mL, 0.626 mmol, 35% solution in
water) was added in one portion and the solution was stirred at
room temperature. After 3 hours the reaction was quenched with
saturated sodium sulfite solution and extracted with EtOAc
(3.times.20 mL). The combined organic layers were dried over sodium
sulfate, concentrated and purified by chromatography (0-10%
MeOH/DCM) to give
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-4,4,4-trifluoro-3-(-
methylsulfinyl) butanamide (76 mg, 0.186 mmol, 89% yield) as white
semi-solid: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.98 (d,
J=2.3 Hz, 1H), 8.63 (td, J=4.8, 2.4 Hz, 1H), 8.14-8.01 (m, 2H),
7.46 (ddd, J=8.3, 4.8, 0.7 Hz, 1H), 4.26 (dd, J=17.2, 8.4 Hz, 1H),
3.89-3.61 (m, 2H), 3.01 (dd, J=17.6, 8.2 Hz, 1H), 2.77 (s, 2H),
2.48 (dd, J=17.7, 3.3 Hz, 1H), 1.19 (t, J=7.2 Hz, 3H) (only one
isomer shown); ESIMS m/z 409 ([M+H].sup.+); IR (Thin film) 1652
cm.sup.-1.
[0407] Compound 571 was prepared from the corresponding
intermediates and starting materials in accordance with the
procedures disclosed in Example 50.
Example 51
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methylsulfinyl)p-
ropanamide (Compound 362)
##STR00106##
[0409] To
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methylt-
hio)propanamide (0.08 g, 0.24 mmol) in glacial acetic acid (0.82
mL) was added sodium perborate tetrahydrate (0.05 g, 0.25 mmol),
and the mixture was heated at 60.degree. C. for 1 hour. The
reaction mixture was carefully poured into a separatory funnel
containing saturated aqueous NaHCO.sub.3 resulting in gas
evolution. When the gas evolution had ceased, ethyl acetate was
added and the layers were separated. The aqueous layer was
extracted twice with ethyl acetate, and all the organic layers were
combined, dried over MgSO.sub.4, filtered and concentrated under
reduced pressure. The crude material was purified by silica gel
chromatography (0-10% methanol/dichloromethane) to give the desired
product as a clear oil (0.03 g, 40%): IR (thin film) 1655
cm.sup.-1; .sup.1H NMR (400 MHz, CDC.sub.13) .delta. 8.95 (t, J=9.2
Hz, 1H), 8.63 (dd, J=4.7, 1.4 Hz, 1H), 8.20-7.86 (m, 2H), 7.59-7.33
(m, 1H), 3.73 (ddt, J=20.5, 13.4, 6.8 Hz, 2H), 3.23-3.06 (m, 1H),
2.94-2.81 (m, 1H), 2.74-2.62 (m, 2H), 2.59 (s, 3H), 1.25-1.07 (m,
3H); ESIMS m/z 341 ([M+H].sup.+).
[0410] Compounds 101-102, 218, 328, 330, and 494 were prepared from
the appropriate sulfides in accordance with the procedures
disclosed in Example 51.
Example 52
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methylsulfonyl)p-
ropanamide (Compound 363)
##STR00107##
[0412] To
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methylt-
hio)propanamide (0.08 g, 0.25 mmol) in glacial acetic acid (0.85
mL) was added sodium perborate tetrahydrate (0.11 g, 0.52 mmol),
and the mixture was heated at 60.degree. C. for 1 hour. The
reaction mixture was carefully poured into a separatory funnel
containing saturated aqueous NaHCO.sub.3 resulting in gas
evolution. When the gas evolution had ceased, ethyl acetate was
added and the layers were separated. The aqueous layer was
extracted twice with ethyl acetate, and all the organic layers were
combined, dried over MgSO.sub.4, filtered and concentrated under
reduced pressure. The crude product was purified by silica gel
column chromatography (0 to 10% methanol/dichloromethane) to give
the desired product as a clear oil (0.04, 47%): (thin film) 1661
cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.95 (t,
J=11.5 Hz, 1H), 8.64 (dd, J=4.8, 1.4 Hz, 1H), 8.17-7.96 (m, 2H),
7.59-7.39 (m, 1H), 3.73 (d, J=7.0 Hz, 2H), 3.44 (dd, J=22.5, 15.7
Hz, 2H), 2.96 (s, 3H), 2.71 (t, J=6.9 Hz, 2H), 1.18 (dd, J=8.8, 5.5
Hz, 3H); ESIMS m/z 357 ([M+H].sup.+).
[0413] Compounds 103, 104, 219, 329, 331 and 495 were prepared from
the appropriate sulfides in accordance with the procedures
disclosed in Example 52.
Example 53
Preparation of
N-(3-methyl-1-(3-fluoropyridin-5-yl)-1H-pyrazol-4-yl)N-ethyl-2-methyl-(3--
oxido-.lamda..sup.4-sulfanylidenecyanamide)(methyl)propanamide
(Compound 250)
##STR00108##
[0415] To a solution of
N-ethyl-N-(1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-yl)-2-methyl-3--
(methylthio)propanamide (0.30 g, 0.89 mmol) in dichloromethane
(3.57 mL) at 0.degree. C. was added cyanamide (0.07 g, 1.78 mmol)
and iodobenzenediacetate (0.31 g, 0.98 mmol) and subsequently
stirred at room temperature for 1 hour. The reaction was
concentrated to dryness and the crude material was purified by
silica gel column chromatography (10% methanol/ethyl acetate) to
give the desired sulfilamine as a light yellow solid (0.28 g, 85%).
To a solution of 70% mCPBA (0.25 g, 1.13 mmol) in ethanol (4.19 mL)
at 0.degree. C. was added a solution of potassium carbonate (0.31
g, 2.26 mmol) in water (4.19 mL) and stirred for 20 minutes after
which a solution of sulfilamine (0.28 g, 0.75 mmol) in ethanol
(4.19 mL) was added in one portion. The reaction was stirred for 1
hour at 0.degree. C. The excess mCPBA was quenched with 10% sodium
thiosulfite and the reaction was concentrated to dryness. The
residue was purified by silica gel chromatography (0-10%
methanol/dichloromethane) to give the desired product as a clear
oil (0.16 g, 56%): IR (thin film) 1649 cm.sup.-1; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.80 (dd, J=43.8, 10.1 Hz, 1H), 8.51-8.36
(m, 1H), 8.11 (d, J=38.7 Hz, 1H), 7.96-7.77 (m, 1H), 4.32-3.92 (m,
2H), 3.49-3.11 (m, 6H), 2.32 (s, 3H), 1.27-1.05 (m, 6H); ESIMS m/z
393 ([M+H].sup.+).
Example 54
Preparation of
N-ethyl-4,4,4-trifluoro-3-methoxy-N-(3-methyl-1-(pyridin-3-yl)-1H-pyrazol-
-4-yl)-3-(trifluoromethyl)butanamide (Compound 276)
##STR00109##
[0417] To a solution of
N-ethyl-4,4,4-trifluoro-3-hydroxy-N-(3-methyl-1-(pyridin-3-yl)-1H-pyrazol-
-4-yl)-3-(trifluoromethyl)butanamide (184 mg, 0.448 mmol) in DMF (3
mL) stirring at 0.degree. C. was added sodium hydride (26.9 mg,
0.673 mmol). The solution was stirred at 0.degree. C. for 0.5 hour.
Then iodomethane (0.034 mL, 0.538 mmol) was added and ice bath was
removed and the mixture was stirred at 25.degree. C. overnight.
Reaction was worked up by slow addition of water and further
diluted with 20 mL of water, then extracted with 4.times.20 mL of
EtOAc. The combined organic layers were washed with water, dried
over Na.sub.2SO.sub.4 and concentrated. Silica Gel chromatography
(0-100% EtOAc/hexane) gave
N-ethyl-4,4,4-trifluoro-3-methoxy-N-(3-methyl-1-(pyridin-3-yl)-1H-pyrazol-
-4-yl)-3-(trifluoromethyl)butanamide (52 mg, 0.123 mmol, 27.3%
yield) as a white solid: mp=83-86.degree. C.; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.94 (d, J=2.5 Hz, 1H), 8.59 (dd, J=4.7, 1.3
Hz, 1H), 8.01 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.85 (s, 1H), 7.44
(ddd, J=8.3, 4.8, 0.6 Hz, 1H), 4.00 (brs, 1H), 3.73 (s, 3H), 3.39
(brs, 1H), 2.86 (s, 2H), 2.26 (s, 3H), 1.16 (t, J=7.1 Hz, 3H);
ESIMS m/z 425 ([M+H].sup.+); IR (Thin film) 1664 cm.sup.-1.
[0418] Compound 327 was prepared from the corresponding
intermediates and starting materials in accordance with the
procedures disclosed in Example 54.
Example 55
Step 1: Preparation of
N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(3-chloro-1-(pyridin-3-yl)-1H-
-pyrazol-4-yl)-2-methyl-3-(methylthio)propanamide
##STR00110##
[0420] A solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-methyl-3-(methylthio)prop-
anamide (0.150 g, 0.483 mmol) in N,N-dimethylformamide (2.413 ml)
was cooled to 0.degree. C. Sodium hydride (0.039 g, 0.965 mmol, 60%
dispersion) was added at and the reaction was stirred at 0.degree.
C. for 30 minutes. (2-Bromoethoxy)(tert-butyl)dimethylsilane (0.231
g, 0.965 mmol) was added, the ice bath was removed, and the
reaction was stirred at room temperature for 2 hours. The reaction
was heated at 65.degree. C. for 1.5 hours and then cooled to room
temperature. Brine was added and the mixture was extracted with
dichloromethane. The combined organic phases were concentrated and
chromatographed (0-100% ethyl acetate/hexanes) to give
N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(3-chloro-1-(pyridin-3-yl)-1H-
-pyrazol-4-yl)-2-methyl-3-(methylthio)propanamide (0.120 g, 0.243
mmol, 50.4%) as an orange oil: IR (thin film) 1669 cm.sup.-1;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.88 (d, J=2.5 Hz, 1H),
8.55 (dd, J=4.7, 1.4 Hz, 1H), 8.05 (s, 1H), 7.98 (ddd, J=8.3, 2.6,
1.4 Hz, 1H), 7.41 (ddd, J=8.4, 4.8, 0.5 Hz, 1H), 4.35-3.06 (m, 4H),
2.86-2.73 (m, 1H), 2.73-2.59 (m, 1H), 2.41 (dd, J=12.8, 5.7 Hz,
1H), 1.94 (s, 3H), 1.11 (d, J=6.7 Hz, 3H), 0.80 (s, 9H), 0.00 (s,
3H), -0.01 (s, 3H); ESIMS m/z 470 ([M+H].sup.+).
Example 55
Step 2: Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-(2-hydroxyethyl)-2-methyl-
-3-(methylthio)propanamide (Compound 535)
##STR00111##
[0422] To a solution of
N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(3-chloro-1-(pyridin-3-yl)-1H-
-pyrazol-4-yl)-2-methyl-3-(methylthio)propanamide (0.180 g, 0.384
mmol) in tetrahydrofuran (1.54 ml) was added tetrabutylammonium
fluoride (0.201 g, 0.767 mmol) and the reaction was stirred at room
temperature for 2 hours. Brine was added and the mixture was
extracted with ethyl acetate. The combined organic phases were
concentrated and chromatographed (0-100% water/acetonitrile) to
give
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-(2-hydroxyethyl)-2-methyl-
-3-(methylthio)propanamide as a white oil (0.081 g, 0.217 mmol,
56.5%): IR (thin film) 3423, 1654 cm.sup.-1; H NMR (400 MHz,
CDCl.sub.3) .delta. 9.00 (d, J=2.5 Hz, 1H), 8.62 (dd, J=4.7, 1.2
Hz, 1H), 8.25 (s, 1H), 8.07 (ddd, J=8.3, 2.4, 1.3 Hz, 1H), 7.47
(dd, J=8.3, 4.7 Hz, 1H), 4.47-3.70 (m, 3H), 3.65-3.09 (m, 2H),
2.91-2.68 (m, 2H), 2.48 (dd, J=12.4, 5.0 Hz, 1H), 2.01 (s, 3H),
1.18 (d, J=6.5 Hz, 3H); ESIMS m/z 356 ([M+H].sup.+).
Example 56
Preparation of
2-(N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-methyl-3-(methylthio)p-
ropanamido)ethyl acetate (Compound 547)
##STR00112##
[0424] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-(2-hydroxyethyl)-2-methyl-
-3-(methylthio)propanamide (0.045 g, 0.127 mmol) in dichloromethane
(1.27 ml) was added N,N-dimethylpyridin-4-amine (0.023 g, 0.190
mmol) and triethylamine (0.019 g, 0.190 mmol) followed by acetyl
chloride (0.015 g, 0.190 mmol). The reaction was stirred at room
temperature overnight. Water was added and the mixture was
extracted with dichloromethane. The combined organic phases were
concentrated and chromatographed (0-100% ethyl acetate/hexanes) to
give
2-(N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-methyl-3-(methylthio)p-
ropanamido)ethyl acetate as a yellow oil (0.015 g, 0.034 mmol,
26.8%): IR (thin film) 1739, 1669 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.97 (d, J=2.3 Hz, 1H), 8.64 (dd, J=4.7, 1.4
Hz, 1H), 8.15 (s, 1H), 8.04 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.47
(ddd, J=8.3, 4.8, 0.7 Hz, 1H), 4.50-3.40 (m, 4H), 2.84 (dd, J=12.7,
8.9 Hz, 1H), 2.78-2.63 (m, 1H), 2.46 (dd, J=12.7, 5.4 Hz, 1H), 2.03
(s, 3H), 2.01 (s, 3H), 1.16 (d, J=6.6 Hz, 3H); ESIMS m/z 398
([M+H].sup.+).
Example 57
Preparation of 2,2-dideuterio-3-methylsulfanyl-propanoic acid
##STR00113##
[0426] To a 100 mL round bottom flask was added
3-(methylthio)propanoic acid (3 g, 24.96 mmol), followed by
D.sub.2O (23 mL) and KOD (8.53 mL, 100 mmol) (40% wt solution in
D.sub.2O), the solution was heated to reflux overnight. NMR showed
ca. 95% D at alpha-position. The reaction was cooled down and
quenched with concentrated HCl until pH<2. White precipitate
appeared in aqueous layer upon acidifying. Reaction mixture was
extracted with 3.times.50 mL EtOAc, the combined organic layers
were dried over Na.sub.2SO.sub.4, concentrated in vacuo to almost
dryness. 100 mL hexane was added and the solution was concentrated
again to give 2,2-dideuterio-3-methylsulfanyl-propanoic acid as a
colorless oil (2.539 g, 20.78 mmol, 83%): IR (Thin film) 3430, 1704
cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 2.76 (s, 2H), 2.14
(s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 178.28,
38.14-28.55 (m), 28.55, 15.51; EIMS m/z 122.
[0427] 2-Deuterio-2-methyl-3-methylsulfanyl-propanoic acid was
prepared as described in Example 57 to afford a colorless oil (3.62
g, 26.8 mmol, 60.9%): IR (Thin film) 2975, 1701 cm.sup.-1; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 11.39-10.41 (brs, 1H), 2.88-2.79
(d, J=13.3 Hz, 1H), 2.61-2.53 (d, J=13.3 Hz, 1H), 2.16-2.09 (s,
3H), 1.32-1.25 (s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
181.74, 39.74-39.02 (m), 37.16, 16.50, 16.03; EIMS m/z 135.
Example 58
Preparation of 2-methyl-3-(trideuteriomethylsulfanyl)propanoic
acid
##STR00114##
[0429] To a 50 mL round bottom flask was added
3-mercapto-2-methylpropanoic acid (5 g, 41.6 mmol), followed by
MeOH (15 mL), the solution was stirred at 25.degree. C. Potassium
hydroxide (5.14 g, 92 mmol) was added slowly as the reaction is
exothermic. Iodomethane-d.sub.3 (6.63 g, 45.8 mmol) was added
slowly and then the reaction mixture was heated at 65.degree. C.
overnight. The reaction was worked up by addition of 2 N HCl until
the mixture was acidic. It was then extracted with EtOAc
(4.times.50 mL) and the combined organic layers were dried over
Na.sub.2SO.sub.4, concentrated and purified with flash
chromatography, eluted with 0-80% EtOAc/hexane to give
2-methyl-3-(trideuteriomethylsulfanyl)propanoic acid (4.534 g, 33.0
mmol, 79%) as colorless oil: IR (Thin film) 3446, 1704 cm.sup.-1; H
NMR (400 MHz, CDCl.sub.3) .delta. 2.84 (dd, J=13.0, 7.1 Hz, 1H),
2.80-2.66 (m, 1H), 2.57 (dd, J=13.0, 6.6 Hz, 1H), 1.30 (d, J=7.0
Hz, 3H); EIMS m/z 137.
Example 59
Preparation of 2-hydroxy-3-(methylthio)propanoic acid
##STR00115##
[0431] Sodium methanethiolate (4.50 g, 64.2 mmol) was added at
25.degree. C. to a solution of 3-chloro-2-hydroxypropanoic acid (2
g, 16.06 mmol) in MeOH (120 mL). The reaction mixture was heated at
reflux for 8 hours, then cooled to 25.degree. C. The precipitate
was removed by filtration and the filtrate was evaporated. The
residue was acidified to pH 2 with 2 N HCl, extracted with EtOAc
(3.times.30 mL), combined organic layers were dried with
Na.sub.2SO.sub.4, concentrated to give
2-hydroxy-3-(methylthio)propanoic acid as a white solid, (1.898 g,
13.94 mmol, 87% yield): mp 55-59.degree. C.; IR (Thin film) 2927,
1698 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 6.33 (s, 3H),
4.48 (dd, J=6.3, 4.2 Hz, 1H), 3.02 (dd, J=14.2, 4.2 Hz, 1H), 2.90
(dd, J=14.2, 6.3 Hz, 1H), 2.20 (s, 3H); EIMS m/z 136.
Example 60
Preparation of 2-methoxy-3-(methylthio)propanoic acid
##STR00116##
[0433] To a stirred solution of sodium hydride (0.176 g, 4.41 mmol)
in DMF (5 mL) was added a solution of
2-hydroxy-3-(methylthio)propanoic acid (0.25 g, 1.836 mmol) in 1 mL
DMF at 25.degree. C. and stirred for 10 min. Vigorous bubbling was
observed upon addition of NaH. Then iodomethane (0.126 mL, 2.020
mmol) was added and the solution was stirred at 25.degree. C.
overnight. The reaction was quenched by addition of 2 N HCl,
extracted with 3.times.10 mL of EtOAc, the combined organic layers
were washed with water (2.times.20 mL), concentrated and purified
by column chromatography, eluted with 0-100% EtOAc/hexane, gave
2-methoxy-3-(methylthio)propanoic acid (126 mg, 0.839 mmol, 45.7%
yield) as colorless oil: H NMR (400 MHz, CDCl.sub.3) .delta. 9.10
(s, 1H), 4.03 (dd, J=6.9, 4.4 Hz, 1H), 3.51 (s, 3H), 2.98-2.93 (m,
1H), 2.86 (dd, J=14.1, 6.9 Hz, 1H), 2.21 (s, 3H); EIMS m/z 150.
Example 61
Preparation of 2-(acetylthiomethyl)-3,3,3-trifluoropropanoic
acid
##STR00117##
[0435] To a 50 mL round bottom flask was added
2-(trifluoromethyl)acrylic acid (6 g, 42.8 mmol), followed by
thioacetic acid (4.59 ml, 64.3 mmol). The reaction was slightly
exothermic. The mixture was then stirred at 25.degree. C.
overnight. NMR showed some starting material (.about.30%). One more
equiv of thioacetic acid was added and the mixture was heated at
95.degree. C. for 1 hour, then allowed to cool to room temperature.
Mixture was purified by vacuum distillation at 2.1-2.5 mm Hg,
fraction distilled at 80-85.degree. C. was mostly thioacetic acid,
fraction distilled at 100-110.degree. C. was almost pure product,
contaminated by a nonpolar impurity (by TLC). It was again purified
by flash chromatography (0-20% MeOH/DCM), to give
2-(acetylthiomethyl)-3,3,3-trifluoropropanoic acid (7.78 g, 36.0
mmol, 84% yield) as colorless oil, which solidified under high
vacuum to give a white solid: mp 28-30.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.52 (brs, 1H), 3.44 (dt, J=7.5, 3.5 Hz,
2H), 3.20 (dd, J=14.9, 11.1 Hz, 1H), 2.38 (s, 3H); .sup.13C NMR
(101 MHz, CDCl.sub.3) .delta. 194.79, 171.14, 123.44 (q, J=281.6
Hz), 50.47 (q, J=27.9 Hz), 30.44, 24.69 (q, J=2.6 Hz); .sup.19F NMR
(376 MHz, CDCl.sub.3) .delta.-67.82.
Example 62
Preparation of 3,3,3-trifluoro-2-(methylthiomethyl)propanoic
acid
##STR00118##
[0437] To a solution of
2-(acetylthiomethyl)-3,3,3-trifluoropropanoic acid (649 mg, 3 mmol)
in MeOH (5 mL) stirring at 25.degree. C. was added pellets of
potassium hydroxide (421 mg, 7.50 mmol) in four portions over 5
minutes. Reaction was exothermic. Then MeI was added in once, the
reaction mixture was then heated at 65.degree. C. for 18 hours. The
reaction was then cooled down and quenched with 2N HCl until
acidic, and the aqueous layer extracted with chloroform (4.times.20
mL). Combined organic layer was dried, concentrated in vacuo,
purified with flash chromatography (0-20% MeOH/DCM), to give
3,3,3-trifluoro-2-(methylthiomethyl)propanoic acid (410 mg, 2.179
mmol, 72.6% yield) as a light yellow oil: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.95 (s, 1H), 3.49-3.37 (m, 1H), 3.02 (dd,
J=13.8, 10.8 Hz, 1H), 2.90 (dd, J=13.8, 4.0 Hz, 1H), 2.18 (s, 3H);
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 172.04 (q, J=2.8 Hz),
123.55 (q, J=281.2 Hz), 50.89 (q, J=27.5 Hz), 29.62 (q, J=2.3 Hz),
15.85; .sup.19F NMR (376 MHz, CDCl.sub.3) .delta.-67.98.
Example 63
Preparation of 3-(methylthio)pentanoic acid
##STR00119##
[0439] S,S-dimethyl carbonodithioate (1.467 g, 12.00 mmol) was
added with vigorous stirring to a solution of (E)-pent-2-enoic acid
(2.002 g, 20 mmol) in 30% KOH solution (prepared from potassium
hydroxide (3.87 g, 69 mmol) and Water (10 mL)). The reaction
mixture was slowly heated to 90.degree. C. over a period of 20-30
min. Heating was continued for 3 hours before the reaction was
cooled down to 25.degree. C. and quenched slowly with HCl. The
mixture was then extracted with DCM (3.times.30 mL), combined
organic layer dried and concentrated to give
3-(methylthio)pentanoic acid (2.7 g, 18.22 mmol, 91% yield) as
light orange oil: IR (Thin film) 2975, 1701 cm.sup.-1; H NMR (400
MHz, CDCl.sub.3) .delta. 2.92 (qd, J=7.3, 5.6 Hz, 1H), 2.63 (d,
J=7.2 Hz, 2H), 2.08 (s, 3H), 1.75-1.51 (m, 2H), 1.03 (t, J=7.4 Hz,
3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 178.14, 43.95,
39.78, 27.04, 12.95, 11.29; EIMS m/z 148.
[0440] 4-methyl-3-(methylthio)pentanoic acid was prepared as
described in Example 63 and isolated as a colorless oil: IR (Thin
film) 2960, 1704 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta.
2.88 (ddd, J=9.1, 5.4, 4.7 Hz, 1H), 2.68 (dd, J=16.0, 5.5 Hz, 1H),
2.55 (dd, J=16.0, 9.1 Hz, 1H), 2.13 (s, 3H), 2.01-1.90 (m, 1H),
1.03 (d, J=6.8 Hz, 3H), 0.99 (d, J=6.8 Hz, 3H); EIMS m/z 162.
##STR00120##
[0441] 3-(Methylthio)hexanoic acid was prepared according to the
procedure described in Example 63 and isolated as a colorless oil:
IR (thin film) 2921, 1705 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.72 (s, 1H), 3.06-2.92 (m, 1H), 2.63 (dd,
J=7.2, 2.6 Hz, 2H), 2.08 (s, 3H), 1.66-1.37 (m, 4H), 0.94 (t, J=7.2
Hz, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 178.19, 42.00,
40.20, 36.33, 20.05, 13.80, 12.86.
##STR00121##
[0442] 3-(Cyclopentylthio)-4,4,4-trifluorobutanoic acid was
prepared according to the procedure described in Example 63 and
isolated as a colorless oil: IR (thin film) 2959, 1714 cm.sup.-1;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.27 (s, 1H), 3.74-3.53
(m, 1H), 3.36 (p, J=6.9 Hz, 1H), 2.96 (dd, J=16.9, 3.9 Hz, 1H),
2.61 (dd, J=16.9, 10.6 Hz, 1H), 2.15-1.92 (m, 2H), 1.84-1.68 (m,
2H), 1.68-1.54 (m, 3H), 1.53-1.43 (m, 1H); EIMS m/z 242.
##STR00122##
[0443] 3-Cyclopropyl-3-(methylthio)propanoic acid was prepared
according to the procedure described in Example 63 and isolated as
a colorless oil: IR (thin film) 3002, 1703 cm.sup.-1; H NMR (400
MHz, CDCl.sub.3) .delta. 2.73 (dd, J=7.1, 2.2 Hz, 2H), 2.39 (dt,
J=9.7, 7.1 Hz, 1H), 2.17 (s, 3H), 0.97 (dddd, J=14.6, 13.0, 6.5,
3.6 Hz, 1H), 0.74-0.52 (m, 2H), 0.43-0.35 (m, 1H), 0.35-0.26 (m,
1H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 177.60, 47.18,
40.66, 16.34, 13.61, 5.30, 4.91.
##STR00123##
[0444] 5-Methyl-3-(methylthio)hexanoic acid was prepared according
to the procedure described in Example 63 and isolated as a light
orange oil: IR (thin film) 2955, 1705 cm.sup.-1; H NMR (400 MHz,
CDCl.sub.3) .delta. 3.12-2.96 (m, 1H), 2.70-2.53 (m, 2H), 2.07 (s,
3H), 1.91-1.78 (m, 1H), 1.49 (ddd, J=14.6, 9.1, 5.6 Hz, 1H), 1.38
(ddd, J=14.1, 8.4, 5.9 Hz, 1H), 0.93 (d, J=2.4 Hz, 3H), 0.92 (d,
J=2.3 Hz, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 178.07,
43.35, 40.53, 39.99, 25.45, 22.91, 21.83, 12.38.
##STR00124##
[0445] 2-(1-(Methylthio)cyclobutyl)acetic acid was prepared
according to the procedure described in Example 63 and isolated as
a white crystalline solid: mp 43-46.degree. C.; IR (thin film)
2955, 1691 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
2.77 (s, 2H), 2.30 (tdd, J=5.4, 3.9, 2.2 Hz, 2H), 2.23-2.13 (m,
3H), 2.04 (s, 3H), 2.00-1.89 (m, 1H); .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 176.84, 47.08, 44.08, 33.27, 16.00, 11.72.
##STR00125##
[0446] 3-(Methylthio)-3-phenylpropanoic acid was prepared according
to the procedure described in Example 63 and isolated as a white
solid: mp 75-77.degree. C.; IR (thin film) 2915, 1704 cm.sup.-1; H
NMR (400 MHz, CDCl.sub.3) .delta. 7.35-7.29 (m, 4H), 7.29-7.20 (m,
1H), 4.17 (t, J=7.6 Hz, 1H), 2.93 (dd, J=7.6, 3.2 Hz, 2H), 1.91 (s,
3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 176.98, 140.60,
128.61, 127.64, 127.56, 46.19, 40.70, 14.33.
##STR00126##
[0447] 3-(Methylthio)-3-(4-(trifluoromethyl)phenyl)propanoic acid
was prepared according to the procedure described in Example 63 and
isolated as a white solid: mp 106-108.degree. C.; IR (thin film)
2924, 1708 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 7.59 (d,
J=8.1 Hz, 2H), 7.45 (d, J=8.1 Hz, 2H), 4.21 (t, J=7.6 Hz, 1H), 2.95
(qd, J=16.3, 7.7 Hz, 2H), 1.92 (s, 3H); EIMS m/z (M-1) 263.
##STR00127##
[0448] 3-(3-Methoxyphenyl)-3-(methylthio)propanoic acid was
prepared according to the procedure described in Example 63 and
isolated as a white solid: mp 61-63.degree. C.; IR (thin film)
2921, 1699 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.28-7.17 (m, 1H), 6.94-6.86 (m, 2H), 6.79 (ddd, J=8.3, 2.5, 0.9
Hz, 1H), 4.14 (t, J=7.6 Hz, 1H), 3.80 (s, 3H), 2.92 (d, J=8.0 Hz,
2H), 1.92 (s, 3H); EIMS m/z 225.
##STR00128##
[0449] 3-(Methylthio)-3-(pyridin-3-yl)propanoic acid was prepared
according to the procedure described in Example 63 and isolated as
a white semi-solid: IR (thin film) 3349, 1547 cm.sup.-1; .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.54 (dd, J=2.3, 0.8 Hz, 1H),
8.39 (dd, J=4.9, 1.6 Hz, 1H), 7.90 (dt, J=7.9, 2.0 Hz, 1H), 7.41
(ddd, J=8.0, 4.9, 0.8 Hz, 1H), 4.26 (dd, J=9.2, 6.5 Hz, 1H), 2.81
(dd, J=14.7, 6.5 Hz, 1H), 2.71 (dd, J=14.8, 9.2 Hz, 1H), 1.94 (s,
3H); EIMS m/z 198.
##STR00129##
[0450] 3-(Methylthio)-3-(pyridin-4-yl)propanoic acid was prepared
according to the procedure described in Example 63 and isolated as
a white solid: mp 187-189.degree. C.; IR (thin film) 1692
cm.sup.-1; H NMR (400 MHz, CD.sub.3OD) .delta. 8.57-8.38 (m, 2H),
7.55-7.37 (m, 2H), 4.19 (dd, J=8.2, 7.3 Hz, 1H), 2.93 (dd, J=7.7,
2.8 Hz, 2H), 1.94 (s, 3H); EIMS m/z 198.
Example 64
Preparation of ethyl 1-(hydroxymethyl)cyclopropanecarboxylate
##STR00130##
[0452] A 1M solution of lithium aluminum tri-tert-butoxyhydride in
tetrahydrofuran (70.90 mL, 70.90 mmol) was added to a stirred
solution of diethyl cyclopropane-1,1'-dicarboxylate (6 g, 32.20
mmol) in tetrahydrofuran (129 mL) at 23.degree. C. The resulting
solution was heated to 65.degree. C. and stirred for 24 h. The
cooled reaction mixture was diluted with a 10% solution of sodium
bisulfate (275 mL) and extracted with ethyl acetate. The combined
organic layers were dried (MgSO.sub.4), filtered, and concentrated
to dryness to give the desired product as a pale yellow oil (4.60,
91%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 4.16 (q, J=7 Hz,
2H), 3.62 (s, 2H), 2.60 (br s, 1H), 1.22-1.30 (m, 5H), 0.87 (dd,
J=7, 4 Hz, 2H).
Example 65
Preparation of ethyl
1-((methylsulfonyloxy)methyl)cyclopropanecarboxylate
##STR00131##
[0454] Triethylamine (5.57 mL, 40.00 mmol) and methanesulfonyl
chloride (2.85 mL, 36.60 mmol) were sequentially added to a stirred
solution of ethyl 1-(hydroxymethyl)cyclopropanecarboxylate (4.80 g,
33.30 mmol) in dichloromethane (83 mL) at 23.degree. C. The
resulting bright yellow solution was stirred at 23.degree. C. for
20 h. The reaction mixture was diluted with water and extracted
with dichloromethane. The combined organic layers were dried
(MgSO.sub.4), filtered, and concentrated to dryness to give the
desired product as a brown oil (6.92 g, 94%): .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 4.33 (s, 2H), 4.16 (q, J=7 Hz, 2H), 3.08 (s,
3H), 1.43 (dd, J=7, 4 Hz, 2H), 1.26 (t, J=7 Hz, 3H), 1.04 (dd, J=7,
4 Hz, 2H).
Example 66
Preparation of ethyl
1-(methylthiomethyl)cyclopropanecarboxylate
##STR00132##
[0456] Sodium methanethiolate (4.36 g, 62.30 mmol) was added to a
stirred solution of ethyl
1-((methylsulfonyloxy)methyl)cyclopropanecarboxylate (6.92 g, 31.10
mmol) in N,N-dimethylformamide (62.30 mL) at 23.degree. C. The
resulting brown suspension was stirred at 23.degree. C. for 18 h.
The reaction mixture was diluted with water and extracted with
diethyl ether. The combined organic layers were dried (MgSO.sub.4),
filtered, and concentrated by rotary evaporation to afford the
title compound as a brown oil (5.43 g, 100%): .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 4.14 (q, J=7 Hz, 2H), 2.83 (s, 2H), 2.16 (s,
3H), 1.31 (dd, J=7, 4 Hz, 2H), 1.25 (t, J=7 Hz, 3H), 0.89 (dd, J=7,
4 Hz, 2H).
Example 67
Preparation of 1-(methylthiomethyl)cyclopropanecarboxylic acid
##STR00133##
[0458] A 50% solution of sodium hydroxide (12.63 mL, 243 mmol) was
added to a stirred solution of ethyl
1-(methylthiomethyl)cyclopropanecarboxylate (5.43 g, 31.20 mmol) in
absolute ethanol (62.30 mL) at 23.degree. C. The resulting solution
was stirred at 23.degree. C. for 20 h. The reaction mixture was
diluted with a 0.5 M solution of sodium hydroxide and washed with
dichloromethane. The aqueous layer was acidified to pH.apprxeq.1
with concentrated hydrochloric acid and extracted with
dichloromethane. The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered, and concentrated and concentrated to
dryness to give the desired product as a light brown oil (2.10 g,
46%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.82 (s, 2H), 2.17
(s, 3H), 1.41 (dd, J=7, 4 Hz, 2H), 0.99 (dd, J=7, 4 Hz, 2H).
Example 68
Preparation of 2,2-dimethyl-3-(methylthio)propanoic acid
##STR00134##
[0460] 2,2-Dimethyl-3-(methylthio)propanoic acid can be prepared as
demonstrated in the literature (reference Musker, W. K.; et al. J.
Org. Chem. 1996, 51, 1026-1029). Sodium methanethiolate (1.0 g, 14
mmol, 2.0 equiv) was added to a stirred solution of
3-chloro-2,2-dimethylpropanoic acid (1.0 g, 7.2 mmol, 1.0 equiv) in
N,N-dimethylformamide (3.7 mL) at 0.degree. C. The resulting brown
suspension was allowed to warm to 23.degree. C. and stirred for 24
h. The reaction mixture was diluted with a saturated solution of
sodium bicarbonate (300 mL) and washed with diethyl ether
(3.times.75 mL). The aqueous layer was acidified to pH.apprxeq.1
with concentrated hydrochloric acid and extracted with diethyl
ether (3.times.75 mL). The combined organic layers were dried
(sodium sulfate), gravity filtered, and concentrated to afford a
colorless oil (1.2 g, 99% crude yield). .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 2.76 (s, 2H), 2.16 (s, 3H), 1.30 (s, 6H).
Example 69
Preparation of 4,4,4-trifluoro-3-(methylthio)butanoic acid
##STR00135##
[0462] To a 100 mL round bottom flask was added
(E)-4,4,4-trifluorobut-2-enoic acid (8 g, 57.1 mmol) and Methanol
(24 mL), the solution was stirred in a water bath, then sodium
methanethiolate (10.01 g, 143 mmol) was added in three portions.
Vigorous bubbling was observed, the mixture was stirred at
25.degree. C. overnight, NMR showed no more starting material. To
the reaction mixture was added 2 N HCl until acidic. The mixture
was extracted with chloroform (5.times.50 mL), combined organic
layer was dried over Na.sub.2SO.sub.4, concentrated in vacuo and
further dried under high vacuum until there was no weight loss to
give 4,4,4-trifluoro-3-(methylthio)butanoic acid (10.68 g, 56.8
mmol, 99% yield) as a colorless oil: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.88 (s, 1H), 3.53 (dqd, J=10.5, 8.3, 4.0 Hz,
1H), 2.96 (dd, J=16.9, 4.0 Hz, 1H), 2.65 (dd, J=16.9, 10.4 Hz, 1H),
2.29 (s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 175.78
(s), 126.61 (q, J.sub.C-F=278.8 Hz), 44.99 (q, J.sub.C-F=30.3 Hz),
34.12 (d, J.sub.C-F=1.7 Hz), 15.95 (s); EIMS m/z 162.
Example 70
Preparation of 3-methyl-3-methylsulfanyl-butyric acid
##STR00136##
[0464] 3-methyl-3-methylsulfanyl-butyric acid was made using the
procedures disclosed in J. Chem Soc Perkin 1, 1992, 10,
1215-21).
Example 71
Preparation of 3-methylsulfanyl-butyric acid
##STR00137##
[0466] 3-Methylsulfanyl-butyric acid was made using the procedures
disclosed in Synthetic Comm., 1985, 15 (7), 623-32.
Example 72
Preparation of tetrahydro-thiophene-3-carboxylic acid
##STR00138##
[0468] Tetrahydro-thiophene-3-carboxylic acid was made using the
procedures disclosed in Heterocycles, 2007, 74, 397-409.
Example 73
Preparation of 2-methyl-3-methylsulfanyl-butyric acid
##STR00139##
[0470] 2-Methyl-3-methylsulfanyl-butyric acid was made as described
in J. Chem Soc Perkin 1, 1992, 10, 1215-21.
Example 74
Preparation of (1S,2S)-2-(methylthio)cyclopropanecarboxylic
acid
##STR00140##
[0472] (1S,2S)-2-(Methylthio)cyclopropanecarboxylic acid was made
using the procedures disclosed in Synthetic Comm., 2003, 33 (5);
801-807.
Example 75
Preparation of 2-(2-(methylthio)ethoxy)propanoic acid
##STR00141##
[0474] 2-(2-(Methylthio)ethoxy)propanoic acid was made as described
in WO 2007/064316 A1.
Example 76
Preparation of 2-((tetrahydrofuran-3-yl)oxy)propanoic acid
##STR00142##
[0476] 2-((Tetrahydrofuran-3-yl)oxy)propanoic acid was made as
described in WO 2007/064316 A1.
Example 77
Preparation of tert-Butyl
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-yl(prop-2-ynyl)carbamate
(Compound 601)
##STR00143##
[0478] To an ice cold solution of tert-butyl
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-ylcarbamate (1200
mg, 4.11 mmol) in dry DMF (4 mL) under nitrogen was added 60% wt
sodium hydride (197 mg, 4.93 mmol) and the mixture stirred for 10
min. 3-Bromoprop-1-yne (733 mg, 6.16 mmol) was then added and the
mixture was stirred for additional 0.5 h at between 0-5.degree. C.
The mixture was allowed to warm to ambient temperature and then
stirred for additional 3 h at room temperature. The brown reaction
mixture poured into saturated aqueous NH.sub.4Cl (20 mL), and
diluted with ethyl acetate (50 mL). The organic phase was separated
and the aqueous phase extracted with ethyl acetate (20 mL). The
combined organic phase was washed with brine, dried over anhydrous
MgSO.sub.4, filtered, and concentrated in vacuo to give a brown
oil. This oil was purified on silica gel eluting with mixtures of
hexanes and ethyl acetate to give the title compound as a light
yellow solid (1103 mg, 81%); mp 81-82.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.73 (s, 1H), 8.37 (d, J=2.5 Hz, 1H), 7.99
(s, 1H), 7.83 (dt, J=9.5, 2.2 Hz, 1H), 4.31 (s, 2H), 2.29 (t, J=2.4
Hz, 1H), 2.27 (s, 3H), 1.45 (s, 8H); ESIMS m/z 229.84
([M].sup.+).
[0479] Compounds 596 and 606 were prepared in accordance with the
procedure disclosed in Example 77 from the corresponding amine.
Example 78
Preparation of
1-(5-fluoropyridin-3-yl)-3-methyl-N-(prop-2-ynyl)-1H-pyrazol-4-amine,
hydrochloride
##STR00144##
[0481] To a solution of tert-butyl
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-yl(prop-2-ynyl)carbamate
(1.03 g, 3.11 mmol) in dioxane (5 mL) was added 4M HCl (3.9 mL,
15.5 mmol) indioxane. The mixture was stirred at room temperature
for 48 h and the resulting white solid was filtered, washed with
ether and dried under vacuum to give to give the title compound as
a white solid (741 mg, 89%): mp 167-168.degree. C.; .sup.1H NMR
(400 MHz, DMSO d.sub.6) .delta. 8.92-8.85 (m, 1H), 8.42 (d, J=2.5
Hz, 1H), 8.15 (s, 1H), 8.12-8.02 (m, 1H), 3.85 (d, J=2.5 Hz, 2H),
3.27-3.19 (m, 1H), 2.22 (s, 3H); ESIMS m/z 230.4 ([M].sup.+).
3-Chloro-N-(prop-2-ynyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine,
hydrochloride was prepared in accordance with the procedure
disclosed in Example 78 from (Compound 606): mp 180-182.degree. C.;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.22 (d, J=2.5 Hz, 1H),
8.67 (dd, J=5.3, 1.0 Hz, 1H), 8.64 (ddd, J=8.6, 2.6, 1.2 Hz, 1H),
8.32 (s, 1H), 7.96 (dd, J=8.6, 5.3 Hz, 1H), 3.81 (d, J=2.4 Hz, 2H),
3.15 (t, J=2.4 Hz, 1H); ESIMS m/z 234 ([M+2].sup.+).
[0482]
3-Methyl-N-(prop-2-yn-1-yl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine,
hydrochloride was prepared in accordance with the procedure
disclosed in Example 78 from Compound 596: mp 161-163.degree. C.;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.05 (s,
OH), 7.83 (d, J=5.9 Hz, 1H), 7.57 (s, 1H), 7.29 (dd, J=8.8, 5.6 Hz,
1H), 3.27 (d, J=2.5 Hz, 2H), 1.52 (s, 3H); EIMS m/z 213.1
([M].sup.+).
Example 79
Preparation of
N-(1-(5-Fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-yl)-3-(methylthio)-N-(p-
rop-2-ynyl)propanamide (Compound 605)
##STR00145##
[0484] To a stirred solution of
1-(5-fluoropyridin-3-yl)-3-methyl-N-(prop-2-yn-1-yl)-1H-pyrazol-4-amine,
HCl (100 mg, 0.38 mmol) and N,N-dimethylpyridin-4-amine (115 mg,
0.94 mmol) in CH.sub.2Cl.sub.2 (2 mL) was added
2-methyl-3-(methylthio)propanoyl chloride (69 mg, 0.45 mmol) and
the mixture stirred at room temperature for 24 h. The mixture was
concentrated in vacuo to give a brown oil, which was purified on
silica gel eluting with mixtures of ethyl acetate and hexanes to
give the title compound as a colorless oil (80 mg, 61%): .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.77 (d, J=1.7 Hz, 1H), 8.43 (d,
J=2.5 Hz, 1H), 8.05 (s, 1H), 7.86 (dt, J=9.4, 2.3 Hz, 1H), 4.49 (s,
1H), 2.88 (dd, J=12.8, 9.4 Hz, 1H), 2.74 (s, 1H), 2.45 (dd, J=12.9,
5.0 Hz, 1H), 2.34 (s, 3H), 2.24 (t, J=2.5 Hz, 1H), 2.02 (s, 3H),
1.14 (d, J=6.8 Hz, 3H); ESIMS m/z 347.5 ([M+H].sup.+).
[0485] Compounds 598, 599, 600, 602, 603, 607, 608 and 610 were
prepared in accordance with the procedure disclosed in Example 79
from the corresponding amines.
Example 80
Preparation of
N-(3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-4,4,4-trifluoro-3-(methylth-
io)-N-(prop-2-yn-1-yl)butanamide (Compound 613)
##STR00146##
[0487] To a 7 mL vial was added
3-chloro-N-(prop-2-yn-1-yl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine
(140 mg, 0.6 mmol), N,N-dimethylpyridin-4-amine (249 mg, 2.040
mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine
hydrochloride (276 mg, 1.440 mmol) followed by
4,4,4-trifluoro-3-(methylthio)butanoic acid (158 mg, 0.840 mmol)
and DCE (1.2 mL). The solution was stirred at 25.degree. C. for 18
hours, the crude reaction mixture was concentrated and purified
with silica gel chromatography (0-100% EtOAc/hexane) to give the
title compound as a brown oil (237 mg, 0.588 mmol, 98%): (IR thin
film) 1674 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 8.97 (d,
J=2.6 Hz, 1H), 8.64 (dd, J=4.7, 1.3 Hz, 1H), 8.13 (s, 1H), 8.07
(ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.48 (ddd, J=8.3, 4.8, 0.5 Hz, 1H),
4.39 (s, 2H), 3.76 (dqd, J=17.2, 8.6, 3.6 Hz, 1H), 2.67 (dd,
J=16.6, 3.6 Hz, 1H), 2.46 (dd, J=16.5, 9.9 Hz, 1H), 2.29 (d, J=2.5
Hz, 4H); ESIMS m/z 403 ([M+H].sup.+).
[0488] Compounds 597, 604, 609, 614-616 were prepared in accordance
with the procedure disclosed in Example 80.
Example 81
Preparation of
3-Chloro-N-(prop-2-ynyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine
##STR00147##
[0490] To a solution of
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(prop-2-yn-1-yl)carb-
amate (2.2 g, 6.61 mmol) in dichloromethane (8.3 ml) was added
2,2,2-trifluoroacetic acid (12.06 g, 106 mmol) and the reaction
mixture was stirred at ambient temperature for 1 hour. The reaction
was quenched by the addition of saturated sodium bicarbonate. The
organic layer was extracted with dichloromethane (2.times.20 mL).
The organic layers were combined and dried over sodium sulfate,
filtered and concentrated without further purification to afford
the title compound as a beige solid (1.5 g, 6.12 mmol, 93%):
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.89 (d, J=2.3 Hz, 1H),
8.50 (dd, J=4.7, 1.4 Hz, 1H), 8.01-7.93 (m, 1H), 7.54 (s, 1H), 7.37
(ddd, J=8.3, 4.8, 0.7 Hz, 1H), 3.90 (s, 2H), 3.38 (s, 1H),
2.44-2.09 (m, 1H); ESIMS m/z 233 ([M+H].sup.+).
Example 82
Preparation of
N-(3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-(methylthio)-N-(prop-2-yn-
-1-yl)propanamide (Compound 611)
##STR00148##
[0492] To a solution of 2-(methylthio)propanoic acid (0.36 g, 3.00
mmol) in dichloromethane (3 mL) was added oxalyl dichloride (0.29
ml, 3.31 mmol) followed by one drop of N,N-dimethylformamide. The
reaction mixture was stirred for 30 minutes before all solvent was
evaporated. The resulting residue was dissolved in dichloromethane
(2 mL) and it was added to a pre-stirred solution of
3-chloro-N-(prop-2-yn-1-yl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine
(0.35 g, 1.50 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.57 ml,
3.31 mmol) in dichloromethane (5.5 mL). The reaction mixture was
stirred at ambient temperature for 16 hours. The reaction mixture
was concentrated and the residue was purified using silica gel
chromatography (0-100% ethyl acetate/hexanes) to afford the title
compound as a yellow oil (432 mg, 1.23 mmol, 85%): .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.97 (d, J=2.5 Hz, 1H), 8.66-8.60 (m, 1H),
8.25 (s, 1H), 8.08-8.01 (m, 1H), 7.49-7.42 (m, 1H), 4.86 (s, 1H),
4.29-3.97 (m, 1H), 3.31 (d, J=6.5 Hz, 1H), 2.30-2.24 (m, 1H), 2.09
(s, 3H), 1.46 (d, J=6.9 Hz, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 171.30, 148.66, 140.71, 140.18, 135.71, 127.87, 126.35,
124.11, 122.12, 78.53, 72.92, 53.39, 37.97, 16.42, 11.07; ESIMS m/z
335 ([M+H].sup.+).
[0493] Compound 612 was prepared in accordance with the procedure
disclosed in Example 82.
Example 83
Preparation of
N-(3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-(methylsulfinyl)-N-(prop--
2-yn-1-yl)propanamide (Compound 617)
##STR00149##
[0495] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-(methylthio)-N-(prop-2-yn-
-1-yl)propanamide (0.1 g, 0.30 mmol) in hexafluoroisoproanol (2.0
ml) was added hydrogen peroxide (35 wt %, 0.08 ml, 0.90 mmol) and
the reaction mixture was stirred vigorously at ambient temperature.
The reaction was complete after 1 hour. The reaction was quenched
with saturated sodium sulfite solution and the organic layer was
extracted with ethyl acetate (3.times.20 mL). The combined organic
layers were dried over sodium sulfate, filtered and concentrated.
The residue was purified using silica gel chromatography (0-20%
methanol/dichloromethane) to afford the title compound as an
off-white foam (82 mg, 0.21 mmol, 78%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.98 (s, 1H), 8.65 (d, J=4.6 Hz, 1H), 8.23 (s,
1H), 8.11-7.97 (m, 1H), 7.51-7.41 (m, 1H), 4.88 (br s, 1H), 4.14
(br s, 1H), 2.64 (s, 1.2H), 2.55 (s, 1.8H), 2.33-2.27 (m, 1H), 1.47
(d, J=6.8 Hz, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
168.11, 148.95, 148.78, 140.45, 140.33, 140.20, 135.56, 126.54,
124.10, 121.68, 121.58, 121.48, 77.69, 73.49, 38.60; ESIMS m/z 351
([M+H].sup.+).
Example 84
Preparation of
N-(3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-(methylsulfonyl)-N-(prop--
2-yn-1-yl)propanamide (Compound 618)
##STR00150##
[0497] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-(methylthio)-N-(prop-2-yn-
-1-yl)propanamide (0.10 g, 0.30 mmol) and acetic acid (2.0 ml). To
this solution was added sodium perborate tetrahydrate (0.11 g, 0.74
mmol) and the vial was heated to 65.degree. C. for 2 hours. The
reaction mixture was cooled to ambient temperature and neutralized
with saturated sodium bicarbonate. The organic layer was extracted
with ethyl acetate (3.times.). The organic layers were combined,
dried over sodium sulfate, filtered and concentrated. The residue
was purified using silica gel chromatography (0-20%
methanol/dichloromethane) to afford the title compound as a yellow
foam (84 mg, 0.21 mmol, 73%): .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.00 (s, 1H), 8.65 (s, 1H), 8.29 (s, 1H), 8.03 (d, J=8.0
Hz, 1H), 7.54-7.39 (m, 1H), 4.89 (d, J=16.9 Hz, 1H), 4.20-4.08 (m,
1H), 4.07-3.92 (m, 1H), 3.01 (s, 3H), 2.34-2.29 (m, 1H), 1.67 (d,
J=7.0 Hz, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 166.97,
166.90, 148.77, 140.43, 140.24, 135.58, 129.36, 126.64, 124.14,
121.34, 73.80, 60.91, 38.78, 36.29, 13.97; ESIMS m/z 367
([M+H].sup.+).
Example 85
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3-(tritylt-
hio)propanamide
##STR00151##
[0499] To a solution of N,N-dimethylpyridin-4-amine (2.60 g, 21.31
mmol), 2-methyl-3-(tritylthio)propanoic acid (4.41 g, 12.18 mmol)
(prepared according to Ondetti, Miguel Angel et. al. DE 2703828)
and N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine
hydrochloride (2.36 g, 15.22 mmol) in CH.sub.2Cl.sub.2 (20 mL) was
added 3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, 2HCl
(3.0 g, 10 mmol). The mixture was stirred at 0.degree. C. for 2
hours, then at room temperature for additional 48 hours. The
mixture was diluted with ethyl acetate (100 mL) and saturated
aqueous NH.sub.4Cl. The organic phase was separated, washed with
brine, dried over MgSO.sub.4 and concentrated in vacuo to give a
light brown gum. This gum was purified on silica gel eluting with
mixtures of ethyl acetate and hexanes to give the title molecule as
a pink solid (2.97 g, 51%): mp 64-66.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.89 (d, J=2.7 Hz, 1H), 8.62 (dd, J=4.7,
1.4 Hz, 1H), 7.93-7.86 (m, 1H), 7.82 (s, 1H), 7.41 (dd, J=8.3, 4.7
Hz, 1H), 7.33-7.14 (m, 15H), 3.68 (d, J=47.9 Hz, 2H), 2.72 (dd,
J=12.0, 8.8 Hz, 1H), 2.37-2.24 (m, 1H), 2.01 (dd, J=12.0, 5.2 Hz,
1H), 1.14 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.7 Hz, 3H); ESIMS m/z 568
([M+H].sup.+).
Example 86
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methyl-3-(tritylthio)prop-
anamide
##STR00152##
[0501] To a solution of
3-chloro-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, HCl (1.5 g,
6.12 mmol) in CH.sub.2Cl.sub.2 (10 mL) were added
3-(tritylthio)propanoic acid (2.35 g, 6.73 mmol) (prepared
according to Ondetti, Miguel Angel et. al. DE 2703828).
N,N-dimethylpyridin-4-amine (0.82 g, 6.73 mmol) and
N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine, HCl
(1.76 g, 9.18 mmol), and the mixture was stirred at room
temperature for 16 h.
[0502] The mixture was diluted with CH.sub.2Cl.sub.2 (100 mL) and
water (50 mL) and the organic phase separated. The aqueous phase
was extracted with ethyl acetate and the combined organic phase was
washed with brine, dried over MgSO.sub.4 and concentrated in vacuo
to give the title molecule as a white powder (1.95 g, 59%): mp
62-64.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.91
(d, J=2.7 Hz, 1H), 8.67-8.61 (m, 1H), 8.06-7.96 (m, 1H), 7.81 (s,
1H), 7.49-7.46 (m, 1H), 7.25-7.45 (m, 15H), 3.17 (s, 3H), 2.56-2.46
(m, 2H), 2.09-1.97 (m, 2H); ESIMS m/z 540 ([M+H].sup.+).
Example 87
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-mercapto-N-methylpropanam-
ide
##STR00153##
[0504] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methyl-3-(tritylthio)prop-
anamide (1.300 g, 2.411 mmol) in CH.sub.2Cl.sub.2 (6.14 g, 72.3
mmol) were added triethylsilane (1.402 g, 12.06 mmol) followed by
2,2,2-trifluoroacetic acid (2.75 g, 24.11 mmol) at room
temperature. The mixture was stirred for 1 hour and quenched with
saturated aqueous NaHCO.sub.3. The mixture was diluted with
CH.sub.2Cl.sub.2 and the organic phase was separated. The aqueous
phase was extracted with CH.sub.2Cl.sub.2 and the organic phases
were combined, washed with brine dried over anhydrous MgSO.sub.4
and concentrated in vacuo to give a light yellow oil. This oil was
purified on silica gel eluting with ethyl acetate and hexanes to
give the title molecule as a colorless oil (701 mg, 93%): IR (thin
film) 3094, 2980, 1657, 1582 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.95 (d, J=2.6 Hz, 1H), 8.63 (s, 1H), 8.06 (s,
1H), 8.04-7.96 (m, 1H), 7.52-7.42 (m, 1H), 3.26 (s, 3H), 2.85-2.73
(m, 2H), 2.56-2.48 (m, 2H).
[0505] The following molecules were made in accordance with the
procedures disclosed in Example 87:
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercatopropanamide
##STR00154##
[0507] The title molecule was isolated as a light brown gum (902
mg, 64%): IR (thin film) 3086, 2980, 2936, 2548, 1657 cm.sup.-1; H
NMR (400 MHz, CDCl.sub.3) .delta. 8.96 (dd, J=2.7, 0.7 Hz, 1H),
8.63 (dd, J=4.8, 1.5 Hz, 1H), 8.06 (ddd, J=8.3, 2.7, 1.4 Hz, 1H),
7.97 (s, 1H), 7.47 (ddd, J=8.4, 4.7, 0.8 Hz, 1H), 3.72 (q, J=7.1
Hz, 2H), 2.79 (dt, J=8.5, 6.8 Hz, 2H), 2.49 (t, J=6.7 Hz, 2H), 1.67
(t, J=8.4 Hz, 1H), 1.17 (t, J=7.2 Hz, 3H); ESIMS m/z 311
([M+H].sup.+), 309 ([M-H].sup.-).
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercapto-2-methylp-
ropanamide
##STR00155##
[0509] The title molecule was isolated as a colorless oil which
solidified upon standing: mp 94-96.degree. C.; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.97 (dd, J=2.7, 0.7 Hz, 1H), 8.63 (dd,
J=4.8, 1.5 Hz, 1H), 8.05 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 8.02 (s,
1H), 7.47 (ddd, J=8.3, 4.8, 0.8 Hz, 1H), 3.85 (m, 1H), 3.60 (m,
1H), 2.91 (ddd, J=13.2, 9.4, 8.1 Hz, 1H), 2.41 (ddd, J=13.2, 9.2,
4.9 Hz, 1H), 1.49 (dd, J=9.2, 8.2 Hz, 1H), 1.18 (t, J=7.2 Hz, 3H),
1.14 (d, J=6.7 Hz, 3H); ESIMS m/z 325 ([M+H].sup.+).
Example 88
Preparation of 3-(((2,2-difluorocyclopropyl)methyl)thio)propanoic
acid
##STR00156##
[0511] Powdered potassium hydroxide (423 mg, 7.54 mmol) and
2-(bromomethyl)-1,1-difluorocyclopropane (657 mg, 3.84 mmol) were
sequentially added to a stirred solution of 3-mercaptopropanoic
acid (400 mg, 3.77 mmol) in methanol (2 mL) at room temperature.
The resulting white suspension was stirred at 65.degree. C. for 3 h
and quenched with 1N aqueous HCl and diluted with ethyl acetate.
The organic phase was separated and the aqueous phase extracted
with ethyl acetate (2.times.50 mL). The combined organic extracts
were dried over MgSO.sub.4, filtered and concentrated in vacuo to
give the title molecule as a colorless oil (652 mg, 84%): IR (KBr
thin film) 3025, 2927, 2665, 2569, 1696 cm.sup.-1; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 2.85 (t, J=7.0 Hz, 2H), 2.82-2.56 (m, 4H),
1.88-1.72 (m, 1H), 1.53 (dddd, J=12.3, 11.2, 7.8, 4.5 Hz, 1H), 1.09
(dtd, J=13.1, 7.6, 3.7 Hz, 1H); ESIMS m/z 195.1 ([M-H].sup.-).
[0512] The following molecules were made in accordance with the
procedures disclosed in Example 88:
4-(((2,2-Difluorocyclopropyl)methyl)thio)butanoic acid: .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 11.31 (s, 1H), 2.71-2.54 (m, 4H),
2.51 (t, J=7.2 Hz, 2H), 2.01-1.86 (m, 2H), 1.85-1.70 (m, 1H), 1.51
(dddd, J=12.3, 11.2, 7.8, 4.5 Hz, 1H), 1.07 (dtd, J=13.2, 7.6, 3.7
Hz, 1H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 179.6, 113.7
(dd, J=286.4, 283.4 Hz), 32.7, 30.7, 28.7 (d, J=4.6 Hz), 24.2, 22.8
(t, J=11.2 Hz), 16.6 (t, J=10.8 Hz); .sup.19F NMR (376 MHz,
CDCl.sub.3) .delta.-128.12 (d, J=156.8 Hz), -142.77 (d, J=156.7
Hz).
[0513] 4-((2,2,2-Trifluoroethyl)thio)butanoic acid: .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 3.47 (q, J=10.8 Hz, 2H), 2.72 (dd,
J=7.8, 6.6 Hz, 2H), 2.32 (td, J=7.3, 4.5 Hz, 2H), 1.96-1.81 (m,
2H).
Example 89
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(((2,2-difluorocyclopropy-
l)methyl)thio)-N-ethylpropanamide (Molecule 626)
##STR00157##
[0515] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercatopropanamid-
e (100 mg, 0.322 mmol) in THF (1 mL) was added sodium hydride (60%
dispersion in oil, 13.5 mg, 0.34 mmol). The resulting mixture was
stirred at room temperature for 10 min followed by addition of
2-(bromomethyl)-1,1-difluorocyclopropane (60 mg, 0.35 mmol). The
mixture was stirred at room temperature for 24 h and diluted with
saturated aqueous ammonium chloride and ethyl acetate. The organic
phase was separated and the aqueous phase extracted with ethyl
acetate (2.times.50 mL). The combined organic extracts were dried
over MgSO.sub.4, filtered and concentrated in vacuo to give a
colorless oil. This oil was purified by chromatography eluting with
mixtures of ethyl acetate and hexanes to give the title molecule as
a colorless gum (101 mg, 78%): IR (thin film) 3092, 2975, 2931,
1659, 1584 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.99-8.90 (m, 1H), 8.63 (dd, J=4.8, 1.5 Hz, 1H), 8.05 (ddd, J=8.3,
2.7, 1.5 Hz, 1H), 7.96 (s, 1H), 7.47 (ddd, J=8.3, 4.7, 0.7 Hz, 1H),
3.72 (q, J=7.2 Hz, 2H), 2.87 (t, J=7.3 Hz, 2H), 2.63-2.55 (m, 2H),
2.46 (t, J=7.3 Hz, 2H), 1.76 (ddq, J=13.2, 11.4, 7.5 Hz, 1H), 1.48
(dddd, J=12.3, 11.2, 7.8, 4.5 Hz, 1H), 1.17 (t, J=7.2 Hz, 3H), 1.04
(dtd, J=13.2, 7.6, 3.7 Hz, 1H); ESIMS m/z 400 ([M+H].sup.+).
[0516] Molecules 624, 625, 629, 633, 643 653 in Table 1 were made
in accordance with the procedures disclosed in Example 89.
Example 90
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(((2,2-difluorocyclopropy-
l)methyl)sulfinyl)-N-ethylpropanamide (Molecule 627)
##STR00158##
[0518] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(((2,2-difluorocyclopropy-
l)methyl)thio)-N-ethylpropanamide (100 mg, 0.25 mmol) in acetic
acid (5 ml, 0.25 mmol) was added sodium perborate tetrahydrate
(38.4 mg, 0.25 mmol) and the mixture stirred at 50.degree. C. for 1
hour. The mixture was cooled to room temperature, quenched with
saturated aqueous sodium bicarbonate and then diluted with ethyl
acetate. The organic phase was separated and the aqueous phase
extracted with ethyl acetate. The combined organic phase was washed
with brine, dried over MgSO.sub.4 and concentrated in vacuo to give
a colorless oil. This oil was purified on silica gel eluting with
methanol and CH.sub.2Cl.sub.2 (0-10% gradient) to give the title
molecule as a colorless gum (91 mg, 88%): IR (thin film) 3448,
3092, 2976, 2933, 1659, 1585, 1440, 1012 cm.sup.-1; .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.97 (d, J=2.6 Hz, 1H), 8.63 (dd,
J=4.8, 1.5 Hz, 1H), 8.04 (m, 2H), 7.46 (ddd, J=8.3, 4.8, 0.7 Hz,
1H), 3.72 (dq, J=13.8, 7.0 Hz, 2H), 3.16 (ddd, J=20.3, 13.9, 6.8
Hz, 1H), 3.00-2.79 (m, 3H), 2.69 (m, 2H), 2.13-1.85 (m, 1H),
1.77-1.62 (m, 1H), 1.41-1.21 (m, 1H), 1.18 (t, J=7.2 Hz, 3H); ESIMS
m/z 417 ([M+H].sup.+).
[0519] Molecules 622, 630, 645 in Table 1 were made in accordance
with the procedures disclosed in Example 90.
Example 91
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(((2,2-difluoro
cyclopropyl)methyl)sulfonyl)-N-ethylpropanamide (Molecule 628)
##STR00159##
[0521] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(((2,2-difluorocyclopropy-
l)methyl)thio)-N-ethylpropanamide (100 mg, 0.25 mmol) in acetic
acid (5 ml, 0.25 mmol) was added sodium perborate tetrahydrate (77
mg, 0.499 mmol) and the mixture stirred at 50.degree. C. for 1
hour. The mixture was cooled to room temperature, quenched with
saturated aqueous sodium bicarbonate and then diluted with ethyl
acetate. The organic phase was separated and the aqueous phase was
extracted with ethyl acetate. The combined organic phase was washed
with brine, dried over MgSO.sub.4 and concentrated in vacuo to give
a brown oil. This oil was purified on silica gel eluting with
mixtures of ethyl acetate and hexanes to give the title molecule as
a colorless gum (90 mg, 83%): IR (thin film) 3104, 2980, 2934,
1662, 1486, 1460 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta.
9.00-8.90 (m, 1H), 8.64 (dd, J=4.7, 1.4 Hz, 1H), 8.09-8.00 (m, 2H),
7.47 (ddd, J=8.4, 4.8, 0.7 Hz, 1H), 3.72 (d, J=7.1 Hz, 2H), 3.43
(s, 2H), 3.30 (dd, J=14.7, 6.8 Hz, 1H), 3.11-3.00 (m, 1H), 2.72 (t,
J=6.9 Hz, 2H), 2.13-1.96 (m, 1H), 1.73 (tdd, J=11.5, 8.3, 5.4 Hz,
1H), 1.45 (ddt, J=16.1, 8.0, 3.8 Hz, 1H), 1.18 (t, J=7.2 Hz, 3H);
ESIMS m/z 433 ([M+H].sup.+).
[0522] Molecules 623, 631, 644 in Table 1 were made in accordance
with the procedures disclosed in Example 91.
Example 92
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-(cyclopropylmethyl)-3-(((-
2,2-difluorocyclopropyl)methyl)thio)propanamid (Molecule 632)
##STR00160##
[0524] To a solution of
3-chloro-N-(cyclopropylmethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine
(108 mg, 0.43 mmol), N,N-dimethylpyridin-4-amine (53 mg, 0.43 mmol)
and 3-(((2,2-difluorocyclopropyl)methyl)thio)propanoic acid (85 mg,
0.43 mmol) in DMF (5 mL) was added
N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine
hydrochloride (101 mg, 0.65 mmol). The resulting brown-yellow
mixture was stirred at ambient temperature for 2 h. The mixture was
diluted with saturated aqueous ammonium chloride and ethyl acetate.
The organic phase was separated and the aqueous phase extracted
with ethyl acetate (2.times.50 mL). The combined organic extracts
were dried over MgSO.sub.4, filtered and concentrated in vacuo to
give the title molecule as a colorless oil (120 mg, 61%): IR (thin
film) 3089, 3005, 2923, 1660 1584 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.95 (d, J=2.6 Hz, 1H), 8.63 (dd, J=4.8, 1.5
Hz, 1H), 8.05 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.99 (s, 1H), 7.47
(ddd, J=8.3, 4.7, 0.7 Hz, 1H), 3.54 (s, 2H), 2.88 (t, J=7.3 Hz,
2H), 2.69-2.54 (m, 2H), 2.48 (t, J=7.3 Hz, 2H), 1.76 (ddt, J=18.7,
13.3, 7.4 Hz, 1H), 1.53-1.42 (m, 1H), 1.12-0.90 (m, 2H), 0.54-0.44
(m, 2H), 0.20 (dt, J=6.1, 4.6 Hz, 2H); ESIMS m/z 427
([M+H].sup.+).
[0525] Molecule 646 in Table 1 was made in accordance with the
procedures disclosed in Example 92.
Example 93
Preparation of
(E)-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-4,4,4-trifluoro-
but-2-enamide
##STR00161##
[0527] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine, 2HCl (1.0 g,
3.38 mmol), N,N-dimethylpyridin-4-amine (827 mg, 6.77 mmol), and
(E)-4,4,4-trifluorobut-2-enoic acid (474 mg, 3.38 mmol) in DMF (3
mL) was added
N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine, HCl
(973 mg, 5.07 mmol). The resulting brown-yellow mixture was stirred
at ambient temperature for 2 hours. The mixture was diluted with
saturated aqueous NH.sub.4Cl and ethyl acetate and saturated with
NaCl. The organic phase was separated and the aqueous phase
extracted with ethyl; acetate (22.times.5050 mL). The combined
organic phase was dried over MgSO.sub.4, filtered and concentrated
in vacuo to give the title molecule as a light brown gum (901 mg,
73%): IR (thin film) 3093, 2978, 2937, 1681, 1649, 1585, 1114
cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.97 (d, J=2.7
Hz, 1H), 8.65 (dd, J=4.9, 1.4 Hz, 1H), 8.07 (ddd, J=8.3, 2.7, 1.5
Hz, 1H), 7.99 (s, 1H), 7.48 (dd, J=8.3, 4.8 Hz, 1H), 6.84 (dq,
J=15.4, 6.8 Hz, 1H), 6.60-6.44 (m, 1H), 3.80 (q, J=7.2 Hz, 2H),
1.22 (t, J=7.2 Hz, 3H); ESIMS m/z 345 ([M+H].sup.+).
Example 94
Preparation of
S-(4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1,1,1-trif-
luoro-4-oxobutan-2-yl) ethanethioate
##STR00162##
[0529] To a solution of
(E)-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-4,4,4-trifluoro-
but-2-enamide (465 mg, 1.349 mmol) in dry DMSO (5 mL) was added
potassium ethanethioacetate (616 mg, 5.40 mmol). The mixture was
stirred at 50.degree. C. for 96 hours under nitrogen. The mixture
was quenched with saturated ammonium chloride and extracted twice
with ethyl acetate. The combined organic phase was washed with
brine, dried over MgSO.sub.4, filtered and concentrated in vacuo to
give a brown gum. Purification of this gum on silica gel eluting
with mixtures of hexane and ethyl acetate gave the title molecule
as a brown gum (265 mg, 44%): IR (thin film) 3099, 2976, 2936,
1708, 1666, 1585, 1102 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3)
.delta. 9.03-8.93 (m, 1H), 8.64 (dd, J=4.7, 1.5 Hz, 1H), 8.12-8.04
(m, 1H), 7.98 (s, 1H), 7.53-7.42 (m, 1H), 4.78 (dd, J=9.0, 4.4 Hz,
1H), 3.90-3.54 (m, 2H), 2.76 (dd, J=16.6, 4.4 Hz, 1H), 2.53 (dd,
J=16.6, 9.4 Hz, 1H), 2.41 (s, 3H), 1.16 (t, J=7.2 Hz, 3H); ESIMS
m/z 421 ([M+H].sup.+).
Example 95
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(((2,2-difluorocyclopropy-
l)methyl)thio)-N-ethyl-4,4,4-trifluorobutanamide (Molecule 634)
##STR00163##
[0531] To a solution of methanol (21.1 mg, 0.66 mmol) in THF (1 mL)
was added sodium hydride (26.5 mg, 0.66 mmol, 60% oil suspension).
The resulting mixture was stirred for 10 minutes at room
temperature and
S-(4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1,1,1-trif-
luoro-4-oxobutan-2-yl) ethanethioate (266 mg, 0.63 mmol) in THF (1
mL) was added. After stirring for 30 minutes,
2-(bromomethyl)-1,1-difluorocyclopropane (130 mg, 0.76 mmol) was
added. The mixture was stirred at room temperature for an
additional 4 hours and diluted with saturated aqueous ammonium
chloride and ethyl acetate. The organic phase was separated and the
aqueous phase extracted with ethyl acetate (2.times.50 mL). The
combined ethyl acetate extracts were dried over MgSO.sub.4,
filtered and concentrated in vacuo to give a colorless oil.
Purification on silica gel eluting with ethyl acetate and hexanes
gave the title molecule as a brown oil (89 mg, 30% yield): IR (thin
film) 3097, 2978, 2937 1664, 1440 cm.sup.-1; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.96 (d, J=2.7 Hz, 1H), 8.64 (dd, J=4.8, 1.4
Hz, 1H), 8.06 (ddd, J=8.4, 2.8, 1.4 Hz, 1H), 7.98 (d, J=2.1 Hz,
1H), 7.47 (dd, J=8.3, 4.8 Hz, 1H), 3.94-3.84 (m, 1H), 3.75 (s, 2H),
2.97 (dd, J=13.4, 7.5 Hz, 0.55H), 2.85 (s, 1H), 2.79-2.65 (m,
0.45H), 2.60 (m, 1H), 2.43 (dt, J=16.3, 10.0 Hz, 1H), 1.89 (tt,
J=12.2, 7.5 Hz, 1H), 1.63-1.49 (m, 1H), 1.23-1.13 (m, 4H); ESIMS
m/z 469 ([M+H].sup.+).
Example 96
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-((cyclopropylmethyl)thio)-
-N-ethylpropanamide (Molecule 621)
##STR00164##
[0533] To a solution of methanol (9.99 mg, 0.312 mmol) in THF (1
mL) was added sodium hydride (12.4 mg, 0.31 mmol, 60% oil
suspension). The mixture was stirred at room temperature for 10
minutes and added
S-(1-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1-oxopropa-
n-2-yl) ethanethioate (100 mg, 0.28 mmol). After stirring the
mixture for 30 min, (bromomethyl)cyclopropane (38 mg, 0.28 mmol)
was added and the mixture stirred for additional 14 hours. The
mixture was diluted with saturated aqueous ammonium chloride (5 mL)
and ethyl acetate (15 mL), and the organic phase was separated. The
aqueous phase was extracted with ethyl acetate (5 mL) and the
combined organic phase was washed with brine, dried over MgSO.sub.4
and concentrated in vacuo to give an oily residue. This residue was
purified on silica gel eluting with mixtures of ethyl acetate and
hexanes to give the title molecule as a colorless gum (31 mg, 30%):
IR (thin film) 3081, 2972, 2930, 2871, 1655, 1438 cm.sup.-1;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.96 (d, J=2.8 Hz, 1H),
8.63 (dd, J=4.8, 1.4 Hz, 1H), 8.13 (s, 1H), 8.04 (ddt, J=8.3, 3.2,
1.6 Hz, 1H), 7.50-7.40 (m, 1H), 3.81 (bs, 1H), 3.59 (bs, 1H), 3.33
(d, J=7.4 Hz, 1H), 2.58-2.41 (m, 2H), 1.47 (d, J=6.9 Hz, 3H), 1.17
(td, J=7.1, 1.8 Hz, 3H), 0.84 (dt, J=10.3, 7.4, 3.7 Hz, 1H),
0.56-0.38 (m, 2H), 0.25-0.07 (m, 2H); ESIMS m/z 365
([M+H].sup.+).
[0534] Molecule 651 in Table 1 was made in accordance with the
procedures disclosed in Example 96.
Example 97
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((cyclopropylmethyl)thio)-
-N-ethylpropanamide (Molecule 619)
##STR00165##
[0536] To a solution of methanol (9.99 mg, 0.31 mmol) in DMSO (1
mL) was added sodium hydride (12.4 mg, 0.31 mmol). The mixture was
stirred at room temperature for 10 minutes and added a solution of
S-(3-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-3-oxopropy-
l) ethanethioate (100 mg, 0.28 mmol). After stirring the mixture
for 30 min, (bromomethyl)cyclopropane (38 mg, 0.28 mmol) was added
and the mixture stirred for an additional 30 minutes. The mixture
was diluted with saturated aqueous NH.sub.4Cl and ethyl acetate and
the organic phase separated. The aqueous phase was extracted with
ethyl acetate and the combined organic phase was washed with brine,
dried over MgSO.sub.4 and concentrated in vacuo to give a light
brown oil. This oil was purified on silica gel eluting with
mixtures of hexanes and ethyl acetate to give the title molecule as
a colorless gum (33 mg, 31%): IR (thin film) 3080, 2978, 2930,
1660, 1584 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.95 (d, J=2.8 Hz, 1H), 8.63 (dd, J=4.7, 1.5 Hz, 1H), 8.12-8.01 (m,
1H), 7.98-7.92 (m, 1H), 7.53-7.40 (m, 1H), 3.78-3.62 (m, 2H),
2.95-2.84 (m, 2H), 2.51-2.38 (m, 4H), 1.20-1.11 (m, 3H), 0.94 (s,
1H), 0.60-0.34 (m, 2H), 0.24-0.09 (m, 2H); ESIMS m/z 365
([M+H].sup.+).
Example 98
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-((cyclopropylmethyl)thio)-
-N-ethylacetamide (Molecule 620)
##STR00166##
[0538] To a solution of methanol (10.4 mg, 0.32 mmol) in DMSO (1
mL) was added sodium hydride (13 mg, 0.32 mmol). The mixture was
stirred at room temperature for 10 minutes and cooled to
0-5.degree. C. and added a solution of
S-(2-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-2-oxoethyl-
) ethanethioate (100 mg, 0.29 mmol). After stirring the mixture for
30 min, (bromomethyl)cyclopropane (39 mg, 0.29 mmol) was added and
the mixture stirred for additional 2 hours. The mixture was diluted
with saturated aqueous ammonium chloride (5 mL) and ethyl acetate
(15 mL), and the organic phase was separated. The aqueous phase was
extracted with ethyl acetate (5 mL) and the combined organic phase
was washed with brine, dried over MgSO.sub.4 and concentrated in
vacuo to give an oily residue. This residue was purified on silica
gel eluting with ethyl acetate and hexanes to give the title
molecule as a colorless gum (38 mg, 37%): IR (thin film) 3080,
2975, 2931, 1657, 1584 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.96 (dd, J=2.7, 0.7 Hz, 1H), 8.63 (dd, J=4.8, 1.4 Hz, 1H),
8.08 (s, 1H), 8.04 (ddd, J=8.4, 2.8, 1.5 Hz, 1H), 7.46 (ddd, J=8.4,
4.7, 0.8 Hz, 1H), 3.6 (bs, 1H), 3.17 (s, 1H), 2.61 (d, J=7.1 Hz,
2H), 1.17 (t, J=7.2 Hz, 2H), 1.05-0.91 (m, 1H), 0.55 (dd, J=7.9,
1.5 Hz, 2H), 1.21-1.10 (m, 3H), 0.24 (dd, J=4.8, 1.4 Hz, 2H); ESIMS
m/z 351 ([M+H].sup.+).
[0539] Molecule 650 in Table 1 was made in accordance with the
procedures disclosed in Example 98.
Example 99
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((3,3-dichloroallyl)thio)-
-N-methylpropanamide (Molecule 649)
##STR00167##
[0541] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-mercapto-N-methylpropanam-
ide (100 mg, 0.34 mmol) in DMSO (1 mL) was added sodium hydride
(14.8 mg, 0.37 mmol). The mixture was stirred at room temperature
for 10 min and cooled to 0-5.degree. C. 1,1,3-Trichloroprop-1-ene
(49.0 mg, 0.34 mmol) was added, and the mixture stirred for an
additional 45 minutes. The mixture was diluted with saturated
aqueous NH.sub.4Cl and ethyl acetate and the organic phase was
separated. The aqueous phase was extracted with ethyl acetate and
the combined organic phase was washed with brine, dried over
MgSO.sub.4 and concentrated in vacuo to give a light brown oil.
This oil was purified on silica gel eluting with mixtures of
hexanes to give the title molecule as a colorless gum (60 mg,
43.9%): IR (thin film) 3078, 2926, 1659, 1583, 1458, 1437, 803
cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 8.94 (dd, J=2.7, 0.7
Hz, 1H), 8.63 (dd, J=4.8, 1.5 Hz, 1H), 8.04 (ddd, J=8.3, 2.7, 1.4
Hz, 1H), 7.98 (s, 1H), 7.47 (ddd, J=8.3, 4.7, 0.7 Hz, 1H), 5.30 (s,
1H), 3.51 (s, 2H), 3.25 (s, 3H), 2.87 (t, J=7.3 Hz, 2H), 2.52 (t,
J=7.3 Hz, 2H); ESIMS m/z 406 ([M+2].sup.+), 403.7
([M-1].sup.-).
Example 100
Preparation of
2-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylpropanamide
##STR00168##
[0543] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (1.0 g, 4.49
mmol) in 1,2-dichloroethane (44.9 ml) at 0.degree. C. were added
diisopropylethylamine (0.941 ml, 5.39 mmol) and 2-chloropropanoyl
chloride (0.436 ml, 4.49 mmol), sequentially. The reaction was
allowed to warm to ambient temperature and was stirred for 1.5 hr.
The reaction was quenched with the addition of aqueous NaHCO.sub.3
and the layers were quickly separated. The aqueous layer was
extracted with CH.sub.2Cl.sub.2 (3.times.50 mL) and the combined
organics were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude residue was purified via flash
chromatography (30 to 100% EtOAc/Hex) to give the title molecule as
a white solid (1.301 g, 93%): mp 94-105.degree. C.; .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.97 (d, J=2.7 Hz, 1H), 8.64 (dd,
J=4.8, 1.5 Hz, 1H), 8.09 (s, 1H), 8.04 (ddd, J=8.4, 2.7, 1.5 Hz,
1H), 7.47 (dd, J=8.3, 4.8 Hz, 1H), 4.27 (q, J=6.5 Hz, 1H), 3.83 (s,
1H), 3.63 (s, 1H), 1.64 (d, J=6.5 Hz, 3H), 1.19 (t, J=7.2 Hz, 3H);
ESIMS m/z 313 ([M+H].sup.+).
[0544] The following molecules were made in accordance with the
procedures disclosed in Example 100:
2-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylbutanamide
##STR00169##
[0546] Mp 95-103.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.98 (d, J=2.6 Hz, 1H), 8.64 (dd, J=4.8, 1.4 Hz, 1H), 8.08
(s, 1H), 8.05 (ddd, J=8.4, 2.7, 1.4 Hz, 1H), 7.47 (dd, J=8.3, 4.7
Hz, 1H), 3.99 (m, 1H), 3.86 (br. s, 1H), 3.60 (br. s, 1H), 2.13
(dt, J=14.6, 7.3 Hz, 1H), 1.91 (dt, J=14.5, 7.3 Hz, 1H), 1.19 (t,
J=7.2 Hz, 3H), 0.97 (t, J=7.3 Hz, 3H); ESIMS m/z 327
([M+H].sup.+).
2-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylacetamide
(Compound Y2007)
##STR00170##
[0548] Due to observed decomposition when left at ambient
temperatures overnight, the title molecule was immediately used in
subsequent reactions: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.96 (d, J=2.6 Hz, 1H), 8.65 (dd, J=4.7, 1.3 Hz, 1H), 8.07-8.01 (m,
2H), 7.47 (dd, J=8.3, 4.7 Hz, 1H), 3.93 (s, 2H), 3.79-3.68 (bs,
2H), 1.19 (t, J=7.2 Hz, 3H).
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-((1-chloro-2,2,2-trifluoro-
ethyl)thio)-N-ethylacetamide (Molecule 638)
##STR00171##
[0550] Supporting analytical data for the title molecule can be
found in Table 2.
Example 101
Preparation of
S-(1-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1-oxopropa-
n-2-yl) ethanethioate (Molecule 685)
##STR00172##
[0552] To a solution of
2-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylpropanamide
(1.0 g, 3.19 mmol) in acetone (6.39 ml) was added potassium
ethanethioate (0.438 g, 3.83 mmol). Reaction vessel was capped and
heated to 60.degree. C. for 1.5 h. The reaction was cooled and
poured into a separatory funnel containing water (20 mL) and EtOAc
(20 mL). The layers were separated and aqueous layer was extracted
with EtOAc (3.times.20 mL). The combined organic extract was dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The crude residue was purified (flash chromatography, 20 to
100% EtOAc/Hex) to give the title molecule as a brown, highly
viscous oil (1.07 g, 90%).
[0553] The following molecules were made in accordance with the
procedures disclosed in Example 101:
S-(1-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1-oxobutan--
2-yl) ethanethioate
##STR00173##
[0555] Mp 116-122.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.97 (d, J=2.6 Hz, 1H), 8.63 (dd, J=4.8, 1.5 Hz, 1H),
8.13-7.99 (m, 2H), 7.46 (dd, J=8.3, 4.7 Hz, 1H), 4.14 (t, J=7.3 Hz,
1H), 3.85 (br. s, 1H), 3.57 (br. s, 1H), 2.27 (s, 3H), 1.98 (dt,
J=14.2, 7.1 Hz, 1H), 1.74-1.62 (m, 1H), 1.16 (t, J=7.2 Hz, 3H),
0.92 (t, J=7.4 Hz, 3H); ESIMS m/z 367 ([M+H].sup.+).
S-(2-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-2-oxoethyl)
ethanethioate (Molecule 694)
##STR00174##
[0557] Mp 117-124.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.98 (dd, J=2.7, 0.7 Hz, 1H), 8.64 (dd, J=4.8, 1.5 Hz, 1H),
8.09 (s, 1H), 8.06 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.47 (ddd, J=8.3,
4.8, 0.7 Hz, 1H), 3.84-3.65 (m, 2H), 3.61 (s, 2H), 2.33 (s, 3H),
1.17 (t, J=7.2 Hz, 3H); ESIMS m/z 339 ([M+H].sup.+).
Example 102
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-((2,2,2-trifluoro-
ethyl)thio)propanamide (Molecule 635)
##STR00175##
[0559] To a dry round-bottom flask under N.sub.2 were added sodium
hydride (0.018 g, 0.446 mmol) and THF (2.1 mL), followed by
methanol (0.018 mL, 0.446 mmol). The reaction was allowed to stir
at ambient temperature until cessation of hydrogen evolution was
observed (.about.45 min). The reaction was then cooled at 0.degree.
C. and
S-(1-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1-oxopropa-
n-2-yl) ethanethioate (0.150 g, 0.425 mmol) in THF (2.1 mL) was
added. The reaction was warmed to ambient temperature and stirred
for 30 min. The reaction was again cooled at 0.degree. C. and
1,1,1-trifluoro-2-iodoethane (0.063 ml, 0.638 mmol) in THF (2.1 mL)
was added. The reaction was warmed to room temperature and stirred
overnight. The reaction was diluted in EtOAc (20 mL) and quenched
with H.sub.2O (5 mL). The layers were separated and the aqueous
layer was extracted with EtOAc (3.times.10 mL). The combined
organic extracts were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo to give a yellow oil. The crude product was
purified via flash chromatography (0 to 75% CH.sub.2Cl.sub.2/EtOAc)
to give the title molecule as an opaque, viscous oil (43 mg, 25%):
IR (thin film) 1657 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.96 (d, J=2.6 Hz, 1H), 8.64 (dd, J=4.8, 1.4 Hz, 1H),
8.14-7.96 (m, 2H), 7.47 (dd, J=8.3, 4.8 Hz, 1H), 3.82 (s, 1H), 3.59
(s, 1H), 3.44 (s, 1H), 3.25 (qd, J=10.2, 3.8 Hz, 2H), 1.48 (d,
J=6.8 Hz, 3H), 1.17 (t, J=7.2 Hz, 3H); .sup.19F NMR (376 MHz,
CDCl.sub.3) .delta.-66.16; ESIMS m/z 393 ([M+H].sup.+).
[0560] Molecules 637, 639-642, and 652 in Table 1 were made in
accordance with the procedures disclosed in Example 102.
Example 103
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-((2-fluorovinyl)t-
hio)propanamide (Molecule 654)
##STR00176##
[0562] To a dry round-bottom flask under N.sub.2 were added a 60%
dispersion of NaH in mineral oil (0.043 g, 1.063 mmol) and THF (2.1
mL), followed by methanol (0.086 mL, 2.126 mmol). The reaction was
allowed to stir at ambient temperature until cessation of hydrogen
evolution was observed (.about.45 min). The reaction was then
cooled at 0.degree. C. and
S-(1-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1-oxop-
ropan-2-yl) ethanethioate (0.150 g, 0.425 mmol) in THF (2.1 mL) was
added. Reaction was warmed to room temperature and stirred for 30
min. The reaction was again cooled at 0.degree. C. and
2-bromo-1,1-difluoroethane (0.101 mL, 1.275 mmol) in THF (2.1 mL)
was added. Reaction was warmed to room temperature and stirred
overnight. LC-MS analysis indicated presence of two products, the
major corresponding to the desired elimination product and the
minor corresponding to the initial alkylation. Therefore, the
reaction was cooled to 0.degree. C. and transferred to a vial
containing additional NaOMe (freshly prepared by mixing NaH (5.86
mg, 0.147 mmol) and MeOH (5.93 .mu.L, 0.147 mmol) in THF (0.73 mL)
at 0.degree. C. After stirring an additional 18 h, reaction was
diluted in EtOAc (5 mL) and quenched with H.sub.2O (5 mL). Aqueous
layer was extracted with EtOAc (3.times.10 mL) and the combined
organic extracts were dried over Na.sub.2SO.sub.4, filtered, and
concentrated in vacuo to give a yellow oil. The crude residue was
purified via flash chromatography (25-80% EtOAc/Hex) to give an
inseparable mixture of olefin isomers (.about.3:2, E/Z) as an
opaque, viscous oil (15 mg, 10%): IR (thin film) 3091, 1656
cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 8.97 (m, 1H), 8.64
(dd, J=4.7, 1.4 Hz, 1H), 8.13 (s, 0.4H), 8.04 (m, 1.6H), 7.54-7.41
(m, 1H), 6.79 (dd, J=83.3, 11.0 Hz, 0.6H), 6.75 (dd, J=82.7, 4.3
Hz, 0.4H), 5.97 (dd, J=12.7, 11.0 Hz, 0.6H), 5.68 (dd, J=39.8, 4.3
Hz, 0.4H), 3.82 (br. s, 1H), 3.72-3.47 (m, 1H), 3.47-3.20 (m, 1H),
1.50 (d, J=6.9 Hz, 1.2H), 1.42 (d, J=6.8 Hz, 1.8H), 1.17 (m, 3H);
ESIMS m/z 355 ([M+H].sup.+).
Example 104
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((2,2,2-trifluoro-
ethyl)thio)propanamide (Molecule 636)
##STR00177##
[0564] To a solution of
3-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylpropanamide
(100 mg, 0.32 mmol) in THF (0.3 mL) was added sodium iodide (4.7
mg, 0.032 mmol), 2,2,2-trifluoroethanethiol (148 mg, 1.3 mmol), and
N,N-di-iso-propylethylamine (222 .mu.l, 1.277 mmol). The reaction
mixture was heated overnight at 50.degree. C., diluted with DCM and
washed with 5% KOH solution. The phases were separated,
concentrated, and purified by silica gel chromatography eluting
with 0-40% acetone in hexanes to afford the title molecule as a
colorless oil (109 mg, 83%): .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.95 (d, J=2.4 Hz, 1H), 8.63 (dd, J=4.7, 1.4 Hz, 1H), 8.05
(ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.96 (d, J=7.1 Hz, 1H), 7.46 (ddd,
J=8.3, 4.8, 0.6 Hz, 1H), 3.72 (q, J=7.1 Hz, 2H), 3.10 (q, J=10.0
Hz, 2H), 2.96 (t, J=7.0 Hz, 2H), 2.47 (t, J=7.0 Hz, 2H), 1.17 (t,
J=7.2 Hz, 3H); .sup.19F NMR (376 MHz, CDCl.sub.3) .delta.-66.56
(s); ESIMS m/z 393 ([M+H].sup.+).
Example 105
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N,2-dimethyl-3-((trifluorom-
ethyl)thio)propanamide (Molecule 647)
##STR00178##
[0566] To a solution of 2-methyl-3-((trifluoromethyl)thio)propanoic
acid (0.200 g, 1.065 mmol) in DCM (1.0 mL) was added oxalyl
dichloride (0.093 mL, 1.065 mmol) and 1 drop of DMF and stirred at
ambient temperature for 1 hour (gas evolution was observed). The
reaction mixture was concentrated and the crude acid chloride was
dissolved in DCM (0.3 mL) which was subsequently added to a
pre-stirred solution of
3-chloro-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
dihydrochloride (0.100 g, 0.355 mmol) and
N,N-dimethylpyridin-4-amine (0.130 g, 1.065 mmol) in DCM (1.0 mL)
and stirred overnight at room temperature. The reaction mixture was
diluted with saturated NaHCO.sub.3 and extracted with DCM. The
organic layer was dried over Na.sub.2SO.sub.4, filtered and
concentrated. The crude material was purified via flash
chromatography eluting with 0-100% EtOAc/hexanes to give the title
molecule as a yellow oil (93 mg, 65.7%): IR (thin film) 1654
cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 8.96 (d, J=2.6 Hz,
1H), 8.64 (dd, J=4.7, 1.3 Hz, 1H), 8.08-8.00 (m, 1H), 7.98 (d,
J=8.3 Hz, 1H), 7.51-7.44 (m, 1H), 4.07-3.36 (m, 2H), 3.25-3.11 (m,
1H), 2.94-2.77 (m, 2H), 1.22-1.15 (m, 6H); ESIMS m/z 394
([M+H]).sup.+).
[0567] Molecule 648 in Table 1 was made in accordance with the
procedures disclosed in Example 105
Example 106
Preparation of
N-methyl-N-(1-methyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)-3-((3,3,3-trifluor-
opropyl)thio)propanamide (Compound 1011)
##STR00179##
[0569] A solution of 3-((3,3,3-trifluoropropyl)thio)propanoic acid
(75 mg, 0.372 mmol), DMAP (110 mg, 0.903 mmol), and N,
1-dimethyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine (50 mg, 0.266 mmol)
in dry diethyl ether (886 .mu.L) was cooled to 0.degree. C. under
N.sub.2. N,N'-Dicyclohexylcarbodiimide (DCC) (132 mg, 0.638 mmol)
was added and the reaction was warmed up to room temperature under
N.sub.2, then stirred at room temperature overnight. The reaction
mixture was filtered using additional diethyl ether (0.5 mL) to
remove salts and concentrated under reduced pressure. Purification
by silica gel chromatography by eluting with 0-90% hexanes/EtOAc
afforded the title compound as a clear oil (64 mg, 61%).
Example 107
Preparation of
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(2-hydroxyethyl)carb-
amate (Compound Y2151)
##STR00180##
[0571] To a solution of
2-((tert-butoxycarbonyl)(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)-
ethyl acetate (841 mg, 2.21 mmol) in MeOH (7.3 mL) was added
potassium carbonate (305 mg, 2.21 mmol). The reaction was stirred
at room temperature overnight. The reaction mixture was diluted
with water (10 mL) and extracted with EtOAc (2.times.10 mL). The
organic layer was washed with saturated aqueous NaHCO.sub.3 (10
mL), dried over MgSO.sub.4 and concentrated. Et.sub.2O was added
and the resulting precipitate was collected by filtration to afford
the title compound as a white solid (249 mg, 32%).
Example 108
Preparation of
2-((tert-butoxycarbonyl)(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)-
ethyl methanesulfonate
##STR00181##
[0573] To a solution of
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(2-hydroxyethyl)carb-
amate (574 mg, 1.69 mmol) in dry CH.sub.2Cl.sub.2 (4.0 mL),
triethylamine (260 .mu.l, 1.86 mmol) was added under N.sub.2.
Methanesulfonyl chloride (145 .mu.l, 1.864 mmol) was added dropwise
and the reaction was stirred at room temperature for 4 h. After the
reaction was deemed complete by LCMS, the reaction mixture was
diluted with CH.sub.2Cl.sub.2 (10 mL) and washed with water
(2.times.10 mL) and brine (10 mL). The organic layer was dried and
concentrated under reduced pressure. Purification by silica gel
chromatography by eluting with 10-100% hexanes/EtOAc afforded the
title compound as a colorless liquid (330 mg, 44%): .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 9.00 (s, 1H), 8.59 (dd, J=4.9, 1.5
Hz, 1H), 8.12 (s, 1H), 8.06 (ddd, J=8.4, 2.8, 1.3 Hz, 1H), 7.46
(dd, J=8.4, 4.7 Hz, 1H), 4.52-4.31 (m, 2H), 3.89 (t, J=5.1 Hz, 2H),
3.04 (s, 3H), 2.19 (s, 3H), 1.68-1.32 (m, 6H); ESIMS m/z 417
([M+H].sup.+).
Example 109
Preparation of
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(2-(pyrrolidin-1-yl)-
ethyl)carbamate (Compound Y2152)
##STR00182##
[0575] To a solution of
2-((tert-butoxycarbonyl)(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)-
ethyl methanesulfonate (129 mg, 0.309 mmol) in dry DMF (884 al),
triethylamine (51.8 .mu.l, 0.371 mmol) and pyrrolidine (37.5 al,
0.449 mmol) was added under N.sub.2. The reaction was then heated
at 80.degree. C. under N.sub.2 overnight. After the reaction was
deemed complete by LCMS, the reaction mixture was diluted with
water (10 mL) and saturated aqueous NaHCO.sub.3 (5 mL), then
extracted with EtOAc (3.times.10 mL). The organic layer was dried
over MgSO.sub.4 and concentrated under reduced pressure.
Purification by silica gel chromatography by eluting with 0-50%
CH.sub.2Cl.sub.2/MeOH afforded the title compound as an off-white
solid (65 mg, 51%).
Example 110
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-(oxiran-2-ylmethyl)-3-((3-
,3,3-trifluoropropyl)thio)propanamide (Compound 928)
##STR00183##
[0577] A solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((3,3,3-trifluoropropyl)t-
hio)propanamide (109 mg, 0.288 mmol) in dry DMF (882 .mu.l) was
cooled to 0.degree. C. in an ice bath under N.sub.2. Sodium hydride
(16.11 mg, 0.403 mmol, 60% dispersion in mineral oil) was carefully
added and the reaction was stirred at 0.degree. C. for 30 min.
2-(Bromomethyl)oxirane (47.6 .mu.l, 0.576 mmol) was then added and
stirred for 30 min at 0.degree. C. The reaction was slowly warmed
up to room temperature and stirred overnight under N.sub.2. The
reaction mixture was quenched with water (15 mL) and extracted with
EtOAc (3.times.10 mL). The organic layer was dried over MgSO.sub.4
and concentrated under reduced pressure. Purification by silica gel
chromatography by eluting with 0-90% hexane/EtOAc afforded the
title compound as an yellow oil (28 mg, 21%).
Example 111
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-(ethylcarbamoyl)-3-((3,3,-
3-trifluoropropyl)thio)propanamide (Compound 988)
##STR00184##
[0579] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((3,3,3-trifluoropropyl)t-
hio)propanamide (106 mg, 0.280 mmol) in dry CH.sub.2Cl.sub.2 (1.8
mL), isocyanatoethane (44.3 .mu.l, 0.560 mmol) was added. The
reaction mixture was stirred at room temperature overnight then
refluxed for 2 h. The solvent was switched to THF and another
portion of isocyanatoethane (44.3 .mu.l, 0.560 mmol) was added and
refluxed for additional 2 h. Toluene (1.9 mL) was added along with
another portion of isocyanatoethane (44.3 .mu.l, 0.560 mmol) and
the reaction was refluxed overnight. A small amount of product
formation was observed by LCMS. The reaction mixture was poured
into a 5 mL microwave vial with additional toluene (0.5 mL) and
acetonitrile (0.5 mL) along with another portion of
isocyanatoethane (44.3 .mu.l, 0.560 mmol). The reaction was capped
and placed on a Biotage.RTM. Initiator microwave reactor for total
of 9 h at 120.degree. C., then for 8 h at 125.degree. C., with
external IR-sensor temperature monitoring from the side of the
vessel. The reaction mixture was concentrated under reduced
pressure. Purification by silica gel chromatography by eluting with
0-10% CH.sub.2Cl.sub.2/MeOH and a subsequent purification eluting
with 0-100% water/acetonitrile afforded the title compound as a
white solid (36 mg, 27%). Reference: J. Org. Chem., 1951, 16,
1879-1890.
Example 112
Preparation of
4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-4-oxobutanoic
acid (Compound Y2187)
##STR00185##
[0581] In a 100 mL round bottom flask (RBF),
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (500 mg, 2.25
mmol), DMAP (27.4 mg, 0.225 mmol), triethylamine (0.469 mL, 3.37
mmol), and dihydrofuran-2,5-dione (449 mg, 4.49 mmol) was added
with dichloroethane (22.5 mL). The reaction was heated at
60.degree. C. under N.sub.2 overnight. The reaction mixture was
concentrated and purified by silica gel chromatography by eluting
with 0-15% CH.sub.2Cl.sub.2/MeOH to afford the title compound as an
off-white solid (635 mg, 86%).
Example 113
Preparation of S-(3,3,3-trifluoropropyl)
4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-4-oxobutaneth-
ioate (Compound 979)
##STR00186##
[0583] A solution of
4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-4-oxobutanoic
acid (100 mg, 0.310 mmol), 3,3,3-trifluoropropane-1-thiol (42.0
.mu.l, 0.387 mmol), and DMAP (3.79 mg, 0.031 mmol) in dry
CH.sub.2Cl.sub.2 (620 .mu.l) was cooled to 0.degree. C. DCC (63.9
mg, 0.310 mmol) was added and the reaction was warmed up to room
temperature under N.sub.2, then stirred overnight. The reaction
mixture was filtered using additional CH.sub.2Cl.sub.2 (1 mL) to
remove salts and concentrated under reduced pressure. Purification
by silica gel flash column chromatography eluting with 10-90%
hexanes/EtOAc afforded the title compound as a slightly yellow
clear viscous semi-solid (83 mg, 60%). Reference: J. Am. Chem.
Soc., 2009, 131, 14604-14605.
Example 114
Preparation of 3,3,3-trifluoropropyl
4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-4-oxobutanoat-
e (Compound Y2154)
##STR00187##
[0585] A solution of
4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-4-oxobutanoic
acid (101 mg, 0.313 mmol), sodium bicarbonate (526 mg, 6.26 mmol),
and 3-bromo-1,1,1-trifluoropropane (66.6 .mu.l, 0.626 mmol) in DMF
(1565 .mu.l) was stirred at room temperature under N.sub.2
overnight. The reaction was quenched with water (15 mL) and
extracted with CH.sub.2Cl.sub.2 (3.times.10 mL). The organic layer
was dried and concentrated under reduced pressure. Purification by
silica gel chromatography by eluting with 0-100% hexanes/EtOAc
afforded the title compound as a clear oil (36 mg, 26%). Reference:
Syn. Commun., 2008, 38, 54-71.
Example 115
Preparation of
2-((2,2,2-trifluoroethyl)thio)ethyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol--
4-yl)(ethyl)carbamate (Compound 970)
##STR00188##
[0587] A solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (170 mg, 0.763
mmol) in dichloroethane (2 mL) was cooled to 0.degree. C. Under
N.sub.2, phosgene (708 .mu.l, 0.992 mmol, 15 wt % in toluene) was
added and after 5 minutes N,N-dimethylpyridin-4-amine (196 mg,
1.603 mmol) was added in one portion. The ice bath was removed and
the mixture was stirred at room temperature for 5 minutes and at
80.degree. C. for 50 min. The mixture was cooled to room
temperature and then 2-((2,2,2-trifluoroethyl)thio)ethanol (251 mg,
1.57 mmol) was added with CH.sub.2Cl.sub.2 (0.5 mL) followed by
another portion of N,N-dimethylpyridin-4-amine (196 mg, 1.60 mmol).
The reaction mixture was heated under N.sub.2 at 80.degree. C. for
2 h. The reaction mixture was diluted with CH.sub.2Cl.sub.2 (10 mL)
and saturated aqueous NH.sub.4Cl (10 mL). The organic layer was
separated, dried, and concentrated. Purification by silica gel
chromatography by eluting with 0-100% hexanes/EtOAc and a
subsequent purification eluting with 0-100% water/acetonitrile
afforded the title compound as a cloudy white oil (33 mg, 10%).
Example 116
Preparation of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-1-ethyl-3-(((3,3,3-trifluor-
opropyl)thio)methyl)urea (Compound 990)
##STR00189##
[0589] To a solution of 2-((3,3,3-trifluoropropyl)thio)acetic acid
(696 mg, 3.70 mmol) in CH.sub.2Cl.sub.2 (7.40 mL), oxalyl chloride
(1.619 mL, 18.49 mmol) was added along with a drop of DMF at room
temperature. Once DMF was added, gas evolution was observed and
continued for about 30 min. The reaction mixture was stirred at
room temperature for total of 1 h then the solvent was removed
under reduced pressure. Acetone (18.50 mL) was added to the
concentrated material and the reaction was cooled to 0.degree. C.
in an ice bath. To that, a solution of sodium azide (265 mg, 4.07
mmol) in water (1 mL) was added dropwise. The reaction was stirred
at 0.degree. C. for 1 h. The reaction mixture was diluted with
water (15 mL) and stirred at room temperature for 5 min.
Dichloromethane (10 mL) was added and the organic layer was
separated, dried, and concentrated under reduced pressure to afford
2-((3,3,3-trifluoropropyl)thio)acetyl azide as dark brown-green
oil. Dry CH.sub.2Cl.sub.2 (4193 .mu.l) was added to the crude azide
and refluxed for 2 h. The reaction was cooled to room temperature
and 3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (140 mg,
0.629 mmol) was added. The reaction was stirred overnight at room
temperature. The reaction was concentrate under reduced pressure
and purified by silica gel chromatography by eluting with 0-10%
CH.sub.2Cl.sub.2/MeOH to afford title compound as a light brown
solid (179 mg, 68%). Reference: J. Org. Chem., 2003, 68,
9453-9455.
Example 117
Preparation of
3-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-5-(hydroxymethyl)oxazolidin-
-2-one (Compound Y2148)
##STR00190##
[0591] To a solution of
tert-butyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(oxiran-2-ylmethyl)c-
arbamate (321 mg, 0.915 mmol) in dry CH.sub.2Cl.sub.2 (915 .mu.L),
trifluoroacetic acid (915 .mu.L) was added under N.sub.2. The
reaction mixture was stirred at room temperature for 90 min under
N.sub.2. The reaction mixture was diluted with toluene (10 mL) and
concentrated under reduced pressure to almost dryness. EtOAc (5 mL)
was added and the reaction was quenched with saturated aqueous
NaHCO.sub.3 (10 mL). The organic layer was separated and the
aqueous layer was further extracted with EtOAc (3.times.5 mL),
dried over MgSO.sub.4, and concentrated under reduced pressure to
afford the title compound as a white foam (134 mg, 47%).
Example 118
Preparation of
N-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)carbamoyl)-4-methoxy-
benzamide (Compound Y2189)
##STR00191##
[0593] A solution of 4-methoxybenzamide (61.1 mg, 0.404 mmol) and
oxalyl chloride (44.2 .mu.l, 0.505 mmol) in DCE (1684 .mu.l) was
refluxed for 15 h under N.sub.2. The reaction was cooled to room
temperature and
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (75 mg, 0.337
mmol) was added and stirred overnight at room temperature. The
reaction mixture was diluted with saturated aqueous NaHCO.sub.3 (5
mL) and CH.sub.2Cl.sub.2 (3 mL). The phases were separated and the
aqueous layer was washed with CH.sub.2Cl.sub.2 (2.times.3 mL). The
combined organic layer was dried and concentrated. Purification by
silica gel chromatography eluting with 15-100% hexanes/EtOAc
afforded the title compound as white solid (107 mg, 78%).
Reference: J. Org. Chem., 1963, 73, 1805.
Example 119
Preparation of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-1-ethylurea (Compound
Y2186)
##STR00192##
[0595] A solution of
N-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)carbamoyl)benzamide
(300 mg, 0.811 mmol) in dry MeOH (2028 .mu.l) and 2 N aqueous NaOH
(811 .mu.l, 1.62 mmol) was heated at 65.degree. C. for 3 h. The
reaction mixture was cooled to room temperature and neutralized
with 2 N aqueous HCl and concentrated under reduced pressure which
produced yellow precipitate. The precipitate was collected by
filtration, washed with hexanes (3 mL), and dried under vacuum to
afford the title compound (109 mg, 48%).
Example 120
Preparation of
N-ethyl-N-(3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-4-oxobutanamide
(Compound Y2185)
##STR00193##
[0597] A solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-4-hydroxybutanamide
(41 mg, 0.133 mmol) in dry CH.sub.2Cl.sub.2 (1328 .mu.l) was cooled
to 0.degree. C. in an ice bath under N.sub.2. Sodium bicarbonate
(112 mg, 1.328 mmol) and Dess-Martin periodinane (64.8 mg, 0.153
mmol) was added and the reaction was warmed up to room temperature
and stirred for 5 h. LCMS indicated no product formation so another
portion of Dess-Martin periodinane (64.8 mg, 0.153 mmol) was added
and stirred at room temperature overnight. The reaction mixture was
diluted with saturated aqueous NaHCO.sub.3 (5 mL) and extracted
with CH.sub.2Cl.sub.2 (3.times.5 mL). The organic layer was dried,
concentrated, and purified by silica gel chromatography eluting
with 0-50% CH.sub.2Cl.sub.2/MeOH to afford the title compound as
clear oil (21 mg, 46%).
Example 121
Preparation of 1,1,1-trifluoro-7,7-dimethoxyheptan-4-ol
##STR00194##
[0599] In an oven dried vial with a stir bar, magnesium (77 mg,
3.17 mmol) was added and the head space was purged with N.sub.2.
Dry THF (4957 .mu.L) was added with a crystal of I.sub.2 and heated
with a heat gun until bubbles from Mg evolved. Slowly
3-bromo-1,1-dimethoxypropane (395 .mu.L, 2.97 mmol) was added and
heating continued with a heat gun until Mg was bubbling and the
iodine color disappeared. The reaction mixture was refluxed for 1 h
under N.sub.2 to give a cloudy colorless solution. In a separate
oven dried round bottom flask, 4,4,4-trifluorobutanal (208 .mu.L,
1.983 mmol) was added with dry THF (10 mL, 0.2M) and cooled to 0
OC. Room temperature Grignard reagent was added drop wise over 8
min and stirred at 0.degree. C. for 30 min. The reaction was warmed
up to room temperature and stirred for 1.5 h. The reaction was
quenched with saturated aqueous NH.sub.4Cl (15 mL) and extracted
with CH.sub.2Cl.sub.2 (3.times.15 mL). The organic layer was dried,
concentrated, and purified by silica gel chromatography eluting
with 0-10% CH.sub.2Cl.sub.2/MeOH to afford the title product as 85%
pure clear semi-solid (372 mg, 69%): IR (thin film) 3442 cm.sup.-1;
H NMR (400 MHz, CDCl.sub.3) .delta. 4.39 (t, J=5.2 Hz, 1H), 3.65
(tq, J=8.2, 3.9 Hz, 1H), 3.35 (d, J=0.7 Hz, 6H), 2.40 (dd, J=4.6,
0.7 Hz, 1H), 2.39-2.24 (m, 1H), 2.24-2.06 (m, 1H), 1.80-1.72 (m,
2H), 1.72-1.59 (multiple peaks, 3H), 1.52 (ddt, J=15.7, 14.2, 7.0
Hz, 1H); .sup.19F NMR (376 MHz, CDCl.sub.3) .delta.-66.37; HRMS-FAB
(m/z) [M+Na].sup.+ calcd for C.sub.9H.sub.17F.sub.3NaO.sub.3,
253.1022. found, 253.1025.
Example 122
Preparation of 7,7,7-trifluoro-4-oxoheptanoic acid
##STR00195##
[0601] To a solution of 1,1,1-trifluoro-7,7-dimethoxyheptan-4-ol
(372 mg, 1.616 mmol) in dry THF (10.8 mL), 1 N aqueous HCl (8079
.mu.L, 8.08 mmol) was added at room temperature. The reaction
mixture was stirred for 1 h then diluted with water (10 mL) and
Et.sub.2O (10 mL). The organic layer was separated and the aqueous
layer was washed with Et.sub.2O (2.times.10 mL). The combined
organic layer was washed with saturated aqueous NaHCO.sub.3 (10
mL), dried over MgSO.sub.4, and concentrated. The concentrated
crude material was dissolved in acetone (5 mL) and glacial acetic
acid (0.5 mL). Then KMnO.sub.4 (766 mg, 4.85 mmol) dissolved in
water (10 mL) was added to the stirring solution drop wise and
stirred at room temperature for 2.5 h. GCMS analysis showed
incomplete conversion so more KMnO.sub.4 (510 mg) was added and the
reaction was left stirring overnight at room temperature. The
reaction was diluted with AcOH (15 mL; 2 mL glacial AcOH in 13 mL
water) and CH.sub.2Cl.sub.2 (10 mL). The organic layer was
separated and the aqueous layer was extracted with CH.sub.2Cl.sub.2
(2.times.10 mL). The combined organic layer was washed with water
(15 mL), dried, and concentrated. Purification by silica gel
chromatography eluting with 0-10% CH.sub.2Cl.sub.2/MeOH afforded
the title compound as white solid (66 mg, 15%): IR (thin film) 1715
cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta. 2.81-2.72 (multiple
peaks, 4H), 2.69 (ddd, J=6.8, 5.5, 1.2 Hz, 2H), 2.50-2.35 (m, 2H),
1.59 (br s, 1H); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta.-66.66.
Example 123
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-7,7,7-trifluoro-4-o-
xoheptanamide (Compound Y2188)
##STR00196##
[0603] A solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (62 mg, 0.278
mmol), 7,7,7-trifluoro-4-oxoheptanoic acid (66.2 mg, 0.334 mmol),
and DMAP (51.0 mg, 0.418 mmol) in dry Et.sub.2O (928 .mu.L) was
cooled to 0.degree. C. in an ice bath under N.sub.2. DCC (138 mg,
0.668 mmol) was added and the reaction was warmed up to room
temperature slowly. The reaction was stirred under N.sub.2
overnight at room temperature. A white precipitate was filtered off
with Et.sub.2O (1 mL) and the filtrate was concentrated.
Purification by silica gel chromatography eluting with 0-75%
hexanes/EtOAc afforded the title product as brown viscous oil (59
mg, 50%).
Example 124
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-hydroxypropanamid-
e
##STR00197##
[0605] To a solution of
1-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1-oxopropan-2-
-yl acetate (2.4 g, 7.1 mmol) in methanol (8.9 mL) and
tetrahydrofuran (8.9 mL) was added 2M lithium hydroxide (7.1 mL,
14.2 mmol). The reaction mixture was stirred for 2 hours at
25.degree. C. The reaction mixture pH was then made neutral by the
addition of a 2M HCl. The mixture was extracted with ethyl acetate,
and the organic portions were combined, dried over MgSO.sub.4,
filtered and concentrated in vacuo to afford the title compound as
a white solid (1.85 g, 88%): mp 137-138.degree. C.; .sup.1H NMR
(400 MHz, DMSO) .delta. 9.08 (d, J=2.5 Hz, 1H), 8.98 (s, 1H), 8.58
(dd, J=4.7, 1.1 Hz, 1H), 8.23 (ddd, J=8.4, 2.6, 1.3 Hz, 1H), 7.59
(dd, J=8.3, 4.7 Hz, 1H), 4.97 (d, J=7.6 Hz, 1H), 4.08 (m, 1H), 3.57
(d, J=50.6 Hz, 2H), 1.10 (d, J=6.5 Hz, 3H), 1.07 (t, J=7.1 Hz, 3H);
ESIMS m/z 295.6 ([M+H].sup.+).
Example 125
1-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1-oxopropan-2--
yl methanesulfonate (Compound Y2008)
##STR00198##
[0607] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-hydroxypropanamid-
e (100 mg, 0.34 mmol) in tetrahydrofuran (1.1 mL) was added sodium
hydride (14.9 mg, 0.34 mmol). The mixture was stirred for 15 min
and then methanesulfonyl chloride (58.3 mg, 0.51 mmol) was added.
The reaction mixture was stirred for 16 hours, diluted with
CH.sub.2Cl.sub.2, and washed with water. The phases were separated,
dried, concentrated in vacuo and purified by silica gel
chromatography eluting with 0-70% acetone in hexanes to afford the
title compound as a light yellow oil (88 mg, 70%): IR (thin film)
2980, 2936, 1676 cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.00 (d, J=2.5 Hz, 1H), 8.64 (dd, J=4.8, 1.4 Hz, 1H), 8.12
(s, 1H), 8.02 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.46 (ddd, J=8.3, 4.8,
0.6 Hz, 1H), 5.17 (q, J=6.7 Hz, 1H), 3.71 (m, 2H), 3.13 (s, 3H),
1.50 (d, J=6.7 Hz, 3H), 1.19 (t, J=7.2 Hz, 3H); ESIMS m/z 373.6
([M+H].sup.+).
Example 126
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((3,3-difluorocyclobutyl)-
thio)-N-ethylpropanamide (Compound 910)
##STR00199##
[0609]
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3-oxocycl-
obutyl)thio)propanamide (100 mg, 0.264 mmol) was dissolved in
CH.sub.2Cl.sub.2 (2 mL) and stirred at 0.degree. C. Deoxofluor.RTM.
(0.083 mL, 0.449 mmol) and EtOH (2.312 .mu.l, 0.040 mmol) was added
to the solution at 0.degree. C. The resulting solution was warmed
to 25.degree. C. slowly and stirred at 25.degree. C. After 4 hours,
1 more equivalent of Deoxofluor.RTM. (50 .mu.L) and another 2.5
.mu.L of EtOH was added. The reaction was worked up by slow
addition of NaHCO.sub.3 solution and stirred for 30 min at
25.degree. C. The mixture was diluted with water (20 mL) and
extracted with CH.sub.2Cl.sub.2 (3.times.20 mL). The combined
organic layer was washed with 0.01 M HCl, dried over
Na.sub.2SO.sub.4 and purified with silica gel chromatography
(0-100% EtOAc/hexane) to give the title compound as a light yellow
oil (19 mg, 18%).
Example 127
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(vinylsulfinyl)pr-
opanamide (Compound 1004)
##STR00200##
[0611] To a 7 mL vial was added
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercaptopropanami-
de (0.050 g, 0.161 mmol), 1,2-dibromoethane (0.907 g, 4.83 mmol)
followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.024 g,
0.161 mmol). The solution was stirred at 25.degree. C. overnight,
then it was concentrated and re-dissolved in hexafluoroisopropanol
(1 mL). Hydrogen peroxide (0.055 g, 0.483 mmol) was added and the
solution was stirred at 25.degree. C. for 2 hours, then worked up
with sodium sulfite solution and extracted with CH.sub.2Cl.sub.2.
The crude reaction mixture was purified by silica gel
chromatography (0-10% MeOH/CH.sub.2Cl.sub.2) to give the title
compound as a brown oil (33 mg, 58%).
Example 128
Preparation of
3-(N-carbamoyl-S-methylsulfonimidoyl)-N-(3-chloro-1-(pyridin-3-yl)-1H-pyr-
azol-4-yl)-N-ethylpropanamide (Compound Y2099)
##STR00201##
[0613]
N-[3-chloro-1-(3-pyridyl)pyrazol-4-yl]-3-(N-cyano-S-methyl-sulfonim-
idoyl)-N-ethyl-propanamide (320 mg, 0.840 mmol) was dissolved in
cone. sulfuric acid (4 mL, 75 mmol) and stirred at 25.degree. C.
for 16 h. The solution was poured into a flask with ice and solid
NaHCO.sub.3 was added slowly until the aqueous layer was neutral.
The aqueous layer was extracted with CH.sub.2Cl.sub.2 and the
combined organic layers were dried over Na.sub.2SO.sub.4 and
concentrated. The crude reaction mixture was purified by silica gel
chromatography (0-10% MeOH/CH.sub.2Cl.sub.2) to give the title
compound as white solid (135 mg, 40%).
Example 129
Preparation of
4-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)butanamide
(Compound Y2166)
##STR00202##
[0615] To a solution of
3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine (1.34 g, 6.89 mmol) in
CH.sub.2Cl.sub.2 (11 mL) cooled to 0.degree. C. was added
triethylamine (1.439 mL, 10.33 mmol) and 4-chlorobutanoyl chloride
(0.971 g, 6.89 mmol). The solution was allowed to slowly warm to
25.degree. C. and stirred for 1 h. The reaction was diluted with
water (20 mL) and extracted with CH.sub.2Cl.sub.2 (3.times.20 mL).
The combined organic layers were dried, concentrated and purified
with chromatography (0-100% EtOAc/hexane) to give the title
compound as white solid (1.87 g, 91%).
Example 130
Preparation of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)pyrrolidin-2-one
(Compound Y2167)
##STR00203##
[0617] A solution of
4-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)butanamide
(1.82 g, 6.08 mmol) in THF (50 mL) was cooled to 0.degree. C. NaH
(0.280 g, 7.00 mmol) was added and the mixture was slowly warmed to
25.degree. C. and stirred for 2 h. The mixture was diluted with
water and extracted with CH.sub.2Cl.sub.2 (3.times.20 mL). The
combined organic layers were dried, concentrated and purified with
silica gel chromatography (0-10% MeOH/CH.sub.2Cl.sub.2) to give the
title compound as yellow solid (1.70 g, 96%).
Example 131
Preparation of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-methylenepyrrolidin-2-one
(Compound Y2168)
##STR00204##
[0619] A solution of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)pyrrolidin-2-one (1600
mg, 6.09 mmol) in CH.sub.2Cl.sub.2 (15 mL) was cooled to 0.degree.
C. Triethylamine (1.273 mL, 9.14 mmol) and trimethylsilyl
trifluoromethanesulfonate (1.431 mL, 7.92 mmol) were added, and the
resulting deep red solution was stirred at 0.degree. C. for 45 min.
Eschenmoser's salt (dimethylmethylideneammonium iodide)(1465 mg,
7.92 mmol) was then added and the solution was allowed to warm to
25.degree. C. and stir overnight. The solution was diluted with
CH.sub.2Cl.sub.2 (30 mL) and 1N HCl (30 mL) was added and the
mixture was stirred for 10 min before it was neutralized with NaOH
solution to pH=12. The mixture was extracted with CH.sub.2Cl.sub.2,
and the combined organic layers were dried, concentrated and
purified with silica gel chromatography (0-10%
MeOH/CH.sub.2Cl.sub.2) to give the title compound as light yellow
solid (866 mg, 52%).
Example 132
Preparation of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((methylthio)methyl)pyrro-
lidin-2-one (Compound 955)
##STR00205##
[0621]
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-methylenepyrrolidin-
-2-one (400 mg, 1.46 mmol) was dissolved in THF (6 mL). Potassium
hydroxide (384 mg, 5.82 mmol) dissolved in water (1 mL) was added
to the mixture, followed by S,S-dimethyl carbonodithioate (125 mg,
1.019 mmol). The mixture was heated to reflux for 3 hours, then it
was diluted with water (20 mL) and extracted with CH.sub.2Cl.sub.2
(3.times.20 mL). The combined organic layers were dried and
concentrated, and the crude mixture was purified by silica gel
chromatography (0-10% MeOH/CH.sub.2Cl.sub.2) to give the title
compound as white solid (385 mg, 82%).
Example 133
Preparation of methyl 2-cyclobutylideneacetate
##STR00206##
[0623] To a 250 mL round bottom flask was added methyl
2-(triphenylphosphoranylidene)acetate (12.04 g, 36 mmol) and
benzene (90 mL). Cyclobutanone (5.05 g, 72.0 mmol) was added and
the solution was heated to reflux for 2 days. The reaction was
cooled and hexane (70 mL) was added. The white precipitate was
filtered off and the solution was concentrated and purified by
silica gel chromatography to give the title compound as a colorless
oil (3.22 g, 71%): IR (thin film) 1714 cm.sup.-1; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 5.60 (t, J=2.3 Hz, 1H), 3.68 (s, 3H), 3.13
(dddd, J=9.0, 4.5, 2.2, 1.1 Hz, 2H), 2.90-2.76 (m, 2H), 2.09 (tt,
J=11.4, 5.8 Hz, 2H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
167.92, 166.95, 111.93, 50.79, 33.71, 32.32, 17.62.
Example 134
Preparation of 2-cyclobutylideneacetic acid
##STR00207##
[0625] To a solution of methyl 2-cyclobutylideneacetate (100 mg,
0.793 mmol) in MeOH (1.00 mL) stirring at RT was added 2N LiOH
solution (prepared from lithium hydroxide hydrate (100 mg, 2.378
mmol) and water (1 mL)). The mixture was stirred at 25.degree. C.
overnight, then it was worked up by addition of 2N HCl and
extracted with CH.sub.2Cl.sub.2. The combined organic layer was
dried to give a white solid, which was purified by silica gel
chromatography (0-70% EtOAc/hexane) to give the title compound as a
white solid (20 mg, 23%): IR (thin film) 2923, 1647 cm.sup.-1; H
NMR (400 MHz, CDCl.sub.3) .delta. 10.89 (s, 1H), 5.60 (dd, J=4.3,
2.1 Hz, 1H), 3.38-3.02 (m, 2H), 2.97-2.71 (m, 2H), 2.10 (dq,
J=15.9, 8.0 Hz, 2H); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
172.35, 171.33, 112.13, 34.10, 32.58, 17.56.
Example 135
Preparation of 3-((3,3,3-trifluoropropyl)thio)propanoic acid
##STR00208##
[0627] 3-Mercaptopropanoic acid (3.2 g, 30.1 mmol) was dissolved in
MeOH (20 mL) and stirred at RT. Powdered potassium hydroxide (3.72
g, 66.3 mmol) was added to the solution, followed by
3-bromo-1,1,1-trifluoropropane (6.14 g, 34.7 mmol). The solution
was then stirred at 65.degree. C. for 3 h and then the reaction was
quenched with 1N HCl until the pH of the solution was acidic. The
mixture was extracted with CH.sub.2Cl.sub.2 (3.times.30 mL) and the
combined organic phases were dried, concentrated and purified by
silica gel chromatography (0-50% EtOAc/hexane) to give the title
compound as colorless oil mixed with some white suspension (5.5 g,
90%): IR (thin film) 2936, 1708 cm.sup.-1; H NMR (300 MHz,
CDCl.sub.3) .delta. 2.86-2.78 (m, 2H), 2.78-2.58 (m, 4H), 2.52-2.25
(m, 2H); EIMS m/z 202.
Example 136
Preparation of
N-[3-chloro-1-(3-pyridyl)pyrazol-4-yl]-3-[3-[[3-chloro-1-(3-pyridyl)pyraz-
ol-4-yl]-methyl-amino]-3-oxo-propyl]sulfanyl-N-ethyl-2-methyl-propanamide
(Compound 790)
##STR00209##
[0629] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3-mercatop-
ropanamide (100 mg, 0.308 mmol) and
3-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4yl)-N-methylpropanamide
(100 mg, 0.334 mmol) in DMF (1 mL) was added sodium hydride (60%
dispersion in oil, 15 mg, 0.375 mmol). The mixture was stirred at
room temperature for 18 h and diluted with water and
CH.sub.2Cl.sub.2. The organic phase was separated, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to give an
orange oil. This oil was purified by chromatography eluting with
mixtures of methanol and methylene chloride to give the title
compound as a yellow oil (120 mg, 66%).
Example 137
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((2-((3-chloro-1-(pyridin-
-3-yl)-1H-pyrazol-4-yl)(methyl)amino)-2-oxoethyl)thio)-N-ethylpropanamide
(Compound 789)
##STR00210##
[0631] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercaptopropanami-
de (100 mg, 0.322 mmol) in DMSO (1 mL) was added sodium hydride
(60% dispersion in oil, 15 mg, 0.375 mmol). Freshly prepared
2-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methylacetamide
(150 mg, 0.526 mmol) was added and the mixture was left to stand
for one hour with occasional swirling. The reaction mixture was
diluted with saturated sodium bicarbonate and Et.sub.2O. To the
organic phase was added ammonia in MeOH (7 M, 1 mL, 1 mmol)
followed by Na.sub.2SO.sub.4. After standing 10 minutes, the
mixture was filtered and concentrated in vacuo to give an orange
oil. The oil was purified by silica gel chromatography eluting with
mixtures of methanol and CH.sub.2Cl.sub.2 to give the title
molecule as an orange oil (120 mg, 66%).
Example 138
Preparation of
tert-butyl((1R,4S)-4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(methyl)-
carbamoyl)cyclopent-2-en-1-yl)carbamate
##STR00211##
[0633] A solution of
3-chloro-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (200 mg, 0.96
mmol) in THF (10 mL) was cooled to -78.degree. C. Lithium
bis(trimethylsilyl)amide (1 mL, 1.00 mmol, 1M solution in hexane)
was added and the solution was stirred at -78.degree. C. for 15
minutes. A solution of (1R,4S)-tert-butyl
3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate (201 mg, 0.96
mmol) dissolved in THF (3 mL) was added to the solution at
-78.degree. C. in one portion. After stirring for 1 hour at
-78.degree. C. the cooling bath was removed and the reaction warmed
to 20.degree. C. After stirring for an additional five minutes,
acetic acid (0.1 mL) was added to the solution. The reaction
mixture was concentrated and purified via silica gel chromatography
utilizing a mobile phase of hexanes and ethyl acetate to give the
title compound as a white solid (250 mg, 59%): .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 9.01-8.93 (d, J=2.8 Hz, 1H), 8.66-8.60 (m,
1H), 8.11-8.02 (m, 2H), 7.52-7.42 (m, 1H), 5.93-5.85 (m, 1H),
5.72-5.66 (m, 1H), 5.53-5.44 (d, J=9.5 Hz, 1H), 4.80-4.67 (m, 1H),
3.58-3.47 (m, 1H), 3.30-3.21 (s, 3H), 2.35-2.22 (m, 1H), 1.90-1.80
(m, 1H), 1.51-1.34 (s, 9H); .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 175.26, 155.23, 148.70, 140.31, 140.00, 135.61, 135.18,
130.99, 126.34, 125.92, 125.78, 124.12, 79.04, 55.69, 47.33, 37.49,
35.55, 28.45; ESIMS m/z 418 [M+H].sup.+, 416 ([M-H].sup.-).
Example 139
Preparation
(1S,4R)-4-amino-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methylcyc-
lopent-2-enecarboxamide 2,2,2-trifluoroacetate
##STR00212##
[0635] To a solution of
tert-butyl((1R,4S)-4-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(methyl)-
carbamoyl)cyclopent-2-en-1-yl)carbamate (130 mg, 0.31 mmol) in
CH.sub.2Cl.sub.2 (4 mL) was added trifluoroacetic acid (4 mL). The
reaction was left to stand for 20 minutes with occasional swirling.
The reaction mixture was concentrated in vacuo at 40.degree. C.
resulting in the isolation of the title compound as a clear oil
(130 mg, 94%): .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.02 (dd,
J=2.7, 0.7 Hz, 1H), 8.70 (s, 1H), 8.54 (dd, J=5.0, 1.4 Hz, 1H),
8.30 (ddd, J=8.4, 2.7, 1.4 Hz, 1H), 7.63 (ddd, J=8.4, 5.0, 0.7 Hz,
1H), 6.09 (ddd, J=5.6, 2.7, 1.0 Hz, 1H), 5.92 (dt, J=5.6, 2.1 Hz,
1H), 4.16 (d, J=7.7 Hz, 1H), 3.80-3.72 (m, 1H), 2.98 (s, 3H), 2.29
(dt, J=14.3, 7.9 Hz, 1H), 2.01 (dt, J=14.3, 2.5 Hz, 1H); .sup.13C
NMR (101 MHz, CDCl.sub.3) .delta. 179.16, 163.52 (q, J=19 Hz),
145.04, 142.05, 141.15, 137.81, 136.71, 134.11, 134.06, 132.73,
131.26, 129.77, 119.49 (q, J=289 Hz) 59.80, 51.85, 40.50, 36.87;
ESIMS m/z 318 ([M+H].sup.+).
Example 140
Preparation of
(1S,4R)--N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methyl-4-(methyl-
sulfonamido)cyclopent-2-enecarboxamide (Compound Y2054)
##STR00213##
[0637] To a solution of
(1S,4R)-4-amino-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methylcyc-
lopent-2-enecarboxamide 2,2,2-trifluoroacetate (541 mg, 1.25 mmol)
dissolved in CH.sub.2Cl.sub.2 (15 mL) was added triethylamine
(0.380 mg, 3.76 mmol) followed by methanesulfonyl chloride (215 mg,
1.88 mmol). After stirring for 24 hours the reaction was diluted
with saturated aqueous sodium bicarbonate (15 mL) and the phases
were separated. The organic layer was dried with anhydrous sodium
sulfate, filtered, and concentrated. The resulting residue was
purified by silica gel chromatography utilizing methanol and
CH.sub.2Cl.sub.2 resulting in the isolation of the title compound
as a white foam (319 mg, 64%).
Example 141
Preparation of
(1S,3R)--N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methyl-3-(methyl-
sulfonamido)cyclopentanecarboxamide (Compound Y2092)
##STR00214##
[0639] A solution of
(1R,4S)-4-amino-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methylcyc-
lopent-2-enecarboxamide 2,2,2-trifluoroacetate (60 mg, 0.15 mmol)
in methanol (1.5 mL) was passed through an H-Cube.RTM. continuous
flow hydrogenator equipped with a 10% Pd/C cartridge (full H.sub.2,
25 OC, 1 mL/min flow rate). The resulting solution was concentrated
and purified by silica gel chromatography utilizing methanol and
CH.sub.2Cl.sub.2 as a mobile phase to provide the title compound as
white solid (16 mg, 24%).
Example 142
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(1H-tetrazol-5-yl)-N-ethy-
lpropanamide (Compound Y2178)
##STR00215##
[0641] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-cyano-N-ethylpropanamide
(0.176 g, 0.579 mmol) in toluene (5.79 mL) at ambient temperature
and under N.sub.2 were added azidotrimethylsilane (0.154 mL, 1.159
mmol) and dibutylstannanone (0.014 g, 0.058 mmol). The reaction
vessel was fitted with a condenser and heated to 110.degree. C. The
reaction was allowed to stir at the same temperature for 24 h at
which point UPLC-MS analysis indicated nearly complete conversion
to a product of the desired mass. The reaction was cooled, diluted
(slowly) in MeOH (20 mL) and concentrated in vacuo to afford a dark
brown oil. The residue was absorbed onto Celite and purified via
reverse phase flash chromatography (0 to 100% CH.sub.3CN/H.sub.2O)
to afford the desired product as a pale brown glassy solid (49 mg,
24%).
Example 143
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoro-
-2-methylpropyl)thio)propanamide (Compound 919)
##STR00216##
[0643] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((2-(trifluoromet-
hyl)allyl)thio)propanamide (0.056 g, 0.134 mmol) in DME (2.5 mL)
and water (0.5 mL) were added 4-methylbenzenesulfonohydrazide
(0.249 g, 1.337 mmol) and sodium acetate (0.110 g, 1.337 mmol). The
reaction was heated to 90.degree. C. and was stirred for 1.5 h.
UPLC-MS analysis indicated .about.30% conversion to a product of
the desired mass. The reaction was stirred at 90.degree. C. for an
additional 1.5 h at which point UPLC-MS analysis indicated
.about.75% conversion to a product of the desired mass. The
reaction was cooled and an additional 5 equivalents of both the
hydrazide and sodium acetate were added. The reaction was again
heated to 90.degree. C. and stirred for an additional 2 h. UPLC-MS
indicated only minor amount of starting material remaining.
Therefore, an additional 5 equivalents of both hydrazide and sodium
acetate were added. The reaction was stirred at 90.degree. C. for
additional 3 h. The reaction was cooled, diluted in EtOAc (10 mL)
and washed with water (2.times.5 mL) and brine (1.times.5 mL). The
organic layer was dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo to afford a yellow oil. The crude residue was
purified via normal phase flash chromatography (0 to 100%
EtOAc/CH.sub.2Cl.sub.2) to afford the desired product as a pale
yellow oil (46 mg, 79%).
Example 144
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-(vinylthio)propan-
amide (Compound 787)
##STR00217##
[0645] To a dry round bottom flask under N.sub.2 were added sodium
hydride (0.043 g, 1.063 mmol, 60% dispersion in mineral oil) and
THF (2.126 mL), followed by methanol (0.086 mL, 2.126 mmol). The
reaction was allowed to stir at ambient temperature until cessation
of gas evolution was observed (.about.45 min). The reaction was
then cooled to 0.degree. C. and
S-(1-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-1-oxopropa-
n-2-yl) ethanethioate (0.150 g, 0.425 mmol) in THF (2.126 mL) was
added. The reaction was warmed to ambient temperature and stirred
for 30 min. The reaction was again cooled to 0.degree. C. and
1-fluoro-2-iodoethane (0.104 mL, 1.275 mmol) in THF (2.126 mL) was
added. The reaction was warmed to ambient temperature and stirred
overnight. The reaction was diluted in EtOAc (5 mL) and quenched
with H.sub.2O (1 mL). The layers were separated and the aqueous
layer was extracted with EtOAc (3.times.10 mL). The combined
organic extracts were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo to give a brown oil. The crude residue was
purified via flash chromatography (25-80% EtOAc/Hexanes) to give
the desired product as an opaque oil (29 mg, 20%).
Example 145
Preparation of
(E)-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifl-
uoroprop-1-en-1-yl)thio)propanamide (Compound 890)
##STR00218##
[0647] To an oven-dried microwave vial under N.sub.2 were added
dioxane (0.241 mL), Cu.sub.2O (3.45 mg, 0.024 mmol), KOH (0.0154 g,
0.965 mmol), (E)-1-bromo-3,3,3-trifluoroprop-1-ene (0.563 mL, 4.83
mmol), and
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercaptopropanami-
de (0.150 g, 0.483 mmol), sequentially. The reaction was capped and
placed on a Biotage.RTM. Initiator microwave reactor for 3 h at
110.degree. C., with external IR-sensor temperature monitoring from
the side of the vessel. During this time, the reaction mixture went
from a thick, yellow mixture to a black mixture. The heterogeneous
mixture was cooled to room temperature and diluted with EtOAc (20
mL). The mixture was filtered through a pad of Celite (EtOAc wash)
and the filtrate was concentrated in vacuo to give an dark brown
oil. The crude residue was purified via normal phase flash
chromatography (0 to 100% EtOAc/CH.sub.2Cl.sub.2) to afford the
desired product as a pale yellow oil (71 mg, 35%). Reference: Kao,
H.-L.; Lee, C.-F. Org. Lett. 2011, 13, 5204-5207.
Example 146
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methylsulfonamid-
o)propanamide (Compound Y2145)
##STR00219##
[0649] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylacrylamide
(0.538 g, 1.944 mmol) in DMF (19.44 mL) at ambient temperature were
added K.sub.2CO.sub.3 (0.672 g, 4.86 mmol) and methanesulfonamide
(0.277 g, 2.92 mmol). The reaction was fitted with a reflux
condenser and heated to 80.degree. C. After stirring for 1 h, the
reaction was cooled to ambient temperature and diluted in EtOAc (50
mL) and water (50 mL). The layers were mixed vigorously for 2 min
and then separated. The aqueous phase was extracted with EtOAc
(3.times.50 mL) and the combined organic extracts were washed with
brine (3.times.100 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo to afford a clear oil. The crude residue was
purified via normal phase flash chromatography (0 to 30%
MeOH/EtOAc) to afford the desired product as a clear semi-solid
(524 mg, 69%).
Example 147
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(N-(cyanomethyl)methylsul-
fonamido)-N-methylpropanamide (Compound 803)
##STR00220##
[0651] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methyl-3-(methylsulfonami-
do)propanamide (0.085 g, 0.238 mmol) in THF (2.376 mL) at 0.degree.
C. was added NaH (9.98 mg, 0.249 mmol, 60% dispersion in mineral
oil). The reaction was allowed to stir for 10 min at which point
2-bromoacetonitrile (0.025 mL, 0.356 mmol) was added. The reaction
was allowed to warm to room temperature and was stirred for 1 h.
The reaction was quenched with the addition of water (5 mL) and was
diluted in EtOAc (10 mL). The layers were separated and the aqueous
layer was extracted with EtOAc (3.times.10 mL). The combined
organic extracts were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude residue was purified via flash
chromatography (0 to 10% MeOH/CH.sub.2Cl.sub.2) to give the desired
product as a pale yellow foam (86 mg, 87%).
Example 148
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoro-
propyl)amino)propanamide
##STR00221##
[0653] To a microwave vial were added MeOH (2.0 mL),
3,3,3-trifluoropropan-1-amine (0.386 g, 3.42 mmol) and
3-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylpropanamide
(0.107 g, 0.342 mmol), sequentially. The reaction was capped and
placed in a Biotage.RTM. Initiator microwave reactor for 3 h at
100.degree. C., with external IR-sensor temperature monitoring from
the side of the vessel. After cooling, the reaction was
concentrated in vacuo and purified via normal phase flash
chromatography (0 to 15% MeOH/EtOAc) to afford the desired product
as an opaque viscous oil (127 mg, 94%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.94 (dd, J=2.8, 0.7 Hz, 1H), 8.63 (dd, J=4.7,
1.5 Hz, 1H), 8.04 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.95 (s, 1H), 7.46
(ddd, J=8.4, 4.8, 0.8 Hz, 1H), 3.71 (q, J=7.2 Hz, 2H), 2.93-2.80
(m, 4H), 2.35 (t, J=6.2 Hz, 2H), 2.28 (ddt, J=14.6, 7.3, 3.6 Hz,
2H), 1.16 (t, J=7.2 Hz, 3H); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta.-65.13; ESIMS m/z 390 ([M+H].sup.+).
[0654]
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methylamin-
o)propanamide was prepared as in Example 148: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.01 (d, J=2.6 Hz, 1H), 8.61 (dd, J=4.8, 1.4
Hz, 1H), 8.23 (s, 1H), 8.06 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.45
(dd, J=8.3, 4.8 Hz, 1H), 7.24 (s, 1H), 3.68 (q, J=7.2 Hz, 2H), 3.14
(t, J=6.1 Hz, 2H), 2.71-2.56 (m, 5H), 1.14 (t, J=7.2 Hz, 3H);
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 172.1, 148.6, 140.8,
140.1, 135.6, 126.6, 126.3, 124.1, 123.8, 47.1, 43.8, 36.1, 33.5,
13.1; ESIMS m/z 308 ([M+H].sup.+).
[0655]
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((4,4,4-tri-
fluorobutyl)amino)propanamide was prepared as in Example 148:
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.04 (d, J=2.7 Hz, 1H),
8.61 (dd, J=4.7, 1.5 Hz, 1H), 8.36 (s, 1H), 8.08 (ddd, J=8.4, 2.8,
1.5 Hz, 1H), 7.45 (ddd, J=8.4, 4.8, 0.7 Hz, 1H), 3.69 (q, J=7.2 Hz,
2H), 3.18 (t, J=6.0 Hz, 2H), 3.02 (t, J=7.7 Hz, 3H), 2.75 (t, J=6.0
Hz, 2H), 2.25 (tdt, J=16.1, 10.6, 5.5 Hz, 2H), 2.14-1.98 (m, 2H),
1.16 (t, J=7.2 Hz, 3H); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta.-66.03; ESIMS m/z 404 ([M+H].sup.+).
[0656]
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(ethylamino-
)propanamide was prepared as in Example 148: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.05 (s, 1H), 8.61 (s, 1H), 8.41 (dd, J=7.6,
2.1 Hz, 1H), 8.09 (dd, J=8.3, 1.4 Hz, 1H), 7.44 (dd, J=8.4, 4.8 Hz,
1H), 3.83-3.59 (m, 2H), 3.21 (t, J=6.0 Hz, 2H), 3.14-2.97 (m, 2H),
2.86 (s, 2H), 1.52-1.32 (m, 3H), 1.23-1.06 (m, 3H); .sup.13C NMR
(101 MHz, CDCl.sub.3) .delta. 170.7, 148.5, 140.5, 140.0, 135.6,
128.1, 126.4, 124.0, 122.4, 44.0, 43.3, 43.3, 30.1, 12.8, 11.4;
ESIMS m/z 322 ([M+H].sup.+).
[0657]
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(phenylamin-
o)propanamide was prepared as in Example 148: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.81 (d, J=2.7 Hz, 1H), 8.60 (dd, J=4.8, 1.4
Hz, 1H), 7.89 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.54 (s, 1H), 7.42
(ddd, J=8.3, 4.8, 0.8 Hz, 1H), 7.17-7.05 (m, 2H), 6.64 (tt, J=7.3,
1.1 Hz, 1H), 6.59-6.49 (m, 2H), 4.22 (s, 1H), 3.70 (dt, J=14.8, 7.4
Hz, 2H), 3.48 (t, J=6.0 Hz, 2H), 2.45 (t, J=6.2 Hz, 2H), 1.14 (t,
J=7.1 Hz, 3H); ESIMS m/z 370 ([M+H].sup.+).
Example 149
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(N-(3,3,3-trifluo-
ropropyl)methylsulfonamido)propanamide (Compound 978)
##STR00222##
[0659] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoro-
propyl)amino)propanamide (0.085 g, 0.218 mmol) in CH.sub.2Cl.sub.2
(2.181 mL) at ambient temperature and under N.sub.2 were added
diisopropylethylamine (0.152 mL, 0.872 mmol) and methanesulfonyl
chloride (0.025 mL, 0.327 mmol). The reaction was allowed to stir
overnight after which the reaction was diluted in CH.sub.2Cl.sub.2
(5 mL) and water (3 mL). The phases were mixed and then separated
by a phase separator. The organic layer was concentrated in vacuo
to afford a dark orange oil. The crude product was purified via
normal phase flash chromatography (0 to 100%
EtOAc/CH.sub.2Cl.sub.2) to afford the desired product as a pale
yellow, viscous oil (78 mg, 73%).
Example 150
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methyl(3,3,3-tri-
fluoropropyl)amino)propanamide (Compound Y2146)
##STR00223##
[0661] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methylamino)prop-
anamide (0.139 g, 0.452 mmol) in DMF (4.52 mL) at ambient
temperature were added K.sub.2CO.sub.3 (0.125 g, 0.903 mmol) and
3-bromo-1,1,1-trifluoropropane (0.060 mL, 0.565 mmol). The reaction
was fitted with a condenser, heated to 70 OC, and stirred
overnight. UPLC-MS analysis indicated the presence of unreacted
starting material. Therefore, an additional 3 equivalents of
3-bromo-1,1,1-trifluoropropane were added and reaction was left to
stir at 70.degree. C. for 3 h. UPLC-MS analysis indicated complete
consumption of starting material and conversion to product of the
desired mass. The reaction was cooled, diluted in EtOAc (20 mL) and
filtered through a pad of Celite. The filtrate was then washed with
half-saturated brine (3.times.20 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The crude residue was purified
via normal phase flash chromatography (0 to 15%
MeOH/CH.sub.2Cl.sub.2) to afford the desired product as a clear oil
(84 mg, 44%).
Example 151
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3-oxobutyl)thio-
)propanamide (Compound 877)
##STR00224##
[0663] To a solution of but-3-en-2-one (0.040 mL, 0.444 mmol) in
water (0.370 mL) and dioxane (0.370 mL) was added
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercaptopropanami-
de (0.115 g, 0.370 mmol) at ambient temperature. The reaction was
allowed to stir for 1 h at which point the reaction was diluted in
CH.sub.2Cl.sub.2 and the mixture was stirred vigorously for 1 h.
The mixture was then passed through a phase separator and the
remaining aqueous phase was washed with CH.sub.2Cl.sub.2 (3.times.5
mL). The combined organic extracts were concentrated in vacuo to
provide the desired product as an orange oil that was analytically
pure by .sup.1H NMR and UPLC-MS analyses (140 mg, 94%). Reference:
Khatik, G. L.; Kumar, R.; Chakraborti, A. K. Org. Lett. 2006, 8,
2433-2436.
Example 152
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((3,3-difluorobutyl)thio)-
-N-ethylpropanamide (Compound 889)
##STR00225##
[0665] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3-oxobutyl)thio-
)propanamide (0.184 g, 0.483 mmol) in CH.sub.2Cl.sub.2 (4.83 mL) at
0.degree. C. was added Deoxo-Fluor.RTM. (0.534 mL, 2.90 mmol)
followed by EtOH (0.017 mL, 0.290 mmol). The reaction was stirred
at ambient temperature for 48 h during which time the solution went
from pale yellow to dark brown. The reaction was diluted in
CH.sub.2Cl.sub.2 (10 mL) and quenched with the careful addition of
NaHCO.sub.3(aq) (5 mL). The layers were separated and the aqueous
phase was extracted with CH.sub.2Cl.sub.2 (3.times.10 mL). The
combined organic extracts were dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The crude residue was purified
via normal phase flash chromatography (0 to 100%
EtOAc/CH.sub.2Cl.sub.2) to afford the desired product as a pale
yellow oil (43 mg, 21%).
Example 153
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((3,3-difluoropropyl)thio-
)-N-ethylpropanamide (Compound 927)
##STR00226##
[0667] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((3,3-dimethoxypropyl)thi-
o)-N-ethylpropanamide (0.307 g, 0.743 mmol) in THF (7.43 mL) was
added a 1.0 M aqueous solution of HCl (7.43 mL, 7.43 mmol). The
reaction was allowed to stir at ambient temperature for 1 h at
which point TLC/UPLC-MS analysis indicated complete hydrolysis to
the desired aldehyde product had occurred. The mixture was diluted
in EtOAc (20 mL) and water (10 mL). The layers were mixed,
separated, and the aqueous layer was extracted with EtOAc
(3.times.20 mL). The combined organic extracts were washed with
NaHCO.sub.3 (1.times.25 mL), water (1.times.25 mL) and brine
(1.times.25 mL) and then dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude product was dried via azeotropic
distillation from toluene (3.times.10 mL) and then placed under
N.sub.2. To the flask was added CH.sub.2Cl.sub.2 (7.44 mL) and the
solution was cooled to 0.degree. C. Deoxo-Fluor.RTM. (0.686 mL,
3.72 mmol) and EtOH (4.34 .mu.l, 0.074 mmol) were added and the
reaction was warmed to ambient temperature. After 18 h, the
reaction was diluted in CH.sub.2Cl.sub.2 (10 mL) and quenched with
the careful addition of NaHCO.sub.3(aq) (5 mL). The layers were
separated and the aqueous phase was extracted with CH.sub.2Cl.sub.2
(3.times.10 mL). The combined organic extracts were dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude
material was purified via normal phase flash chromatography (0 to
100% EtOAc/CH.sub.2Cl.sub.2) to afford the desired product as a
pale yellow oil (151 mg, 50%).
Example 154
Preparation of 1,1,1-trifluoro-3-iodo-5-methylhexane
##STR00227##
[0669] To a microwave vial equipped with a magnetic stir bar were
added water (5.94 mL), acetonitrile (5.94 mL), sodium dithionite
(0.569 g, 3.27 mmol), sodium bicarbonate (0.499 g, 5.94 mmol), and
4-methylpent-1-ene (0.379 mL, 2.97 mmol). The vessel was sealed
with a microwave cap (crimped), cooled to -78.degree. C. and
evacuated under house vacuum. Next, trifluoroiodomethane (0.873 g,
4.46 mmol) (approximate) was condensed into the reaction vessel.
After warming to ambient temperature, the reaction was stirred for
2.5 h. Prior to removing the cap, the reaction was vented with a
needle and substantial gas evolution was observed. The reaction was
then diluted in water (5 mL) and the mixture was extracted with
Et.sub.2O (3.times.20 mL) and the combined extracts were dried over
MgSO.sub.4, filtered and concentrated in vacuo to afford a clear
oil (740 mg, 80%). Crude .sup.1H NMR analysis indicated desired
product to be of .about.90% purity. Product was therefore used in
subsequent reactions without further purification: .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 4.25-4.06 (m, 1H), 2.94 (dqd, J=15.5,
10.6, 6.1 Hz, 1H), 2.77 (dqd, J=15.5, 10.0, 7.5 Hz, 1H), 1.92-1.74
(m, 2H), 1.45-1.28 (m, 1H), 0.98 (d, J=6.5 Hz, 3H), 0.87 (d, J=6.5
Hz, 3H); .sup.19F NMR (376 MHz, CDCl.sub.3) .delta.-63.63.
Reference: Ignatowska, J.; Dmowski, W. J. Fluor. Chem., 2007, 128,
997-1006.
[0670] (4,4,4-trifluoro-2-iodobutyl)benzene was prepared as in
Example 154: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.41-7.27
(m, 3H), 7.23-7.16 (m, 2H), 4.33 (dq, J=8.2, 6.7 Hz, 1H), 3.31-3.15
(m, 2H), 2.96-2.72 (m, 2H); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta.-63.63; EIMS m/z 314.
[0671] 1-(4,4,4-trifluoro-2-iodobutyl)-1H-imidazole was prepared as
in Example 154: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.61 (t,
J=1.1 Hz, 1H), 7.12 (t, J=1.1 Hz, 1H), 7.00 (t, J=1.4 Hz, 1H),
4.46-4.31 (m, 3H), 2.88-2.66 (m, 2H); .sup.19F NMR (376 MHz,
CDCl.sub.3) .delta.-63.57; EIMS m/z 304.
[0672] 1,1,1-trifluoro-3-iodopentane was prepared as in Example
154: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 4.20 (tdd, J=7.9,
6.2, 4.4 Hz, 1H), 3.01-2.84 (m, 1H), 2.84-2.69 (m, 1H), 1.84-1.74
(m, 2H), 1.06 (t, J=7.1 Hz, 3H); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta.-64.06; EIMS m/z 252.
Example 155
Preparation of
S-(1,1,1-trifluoro-5-methylhexan-3-yl)benzothioate
##STR00228##
[0674] To a solution of 1,1,1-trifluoro-3-iodo-5-methylhexane
(0.047 g, 0.168 mmol) in DMF (1.678 mL) at ambient temperature was
added potassium benzothioate (0.035 g, 0.201 mmol). The reaction
was allowed to stir for 18 h at which point the reaction was
diluted in water (3 mL) and EtOAc (5 mL). The layers were mixed and
then separated. The aqueous layer was extracted with EtOAc
(3.times.5 mL) and the combined organic extracts were washed with
water (1.times.10 mL) and half saturated brine (2.times.10 mL),
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo.
Residue was purified via flash chromatography (0 to 30%
EtOAc/Hexanes) to afford the desired product as a clear oil (37 mg,
68%): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.99-7.92 (m, 2H),
7.62-7.55 (m, 1H), 7.50-7.41 (m, 2H), 4.10-3.95 (m, 1H), 2.73-2.56
(m, 1H), 2.56-2.40 (m, 1H), 1.94-1.73 (m, 1H), 1.73-1.61 (m, 2H),
0.97 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H); .sup.19F NMR (376
MHz, CDCl.sub.3) .delta.-62.89.
[0675] S-(4,4,4-trifluoro-1-phenylbutan-2-yl)benzothioate was
prepared as in Example 155: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.97-7.89 (m, 2H), 7.58 (ddt, J=7.9, 6.9, 1.3 Hz, 1H),
7.49-7.41 (m, 2H), 7.39-7.26 (m, 5H), 4.29-4.15 (m, 1H), 3.11 (d,
J=7.2 Hz, 2H), 2.54 (qd, J=10.6, 6.6 Hz, 2H); .sup.19F NMR (376
MHz, CDCl.sub.3) .delta.-62.86; EIMS m/z 324.
[0676]
S-(4,4,4-trifluoro-1-(1H-imidazol-1-yl)butan-2-yl)benzothioate was
prepared as in Example 155: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.98-7.89 (m, 2H), 7.68-7.60 (m, 1H), 7.56 (t, J=1.1 Hz,
1H), 7.53-7.45 (m, 2H), 7.11 (t, J=1.1 Hz, 1H), 7.05 (t, J=1.3 Hz,
1H), 4.42-4.18 (m, 3H), 2.64-2.39 (m, 2H); .sup.19F NMR (376 MHz,
CDCl.sub.3) .delta.-62.98; EIMS m/z 314.
[0677] S-(1,1,1-trifluoropentan-3-yl)benzothioate was prepared as
in Example 155: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.02-7.91
(m, 2H), 7.64-7.55 (m, 1H), 7.51-7.40 (m, 2H), 4.06-3.90 (m, 1H),
2.70-2.41 (m, 2H), 2.02-1.86 (m, 1H), 1.86-1.71 (m, 1H), 1.05 (t,
J=7.3 Hz, 3H); .sup.19F NMR (376 MHz, CDCl.sub.3) .delta.-63.32;
EIMS m/z 262.
Example 156
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((1,1,1-trifluoro-
-5-methylhexan-3-yl)thio)propanamide (Compound 1053)
##STR00229##
[0679] To a suspension of NaH (60% in mineral oil, 0.012 g, 0.300
mmol) in THF (2.86 mL) at ambient temperature and under N.sub.2 was
added MeOH (0.058 mL, 1.429 mmol). The reaction became homogenous
and gas evolution was observed. After stirring for 30 min, the
reaction was cooled to 0.degree. C. and a solution of
S-(1,1,1-trifluoro-5-methylhexan-3-yl)benzothioate (0.083 g, 0.286
mmol) in THF (2 mL) was added slowly. The reaction was warmed to
ambient temperature, stirred for 45 min, and then returned to
0.degree. C. To the reaction was added a solution of
3-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylpropanamide
(0.090 g, 0.286 mmol) in THF (2 mL). The reaction was warmed to
ambient temperature and stirred for 18 h. The reaction was diluted
in EtOAc (20 mL) and water (10 mL). The layers were mixed and then
separated. The aqueous layer was extracted with EtOAc (3.times.20
mL) and the combined organic extracts were dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude
residue was purified via normal phase flash chromatography (0 to
100% EtOAc/CH.sub.2Cl.sub.2) to afford the desired product as a
pale yellow oil (63 mg, 45%).
Example 157
Preparation of
tert-butyl(2-(2,2-difluorocyclopropyl)ethoxy)diphenylsilane
##STR00230##
[0681] To an oven-dried 3-neck round bottom flask equipped with
reflux condenser and addition funnel under N.sub.2 were added
(but-3-en-1-yloxy)(tert-butyl)diphenylsilane (3.6 g, 11.59 mmol)
and sodium fluoride (7.30 mg, 0.174 mmol) (For preparation of
starting olefin, see: Waser, J.; Gaspar, B.; Nambu, H.; Carreira,
E. M. J. Am. Chem. Soc. 2006, 128, 11693-11712). To the closed
addition funnel was added trimethylsilyl
2,2-difluoro-2-(fluorosulfonyl)acetate (4.57 mL, 23.19 mmol). The
reaction vessel and its contents were heated to 120.degree. C. and
the addition funnel was then opened to allow the sulfonyl fluoride
to add over 1 h. Once the addition was complete, the reaction was
allowed to continue stirring at 120.degree. C. for 30 min. The
reaction was cooled to ambient temperature, diluted in
CH.sub.2Cl.sub.2 (50 mL) and washed with NaHCO.sub.3(aq)
(2.times.50 mL). The organic phase was separated, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to provide a
brown oil. The crude residue was purified via normal phase flash
chromatography (0 to 15% CH.sub.2Cl.sub.2/Hexanes) to provide the
desired product as a clear oil (3.07 g, 73%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.72-7.63 (m, 4H), 7.49-7.34 (m, 6H), 3.73 (t,
J=6.0 Hz, 2H), 1.88-1.73 (m, 1H), 1.73-1.55 (m, 2H), 1.42-1.27 (m,
1H), 1.06 (s, 9H), 0.94-0.81 (m, 1H); .sup.19F NMR (376 MHz,
CDCl.sub.3) .delta.-128.54 (d, J=156.2 Hz), -143.96 (d, J=155.5
Hz); .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 135.5, 133.7 (d,
J=3.7 Hz), 129.6, 127.7, 114.5, 62.8, 30.0 (d, J=3.5 Hz), 26.8,
19.9 (t, J=10.9 Hz), 19.2, 15.9 (t, J=11.0 Hz).
Example 158
Preparation of 2-(2,2-difluorocyclopropyl)ethyl
4-methylbenzenesulfonate
##STR00231##
[0683] To a solution of
tert-butyl(2-(2,2-difluorocyclopropyl)ethoxy)diphenylsilane (0.386
g, 1.071 mmol) in THF (10.71 mL) at 0.degree. C. was added a 1.0 M
solution of TBAF (3.21 mL, 3.21 mmol) in THF. The reaction was
warmed to ambient temperature and stirred for 3 h. The reaction was
quenched with the addition of NH.sub.4Cl.sub.(aq) (1 mL) and the
mixture was partitioned between water (15 mL) and EtOAc (15 mL).
The layers were mixed well and then separated. The aqueous layer
was extracted with EtOAc (3.times.20 mL) and the combined organic
extracts were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude residue was then taken up in
CH.sub.2Cl.sub.2 (7.15 mL). To the solution were then added
pyridine (0.434 mL, 5.36 mmol) and p-toluenesulfonyl chloride
(0.614 g, 3.22 mmol). The reaction was stirred at ambient
temperature for 48 h at which point the reaction was partitioned
between CH.sub.2Cl.sub.2 (50 mL) and water (25 mL). The layers were
separated and the organic layer was washed with 1N HCl.sub.(aq) (20
mL), water (20 mL) and brine (20 mL). The organic layer was then
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo.
The crude residue was purified via normal phase flash
chromatography (0 to 50% EtOAc/Hexanes) to afford the desired
product as a clear oil (142 mg, 46%, 2 steps): .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.89-7.71 (m, 2H), 7.42-7.29 (m, 2H),
4.20-3.96 (m, 2H), 2.46 (s, 3H), 1.92-1.81 (m, 1H), 1.81-1.69 (m,
1H), 1.63-1.48 (m, 1H), 1.39 (dddd, J=12.2, 11.2, 7.7, 4.3 Hz, 1H),
0.93 (dtd, J=13.0, 7.6, 3.5 Hz, 1H); .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 145.0, 132.9, 129.9, 127.9, 113.5 (t, J=282.4
Hz), 69.0 (d, J=2.2 Hz), 26.6 (d, J=4.3 Hz), 21.7, 18.9 (t, J=11.1
Hz), 15.9 (t, J=11.0 Hz); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta.-129.09 (d, J=157.8 Hz), -144.18 (d, J=158.1 Hz).
Example 159
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-methylacrylamide
(Compound Y2098)
##STR00232##
[0685] To a solution of
3-chloro-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.526 g,
2.52 mmol) in 1,2-dichloroethane (25.2 mL) at 0.degree. C. were
added diisopropylethylamine (0.484 mL, 2.77 mmol) and acryloyl
chloride (0.205 mL, 2.52 mmol). The reaction was allowed to warm to
ambient temperature and was stirred for 1 h. The reaction was
quenched with the addition of NaHCO.sub.3(aq) and was diluted with
CH.sub.2Cl.sub.2. The layers were separated and the aqueous layer
was extracted with CH.sub.2Cl.sub.2. The combined organic extracts
were dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The crude product was purified via flash chromatography (0
to 10% MeOH/CH.sub.2Cl.sub.2) to give the desired product as an
orange solid (634 mg, 91%).
Example 160
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoro-
propyl)thio)propanamide (Compound 653)
##STR00233##
[0687] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (10 g, 44.9
mmol) in CH.sub.2Cl.sub.2 (100 mL) at 0.degree. C. and under
N.sub.2 were added pyridine (5.45 mL, 67.4 mmol),
4-dimethylaminopyridine (DMAP) (2.74 g, 22.45 mmol), and
3-((3,3,3-trifluoropropyl)thio)propanoyl chloride (9.91 g, 44.9
mmol), sequentially. The reaction was warmed to ambient temperature
and stirred for 1 h. The reaction was poured into water (100 mL)
and the resulting mixture was stirred for 5 min. The mixture was
transferred to a separatory funnel and the layers were separated.
The aqueous phase was extracted with CH.sub.2Cl.sub.2 (3.times.50
mL) and the combined organic extracts were dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude
product was purified via normal phase flash chromatography (0 to
100% EtOAc/CH.sub.2Cl.sub.2) to afford the desired product as a
pale yellow solid (17.21 g, 89%).
Example 161
Preparation of
N-(1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-yl)-2-oxooxazolidine-3--
carbothioamide (Compound Y2032)
##STR00234##
[0689] To a solution of
1-(5-fluoropyridin-3-yl)-3-methyl-1H-pyrazol-4-amine (0.10 g, 0.52
mmol) and triethylamine (0.24 mL, 1.71 mmol) in dry THF (0.52 mL)
was added carbon disulfide (0.03 mL, 0.52 mmol) via syringe over 15
minutes. After stirring for 1 hour, the mixture was cooled in an
ice bath and 4-methylbenzene-1-sulfonyl chloride (0.11 g, 0.57
mmol) was added in one portion, stirred for 5 minutes at 0.degree.
C. and then warmed to 25.degree. C. and stirred for 1 hour. The
reaction mixture was quenched with 1N HCl and extracted with
diethyl ether. The ether layers were combined, washed with water
and half saturated aqueous sodium bicarbonate, dried (MgSO.sub.4),
filtered and concentrated to dryness to give the desired
isothiocyanate (0.12 g, 98%). To a solution of oxazolidin-2-one
(0.05 g, 0.61 mmol) dissolved in dry DMF (2.05 mL) was added sodium
hydride (0.03 g, 0.61 mmol, 60% dispersion in mineral oil) in one
portion and the suspension was stirred for 20 minutes. The reaction
mixture was cooled to 0.degree. C. and
3-fluoro-5-(4-isothiocyanato-3-methyl-1H-pyrazol-1-yl)pyridine
(0.12 g, 0.51 mmol) was added in one portion in a minimum amount of
dry DMF and stirred for 20 minutes. Water and ethyl acetate were
added and the resulting biphasic mixture was separated and the
aqueous layer was extracted one time with ethyl acetate. The
combined organic extracts were washed with 1:1 hexanes/water, dried
(MgSO.sub.4), filtered and concentrated to dryness. The crude
product was purified by silica gel chromatography eluting with
0-75% ethyl acetate/hexanes to give the desired product as a white
solid (0.03 g, 18%).
Example 162
Preparation of
3-(4-isothiocyanato-3-methyl-1H-pyrazol-1-yl)pyridine
##STR00235##
[0691] To a solution of
3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.50 g, 2.87 mmol)
and triethylamine (1.3 mL, 1.71 mmol) in dry THF (2.8 mL) was added
carbon disulfide (0.17 mL, 2.87 mmol) via syringe over 15 minutes.
After stirring for 1 hour, the mixture was cooled in an ice bath
and 4-methylbenzene-1-sulfonyl chloride (0.60 g, 0.3.16 mmol) was
added in one portion, stirred for 5 minutes at 0.degree. C. and
then warmed to 25.degree. C. and stirred for 1 hour. The reaction
mixture was quenched with 1N HCl and extracted with diethyl ether.
The ether layers were combined, washed with water and half
saturated aqueous NaHCO.sub.3, dried (MgSO.sub.4), filtered and
concentrated to dryness. The crude material was purified by silica
gel chromatography eluting with 0-100% ethyl acetate/hexanes to
give the desired product as a light yellow solid (0.48 g, 78%):
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.89 (d, J=2.6 Hz, 1H),
8.56 (dd, J=4.7, 1.4 Hz, 1H), 7.96 (ddd, J=8.3, 2.7, 1.5 Hz, 1H),
7.89 (s, 1H), 7.40 (ddd, J=8.3, 4.8, 0.7 Hz, 1H), 2.40 (s, 3H);
ESIMS m/z 218 ([M+H].sup.+).
Example 163
Preparation of
N-(3-methyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl)-2-oxooxazolidine-3-carbothi-
amide (Compound Y2034)
##STR00236##
[0693] To a solution of oxazolidin-2-one (0.06 g, 0.66 mmol)
dissolved in dry DMF (2.2 mL) was added sodium hydride (0.03 g,
0.67 mmol, 60% dispersion in mineral oil) in one portion and the
suspension was stirred for 20 minutes. The reaction mixture was
cooled to 0.degree. C. and
3-(4-isothiocyanato-3-methyl-1H-pyrazol-1-yl)pyridine (0.12 g, 0.56
mmol) was added in one portion in a minimum amount of dry DMF and
stirred for 20 minutes. Water and ethyl acetate were added and the
resulting biphasic mixture was separated and the aqueous layer was
extracted one time with ethyl acetate. The combined organic
extracts were washed with 1:1 hexanes/water, dried (MgSO.sub.4),
filtered and concentrated to dryness. The crude product was
purified by silica gel chromatography eluting with 0-75% ethyl
acetate/hexanes to give the desired product as a white solid (0.07
g, 41%).
Example 164
Preparation of methyl
N-(3-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2-oxooxazolidine-3-carbimid-
othioate (Compound Y2035)
##STR00237##
[0695] To a solution of oxazolidin-2-one (0.05 g, 0.66 mmol)
dissolved in dry DMF (2.22 mL) was added sodium hydride (0.03 g,
0.66 mmol, 60% dispersion in mineral oil) in one portion and the
suspension was stirred for 20 minutes. The reaction mixture was
cooled to 0.degree. C. and
3-(4-isothiocyanato-3-methyl-1H-pyrazol-1-yl)pyridine (0.12 g, 0.55
mmol) was added in one portion in a minimum amount of dry DMF and
stirred for 20 minutes. Iodomethane (0.04 mL, 0.66 mmol) was added
and the reaction was monitored by TLC. Aqueous ammonium chloride
and 50% ethyl acetate/hexanes were added and the resulting biphasic
mixture was separated and the organic extract washed with water and
saturated aqueous sodium bicarbonate and concentrated to dryness.
The crude product was purified by silica gel chromatography eluting
with 0-10% methanol/CH.sub.2Cl.sub.2 to give the desired product as
a light yellow solid (0.14 g, 82%).
Example 165
Preparation of
N-acetyl-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)cyclopropanecarboxa-
mide (Compound Y2060)
##STR00238##
[0697] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)cyclopropanecarboxamide
(0.15 g, 0.57 mmol) in dichloroethane (2.5 mL) was added
diisopropylethylamine (0.12 mL, 0.68 mmol) followed by acetyl
chloride (0.54 g, 0.68 mmol) and the reaction was stirred at room
temperature overnight. Saturated aqueous NaHCO.sub.3 was added and
the mixture was extracted with CH.sub.2Cl.sub.2. The combined
organic phases were concentrated to dryness and purified by silica
gel chromatography eluting with 0-100% ethyl acetate/hexanes to
give the desired product as a white solid (10 mg, 6%).
Example 166
Preparation of
S-methyl(3-chloro-5-(methylthio)-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)-
carbamothioate (Compound Y2076)
##STR00239##
[0699] To a solution of THF (1.35 mL) and diisopropylethylamine
(0.07 mL, 0.40 mmol) was added 2.5M n-butyllithium (0.16 mL, 0.40
mmol) and the reaction was stirred for 30 minutes. The reaction was
cooled further to -78.degree. C. and to this was added dropwise
S-methyl(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)carbamothioate
(0.10 g, 0.33 mmol) in a minimum amount of dry THF and stirred for
45 minutes. To this was then added 1,2-dimethyldisulfane (0.04 g,
0.37 mmol) and the reaction was stirred for additional 20 minutes.
The reaction was poured into water and extracted with ethyl
acetate. The ethyl acetate layers were combined, dried
(MgSO.sub.4), filtered and concentrated to dryness. The crude
product was purified by silica gel chromatography eluting with
0-100% ethyl acetate/hexanes to give the desired product as a clear
oil (53 mg, 46%).
Example 167
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(3,3,3-trifluorop-
ropyl)thio)propanamide (Compound 653)
##STR00240##
[0701] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercaptopropanami-
de (0.10 g, 0.32 mmol) dissolved in dry THF (1.07 mL) and cooled in
an ice bath was added sodium hydride (0.02 g, 0.34 mmol, 60%
dispersion in mineral oil) in one portion and the reaction was
stirred for 10 minutes. To this was added
3-bromo-1,1,1-trifluoropropane (0.06 g, 0.35 mmol) in one portion
in a minimum amount of dry DMF and the reaction was stirred at room
temperature for 2 hours. The reaction mixture was poured into water
and extracted with ethyl acetate. The ethyl acetate layers were
combined and concentrated to dryness. The crude product was
purified by silica gel chromatography eluting with 0-75% ethyl
acetate hexanes to give the desired product as a clear oil (83 mg,
63%).
Example 168
Preparation of
tert-butyl(2-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-2--
oxoethyl)(methyl)carbamate
##STR00241##
[0703] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.40 g, 1.79
mmol) in dichloroethane (3.59 mL) was added
2-((tert-butoxycarbonyl)(methyl)amino)acetic acid (0.37 g, 1.97
mmol), 4-N,N-dimethylaminopyridine (0.24 g, 1.97 mmol) and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.51
g, 2.69 mmol) and the reaction was stirred overnight at room
temperature. The reaction mixture was concentrated to dryness and
the crude product was purified by silica gel chromatography eluting
with 0-100% ethyl acetate/hexanes to give the desired product as a
white semi solid (0.61 g, 87%): IR (thin film) 1673 cm.sup.-1;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.96 (d, J=2.4 Hz, 1H),
8.63 (dd, J=5.3 Hz, 1H), 8.11-7.86 (m, 2H), 7.51-7.36 (m, 1H),
3.92-3.57 (m, 4H), 2.96-2.81 (m, 3H), 1.50-1.37 (s, 9H), 1.20-1.11
(m, 3H); ESIMS m/z 394 ([M+H].sup.+).
[0704] The following molecules were made in accordance with the
procedures disclosed in Example 168:
[0705]
tert-Butyl(2-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(methyl)am-
ino)-2-oxoethyl)(methyl)carbamate: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.95 (d, J=2.5 Hz, 1H), 8.62 (d, J=4.8 Hz, 1H),
8.14-7.84 (m, 2H), 7.59-7.35 (m, 1H), 3.85 (d, J=25.9 Hz, 2H),
3.31-3.15 (m, 3H), 2.99-2.81 (m, 3H), 1.53-1.31 (s, 9H).
[0706]
tert-Butyl(2-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(cycloprop-
ylmethyl)amino)-2-oxoethyl)(methyl)carbamate: IR (thin film) 1675
cm.sup.-1; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.95 (bs, 1H),
8.63 (dd, J=5.1 Hz, 1H), 8.17-7.88 (m, 2H), 7.54-7.36 (m, 1H),
3.99-3.41 (m, 4H), 2.97-2.82 (m, 3H), 1.44 (s, 9H), 1.12-0.83 (m,
1H), 0.59-0.39 (m, 2H), 0.28-0.08 (m, 2H); ESIMS m/z 420
([M+H].sup.+).
Example 169
Preparation of
N-(3-chloro-1-pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-(methylamino)aceta-
mide
##STR00242##
[0708] To a solution of
tert-butyl(2-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-2--
oxoethyl)(methyl)carbamate (0.57 g, 1.44 mmol) in CH.sub.2Cl.sub.2
(1.44 mL) was added trifluoroacetic acid (1.44 mL) and the reaction
was stirred at room temperature for 1 hour. Toluene was added and
the reaction was concentrated to near dryness. The mixture was
poured into a separatory funnel containing saturated aqueous
NaHCO.sub.3 and was extracted with CH.sub.2Cl.sub.2. The
CH.sub.2Cl.sub.2 layers were combined and concentrated to dryness.
The crude product was purified by silica gel chromatography eluting
with 0-15% methanol/CH.sub.2Cl.sub.2 to give the desired product as
a yellow oil (0.31 g, 73%): IR (thin film) 1666 cm.sup.-1; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.98 (d, J=2.6 Hz, 1H), 8.63 (dd,
J=4.7, 1.3 Hz, 1H), 8.06 (m, 2H), 7.47 (dd, J=8.3, 4.8 Hz, 1H),
3.72 (q, J=7.1 Hz, 2H), 3.30 (s, 2H), 2.48 (s, 3H), 1.17 (t, J=7.2
Hz, 3H); ESIMS m/z 294 ([M+H].sup.+).
[0709] The following compounds were made in accordance with the
procedures disclosed in Example 169:
[0710]
N-(3-Chloro-1-(pyridin-3-yl)-H-pyrazol-4-yl)-N-methyl-2-(methylamin-
o)acetamide: IR (thin film) 1666 cm.sup.-1; H NMR (400 MHz,
CDCl.sub.3) .delta. 8.96 (d, J=2.6 Hz, 1H), 8.64 (dd, J=4.8, 1.3
Hz, 1H), 8.11-7.94 (m, 2H), 7.47 (dd, J=8.4, 4.4 Hz, 1H), 3.30 (s,
2H), 3.27 (s, 3H), 2.47 (s, 3H); ESIMS m/z 280 ([M+H].sup.+).
[0711]
N-(3-Chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-(cyclopropylmethyl)-
-2-(methylamino)acetamide: IR (thin film) 1667 cm.sup.-1; H NMR
(400 MHz, CDCl.sub.3) .delta. 8.98 (d, J=2.6 Hz, 1H), 8.63 (dd,
J=4.7, 1.3 Hz, 1H), 8.11 (s, 1H), 8.06 (ddd, J=8.3, 2.7, 1.4 Hz,
1H), 7.47 (dd, J=8.3, 4.8 Hz, 1H), 3.53 (bs, 2H), 3.27 (bs, 2H),
2.49 (s, 3H), 1.02-0.91 (m, 1H), 0.55-0.44 (m, 2H), 0.22-0.15 (m,
2H); ESIMS m/z 320 ([M+H].sup.+).
Example 170
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-(N-methylmethylsu-
lfonamido)acetamide (Compound 800)
##STR00243##
[0713] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-(methylamino)acet-
amide (0.10 g, 0.34 mmol) in CH.sub.2Cl.sub.2 (0.68 mL) was added
methanesulfonyl chloride (0.06 g, 0.51 mmol) followed by
diisopropylethylamine (0.12 mL, 0.68 mmol) and the reaction was
stirred overnight at room temperature. The reaction mixture was
poured into saturated aqueous NaHCO.sub.3 and extracted with
CH.sub.2Cl.sub.2. The CH.sub.2Cl.sub.2 layers were combined and
concentrated to dryness. The crude product was purified by silica
gel chromatography eluting with 50-100% ethyl acetate/hexanes to
give the desired product as a white semi-solid (81 mg, 64%).
Example 171
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoro-
propyl)sulfinyl)propanamide (Compound 861)
##STR00244##
[0715] Method A: To
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoro-
propyl)thio)propanamide (0.17 g, 0.43 mmol) in glacial acetic acid
(4.35 mL) was added sodium perborate tetrahydrate (0.07 g, 0.45
mmol), and the mixture was heated at 55.degree. C. for 1 hour. The
reaction mixture was carefully poured into a separatory funnel
containing saturated aqueous NaHCO.sub.3 resulting in gas
evolution. When the gas evolution had ceased, ethyl acetate was
added and the layers were separated. The aqueous layer was
extracted twice with ethyl acetate, and the organic layers were
combined, dried over MgSO.sub.4, filtered and concentrated under
reduced pressure. The crude material was purified by silica gel
chromatography eluting with 0-5% methanol/CH.sub.2Cl.sub.2 to give
the desired product as a dark oil (60 mg, 33%).
[0716] Method B: To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoro-
propyl)thio)propanamide (500 mg, 1.229 mmol) in
hexafluoroisopropanol (5 mL) stirring at room temperature was added
30% hydrogen peroxide (523 mg, 4.92 mmol). The solution was stirred
at room temperature for 15 min. It was quenched with saturated
sodium sulfite solution and extracted with CH.sub.2Cl.sub.2. Silica
gel chromatography (0-10% MeOH/CH.sub.2Cl.sub.2) gave the title
compound as white semi-solid (495 mg, 95%).
Example 172
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-(methylamino)prop-
anamide
##STR00245##
[0718]
2-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylpropa-
namide (0.51 g, 1.62 mmol) and methylamine (4.05 mL, 32.6 mmol, 33%
in ethanol) were placed in a 25 mL vial on a Biotage.RTM. Initiator
microwave reactor for 45 minutes at 100.degree. C., with external
IR-sensor temperature monitoring from the side of the vessel. The
reaction was concentrated to dryness and purified by silica gel
chromatography (0-10% methanol/CH.sub.2Cl.sub.2 to give the desired
product as a yellow solid (0.21 g, 43%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.96 (d, J=2.6 Hz, 1H), 8.64 (dd, J=4.7, 1.3
Hz, 1H), 8.06 (ddd, J=8.3, 2.7, 1.4 Hz, 1H), 7.98 (s, 1H), 7.47
(dd, J=8.3, 4.8 Hz, 1H), 3.93-3.57 (m, 2H), 3.25-3.11 (m, 1H), 2.34
(s, 3H), 1.21-1.17 (m, 6H).
[0719] The following compound was made in accordance with the
procedures disclosed in Example 172:
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(methylamino)propa-
namide
##STR00246##
[0721] .sup.1H NMR (400 MHz, Acetone) .delta. 9.12 (dd, J=6.7, 2.6
Hz, 1H), 8.90 (s, 1H), 8.58 (dd, J=4.7, 1.4 Hz, 1H), 8.25 (m, 1H),
7.56 (m, 1H), 3.67 (q, J=7.1 Hz, 2H), 3.01 (t, J=6.5 Hz, 2H), 2.66
(t, J=6.4 Hz, 2H), 2.50 (s, 3H), 1.12 (t, J=7.2 Hz, 3H); LC/MS
(ESI) m/z 308.4 ([M+H].sup.+); IR (KBr thin film) 3055, 2971, 2773,
1656 cm.sup.-1.
Example 173
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-(2-methoxyethoxy)-
acetamide (Compound Y2195)
##STR00247##
[0723] To a stirred solution of 2-methoxyethanol (0.07 mL, 0.87
mmol) in THF (4 mL) at 0.degree. C. was added sodium hydride (0.032
g, 0.80 mmol, 60% dispersion in oil). After stirring for 10 min
2-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylacetamide
(0.2 g, 0.7 mmol) was added in one portion. The reaction was
stirred for 20 minutes then the reaction vessel was removed from
the ice bath and allowed to warm to room temperature and was
stirred overnight (ca 16 h), at which point the reaction was deemed
complete by TLC. The reaction mixture was diluted with water and
ethyl acetate and the layers were separated. The aqueous layer was
extracted with ethyl acetate once. The combined organic layers were
dried over MgSO.sub.4, concentrated under reduced pressure, and
purified by flash chromatography (SiO.sub.2, 100-200 mesh; eluting
with 0 to 20% methanol in CH.sub.2Cl.sub.2) to afford the title
compound as a tan solid (0.045 g, 20%).
Example 174
Preparation of
N-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(methyl)carbamoyl)-N-ethylp-
ivalamide (Compound Y2082)
##STR00248##
[0725] To a solution of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-ethyl-1-methylurea
(0.075 g, 0.268 mmol) in THF (2.68 mL) at -78.degree. C. was added
1 M lithium bis(trimethylsilyl)amide (LiHMDS) (0.282 mL, 0.282
mmol) in toluene. The reaction was stirred at -78.degree. C. for 15
min and pivaloyl chloride (0.036 mL, 0.295 mmol) was added and the
reaction was stirred at -78.degree. C. for 10 min and room
temperature for 30 min. Brine was added and the reaction was
extracted with EtOAc. The combined organic phases were concentrated
and purified by flash chromatography (0-15% MeOH/CH.sub.2Cl.sub.2)
to give the title compound as a yellow oil (54 mg, 55%): IR (thin
film) 2969, 1681 cm.sup.-1; H NMR (400 MHz, CDCl.sub.3) .delta.
8.93 (d, J=2.5 Hz, 1H), 8.61 (dd, J=4.7, 1.3 Hz, 1H), 8.06 (s, 1H),
8.00 (ddd, J=8.3, 2.6, 1.4 Hz, 1H), 7.44 (dd, J=8.3, 4.7 Hz, 1H),
3.58 (q, J=7.0 Hz, 2H), 3.35 (s, 3H), 1.25-1.13 (m, 12H); ESIMS m/z
365 ([M+H].sup.+).
Example 175
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-(methylthio)propanimidami-
de (Compound 706)
##STR00249##
[0727] To a solution of
3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.058 g, 0.297 mmol)
in EtOH (0.992 mL) was added naphthalen-2-ylmethyl
3-(methylthio)propanimidothioate hydrobromide (0.106 g, 0.297
mmol). The reaction was stirred at 0.degree. C. for 1 hour. The
solvent was removed under reduced pressure and water and Et.sub.2O
were added. The phases were separated and the aqueous phase was
concentrated to give a crude mixture. The residue was dissolved in
MeOH (1 mL) and MP-carbonate (0.281 g, 0.892 mmol) was added. The
reaction was stirred at room temperature for 1 hour. The reaction
was filtered, concentrated and purified by flash chromatography
(0-15% MeOH/hexanes) to give the title compound as light brown
solid (32 mg, 31%): mp 137.degree. C.; .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.86 (d, J=2.6 Hz, 1H), 8.49 (dd, J=4.8, 1.2
Hz, 1H), 7.95 (ddd, J=8.3, 2.5, 1.3 Hz, 1H), 7.68 (s, 1H), 7.37
(dd, J=8.3, 4.8 Hz, 1H), 5.29 (br s, 2H), 3.02-2.73 (m, 2H), 2.64
(t, J=7.1 Hz, 2H), 2.18 (s, 3H); ESIMS m/z 297 ([M+H].sup.+).
Example 176
Preparation of naphthalen-2-ylmethyl
3-(methylthio)propanimidothioate hydrobromide
##STR00250##
[0729] To a solution of 3-(methylthio)propanethioamide (0.062 g,
0.458 mmol) in CHCl.sub.3 (1.146 mL) was added
2-(bromomethyl)naphthalene (0.101 g, 0.458 mmol). The mixture was
heated at reflux for 1.5 hours. The reaction was cooled to room
temperature, Et.sub.2O was added and a precipitate formed. The
solvent was removed under reduced pressure. Et.sub.2O was added and
subsequently decanted. The residual solid was dried under reduced
pressure to give the title compound as a faint yellow solid (109
mg, 67%): .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 11.78 (br s,
1H), 8.00 (s, 1H), 7.98-7.85 (m, 3H), 7.59-7.49 (m, 3H), 4.74 (s,
2H), 3.10 (t, J=7.1 Hz, 2H), 2.84 (t, J=7.2 Hz, 2H), 2.08 (s, 3H).
Reference: Shearer, B. G. et al. Tetrahedron Letters 1997, 38,
179-182.
[0730] Naphthalen-2-ylmethyl
N-methyl-3-(methylthio)propanimidothioate hydrobromide was prepared
in accordance with the procedure disclosed in Example 176 and
isolated as an off-white semi-solid; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.08 (s, 1H), 8.02-7.93 (m, 3H), 7.63-7.56
(m, 3H), 5.02 (s, 2H), 3.40-3.32 (m, 2H), 3.21 (s, 3H), 2.89-2.83
(m, 2H), 2.13 (s, 3H); ESIMS m/z 290 ([M+H].sup.+).
[0731] Naphthalen-2-ylmethyl N-methylethanimidothioate hydrobromide
was prepared in accordance with the procedure disclosed in Example
176 and isolated as a white solid; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.02 (s, 1H), 8.01-7.92 (m, 3H), 7.61-7.53
(m, 3H), 4.93 (s, 2H), 3.15 (d, J=1.1 Hz, 3H), 2.81 (d, J=1.1 Hz,
3H); ESIMS m/z 230 ([M+H].sup.+).
[0732] Naphthalen-2-ylmethyl ethanimidothioate hydrobromide was
prepared as described in Shearer, B. G. et al. Tetrahedron Letters
1997, 38, 179-182.
[0733] Naphthalen-2-ylmethyl cyclopropanecarbimidothioate
hydrobromide was prepared in accordance with the procedure
disclosed in Example 176 and isolated as a yellow solid; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.58 (s, 1H), 8.01 (s, 1H),
7.99-7.88 (m, 3H), 7.59-7.51 (m, 3H), 4.77 (s, 2H), 2.42-2.29 (m,
1H), 1.46-1.37 (m, 2H), 1.36-1.29 (m, 2H); ESIMS m/z 242
([M+H].sup.+).
Example 177
Preparation of ethyl
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N'-ethyl-N-methylcarbamimid-
othioate (Compound Y2049)
##STR00251##
[0735] To a solution of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-ethyl-1-methylthiourea
(0.085 g, 0.287 mmol) in ethanol (1.916 mL) in a microwave vial was
added iodoethane (0.028 mL, 0.345 mmol). The reaction was heated in
a microwave (CEM Discover.RTM.) with external IR-sensor temperature
monitoring from the bottom of the vessel at 80.degree. C. for 6
hours. The reaction was concentrated and purified by flash
chromatography (0-100% EtOAc/Hexanes) to give the title compound as
a yellow oil (56 mg, 57%): IR (thin film) 3050, 2931, 1583
cm.sup.-1; H NMR (300 MHz, CDCl.sub.3) .delta. 9.05 (d, J=2.6 Hz,
1H), 8.91 (s, 1H), 8.59-8.48 (m, 1H), 8.13-8.04 (m, 1H), 7.40 (dd,
J=8.4, 4.8 Hz, 1H), 3.81 (q, J=7.2 Hz, 2H), 3.73 (s, 3H), 2.95 (q,
J=14.1, 7.0 Hz, 2H), 1.44-1.28 (m, 6H); ESIMS m/z 325
([M+H].sup.+).
Example 178
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-(N-methyl-N-(3,3,-
3-trifluoropropyl)sulfamoyl)propanamide (Compound 965)
##STR00252##
[0737] To a stirred solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercaptopropanami-
de (200 mg, 0.64 mmol), tetrabutylammonium chloride (715 mg, 2.57
mmol) and water (29 mg, 1.61 mmol) in acetonitrile (30 mL) at
0.degree. C. was added 1-chloropyrrolidine-2,5-dione (258 mg, 1.93
mmol) in portions over 3 min. After stirring for 1 hour,
3,3,3-trifluoro-N-methylpropan-1-amine (82 mg, 0.64 mmol) was added
and the reaction was stirred for additional 14 hours at room
temperature. The mixture was filtered and concentrated in vacuo to
give a brown residue. Purification of this residue on silica gel
eluting with CH.sub.2Cl.sub.2 and methanol afforded the title
compound as an off-white gum (71 mg, 22%).
Example 179
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((1-chloro-2,2,2-trifluor-
oethyl)thio)-N-ethylpropanamide (Compound 859)
##STR00253##
[0739] To a suspension of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercaptopropanami-
de (0.100 g, 0.322 mmol), sodium dithionite (0.070 g, 0.338 mmol)
and sodium bicarbonate (0.028 g, 0.338 mmol) in DMSO (3.22 mL) at
40.degree. C. was added 2-bromo-2-chloro-1,1,1-trifluoroethane
(0.079 g, 0.402 mmol) dropwise. The reaction was stirred at the
same temperature for 3 h after which the reaction was cooled,
poured into water (10 mL) and extracted with EtOAc (3.times.20 mL).
The combined organic extracts were washed with water (2.times.50
mL) and half-saturated brine (3.times.50 mL) and then dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude
residue was purified via normal phase flash chromatography (0 to
100% EtOAc/CH.sub.2Cl.sub.2) to afford the desired product as a
clear, viscous oil (111 mg, 77%). (Reference: Pustovit, et al.,
Synthesis, 2010, 7, 1159-1165).
Example 180
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3-(mesitylamino-
)-3-oxopropyl)thio)propanamide (Compound 1024)
##STR00254##
[0741] To a stirred solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-mercaptopropanami-
de (0.20 g, 0.64 mmol) in acetonitrile (2.1 mL) was added
3-bromo-N-mesitylpropanamide (0.17 g, 0.64 mmol) and cesium
carbonate (0.23 g, 0.70 mmol) and the reaction was stirred
overnight at room temperature. The reaction was loaded directly
onto celite and placed in a vacuum oven overnight at 25.degree. C.
The crude product was purified by silica gel chromatography eluting
with 0-75% ethyl acetate/hexanes to give the desired product as a
white semi-solid (226 mg, 53%).
Example 181
Preparation of two enantiomers of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoro-
propyl)sulfinyl)propanamide (Compounds 1028
##STR00255##
[0743] The two enantiomers of the title molecule were separated by
chiral HPLC using a RegisCell.TM. semi-preparative column (25
cm.times.10.0 mm, 5 micron) using 0.1% TFA in hexane and
isopropanol as the mobile phase (15 to 30% gradient IPA/hexane in
15 minutes, then hold to 20 minutes) with a flow rate of 15 mL/min
at ambient temperature. Under these conditions compound 1028 was
collected at a retention time of 6.0 min and possessed an optical
rotation of [.alpha.].sub.D.sup.30=+25.9 (c 0.27% in CDCl.sub.3).
Compound 1029 was collected at a retention time of 7.5 min and
possessed an optical rotation of [.alpha.].sub.D.sup.30=-27.4 (c
0.27% in CDCl.sub.3). Characterization data for these molecules are
listed in Table 2.
Example 182
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-4,4,4-trifluoro-N-methyl-3--
(methylsulfonyl)butanamide (Compound 714)
##STR00256##
[0745] To a 20 mL vial was added
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-4,4,4-trifluoro-N-methyl-3--
(methylsulfinyl)butanamide (130 mg, 0.329 mmol) and DCM (3 mL).
m-CPBA (83 mg, 0.362 mmol) was added and the solution was stirred
at room temperature for 3 hours. The reaction was quenched by the
addition of sodium sulfite solution, extracted with DCM and
concentrated. Purification with silica gel chromatography (0-100%
EtOAc/hexane) afforded
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-4,4,4-trifluoro-N--
methyl-3-(methylsulfonyl)butanamide as a white solid (25 mg,
18%).
Example 183
Preparation of enantiomers of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-methyl-3-(methyls-
ulfinyl)propanamide (Compounds 804-807)
##STR00257##
[0747] The four stereoisomers of the title compound were separated
by chiral HPLC using Chiralpak IC column (30.times.250 mm) using
0.2% TFA and 0.2% isopropylamine in hexane and isopropanol as the
mobile phase (25% IPA in hexane) at ambient temperature. Under
these conditions compound 804 was collected at a retention time of
8.4 minutes and possessed an optical rotation of
[.alpha.].sub.D.sup.30=-43.8 (c 0.5% in CDCl.sub.3). Compound 805
was collected at a retention time of 11.9 minutes and possessed an
optical rotation of [.alpha.].sub.D.sup.30=+48.2 (c 0.5% in
CDCl.sub.3). Compound 806 was collected at a retention time of 16.4
minutes and possessed an optical rotation of
[.alpha.].sub.D.sup.30=+113.4 (c 0.5% in CDCl.sub.3). Compound 807
was collected at a retention time of 20.6 minutes and possessed an
optical rotation of [.alpha.].sub.D.sup.30=-93.0 (c 0.5% in
CDCl.sub.3). Characterization data for these molecules are listed
in Table 2.
Example 184
Preparation of 3-((3,3,3-trifluoropropyl)thio)propanoyl
chloride
##STR00258##
[0749] A dry 5 L round bottom flask equipped with magnetic stirrer,
nitrogen inlet, reflux condenser, and thermometer, was charged with
3-((3,3,3-trifluoropropyl)thio)propanoic acid (188 g, 883 mmol) in
dichloromethane (3 L). Thionyl chloride (525 g, 321 mL, 4.42 mol)
was then added dropwise over 50 minutes. The reaction mixture was
heated to reflux (36.degree. C.) for two hours, then cooled to
ambient temperature. Concentration under vacuum on a rotary
evaporator, followed by distillation (40 Torr, product collected
from 123-127.degree. C.) gave the title compound as a clear
colorless liquid (177.3 g, 86%): .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 3.20 (t, J=7.1 Hz, 2H), 2.86 (t, J=7.1 Hz, 2H), 2.78-2.67
(m, 2H), 2.48-2.31 (m, 2H); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta.-66.42, -66.43, -66.44, -66.44.
Example 185
Preparation of
3-chloro-1-(5-chloropyridin-3-yl)-1H-pyrazol-4-amine
##STR00259##
[0751] To a solution of tert-butyl(3-chloro-1H-pyrazol-4-yl)
carbamate (5 g, 22.97 mmol) in a mixture of DMF-H.sub.2O (9:1) (40
mL) was added copper iodide (0.13 g, 0.69 mmol, 0.03 eq), cesium
carbonate (14.97 g, 45.9 mmol), 8-hydroxy quinoline (0.33 g, 2.30
mmol) and 3-bromo-5-chloropyridine (5.29 g, 27.5 mmol). The mixture
was heated at 140.degree. C. under nitrogen for 11 hours. The
reaction mixture was cooled to room temperature, quenched with
ammonium hydroxide (15 mL), filtered through celite and the
filtrate was extracted with ethyl acetate (3.times.50 mL). The
combined organic layer was washed with brine (1.times.50 mL) dried
over anhydrous Na.sub.2SO.sub.4, filtered, and evaporated to
dryness under reduced pressure. The crude product was purified on
silica gel using 0-100% ethyl acetate in hexane as eluent to give
the title compound as dark brown amorphous solid (1.35 g, 26%):
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.93 (d, J=2.24 Hz,
1H), 8.48 (d, J=2.00 Hz, 1H), 8.25 (t, J=2.16 Hz, 1H), 7.96 (s,
1H), 4.52 (bs, 2H); ESIMS m/z 231 ([M+2H].sup.+).
[0752] The following molecules were made in accordance with the
procedures disclosed in Example 185:
[0753] 1-(5-Bromopyridin-3-yl)-3-chloro-1H-pyrazol-4-amine: ESIMS
m/z 274 ([M+H].sup.+).
[0754] 3-Chloro-1-(5-methoxypyridin-3-yl)-1H-pyrazol-4-amine: ESIMS
m/z 225 ([M+H].sup.+).
[0755] 3-Chloro-1-(5-methylpyridin-3-yl)-1H-pyrazol-4-amine:
.sup.1H NMR (400 MHz, DMSO-d.sub.6, D.sub.2O): .delta. 8.68 (s,
1H), 8.27 (s, 1H), 7.86 (d, J=5.64 Hz, 2H), 2.34 (s, 3H); ESIMS m/z
209 ([M+H].sup.+).
Example 186
Preparation of
tert-butyl(3-chloro-1-(5-chloropyridin-3-yl)-1H-pyrazol-4-yl)carbamate
##STR00260##
[0757] To a solution of amine
3-chloro-1-(5-chloropyridin-3-yl)-1H-pyrazol-4-amine (1.00 g, 4.4
mmol) and triethylamine (666 mg, 6.6 mmol) in dry THF (10 mL) was
added di-tert-butyl dicarbonate anhydride (960 mg, 4.62 mmol) over
30 minutes and the reaction was allowed to stir at room temperature
for 18 hours. The reaction was diluted with water (10 mL) and
extracted with ethyl acetate (50 mL.times.2). The organic phase was
washed with brine (10 mL), dried over Na.sub.2SO.sub.4, and
concentrated under reduced pressure. Purification by silica gel
column chromatography using hexanes as an eluent afforded the
titled compound (651 mg, 46%): ESIMS m/z 330 ([M+H].sup.+).
[0758] The following molecules were made in accordance with the
procedures disclosed in Example 186:
[0759]
tert-Butyl(1-(5-bromopyridin-3-yl)-3-chloro-1H-pyrazol-4-yl)carbama-
te: ESIMS m/z 372 ([M+H].sup.+).
[0760]
tert-Butyl(3-chloro-1-(5-methylpyridin-3-yl)-1H-pyrazol-4-yl)carbam-
ate: ESIMS m/z 309 ([M+H].sup.+).
Example 187
Preparation of
tert-butyl(3-chloro-1-(5-chloropyridin-3-yl)-1H-pyrazol-4-yl)(methyl)carb-
amate
##STR00261##
[0762] To a solution of
tert-butyl(3-chloro-1-(5-chloropyridin-3-yl)-1H-pyrazol-4-yl)carbamate
(501 mg, 1.5 mmol) in dry THF (10 mL) was added potassium
tert-butoxide (1.5 mL, 1 M solution in THF) and the reaction was
stirred for 30 min. Methyl iodide (317 mg, 2.25 mmol) was added
slowly at 0.degree. C. and stirred for an additional 18 hours at
room temperature. The mixture was quenched with saturated aqueous
ammonium chloride and extracted with ethyl acetate (2.times.20 mL).
The combined organic extract was washed with brine solution
(1.times.20 mL), dried over Na.sub.2SO.sub.4 and evaporated to
dryness under reduced pressure. The crude product was purified on
silica gel using hexanes and ethyl acetate as eluent (0-10%) to
give the title compound (220 mg, 42%): ESIMS m/z 345
([M+H].sup.+).
[0763] The following molecules were made in accordance with the
procedures disclosed in Example 187:
[0764]
tert-Butyl(1-(5-bromopyridin-3-yl)-3-chloro-1H-pyrazol-4-yl)(methyl-
)carbamate: ESIMS m/z 387 ([M+H].sup.+).
[0765]
tert-Butyl(3-chloro-1-(5-methylpyridin-3-yl)-1H-pyrazol-4-yl)(methy-
l)carbamate: ESIMS m/z 265 ([M-t-Bu].sup.+).
Example 188
Preparation of
3-chloro-1-(5-chloropyridin-3-yl)-N-methyl-1H-pyrazol-4-amine
##STR00262##
[0767]
tert-Butyl(3-chloro-1-(5-chloropyridin-3-yl)-1H-pyrazol-4-yl)(methy-
l)carbamate (343 mg, 1 mmol, 1.0 eq) was dissolved in 1,4-dioxane
(10 mL) and the solution was cooled to 0.degree. C. A solution of
HCl in dioxane (5 mL, 4 M) was added dropwise, and the mixture was
stirred for 2 hours, then concentrated under reduced pressure. The
residue was diluted with CH.sub.2Cl.sub.2 (50 mL), and the solution
washed with aqueous sodium bicarbonate, water (10 mL) and brine (10
mL). The organic layer was dried over Na.sub.2SO.sub.4, and
concentrated under reduced pressure to give the title compound (148
mg, 61%): ESMS m/z 244 ([M+H].sup.+).
[0768] The following molecule was made in accordance with the
procedures disclosed in Example 188:
[0769]
1-(5-Bromopyridin-3-yl)-3-chloro-N-methyl-1H-pyrazol-4-amine: ESIMS
m/z 289 ([M+H].sup.+).
Example 189
Preparation of
N-(3-chloro-1-(5-methoxypyridin-3-yl)-1H-pyrazol-4-yl)-2,2,2-trifluoroace-
tamide
##STR00263##
[0771] To a solution of
3-chloro-1-(5-methoxypyridin-3-yl)-1H-pyrazol-4-amine (1.0 g, 4.46
mmol) and pyridine (530 mg, 6.69 mmol) in dry dichloromethane (10
mL) was added trifluoroacetic anhydride (1.0 eq) dropwise at
0.degree. C. The reaction mixture was slowly warmed to room
temperature and stirred for 4 hours. The reaction mixture was
diluted with water (10 mL) and extracted with ethyl acetate
(2.times.50 mL). The organic phase was washed with brine (10 mL),
dried over Na.sub.2SO.sub.4 and concentrated under reduced
pressure. The crude product was purified over silica eluting with
hexanes and ethyl acetate to afford the title compound (700 mg,
49%): ESIMS m/z 321 ([M+H].sup.+).
Example 190
Preparation of
N-(3-chloro-1-(5-methoxypyridin-3-yl)-1H-pyrazol-4-yl)-2,2,2-trifluoro-N--
methylacetamide
##STR00264##
[0773] To a solution of
N-(3-chloro-1-(5-methoxypyridin-3-yl)-1H-pyrazol-4-yl)-2,2,2-trifluoroace-
tamide (700 mg, 2.18 mmol) in dry THF (10 mL) was added potassium
tert-butoxide (1 M solution in THF, 0.32 mL, 3.2 mmol) at 0.degree.
C. and the reaction was stirred for 30 min. Methyl iodide (466 mg,
3.28 mmol) was added slowly at 0.degree. C. and the reaction was
stirred for an additional 18 hours at room temperature. The
reaction was quenched with saturated ammonium chloride solution and
extracted with ethyl acetate (2.times.20 mL). The combined organic
extract was washed with brine (1.times.20 mL), dried over
Na.sub.2SO.sub.4 and evaporated to dryness under reduced pressure.
The crude product was purified on silica eluting with hexanes and
ethyl acetate (0-30%) to give the title compound (426 mg, 58%
yield): ESIMS m/z 335 ([M+H].sup.+).
Example 191
Preparation of
3-chloro-1-(5-methoxypyridin-3-yl)-N-methyl-1H-pyrazol-4-amine
##STR00265##
[0775] To a suspension of
N-(3-chloro-1-(5-methoxypyridin-3-yl)-1H-pyrazol-4-yl)-2,2,2-trifluoro-N--
methylacetamide (410 mg, 1.23 mmol) in methanol (10 mL) was added
K.sub.2CO.sub.3 (254 mg, 1.8 mmol) and the mixture stirred at room
temperature for 4 hours. The reaction was concentrated under
reduced pressure and the residue suspended in dichloromethane (50
mL), and washed with water (10 mL) and brine (10 mL). The organic
layer was dried over Na.sub.2SO.sub.4, and concentrated under
reduced pressure to give the title compound (206 mg, 71%): ESIMS
m/z 239 ([M+H].sup.+).
Example 192
Preparation of
diethyl(2-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-2-oxo-
ethyl)phosphonate
##STR00266##
[0777] To a solution of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (2.00 g, 8.98
mmol), 2-(diethoxyphosphoryl)acetic acid (1.94 mg, 9.88 mmol) and
N,N-dimethylpyridin-4-amine (2.20 g, 17.96 mmol) in dry DMF (10 mL)
was added
N'-((ethylimino)methylene)-N.sup.3,N.sup.3-dimethylpropane-1,3-diam-
ine hydrochloride (2.58 g, 13.47 mmol), and the mixture was stirred
at 0.degree. C. for 2 hours. The mixture was diluted with water and
extracted with ethyl acetate (75 mL.times.2). The combined organic
extract was washed with saturated aqueous NH.sub.4Cl, sat aqueous
NaHCO.sub.3 and brine, dried over MgSO.sub.4, filtered and
concentrated in vacuo to give a brown residue. This residue was
purified on silica gel eluting with CH.sub.2Cl.sub.2 and methanol
to give the title compound as a brown solid (2.62 g, 69%): mp
46-48.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.00
(dd, J=2.7, 0.7 Hz, 1H), 8.62 (dd, J=4.7, 1.4 Hz, 1H), 8.35 (s,
1H), 8.03 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.44 (ddd, J=8.3, 4.8, 0.8
Hz, 1H), 4.28-4.02 (m, 4H), 3.79 (m, 2H), 2.89 (d, J=22.0 Hz, 2H),
1.40-1.22 (m, 6H), 1.17 (t, J=7.2 Hz, 3H); ESIMS m/z 401
[(M+H).sup.+]399 [(M-H).sup.-].
Example 193
Preparation of
(E)-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-5,5,5-trifluoro-
pent-2-enamide (Compound Y2177)
##STR00267##
[0779] To a solution of
diethyl(2-((3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)(ethyl)amino)-2-oxo-
ethyl)phosphonate (500 mg, 1.25 mmol) in THF (4 mL) was added
sodium hydride (55 mg, 1.37 mmol, 60% wt. oil suspension) and the
mixture stirred at 0.degree. C. for 20 min. The mixture was cooled
to -78.degree. C. and 3,3,3-trifluoropropanal (210 mg, 1.87 mmol)
was added and the reaction was stirred for 1 hour. The mixture was
then warmed to room temperature and stirred at room temperature for
2 hours. Additional NaH (30 mg, 0.75 mmol, 60% wt. oil suspension)
was added and the mixture stirred at room temperature for 0.5 h.
The mixture was diluted with water and ethyl acetate and the
organic phase separated, washed with brine, dried over MgSO.sub.4
and concentrated in vacuo to give a brown oily residue. This
residue was purified on silica gel eluting with CH.sub.2Cl.sub.2
and methanol to give the title compound as a light yellow gum (230
mg, 51%).
Example 194
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-((3,3-difluoroallyl)thio)-
-N-ethylpropanamide (Compound 918)
##STR00268##
[0781] To a solution of
3-((3-bromo-3,3-difluoropropyl)thio)-N-(3-chloro-1-(pyridin-3-yl)-1H-pyra-
zol-4-yl)-N-ethylpropanamide (100 mg, 0.21 mmol) in dioxane (1 mL)
was added 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (32 mg,
0.21 mmol) and the mixture stirred at 120.degree. C. for 30 min in
a Biotage.RTM. Initiator microwave reactor with external IR-sensor
temperature monitoring from the side of the vessel. The mixture was
diluted with ethyl acetate and then washed with saturated aqueous
ammonium chloride and brine, dried over MgSO.sub.4 and concentrated
in vacuo to give a brown gum. This gum was purified on silica gel
eluting with methylene chloride and methanol to give the title
compound as a light yellow oil (76 mg, 92%).
Example 195
Preparation of
1-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-3-ethyl-1,3-dimethylurea
(Compound Y2012)
##STR00269##
[0783] To a solution of
3-chloro-N-methyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine (0.100 g,
0.48 mmol) in CH.sub.2Cl.sub.2 (1.9 ml) was added
N-ethyl-N-isopropylpropan-2-amine (0.21 ml, 1.20 mmol) followed by
ethyl(methyl)carbamic chloride (0.117 g, 0.959 mmol) and the
reaction mixture was stirred at ambient temperature for 2 hours.
The reaction was quenched by the addition of saturated sodium
bicarbonate. The aqueous layer was extracted with CH.sub.2Cl.sub.2.
The combined organic layers were dried over sodium sulfate,
filtered, concentrated in vacuo and purified via silica gel column
chromatography (0-100% ethyl acetate/hexanes) to afford the title
compound as a yellow oil (57 mg, 36%).
Example 196
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-(2,2,2-trifluoroe-
thoxy)propanamide (Compound Y2001)
##STR00270##
[0785] To a solution of 2,2,2-trifluoroethanol (128 mg, 1.3 mmol)
in DMF (1.3 mL) was added sodium hydride (51.1 mg, 1.3 mmol). The
reaction mixture was stirred for 30 min until the mixture became
clear and no H.sub.2 evolution was observed. To this solution was
added
2-chloro-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethylpropanamide
(200 mg, 0.64 mmol) and the reaction mixture was stirred at
50.degree. C. overnight. The reaction mixture was diluted with
CH.sub.2Cl.sub.2 and washed with water, the phases were separated
with a Biotage.RTM. Phase separator and then concentrated. The
residue was purified by silica gel chromatography eluting with
0-50% acetone in hexanes to afford the titled compound as a white
solid (156 mg, 64%).
Example 197
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-((methylthio)meth-
oxy)propanamide (Compound Y2199)
##STR00271##
[0787] To a solution of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-2-hydroxypropanamid-
e (100 mg, 0.34 mmol) in THF (1.1 mL) was added sodium hydride (60%
in mineral oil, 33.9 mg, 0.85 mmol). The mixture was stirred for 15
min and then (chloromethyl)(methyl)sulfane (33.6 .mu.L, 0.41 mmol)
was added. After stirring at ambient temp overnight the reaction
mixture was diluted with CH.sub.2Cl.sub.2 and washed with water.
The phases were separated and dried with a Biotage.RTM. Phases
Separator.COPYRGT. and concentrated in vacuo. The residue was
purified by silica chromatography eluting with 0-70% acetone in
hexanes to afford the titled compound as an off white solid (73 mg,
63%).
Example 198
Preparation of
N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2,2-difluoro-N-methyl-2-(me-
thylthio)acetamide (Compound Y2021)
##STR00272##
[0789] To a solution of
2-bromo-N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2,2-difluoro-N-meth-
ylacetamide (250 mg, 0.684 mmol) in DMSO (2.3 mL) was added
methanethiol, sodium salt (96 mg, 1.37 mmol). The reaction mixture
was heated to 50.degree. C. for 3 h and then diluted with water and
extracted with CH.sub.2Cl.sub.2. The organic phases were dried with
MgSO.sub.4, filtered and concentrated in vacuo. The residue was
purified by silica gel chromatography eluting with 0-80% acetone in
hexanes to afford the titled compound as a red oil (188 mg,
83%).
Example 199
Preparation of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine
[0790] To a 100 mL round bottom flask charged with
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine-bis HCl salt
(2 g, 6.77 mmol) was added DCM (20 mL) and the suspension was
stirred at room temperature. To this suspension was added saturated
NaHCO.sub.3 solution slowly until the bubbling stopped and the
aqueous layer became basic. The mixture was loaded into a
separatory funnel, the organic layer was separated and the aqueous
layer was extracted with DCM (2.times.10 mL). The combined DCM
layers were dried and concentrated to give the title compound as an
off-white solid (1.41 g, 94%). Analytical data of
3-chloro-N-ethyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine can be found
in Example 8.
Example A
Bioassays on Green Peach APHID ("GPA") (Myzus persicae)
(MYZUPE)
[0791] GPA is the most significant aphid pest of peach trees,
causing decreased growth, shriveling of the leaves, and the death
of various tissues. It is also hazardous because it acts as a
vector for the transport of plant viruses, such as potato virus Y
and potato leafroll virus to members of the nightshade/potato
family Solanaceae, and various mosaic viruses to many other food
crops. GPA attacks such plants as broccoli, burdock, cabbage,
carrot, cauliflower, daikon, eggplant, green beans, lettuce,
macadamia, papaya, peppers, sweet potatoes, tomatoes, watercress,
and zucchini, among other plants. GPA also attacks many ornamental
crops such as carnation, chrysanthemum, flowering white cabbage,
poinsettia, and roses. GPA has developed resistance to many
pesticides.
[0792] Certain molecules disclosed in this document were tested
against GPA using procedures described in the following example. In
the reporting of the results, "Table 3: GPA (MYZUPE) and
sweetpotato whitefly-crawler (BEMITA) Rating Table" was used (See
Table Section).
[0793] Cabbage seedlings grown in 3-inch pots, with 2-3 small (3-5
cm) true leaves, were used as test substrate. The seedlings were
infested with 20-50 GPA (wingless adult and nymph stages) one day
prior to chemical application. Four pots with individual seedlings
were used for each treatment. Test compounds (2 mg) were dissolved
in 2 mL of acetone/methanol (1:1) solvent, forming stock solutions
of 1000 ppm test compound. The stock solutions were diluted
5.times. with 0.025% Tween 20 in H.sub.2O to obtain the solution at
200 ppm test compound. A hand-held aspirator-type sprayer was used
for spraying a solution to both sides of cabbage leaves until
runoff. Reference plants (solvent check) were sprayed with the
diluent only containing 20% by volume of acetone/methanol (1:1)
solvent. Treated plants were held in a holding room for three days
at approximately 25.degree. C. and ambient relative humidity (RH)
prior to grading. Evaluation was conducted by counting the number
of live aphids per plant under a microscope. Percent Control was
measured by using Abbott's correction formula (W. S. Abbott, "A
Method of Computing the Effectiveness of an Insecticide" J. Econ.
Entomol. 18 (1925), pp. 265-267) as follows.
Corrected % Control=100*(X-Y)/X [0794] where [0795] X=No. of live
aphids on solvent check plants and [0796] Y=No. of live aphids on
treated plants
[0797] The results are indicated in the table entitled "Table 4.
Biological Data for GPA (MYZUPE) and sweetpotato whitefly-crawler
(BEMITA)" (See Table Section).
Example B
Insecticidal Test for Sweetpotato Whitefly-Crawler (Bemisia tabaci)
(BEMITA) in Foliar Spray Assay
[0798] Cotton plants grown in 3-inch pots, with 1 small (3-5 cm)
true leaf, were used as test substrate. The plants were placed in a
room with whitefly adults. Adults were allowed to deposit eggs for
2-3 days. After a 2-3 day egg-laying period, plants were taken from
the adult whitefly room. Adults were blown off leaves using a
hand-held Devilbiss sprayer (23 psi). Plants with egg infestation
(100-300 eggs per plant) were placed in a holding room for 5-6 days
at 82.degree. F. and 50% RH for egg hatch and crawler stage to
develop. Four cotton plants were used for each treatment. Compounds
(2 mg) were dissolved in 1 mL of acetone solvent, forming stock
solutions of 2000 ppm. The stock solutions were diluted 10.times.
with 0.025% Tween 20 in H.sub.2O to obtain a test solution at 200
ppm. A hand-held Devilbiss sprayer was used for spraying a solution
to both sides of cotton leaf until runoff. Reference plants
(solvent check) were sprayed with the diluent only. Treated plants
were held in a holding room for 8-9 days at approximately
82.degree. F. and 50% RH prior to grading. Evaluation was conducted
by counting the number of live nymphs per plant under a microscope.
Insecticidal activity was measured by using Abbott's correction
formula and presented in "Table 4. Biological Data for GPA (MYZUPE)
and sweetpotato whitefly-crawler (BEMITA)" (see column
"BEMITA"):
Corrected % Control=100*(X-Y)/X
[0799] where X=No. of live nymphs on solvent check plants [0800]
Y=No. of live nymphs on treated plants
Pesticidally Acceptable Acid Addition Salts, Salt Derivatives,
Solvates, Ester Derivatives, Polymorphs, Isotopes and
Radionuclides
[0801] Molecules of Formula One may be formulated into pesticidally
acceptable acid addition salts. By way of a non-limiting example,
an amine function can form salts with hydrochloric, hydrobromic,
sulfuric, phosphoric, acetic, benzoic, citric, malonic, salicylic,
malic, fumaric, oxalic, succinic, tartaric, lactic, gluconic,
ascorbic, maleic, aspartic, benzenesulfonic, methanesulfonic,
ethanesulfonic, hydroxymethanesulfonic, and hydroxyethanesulfonic
acids. Additionally, by way of a non-limiting example, an acid
function can form salts including those derived from alkali or
alkaline earth metals and those derived from ammonia and amines.
Examples of preferred cations include sodium, potassium, and
magnesium.
[0802] Molecules of Formula One may be formulated into salt
derivatives. By way of a non-limiting example, a salt derivative
can be prepared by contacting a free base with a sufficient amount
of the desired acid to produce a salt. A free base may be
regenerated by treating the salt with a suitable dilute aqueous
base solution such as dilute aqueous sodium hydroxide (NaOH),
potassium carbonate, ammonia, and sodium bicarbonate. As an
example, in many cases, a pesticide, such as 2,4-D, is made more
water-soluble by converting it to its dimethylamine salt.
[0803] Molecules of Formula One may be formulated into stable
complexes with a solvent, such that the complex remains intact
after the non-complexed solvent is removed. These complexes are
often referred to as "solvates." However, it is particularly
desirable to form stable hydrates with water as the solvent.
[0804] Molecules of Formula One may be made into ester derivatives.
These ester derivatives can then be applied in the same manner as
the invention disclosed in this document is applied.
[0805] Molecules of Formula One may be made as various crystal
polymorphs. Polymorphism is important in the development of
agrochemicals since different crystal polymorphs or structures of
the same molecule can have vastly different physical properties and
biological performances.
[0806] Molecules of Formula One may be made with different
isotopes. Of particular importance are molecules having .sup.2H
(also known as deuterium) in place of .sup.1H.
[0807] Molecules of Formula One may be made with different
radionuclides. Of particular importance are molecules having
.sup.13C or .sup.14C.
Stereoisomers
[0808] Molecules of Formula One may exist as one or more
stereoisomers. Thus, certain molecules can be produced as racemic
mixtures. It will be appreciated by those skilled in the art that
one stereoisomer may be more active than the other stereoisomers.
Individual stereoisomers may be obtained by known selective
synthetic procedures, by conventional synthetic procedures using
resolved starting materials, or by conventional resolution
procedures. Certain molecules disclosed in this document can exist
as two or more isomers. The various isomers include geometric
isomers, diastereomers, and enantiomers. Thus, the molecules
disclosed in this document include geometric isomers, racemic
mixtures, individual stereoisomers, and optically active mixtures.
It will be appreciated by those skilled in the art that one isomer
may be more active than the others. The structures disclosed in the
present disclosure are drawn in only one geometric form for
clarity, but are intended to represent all geometric forms of the
molecule.
Combinations
[0809] Molecules of Formula One may also be used in combination
(such as, in a compositional mixture, or a simultaneous or
sequential application) with one or more compounds having
acaricidal, algicidal, avicidal, bactericidal, fungicidal,
herbicidal, insecticidal, molluscicidal, nematicidal, rodenticidal,
or virucidal properties. Additionally, the molecules of Formula One
may also be used in combination (such as, in a compositional
mixture, or a simultaneous or sequential application) with
compounds that are antifeedants, bird repellents, chemosterilants,
herbicide safeners, insect attractants, insect repellents, mammal
repellents, mating disrupters, plant activators, plant growth
regulators, or synergists.
[0810] Examples of such compounds in the above groups that may be
used with the Molecules of Formula One are--(3-ethoxypropyl)mercury
bromide, 1,2-dichloropropane, 1,3-dichloropropene,
1-methylcyclopropene, 1-naphthol, 2-(octylthio)ethanol,
2,3,5-tri-iodobenzoic acid, 2,3,6-TBA, 2,3,6-TBA-dimethylammonium,
2,3,6-TBA-lithium, 2,3,6-TBA-potassium, 2,3,6-TBA-sodium, 2,4,5-T,
2,4,5-T-2-butoxypropyl, 2,4,5-T-2-ethylhexyl,
2,4,5-T-3-butoxypropyl, 2,4,5-TB, 2,4,5-T-butometyl,
2,4,5-T-butotyl, 2,4,5-T-butyl, 2,4,5-T-isobutyl, 2,4,5-T-isoctyl,
2,4,5-T-isopropyl, 2,4,5-T-methyl, 2,4,5-T-pentyl, 2,4,5-T-sodium,
2,4,5-T-triethylammonium, 2,4,5-T-trolamine, 2,4-D,
2,4-D-2-butoxypropyl, 2,4-D-2-ethylhexyl, 2,4-D-3-butoxypropyl,
2,4-D-ammonium, 2,4-DB, 2,4-DB-butyl, 2,4-DB-dimethylammonium,
2,4-DB-isoctyl, 2,4-DB-potassium, 2,4-DB-sodium, 2,4-D-butotyl,
2,4-D-butyl, 2,4-D-diethylammonium, 2,4-D-dimethylammonium,
2,4-D-diolamine, 2,4-D-dodecylammonium, 2,4-DEB, 2,4-DEP,
2,4-D-ethyl, 2,4-D-heptylammonium, 2,4-D-isobutyl, 2,4-D-isoctyl,
2,4-D-isopropyl, 2,4-D-isopropylammonium, 2,4-D-lithium,
2,4-D-meptyl, 2,4-D-methyl, 2,4-D-octyl, 2,4-D-pentyl,
2,4-D-potassium, 2,4-D-propyl, 2,4-D-sodium, 2,4-D-tefuryl,
2,4-D-tetradecylammonium, 2,4-D-triethylammonium,
2,4-D-tris(2-hydroxypropyl)ammonium, 2,4-D-trolamine, 2iP,
2-methoxyethylmercury chloride, 2-phenylphenol, 3,4-DA, 3,4-DB,
3,4-DP, 4-aminopyridine, 4-CPA, 4-CPA-potassium, 4-CPA-sodium,
4-CPB, 4-CPP, 4-hydroxyphenethyl alcohol, 8-hydroxyquinoline
sulfate, 8-phenylmercurioxyquinoline, abamectin, abscisic acid,
ACC, acephate, acequinocyl, acetamiprid, acethion, acetochlor,
acetophos, acetoprole, acibenzolar, acibenzolar-S-methyl,
acifluorfen, acifluorfen-methyl, acifluorfen-sodium, aclonifen,
acrep, acrinathrin, acrolein, acrylonitrile, acypetacs,
acypetacs-copper, acypetacs-zinc, alachlor, alanycarb, albendazole,
aldicarb, aldimorph, aldoxycarb, aldrin, allethrin, allicin,
allidochlor, allosamidin, alloxydim, alloxydim-sodium, allyl
alcohol, allyxycarb, alorac, alpha-cypermethrin, alpha-endosulfan,
ametoctradin, ametridione, ametryn, amibuzin, amicarbazone,
amicarthiazol, amidithion, amidoflumet, amidosulfuron, aminocarb,
aminocyclopyrachlor, aminocyclopyrachlor-methyl,
aminocyclopyrachlor-potassium, aminopyralid,
aminopyralid-potassium, aminopyralid-tris(2-hydroxypropyl)ammonium,
amiprofos-methyl, amiprophos, amisulbrom, amiton, amiton oxalate,
amitraz, amitrole, ammonium sulfamate, ammonium
.alpha.-naphthaleneacetate, amobam, ampropylfos, anabasine,
ancymidol, anilazine, anilofos, anisuron, anthraquinone, antu,
apholate, aramite, arsenous oxide, asomate, aspirin, asulam,
asulam-potassium, asulam-sodium, athidathion, atraton, atrazine,
aureofungin, aviglycine, aviglycine hydrochloride, azaconazole,
azadirachtin, azafenidin, azamethiphos, azimsulfuron,
azinphos-ethyl, azinphos-methyl, aziprotryne, azithiram,
azobenzene, azocyclotin, azothoate, azoxystrobin, bachmedesh,
barban, barium hexafluorosilicate, barium polysulfide, barthrin,
BCPC, beflubutamid, benalaxyl, benalaxyl-M, benazolin,
benazolin-dimethylammonium, benazolin-ethyl, benazolin-potassium,
bencarbazone, benclothiaz, bendiocarb, benfluralin, benfuracarb,
benfuresate, benodanil, benomyl, benoxacor, benoxafos, benquinox,
bensulfuron, bensulfuron-methyl, bensulide, bensultap, bentaluron,
bentazone, bentazone-sodium, benthiavalicarb,
benthiavalicarb-isopropyl, benthiazole, bentranil, benzadox,
benzadox-ammonium, benzalkonium chloride, benzamacril,
benzamacril-isobutyl, benzamorf, benzfendizone, benzipram,
benzobicyclon, benzofenap, benzofluor, benzohydroxamic acid,
benzoximate, benzoylprop, benzoylprop-ethyl, benzthiazuron, benzyl
benzoate, benzyladenine, berberine, berberine chloride,
beta-cyfluthrin, beta-cypermethrin, bethoxazin, bicyclopyrone,
bifenazate, bifenox, bifenthrin, bifujunzhi, bilanafos,
bilanafos-sodium, binapacryl, bingqingxiao, bioallethrin,
bioethanomethrin, biopermethrin, bioresmethrin, biphenyl, bisazir,
bismerthiazol, bispyribac, bispyribac-sodium, bistrifluron,
bitertanol, bithionol, bixafen, blasticidin-S, borax, Bordeaux
mixture, boric acid, boscalid, brassinolide, brassinolide-ethyl,
brevicomin, brodifacoum, brofenvalerate, brofluthrinate, bromacil,
bromacil-lithium, bromacil-sodium, bromadiolone, bromethalin,
bromethrin, bromfenvinfos, bromoacetamide, bromobonil, bromobutide,
bromocyclen, bromo-DDT, bromofenoxim, bromophos, bromophos-ethyl,
bromopropylate, bromothalonil, bromoxynil, bromoxynil butyrate,
bromoxynil heptanoate, bromoxynil octanoate, bromoxynil-potassium,
brompyrazon, bromuconazole, bronopol, bucarpolate, bufencarb,
buminafos, bupirimate, buprofezin, Burgundy mixture, busulfan,
butacarb, butachlor, butafenacil, butamifos, butathiofos,
butenachlor, butethrin, buthidazole, buthiobate, buthiuron,
butocarboxim, butonate, butopyronoxyl, butoxycarboxim, butralin,
butroxydim, buturon, butylamine, butylate, cacodylic acid,
cadusafos, cafenstrole, calcium arsenate, calcium chlorate, calcium
cyanamide, calcium polysulfide, calvinphos, cambendichlor,
camphechlor, camphor, captafol, captan, carbamorph, carbanolate,
carbaryl, carbasulam, carbendazim, carbendazim benzenesulfonate,
carbendazim sulfite, carbetamide, carbofuran, carbon disulfide,
carbon tetrachloride, carbophenothion, carbosulfan, carboxazole,
carboxide, carboxin, carfentrazone, carfentrazone-ethyl,
carpropamid, cartap, cartap hydrochloride, carvacrol, carvone,
CDEA, cellocidin, CEPC, ceralure, Cheshunt mixture, chinomethionat,
chitosan, chlobenthiazone, chlomethoxyfen, chloralose, chloramben,
chloramben-ammonium, chloramben-diolamine, chloramben-methyl,
chloramben-methylammonium, chloramben-sodium, chloramine
phosphorus, chloramphenicol, chloraniformethan, chloranil,
chloranocryl, chlorantraniliprole, chlorazifop,
chlorazifop-propargyl, chlorazine, chlorbenside, chlorbenzuron,
chlorbicyclen, chlorbromuron, chlorbufam, chlordane, chlordecone,
chlordimeform, chlordimeform hydrochloride, chlorempenthrin,
chlorethoxyfos, chloreturon, chlorfenac, chlorfenac-ammonium,
chlorfenac-sodium, chlorfenapyr, chlorfenazole, chlorfenethol,
chlorfenprop, chlorfenson, chlorfensulphide, chlorfenvinphos,
chlorfluazuron, chlorflurazole, chlorfluren, chlorfluren-methyl,
chlorflurenol, chlorflurenol-methyl, chloridazon, chlorimuron,
chlorimuron-ethyl, chlormephos, chlormequat, chlormequat chloride,
chlornidine, chlornitrofen, chlorobenzilate,
chlorodinitronaphthalenes, chloroform, chloromebuform,
chloromethiuron, chloroneb, chlorophacinone,
chlorophacinone-sodium, chloropicrin, chloropon, chloropropylate,
chlorothalonil, chlorotoluron, chloroxuron, chloroxynil,
chlorphonium, chlorphonium chloride, chlorphoxim, chlorprazophos,
chlorprocarb, chlorpropham, chlorpyrifos, chlorpyrifos-methyl,
chlorquinox, chlorsulfuron, chlorthal, chlorthal-dimethyl,
chlorthal-monomethyl, chlorthiamid, chlorthiophos, chlozolinate,
choline chloride, chromafenozide, cinerin I, cinerin II, cinerins,
cinidon-ethyl, cinmethylin, cinosulfuron, ciobutide, cisanilide,
cismethrin, clethodim, climbazole, cliodinate, clodinafop,
clodinafop-propargyl, cloethocarb, clofencet, clofencet-potassium,
clofentezine, clofibric acid, clofop, clofop-isobutyl, clomazone,
clomeprop, cloprop, cloproxydim, clopyralid, clopyralid-methyl,
clopyralid-olamine, clopyralid-potassium,
clopyralid-tris(2-hydroxypropyl)ammonium, cloquintocet,
cloquintocet-mexyl, cloransulam, cloransulam-methyl, closantel,
clothianidin, clotrimazole, cloxyfonac, cloxyfonac-sodium, CMA,
codlelure, colophonate, copper acetate, copper acetoarsenite,
copper arsenate, copper carbonate, basic, copper hydroxide, copper
naphthenate, copper oleate, copper oxychloride, copper silicate,
copper sulfate, copper zinc chromate, coumachlor, coumafuryl,
coumaphos, coumatetralyl, coumithoate, coumoxystrobin, CPMC, CPMF,
CPPC, credazine, cresol, crimidine, crotamiton, crotoxyphos,
crufomate, cryolite, cue-lure, cufraneb, cumyluron, cuprobam,
cuprous oxide, curcumenol, cyanamide, cyanatryn, cyanazine,
cyanofenphos, cyanophos, cyanthoate, cyantraniliprole, cyazofamid,
cybutryne, cyclafuramid, cyclanilide, cyclethrin, cycloate,
cycloheximide, cycloprate, cycloprothrin, cyclosulfamuron,
cycloxydim, cycluron, cyenopyrafen, cyflufenamid, cyflumetofen,
cyfluthrin, cyhalofop, cyhalofop-butyl, cyhalothrin, cyhexatin,
cymiazole, cymiazole hydrochloride, cymoxanil, cyometrinil,
cypendazole, cypermethrin, cyperquat, cyperquat chloride,
cyphenothrin, cyprazine, cyprazole, cyproconazole, cyprodinil,
cyprofuram, cypromid, cyprosulfamide, cyromazine, cythioate,
daimuron, dalapon, dalapon-calcium, dalapon-magnesium,
dalapon-sodium, daminozide, dayoutong, dazomet, dazomet-sodium,
DBCP, d-camphor, DCIP, DCPTA, DDT, debacarb, decafentin,
decarbofuran, dehydroacetic acid, delachlor, deltamethrin,
demephion, demephion-O, demephion-S, demeton, demeton-methyl,
demeton-O, demeton-O-methyl, demeton-S, demeton-S-methyl,
demeton-S-methylsulphon, desmedipham, desmetryn,
d-fanshiluquebingjuzhi, diafenthiuron, dialifos, di-allate,
diamidafos, diatomaceous earth, diazinon, dibutyl phthalate,
dibutyl succinate, dicamba, dicamba-diglycolamine,
dicamba-dimethylammonium, dicamba-diolamine,
dicamba-isopropylammonium, dicamba-methyl, dicamba-olamine,
dicamba-potassium, dicamba-sodium, dicamba-trolamine, dicapthon,
dichlobenil, dichlofenthion, dichlofluanid, dichlone,
dichloralurea, dichlorbenzuron, dichlorflurenol,
dichlorflurenol-methyl, dichlormate, dichlormid, dichlorophen,
dichlorprop, dichlorprop-2-ethylhexyl, dichlorprop-butotyl,
dichlorprop-dimethylammonium, dichlorprop-ethylammonium,
dichlorprop-isoctyl, dichlorprop-methyl, dichlorprop-P,
dichlorprop-P-2-ethylhexyl, dichlorprop-P-dimethylammonium,
dichlorprop-potassium, dichlorprop-sodium, dichlorvos,
dichlozoline, diclobutrazol, diclocymet, diclofop, diclofop-methyl,
diclomezine, diclomezine-sodium, dicloran, diclosulam, dicofol,
dicoumarol, dicresyl, dicrotophos, dicyclanil, dicyclonon,
dieldrin, dienochlor, diethamquat, diethamquat dichloride,
diethatyl, diethatyl-ethyl, diethofencarb, dietholate, diethyl
pyrocarbonate, diethyltoluamide, difenacoum, difenoconazole,
difenopenten, difenopenten-ethyl, difenoxuron, difenzoquat,
difenzoquat metilsulfate, difethialone, diflovidazin,
diflubenzuron, diflufenican, diflufenzopyr, diflufenzopyr-sodium,
diflumetorim, dikegulac, dikegulac-sodium, dilor, dimatif,
dimefluthrin, dimefox, dimefuron, dimepiperate, dimetachlone,
dimetan, dimethacarb, dimethachlor, dimethametryn, dimethenamid,
dimethenamid-P, dimethipin, dimethirimol, dimethoate, dimethomorph,
dimethrin, dimethyl carbate, dimethyl phthalate, dimethylvinphos,
dimetilan, dimexano, dimidazon, dimoxystrobin, dinex,
dinex-diclexine, dingjunezuo, diniconazole, diniconazole-M,
dinitramine, dinobuton, dinocap, dinocap-4, dinocap-6, dinocton,
dinofenate, dinopenton, dinoprop, dinosam, dinoseb, dinoseb
acetate, dinoseb-ammonium, dinoseb-diolamine, dinoseb-sodium,
dinoseb-trolamine, dinosulfon, dinotefuran, dinoterb, dinoterb
acetate, dinoterbon, diofenolan, dioxabenzofos, dioxacarb,
dioxathion, diphacinone, diphacinone-sodium, diphenamid, diphenyl
sulfone, diphenylamine, dipropalin, dipropetryn, dipyrithione,
diquat, diquat dibromide, disparlure, disul, disulfiram,
disulfoton, disul-sodium, ditalimfos, dithianon, dithicrofos,
dithioether, dithiopyr, diuron, d-limonene, DMPA, DNOC,
DNOC-ammonium, DNOC-potassium, DNOC-sodium, dodemorph, dodemorph
acetate, dodemorph benzoate, dodicin, dodicin hydrochloride,
dodicin-sodium, dodine, dofenapyn, dominicalure, doramectin,
drazoxolon, DSMA, dufulin, EBEP, EBP, ecdysterone, edifenphos,
eglinazine, eglinazine-ethyl, emamectin, emamectin benzoate, EMPC,
empenthrin, endosulfan, endothal, endothal-diammonium,
endothal-dipotassium, endothal-disodium, endothion, endrin,
enestroburin, EPN, epocholeone, epofenonane, epoxiconazole,
eprinomectin, epronaz, EPTC, erbon, ergocalciferol,
erlujixiancaoan, esdepallethrine, esfenvalerate, esprocarb,
etacelasil, etaconazole, etaphos, etem, ethaboxam, ethachlor,
ethalfluralin, ethametsulfuron, ethametsulfuron-methyl,
ethaprochlor, ethephon, ethidimuron, ethiofencarb, ethiolate,
ethion, ethiozin, ethiprole, ethirimol, ethoate-methyl,
ethofumesate, ethohexadiol, ethoprophos, ethoxyfen,
ethoxyfen-ethyl, ethoxyquin, ethoxysulfuron, ethychlozate, ethyl
formate, ethyl .alpha.-naphthaleneacetate, ethyl-DDD, ethylene,
ethylene dibromide, ethylene dichloride, ethylene oxide, ethylicin,
ethylmercury 2,3-dihydroxypropyl mercaptide, ethylmercury acetate,
ethylmercury bromide, ethylmercury chloride, ethylmercury
phosphate, etinofen, etnipromid, etobenzanid, etofenprox,
etoxazole, etridiazole, etrimfos, eugenol, EXD, famoxadone,
famphur, fenamidone, fenaminosulf, fenamiphos, fenapanil,
fenarimol, fenasulam, fenazaflor, fenazaquin, fenbuconazole,
fenbutatin oxide, fenchlorazole, fenchlorazole-ethyl, fenchlorphos,
fenclorim, fenethacarb, fenfluthrin, fenfuram, fenhexamid,
fenitropan, fenitrothion, fenjuntong, fenobucarb, fenoprop,
fenoprop-3-butoxypropyl, fenoprop-butometyl, fenoprop-butotyl,
fenoprop-butyl, fenoprop-isoctyl, fenoprop-methyl,
fenoprop-potassium, fenothiocarb, fenoxacrim, fenoxanil,
fenoxaprop, fenoxaprop-ethyl, fenoxaprop-P, fenoxaprop-P-ethyl,
fenoxasulfone, fenoxycarb, fenpiclonil, fenpirithrin,
fenpropathrin, fenpropidin, fenpropimorph, fenpyrazamine,
fenpyroximate, fenridazon, fenridazon-potassium, fenridazon-propyl,
fenson, fensulfothion, fenteracol, fenthiaprop, fenthiaprop-ethyl,
fenthion, fenthion-ethyl, fentin, fentin acetate, fentin chloride,
fentin hydroxide, fentrazamide, fentrifanil, fenuron, fenuron TCA,
fenvalerate, ferbam, ferimzone, ferrous sulfate, fipronil,
flamprop, flamprop-isopropyl, flamprop-M, flamprop-methyl,
flamprop-M-isopropyl, flamprop-M-methyl, flazasulfuron,
flocoumafen, flometoquin, flonicamid, florasulam, fluacrypyrim,
fluazifop, fluazifop-butyl, fluazifop-methyl, fluazifop-P,
fluazifop-P-butyl, fluazinam, fluazolate, fluazuron, flubendiamide,
flubenzimine, flucarbazone, flucarbazone-sodium, flucetosulfuron,
fluchloralin, flucofuron, flucycloxuron, flucythrinate,
fludioxonil, fluenetil, fluensulfone, flufenacet, flufenerim,
flufenican, flufenoxuron, flufenprox, flufenpyr, flufenpyr-ethyl,
flufiprole, flumethrin, flumetover, flumetralin, flumetsulam,
flumezin, flumiclorac, flumiclorac-pentyl, flumioxazin,
flumipropyn, flumorph, fluometuron, fluopicolide, fluopyram,
fluorbenside, fluoridamid, fluoroacetamide, fluorodifen,
fluoroglycofen, fluoroglycofen-ethyl, fluoroimide, fluoromidine,
fluoronitrofen, fluothiuron, fluotrimazole, fluoxastrobin,
flupoxam, flupropacil, flupropadine, flupropanate,
flupropanate-sodium, flupyradifurone, flupyrsulfuron,
flupyrsulfuron-methyl, flupyrsulfuron-methyl-sodium,
fluquinconazole, flurazole, flurenol, flurenol-butyl,
flurenol-methyl, fluridone, flurochloridone, fluroxypyr,
fluroxypyr-butometyl, fluroxypyr-meptyl, flurprimidol, flursulamid,
flurtamone, flusilazole, flusulfamide, fluthiacet,
fluthiacet-methyl, flutianil, flutolanil, flutriafol, fluvalinate,
fluxapyroxad, fluxofenim, folpet, fomesafen, fomesafen-sodium,
fonofos, foramsulfuron, forchlorfenuron, formaldehyde, formetanate,
formetanate hydrochloride, formothion, formparanate, formparanate
hydrochloride, fosamine, fosamine-ammonium, fosetyl,
fosetyl-aluminium, fosmethilan, fospirate, fosthiazate, fosthietan,
frontalin, fuberidazole, fucaojing, fucaomi, funaihecaoling,
fuphenthiourea, furalane, furalaxyl, furamethrin, furametpyr,
furathiocarb, furcarbanil, furconazole, furconazole-cis, furethrin,
furfural, furilazole, furmecyclox, furophanate, furyloxyfen,
gamma-cyhalothrin, gamma-HCH, genit, gibberellic acid,
gibberellins, gliftor, glufosinate, glufosinate-ammonium,
glufosinate-P, glufosinate-P-ammonium, glufosinate-P-sodium,
glyodin, glyoxime, glyphosate, glyphosate-diammonium,
glyphosate-dimethylammonium, glyphosate-isopropylammonium,
glyphosate-monoammonium, glyphosate-potassium,
glyphosate-sesquisodium, glyphosate-trimesium, glyphosine,
gossyplure, grandlure, griseofulvin, guazatine, guazatine acetates,
halacrinate, halfenprox, halofenozide, halosafen, halosulfuron,
halosulfuron-methyl, haloxydine, haloxyfop, haloxyfop-etotyl,
haloxyfop-methyl, haloxyfop-P, haloxyfop-P-etotyl,
haloxyfop-P-methyl, haloxyfop-sodium, HCH, hemel, hempa, HEOD,
heptachlor, heptenophos, heptopargil, heterophos,
hexachloroacetone, hexachlorobenzene, hexachlorobutadiene,
hexachlorophene, hexaconazole, hexaflumuron, hexaflurate, hexalure,
hexamide, hexazinone, hexylthiofos, hexythiazox, HHDN, holosulf,
huancaiwo, huangcaoling, huanjunzuo, hydramethylnon, hydrargaphen,
hydrated lime, hydrogen cyanide, hydroprene, hymexazol, hyquincarb,
IAA, IBA, icaridin, imazalil, imazalil nitrate, imazalil
sulfate, imazamethabenz, imazamethabenz-methyl, imazamox,
imazamox-ammonium, imazapic, imazapic-ammonium, imazapyr,
imazapyr-isopropylammonium, imazaquin, imazaquin-ammonium,
imazaquin-methyl, imazaquin-sodium, imazethapyr,
imazethapyr-ammonium, imazosulfuron, imibenconazole, imicyafos,
imidacloprid, imidaclothiz, iminoctadine, iminoctadine triacetate,
iminoctadine trialbesilate, imiprothrin, inabenfide, indanofan,
indaziflam, indoxacarb, inezin, iodobonil, iodocarb, iodomethane,
iodosulfuron, iodosulfuron-methyl, iodosulfuron-methyl-sodium,
iofensulfuron, iofensulfuron-sodium, ioxynil, ioxynil octanoate,
ioxynil-lithium, ioxynil-sodium, ipazine, ipconazole,
ipfencarbazone, iprobenfos, iprodione, iprovalicarb, iprymidam,
ipsdienol, ipsenol, IPSP, isamidofos, isazofos, isobenzan,
isocarbamid, isocarbophos, isocil, isodrin, isofenphos,
isofenphos-methyl, isolan, isomethiozin, isonoruron, isopolinate,
isoprocarb, isopropalin, isoprothiolane, isoproturon, isopyrazam,
isopyrimol, isothioate, isotianil, isouron, isovaledione, isoxaben,
isoxachlortole, isoxadifen, isoxadifen-ethyl, isoxaflutole,
isoxapyrifop, isoxathion, ivermectin, izopamfos, j aponilure, j
apothrins, j asmolin I, j asmolin II, jasmonic acid,
jiahuangchongzong, jiajizengxiaolin, jiaxiangjunzhi, jiecaowan,
jiecaoxi, jodfenphos, juvenile hormone I, juvenile hormone II,
juvenile hormone III, kadethrin, karbutilate, karetazan,
karetazan-potassium, kasugamycin, kasugamycin hydrochloride,
kejunlin, kelevan, ketospiradox, ketospiradox-potassium, kinetin,
kinoprene, kresoxim-methyl, kuicaoxi, lactofen, lambda-cyhalothrin,
latilure, lead arsenate, lenacil, lepimectin, leptophos, lindane,
lineatin, linuron, lirimfos, litlure, looplure, lufenuron,
lvdingjunzhi, lvxiancaolin, lythidathion, MAA, malathion, maleic
hydrazide, malonoben, maltodextrin, MAMA, mancopper, mancozeb,
mandipropamid, maneb, matrine, mazidox, MCPA, MCPA-2-ethylhexyl,
MCPA-butotyl, MCPA-butyl, MCPA-dimethylammonium, MCPA-diolamine,
MCPA-ethyl, MCPA-isobutyl, MCPA-isoctyl, MCPA-isopropyl,
MCPA-methyl, MCPA-olamine, MCPA-potassium, MCPA-sodium,
MCPA-thioethyl, MCPA-trolamine, MCPB, MCPB-ethyl, MCPB-methyl,
MCPB-sodium, mebenil, mecarbam, mecarbinzid, mecarphon, mecoprop,
mecoprop-2-ethylhexyl, mecoprop-dimethylammonium,
mecoprop-diolamine, mecoprop-ethadyl, mecoprop-isoctyl,
mecoprop-methyl, mecoprop-P, mecoprop-P-2-ethylhexyl,
mecoprop-P-dimethylammonium, mecoprop-P-isobutyl,
mecoprop-potassium, mecoprop-P-potassium, mecoprop-sodium,
mecoprop-trolamine, medimeform, medinoterb, medinoterb acetate,
medlure, mefenacet, mefenpyr, mefenpyr-diethyl, mefluidide,
mefluidide-diolamine, mefluidide-potassium, megatomoic acid,
menazon, mepanipyrim, meperfluthrin, mephenate, mephosfolan,
mepiquat, mepiquat chloride, mepiquat pentaborate, mepronil,
meptyldinocap, mercuric chloride, mercuric oxide, mercurous
chloride, merphos, mesoprazine, mesosulfuron, mesosulfuron-methyl,
mesotrione, mesulfen, mesulfenfos, metaflumizone, metalaxyl,
metalaxyl-M, metaldehyde, metam, metam-ammonium, metamifop,
metamitron, metam-potassium, metam-sodium, metazachlor,
metazosulfuron, metazoxolon, metconazole, metepa, metflurazon,
methabenzthiazuron, methacrifos, methalpropalin, methamidophos,
methasulfocarb, methazole, methfuroxam, methidathion,
methiobencarb, methiocarb, methiopyrisulfuron, methiotepa,
methiozolin, methiuron, methocrotophos, methometon, methomyl,
methoprene, methoprotryne, methoquin-butyl, methothrin,
methoxychlor, methoxyfenozide, methoxyphenone, methyl apholate,
methyl bromide, methyl eugenol, methyl iodide, methyl
isothiocyanate, methylacetophos, methylchloroform, methyldymron,
methylene chloride, methylmercury benzoate, methylmercury
dicyandiamide, methylmercury pentachlorophenoxide,
methylneodecanamide, metiram, metobenzuron, metobromuron,
metofluthrin, metolachlor, metolcarb, metominostrobin, metosulam,
metoxadiazone, metoxuron, metrafenone, metribuzin, metsulfovax,
metsulfuron, metsulfuron-methyl, mevinphos, mexacarbate, mieshuan,
milbemectin, milbemycin oxime, milneb, mipafox, mirex, MNAF,
moguchun, molinate, molosultap, monalide, monisouron,
monochloroacetic acid, monocrotophos, monolinuron, monosulfuron,
monosulfuron-ester, monuron, monuron TCA, morfamquat, morfamquat
dichloride, moroxydine, moroxydine hydrochloride, morphothion,
morzid, moxidectin, MSMA, muscalure, myclobutanil, myclozolin,
N-(ethylmercury)-p-toluenesulphonanilide, nabam, naftalofos, naled,
naphthalene, naphthaleneacetamide, naphthalic anhydride,
naphthoxyacetic acids, naproanilide, napropamide, naptalam,
naptalam-sodium, natamycin, neburon, niclosamide,
niclosamide-olamine, nicosulfuron, nicotine, nifluridide,
nipyraclofen, nitenpyram, nithiazine, nitralin, nitrapyrin,
nitrilacarb, nitrofen, nitrofluorfen, nitrostyrene,
nitrothal-isopropyl, norbormide, norflurazon, nornicotine, noruron,
novaluron, noviflumuron, nuarimol, OCH, octachlorodipropyl ether,
octhilinone, ofurace, omethoate, orbencarb, orfralure,
ortho-dichlorobenzene, orthosulfamuron, oryctalure, orysastrobin,
oryzalin, osthol, ostramone, oxabetrinil, oxadiargyl, oxadiazon,
oxadixyl, oxamate, oxamyl, oxapyrazon, oxapyrazon-dimolamine,
oxapyrazon-sodium, oxasulfuron, oxaziclomefone, oxine-copper,
oxolinic acid, oxpoconazole, oxpoconazole fumarate, oxycarboxin,
oxydemeton-methyl, oxydeprofos, oxydisulfoton, oxyfluorfen,
oxymatrine, oxytetracycline, oxytetracycline hydrochloride,
paclobutrazol, paichongding, para-dichlorobenzene, parafluron,
paraquat, paraquat dichloride, paraquat dimetilsulfate, parathion,
parathion-methyl, parinol, pebulate, pefurazoate, pelargonic acid,
penconazole, pencycuron, pendimethalin, penflufen, penfluron,
penoxsulam, pentachlorophenol, pentanochlor, penthiopyrad,
pentmethrin, pentoxazone, perfluidone, permethrin, pethoxamid,
phenamacril, phenazine oxide, phenisopham, phenkapton,
phenmedipham, phenmedipham-ethyl, phenobenzuron, phenothrin,
phenproxide, phenthoate, phenylmercuriurea, phenylmercury acetate,
phenylmercury chloride, phenylmercury derivative of pyrocatechol,
phenylmercury nitrate, phenylmercury salicylate, phorate,
phosacetim, phosalone, phosdiphen, phosfolan, phosfolan-methyl,
phosglycin, phosmet, phosnichlor, phosphamidon, phosphine,
phosphocarb, phosphorus, phostin, phoxim, phoxim-methyl, phthalide,
picloram, picloram-2-ethylhexyl, picloram-isoctyl, picloram-methyl,
picloram-olamine, picloram-potassium, picloram-triethylammonium,
picloram-tris(2-hydroxypropyl)ammonium, picolinafen, picoxystrobin,
pindone, pindone-sodium, pinoxaden, piperalin, piperonyl butoxide,
piperonyl cyclonene, piperophos, piproctanyl, piproctanyl bromide,
piprotal, pirimetaphos, pirimicarb, pirimioxyphos,
pirimiphos-ethyl, pirimiphos-methyl, plifenate, polycarbamate,
polyoxins, polyoxorim, polyoxorim-zinc, polythialan, potassium
arsenite, potassium azide, potassium cyanate, potassium
gibberellate, potassium naphthenate, potassium polysulfide,
potassium thiocyanate, potassium
.alpha.-naphthaleneacetate, pp'-DDT, prallethrin, precocene I,
precocene II, precocene III, pretilachlor, primidophos,
primisulfuron, primisulfuron-methyl, probenazole, prochloraz,
prochloraz-manganese, proclonol, procyazine, procymidone,
prodiamine, profenofos, profluazol, profluralin, profluthrin,
profoxydim, proglinazine, proglinazine-ethyl, prohexadione,
prohexadione-calcium, prohydrojasmon, promacyl, promecarb,
prometon, prometryn, promurit, propachlor, propamidine, propamidine
dihydrochloride, propamocarb, propamocarb hydrochloride, propanil,
propaphos, propaquizafop, propargite, proparthrin, propazine,
propetamphos, propham, propiconazole, propineb, propisochlor,
propoxur, propoxycarbazone, propoxycarbazone-sodium, propyl isome,
propyrisulfuron, propyzamide, proquinazid, prosuler, prosulfalin,
prosulfocarb, prosulfuron, prothidathion, prothiocarb, prothiocarb
hydrochloride, prothioconazole, prothiofos, prothoate,
protrifenbute, proxan, proxan-sodium, prynachlor, pydanon,
pymetrozine, pyracarbolid, pyraclofos, pyraclonil, pyraclostrobin,
pyraflufen, pyraflufen-ethyl, pyrafluprole, pyramat,
pyrametostrobin, pyraoxystrobin, pyrasulfotole, pyrazolynate,
pyrazophos, pyrazosulfuron, pyrazosulfuron-ethyl, pyrazothion,
pyrazoxyfen, pyresmethrin, pyrethrin I, pyrethrin II, pyrethrins,
pyribambenz-isopropyl, pyribambenz-propyl, pyribencarb,
pyribenzoxim, pyributicarb, pyriclor, pyridaben, pyridafol,
pyridalyl, pyridaphenthion, pyridate, pyridinitril, pyrifenox,
pyrifluquinazon, pyriftalid, pyrimethanil, pyrimidifen,
pyriminobac, pyriminobac-methyl, pyrimisulfan, pyrimitate,
pyrinuron, pyriofenone, pyriprole, pyripropanol, pyriproxyfen,
pyrithiobac, pyrithiobac-sodium, pyrolan, pyroquilon,
pyroxasulfone, pyroxsulam, pyroxychlor, pyroxyfur, quassia,
quinacetol, quinacetol sulfate, quinalphos, quinalphos-methyl,
quinazamid, quinclorac, quinconazole, quinmerac, quinoclamine,
quinonamid, quinothion, quinoxyfen, quintiofos, quintozene,
quizalofop, quizalofop-ethyl, quizalofop-P, quizalofop-P-ethyl,
quizalofop-P-tefuryl, quwenzhi, quyingding, rabenzazole,
rafoxanide, rebemide, resmethrin, rhodethanil, rhodojaponin-III,
ribavirin, rimsulfuron, rotenone, ryania, saflufenacil, saijunmao,
saisentong, salicylanilide, sanguinarine, santonin, schradan,
scilliroside, sebuthylazine, secbumeton, sedaxane, selamectin,
semiamitraz, semiamitraz chloride, sesamex, sesamolin, sethoxydim,
shuangjiaancaolin, siduron, siglure, silafluofen, silatrane, silica
gel, silthiofam, simazine, simeconazole, simeton, simetryn,
sintofen, SMA, S-metolachlor, sodium arsenite, sodium azide, sodium
chlorate, sodium fluoride, sodium fluoroacetate, sodium
hexafluorosilicate, sodium naphthenate, sodium
orthophenylphenoxide, sodium pentachlorophenoxide, sodium
polysulfide, sodium thiocyanate, sodium .alpha.-naphthaleneacetate,
sophamide, spinetoram, spinosad, spirodiclofen, spiromesifen,
spirotetramat, spiroxamine, streptomycin, streptomycin
sesquisulfate, strychnine, sulcatol, sulcofuron, sulcofuron-sodium,
sulcotrione, sulfallate, sulfentrazone, sulfiram, sulfluramid,
sulfometuron, sulfometuron-methyl, sulfosulfuron, sulfotep,
sulfoxaflor, sulfoxide, sulfoxime, sulfur, sulfuric acid, sulfuryl
fluoride, sulglycapin, sulprofos, sultropen, swep, tau-fluvalinate,
tavron, tazimcarb, TCA, TCA-ammonium, TCA-calcium, TCA-ethadyl,
TCA-magnesium, TCA-sodium, TDE, tebuconazole, tebufenozide,
tebufenpyrad, tebufloquin, tebupirimfos, tebutam, tebuthiuron,
tecloftalam, tecnazene, tecoram, teflubenzuron, tefluthrin,
tefuryltrione, tembotrione, temephos, tepa, TEPP, tepraloxydim,
terallethrin, terbacil, terbucarb, terbuchlor, terbufos,
terbumeton, terbuthylazine, terbutryn, tetcyclacis,
tetrachloroethane, tetrachlorvinphos, tetraconazole, tetradifon,
tetrafluron, tetramethrin, tetramethylfluthrin, tetramine,
tetranactin, tetrasul, thallium sulfate, thenylchlor,
theta-cypermethrin, thiabendazole, thiacloprid, thiadifluor,
thiamethoxam, thiapronil, thiazafluron, thiazopyr, thicrofos,
thicyofen, thidiazimin, thidiazuron, thiencarbazone,
thiencarbazone-methyl, thifensulfuron, thifensulfuron-methyl,
thifluzamide, thiobencarb, thiocarboxime, thiochlorfenphim,
thiocyclam, thiocyclam hydrochloride, thiocyclam oxalate,
thiodiazole-copper, thiodicarb, thiofanox, thiofluoximate,
thiohempa, thiomersal, thiometon, thionazin, thiophanate,
thiophanate-methyl, thioquinox, thiosemicarbazide, thiosultap,
thiosultap-diammonium, thiosultap-disodium, thiosultap-monosodium,
thiotepa, thiram, thuringiensin, tiadinil, tiaojiean, tiocarbazil,
tioclorim, tioxymid, tirpate, tolclofos-methyl, tolfenpyrad,
tolylfluanid, tolylmercury acetate, topramezone, tralkoxydim,
tralocythrin, tralomethrin, tralopyril, transfluthrin,
transpermethrin, tretamine, triacontanol, triadimefon, triadimenol,
triafamone, tri-allate, triamiphos, triapenthenol, triarathene,
triarimol, triasulfuron, triazamate, triazbutil, triaziflam,
triazophos, triazoxide, tribenuron, tribenuron-methyl, tribufos,
tributyltin oxide, tricamba, trichlamide, trichlorfon,
trichlormetaphos-3, trichloronat, triclopyr, triclopyr-butotyl,
triclopyr-ethyl, triclopyr-triethylammonium, tricyclazole,
tridemorph, tridiphane, trietazine, trifenmorph, trifenofos,
trifloxystrobin, trifloxysulfuron, trifloxysulfuron-sodium,
triflumizole, triflumuron, trifluralin, triflusulfuron,
triflusulfuron-methyl, trifop, trifop-methyl, trifopsime,
triforine, trihydroxytriazine, trimedlure, trimethacarb,
trimeturon, trinexapac, trinexapac-ethyl, triprene, tripropindan,
triptolide, tritac, triticonazole, tritosulfuron, trunc-call,
uniconazole, uniconazole-P, urbacide, uredepa, valerate,
validamycin, valifenalate, valone, vamidothion, vangard,
vaniliprole, vernolate, vinclozolin, warfarin, warfarin-potassium,
warfarin-sodium, xiaochongliulin, xinjunan, xiwojunan, XMC,
xylachlor, xylenols, xylylcarb, yishijing, zarilamid, zeatin,
zengxiaoan, zeta-cypermethrin, zinc naphthenate, zinc phosphide,
zinc thiazole, zineb, ziram, zolaprofos, zoxamide, zuomihuanglong,
.alpha.-chlorohydrin, .alpha.-ecdysone, .alpha.-multistriatin, and
.alpha.-naphthaleneacetic acid. For more information consult the
"COMPENDIUM OF PESTICIDE COMMON NAMES" located at
http://www.alanwood.net/pesticides/index.html. Also consult "THE
PESTICIDE MANUAL" 14th Edition, edited by C D S Tomlin, copyright
2006 by British Crop Production Council, or its prior or more
recent editions.
Biopesticides
[0811] Molecules of Formula One may also be used in combination
(such as in a compositional mixture, or a simultaneous or
sequential application) with one or more biopesticides. The term
"biopesticide" is used for microbial biological pest control agents
that are applied in a similar manner to chemical pesticides.
Commonly these are bacterial, but there are also examples of fungal
control agents, including Trichoderma spp. and Ampelomyces
quisqualis (a control agent for grape powdery mildew). Bacillus
subtilis are used to control plant pathogens. Weeds and rodents
have also been controlled with microbial agents. One well-known
insecticide example is Bacillus thuringiensis, a bacterial disease
of Lepidoptera, Coleoptera, and Diptera. Because it has little
effect on other organisms, it is considered more environmentally
friendly than synthetic pesticides. Biological insecticides include
products based on:
[0812] 1. entomopathogenic fungi (e.g. Metarhizium anisopliae);
[0813] 2. entomopathogenic nematodes (e.g. Steinernema feltiae);
and
[0814] 3. entomopathogenic viruses (e.g. Cydia pomonella
granulovirus).
[0815] Other examples of entomopathogenic organisms include, but
are not limited to, baculoviruses, bacteria and other prokaryotic
organisms, fungi, protozoa and Microsproridia.
[0816] Biologically derived insecticides include, but not limited
to, rotenone, veratridine, as well as microbial toxins; insect
tolerant or resistant plant varieties; and organisms modified by
recombinant DNA technology to either produce insecticides or to
convey an insect resistant property to the genetically modified
organism. In one embodiment, the molecules of Formula One may be
used with one or more biopesticides in the area of seed treatments
and soil amendments. The Manual of Biocontrol Agents gives a review
of the available biological insecticide (and other biology-based
control) products. Copping L. G. (ed.) (2004). The Manual of
Biocontrol Agents (formerly the Biopesticide Manual) 3rd Edition.
British Crop Production Council (BCPC), Farnham, Surrey UK.
Other Active Compounds
[0817] Molecules of Formula One may also be used in combination
(such as in a compositional mixture, or a simultaneous or
sequential application) with one or more of the following:
1.
3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-oxa-1-azaspiro[4,5]dec-3-e-
n-2-one; 2.
3-(4'-chloro-2,4-dimethyl[1,1'-biphenyl]-3-yl)-4-hydroxy-8-oxa-1-azaspiro-
[4,5]dec-3-en-2-one; 3.
4-[[(6-chloro-3-pyridinyl)methyl]methylamino]-2(5H)-furanone; 4.
4-[[(6-chloro-3-pyridinyl)methyl]cyclopropylamino]-2(5H)-furanone;
5.
3-chloro-N2-[(1S)-1-methyl-2-(methylsulfonyl)ethyl]-N1-[2-methyl-4-[1,2,2-
,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]-1,2-benzenedicarboxamide;
6. 2-cyano-N-ethyl-4-fluoro-3-methoxy-benenesulfonamide; 7.
2-cyano-N-ethyl-3-methoxy-benzenesulfonamide; 8.
2-cyano-3-difluoromethoxy-N-ethyl-4-fluoro-benzenesulfonamide; 9.
2-cyano-3-fluoromethoxy-N-ethyl-benzenesulfonamide; 10.
2-cyano-6-fluoro-3-methoxy-N,N-dimethyl-benzenesulfonamide; 11.
2-cyano-N-ethyl-6-fluoro-3-methoxy-N-methyl-benzenesulfonamide; 12.
2-cyano-3-difluoromethoxy-N,N-dimethylbenzenesulfon-amide; 13.
3-(difluoromethyl)-N-[2-(3,3-dimethylbutyl)phenyl]-1-methyl-1H-pyrazole-4-
-carboxamide; 14.
N-ethyl-2,2-dimethylpropionamide-2-(2,6-dichloro-.alpha.,.alpha.,.alpha.--
trifluoro-p-tolyl) hydrazone; 15.
N-ethyl-2,2-dichloro-1-methylcyclopropane-carboxamide-2-(2,6-dichloro-.al-
pha.,.alpha.,.alpha.-trifluoro-p-tolyl) hydrazone nicotine; 16.
O-{(E-)-[2-(4-chloro-phenyl)-2-cyano-1-(2-trifluoromethylphenyl)-vinyl]}S-
-methyl thiocarbonate; 17.
(E)-N1-[(2-chloro-1,3-thiazol-5-ylmethyl)]-N2-cyano-N1-methylacetamidine;
18.
1-(6-chloropyridin-3-ylmethyl)-7-methyl-8-nitro-1,2,3,5,6,7-hexahydro-
-imidazo[1,2-a]pyridin-5-ol; 19.
4-[4-chlorophenyl-(2-butylidine-hydrazono)methyl)]phenyl mesylate;
and 20.
N-Ethyl-2,2-dichloro-1-methylcyclopropanecarboxamide-2-(2,6-dichloro--
alpha, alpha, alpha-trifluoro-p-tolyl)hydrazone.
Synergistic Mixtures
[0818] Molecules of Formula One may be used with certain active
compounds to form synergistic mixtures where the mode of action of
such compounds compared to the mode of action of the molecules of
Formula One are the same, similar, or different. Examples of modes
of action include, but are not limited to: acetylcholinesterase
inhibitor; sodium channel modulator; chitin biosynthesis inhibitor;
GABA and glutamate-gated chloride channel antagonist; GABA and
glutamate-gated chloride channel agonist; acetylcholine receptor
agonist; acetylcholine receptor antagonist; MET I inhibitor;
Mg-stimulated ATPase inhibitor; nicotinic acetylcholine receptor;
Midgut membrane disrupter; oxidative phosphorylation disrupter, and
ryanodine receptor (RyRs). Generally, weight ratios of the
molecules of Formula One in a synergistic mixture with another
compound are from about 10:1 to about 1:10, in another embodiment
from about 5:1 to about 1:5, and in another embodiment from about
3:1, and in another embodiment about 1:1.
Formulations
[0819] A pesticide is rarely suitable for application in its pure
form. It is usually necessary to add other substances so that the
pesticide can be used at the required concentration and in an
appropriate form, permitting ease of application, handling,
transportation, storage, and maximum pesticide activity. Thus,
pesticides are formulated into, for example, baits, concentrated
emulsions, dusts, emulsifiable concentrates, fumigants, gels,
granules, microencapsulations, seed treatments, suspension
concentrates, suspoemulsions, tablets, water soluble liquids, water
dispersible granules or dry flowables, wettable powders, and ultra
low volume solutions. For further information on formulation types
see "Catalogue of Pesticide Formulation Types and International
Coding System" Technical Monograph no 2, 5th Edition by CropLife
International (2002).
[0820] Pesticides are applied most often as aqueous suspensions or
emulsions prepared from concentrated formulations of such
pesticides. Such water-soluble, water-suspendable, or emulsifiable
formulations are either solids, usually known as wettable powders,
or water dispersible granules, or liquids usually known as
emulsifiable concentrates, or aqueous suspensions. Wettable
powders, which may be compacted to form water dispersible granules,
comprise an intimate mixture of the pesticide, a carrier, and
surfactants. The concentration of the pesticide is usually from
about 10% to about 90% by weight. The carrier is usually selected
from among the attapulgite clays, the montmorillonite clays, the
diatomaceous earths, or the purified silicates. Effective
surfactants, comprising from about 0.5% to about 10% of the
wettable powder, are found among sulfonated lignins, condensed
naphthalenesulfonates, naphthalenesulfonates,
alkylbenzenesulfonates, alkyl sulfates, and non-ionic surfactants
such as ethylene oxide adducts of alkyl phenols.
[0821] Emulsifiable concentrates of pesticides comprise a
convenient concentration of a pesticide, such as from about 50 to
about 500 grams per liter of liquid dissolved in a carrier that is
either a water miscible solvent or a mixture of water-immiscible
organic solvent and emulsifiers. Useful organic solvents include
aromatics, especially xylenes and petroleum fractions, especially
the high-boiling naphthalenic and olefinic portions of petroleum
such as heavy aromatic naphtha. Other organic solvents may also be
used, such as the terpenic solvents including rosin derivatives,
aliphatic ketones such as cyclohexanone, and complex alcohols such
as 2-ethoxyethanol. Suitable emulsifiers for emulsifiable
concentrates are selected from conventional anionic and non-ionic
surfactants.
[0822] Aqueous suspensions comprise suspensions of water-insoluble
pesticides dispersed in an aqueous carrier at a concentration in
the range from about 5% to about 50% by weight. Suspensions are
prepared by finely grinding the pesticide and vigorously mixing it
into a carrier comprised of water and surfactants. Ingredients,
such as inorganic salts and synthetic or natural gums may also be
added, to increase the density and viscosity of the aqueous
carrier. It is often most effective to grind and mix the pesticide
at the same time by preparing the aqueous mixture and homogenizing
it in an implement such as a sand mill, ball mill, or piston-type
homogenizer.
[0823] Pesticides may also be applied as granular compositions that
are particularly useful for applications to the soil. Granular
compositions usually contain from about 0.5% to about 10% by weight
of the pesticide, dispersed in a carrier that comprises clay or a
similar substance. Such compositions are usually prepared by
dissolving the pesticide in a suitable solvent and applying it to a
granular carrier which has been pre-formed to the appropriate
particle size, in the range of from about 0.5 to about 3 mm. Such
compositions may also be formulated by making a dough or paste of
the carrier and compound and crushing and drying to obtain the
desired granular particle size.
[0824] Dusts containing a pesticide are prepared by intimately
mixing the pesticide in powdered form with a suitable dusty
agricultural carrier, such as kaolin clay, ground volcanic rock,
and the like. Dusts can suitably contain from about 1% to about 10%
of the pesticide. They can be applied as a seed dressing or as a
foliage application with a dust blower machine.
[0825] It is equally practical to apply a pesticide in the form of
a solution in an appropriate organic solvent, usually petroleum
oil, such as the spray oils, which are widely used in agricultural
chemistry.
[0826] Pesticides can also be applied in the form of an aerosol
composition. In such compositions the pesticide is dissolved or
dispersed in a carrier, which is a pressure-generating propellant
mixture. The aerosol composition is packaged in a container from
which the mixture is dispensed through an atomizing valve.
[0827] Pesticide baits are formed when the pesticide is mixed with
food or an attractant or both. When the pests eat the bait they
also consume the pesticide. Baits may take the form of granules,
gels, flowable powders, liquids, or solids. They can be used in
pest harborages.
[0828] Fumigants are pesticides that have a relatively high vapor
pressure and hence can exist as a gas in sufficient concentrations
to kill pests in soil or enclosed spaces. The toxicity of the
fumigant is proportional to its concentration and the exposure
time. They are characterized by a good capacity for diffusion and
act by penetrating the pest's respiratory system or being absorbed
through the pest's cuticle. Fumigants are applied to control stored
product pests under gas proof sheets, in gas sealed rooms or
buildings or in special chambers.
[0829] Pesticides can be microencapsulated by suspending the
pesticide particles or droplets in plastic polymers of various
types. By altering the chemistry of the polymer or by changing
factors in the processing, microcapsules can be formed of various
sizes, solubility, wall thicknesses, and degrees of penetrability.
These factors govern the speed with which the active ingredient
within is released, which in turn, affects the residual
performance, speed of action, and odor of the product.
[0830] Oil solution concentrates are made by dissolving pesticide
in a solvent that will hold the pesticide in solution. Oil
solutions of a pesticide usually provide faster knockdown and kill
of pests than other formulations due to the solvents themselves
having pesticidal action and the dissolution of the waxy covering
of the integument increasing the speed of uptake of the pesticide.
Other advantages of oil solutions include better storage stability,
better penetration of crevices, and better adhesion to greasy
surfaces.
[0831] Another embodiment is an oil-in-water emulsion, wherein the
emulsion comprises oily globules which are each provided with a
lamellar liquid crystal coating and are dispersed in an aqueous
phase, wherein each oily globule comprises at least one compound
which is agriculturally active, and is individually coated with a
monolamellar or oligolamellar layer comprising: (1) at least one
non-ionic lipophilic surface-active agent, (2) at least one
non-ionic hydrophilic surface-active agent and (3) at least one
ionic surface-active agent, wherein the globules having a mean
particle diameter of less than 800 nanometers. Further information
on the embodiment is disclosed in U.S. patent publication
20070027034 published Feb. 1, 2007, having patent application Ser.
No. 11/495,228. For ease of use, this embodiment will be referred
to as "OIWE".
[0832] For further information consult "Insect Pest Management" 2nd
Edition by D. Dent, copyright CAB International (2000).
Additionally, for more detailed information consult "Handbook of
Pest Control-- The Behavior, Life History, and Control of Household
Pests" by Arnold Mallis, 9th Edition, copyright 2004 by GIE Media
Inc.
Other Formulation Components
[0833] Generally, when the molecules disclosed in Formula One are
used in a formulation, such formulation can also contain other
components. These components include, but are not limited to, (this
is a non-exhaustive and non-mutually exclusive list) wetters,
spreaders, stickers, penetrants, buffers, sequestering agents,
drift reduction agents, compatibility agents, anti-foam agents,
cleaning agents, and emulsifiers. A few components are described
forthwith.
[0834] A wetting agent is a substance that when added to a liquid
increases the spreading or penetration power of the liquid by
reducing the interfacial tension between the liquid and the surface
on which it is spreading. Wetting agents are used for two main
functions in agrochemical formulations: during processing and
manufacture to increase the rate of wetting of powders in water to
make concentrates for soluble liquids or suspension concentrates;
and during mixing of a product with water in a spray tank to reduce
the wetting time of wettable powders and to improve the penetration
of water into water-dispersible granules. Examples of wetting
agents used in wettable powder, suspension concentrate, and
water-dispersible granule formulations are: sodium lauryl sulfate;
sodium dioctyl sulfosuccinate; alkyl phenol ethoxylates; and
aliphatic alcohol ethoxylates.
[0835] A dispersing agent is a substance which adsorbs onto the
surface of particles and helps to preserve the state of dispersion
of the particles and prevents them from reaggregating. Dispersing
agents are added to agrochemical formulations to facilitate
dispersion and suspension during manufacture, and to ensure the
particles redisperse into water in a spray tank. They are widely
used in wettable powders, suspension concentrates and
water-dispersible granules. Surfactants that are used as dispersing
agents have the ability to adsorb strongly onto a particle surface
and provide a charged or steric barrier to reaggregation of
particles. The most commonly used surfactants are anionic,
non-ionic, or mixtures of the two types. For wettable powder
formulations, the most common dispersing agents are sodium
lignosulfonates. For suspension concentrates, very good adsorption
and stabilization are obtained using polyelectrolytes, such as
sodium naphthalene sulfonate formaldehyde condensates.
Tristyrylphenol ethoxylate phosphate esters are also used.
Non-ionics such as alkylarylethylene oxide condensates and EO-PO
block copolymers are sometimes combined with anionics as dispersing
agents for suspension concentrates. In recent years, new types of
very high molecular weight polymeric surfactants have been
developed as dispersing agents. These have very long hydrophobic
`backbones` and a large number of ethylene oxide chains forming the
`teeth` of a `comb` surfactant. These high molecular weight
polymers can give very good long-term stability to suspension
concentrates because the hydrophobic backbones have many anchoring
points onto the particle surfaces. Examples of dispersing agents
used in agrochemical formulations are: sodium lignosulfonates;
sodium naphthalene sulfonate formaldehyde condensates;
tristyrylphenol ethoxylate phosphate esters; aliphatic alcohol
ethoxylates; alkyl ethoxylates; EO-PO block copolymers; and graft
copolymers.
[0836] An emulsifying agent is a substance which stabilizes a
suspension of droplets of one liquid phase in another liquid phase.
Without the emulsifying agent the two liquids would separate into
two immiscible liquid phases. The most commonly used emulsifier
blends contain alkylphenol or aliphatic alcohol with twelve or more
ethylene oxide units and the oil-soluble calcium salt of
dodecylbenzenesulfonic acid. A range of hydrophile-lipophile
balance ("HLB") values from 8 to 18 will normally provide good
stable emulsions. Emulsion stability can sometimes be improved by
the addition of a small amount of an EO-PO block copolymer
surfactant.
[0837] A solubilizing agent is a surfactant which will form
micelles in water at concentrations above the critical micelle
concentration. The micelles are then able to dissolve or solubilize
water-insoluble materials inside the hydrophobic part of the
micelle. The types of surfactants usually used for solubilization
are non-ionics, sorbitan monooleates, sorbitan monooleate
ethoxylates, and methyl oleate esters.
[0838] Surfactants are sometimes used, either alone or with other
additives such as mineral or vegetable oils as adjuvants to
spray-tank mixes to improve the biological performance of the
pesticide on the target. The types of surfactants used for
bioenhancement depend generally on the nature and mode of action of
the pesticide. However, they are often non-ionics such as: alkyl
ethoxylates; linear aliphatic alcohol ethoxylates; aliphatic amine
ethoxylates.
[0839] A carrier or diluent in an agricultural formulation is a
material added to the pesticide to give a product of the required
strength. Carriers are usually materials with high absorptive
capacities, while diluents are usually materials with low
absorptive capacities. Carriers and diluents are used in the
formulation of dusts, wettable powders, granules and
water-dispersible granules.
[0840] Organic solvents are used mainly in the formulation of
emulsifiable concentrates, oil-in-water emulsions, suspoemulsions,
and ultra low volume formulations, and to a lesser extent, granular
formulations. Sometimes mixtures of solvents are used. The first
main groups of solvents are aliphatic paraffinic oils such as
kerosene or refined paraffins. The second main group (and the most
common) comprises the aromatic solvents such as xylene and higher
molecular weight fractions of C9 and C10 aromatic solvents.
Chlorinated hydrocarbons are useful as cosolvents to prevent
crystallization of pesticides when the formulation is emulsified
into water. Alcohols are sometimes used as cosolvents to increase
solvent power. Other solvents may include vegetable oils, seed
oils, and esters of vegetable and seed oils.
[0841] Thickeners or gelling agents are used mainly in the
formulation of suspension concentrates, emulsions and
suspoemulsions to modify the rheology or flow properties of the
liquid and to prevent separation and settling of the dispersed
particles or droplets. Thickening, gelling, and anti-settling
agents generally fall into two categories, namely water-insoluble
particulates and water-soluble polymers. It is possible to produce
suspension concentrate formulations using clays and silicas.
Examples of these types of materials, include, but are not limited
to, montmorillonite, bentonite, magnesium aluminum silicate, and
attapulgite. Water-soluble polysaccharides have been used as
thickening-gelling agents for many years. The types of
polysaccharides most commonly used are natural extracts of seeds
and seaweeds or are synthetic derivatives of cellulose. Examples of
these types of materials include, but are not limited to, guar gum;
locust bean gum; carrageenam; alginates; methyl cellulose; sodium
carboxymethyl cellulose (SCMC); hydroxyethyl cellulose (HEC). Other
types of anti-settling agents are based on modified starches,
polyacrylates, polyvinyl alcohol and polyethylene oxide. Another
good anti-settling agent is xanthan gum.
[0842] Microorganisms can cause spoilage of formulated products.
Therefore preservation agents are used to eliminate or reduce their
effect. Examples of such agents include, but are not limited to:
propionic acid and its sodium salt; sorbic acid and its sodium or
potassium salts; benzoic acid and its sodium salt; p-hydroxybenzoic
acid sodium salt; methyl p-hydroxybenzoate; and
1,2-benzisothiazolin-3-one (BIT).
[0843] The presence of surfactants often causes water-based
formulations to foam during mixing operations in production and in
application through a spray tank. In order to reduce the tendency
to foam, anti-foam agents are often added either during the
production stage or before filling into bottles. Generally, there
are two types of anti-foam agents, namely silicones and
non-silicones. Silicones are usually aqueous emulsions of dimethyl
polysiloxane, while the non-silicone anti-foam agents are
water-insoluble oils, such as octanol and nonanol, or silica. In
both cases, the function of the anti-foam agent is to displace the
surfactant from the air-water interface.
[0844] "Green" agents (e.g., adjuvants, surfactants, solvents) can
reduce the overall environmental footprint of crop protection
formulations. Green agents are biodegradable and generally derived
from natural and/or sustainable sources, e.g. plant and animal
sources.
[0845] Specific examples are: vegetable oils, seed oils, and esters
thereof, also alkoxylated alkyl polyglucosides.
[0846] For further information, see "Chemistry and Technology of
Agrochemical Formulations" edited by D. A. Knowles, copyright 1998
by Kluwer Academic Publishers. Also see "Insecticides in
Agriculture and Environment--Retrospects and Prospects" by A. S.
Perry, I. Yamamoto, I. Ishaaya, and R. Perry, copyright 1998 by
Springer-Verlag.
Pests
[0847] In general, the molecules of Formula One may be used to
control pests e.g. beetles, earwigs, cockroaches, flies. aphids,
scales, whiteflies, leafhoppers, ants, wasps, termites, moths,
butterflies, lice, grasshoppers, locusts, crickets, fleas, thrips,
bristletails, mites, ticks, nematodes, and symphylans.
[0848] In another embodiment, the molecules of Formula One may be
used to control pests in the Phyla Nematoda and/or Arthropoda.
[0849] In another embodiment, the molecules of Formula One may be
used to control pests in the Subphyla Chelicerata, Myriapoda,
and/or Hexapoda.
[0850] In another embodiment, the molecules of Formula One may be
used to control pests in the Classes of Arachnida, Symphyla, and/or
Insecta.
[0851] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Anoplura. A non-exhaustive list
of particular genera includes, but is not limited to, Haematopinus
spp., Hoplopleura spp., Linognathus spp., Pediculus spp., and
Polyplax spp. A non-exhaustive list of particular species includes,
but is not limited to, Haematopinus asini, Haematopinus suis,
Linognathus setosus, Linognathus ovillus, Pediculus humanus
capitis, Pediculus humanus humanus, and Pthirus pubis.
[0852] In another embodiment, the molecules of Formula One may be
used to control pests in the Order Coleoptera. A non-exhaustive
list of particular genera includes, but is not limited to,
Acanthoscelides spp., Agriotes spp., Anthonomus spp., Apion spp.,
Apogonia spp., Aulacophora spp., Bruchus spp., Cerosterna spp.,
Cerotoma spp., Ceutorhynchus spp., Chaetocnema spp., Colaspis spp.,
Ctenicera spp., Curculio spp., Cyclocephala spp., Diabrotica spp.,
Hypera spp., Ips spp., Lyctus spp., Megascelis spp., Meligethes
spp., Otiorhynchus spp., Pantomorus spp., Phyllophaga spp.,
Phyllotreta spp., Rhizotrogus spp., Rhynchites spp., Rhynchophorus
spp., Scolytus spp., Sphenophorus spp., Sitophilus spp., and
Tribolium spp. A non-exhaustive list of particular species
includes, but is not limited to, Acanthoscelides obtectus, Agrilus
planipennis, Anoplophora glabripennis, Anthonomus grandis, Ataenius
spretulus, Atomaria linearis, Bothynoderes punctiventris, Bruchus
pisorum, Callosobruchus maculatus, Carpophilus hemipterus, Cassida
vittata, Cerotoma trifurcata, Ceutorhynchus assimilis,
Ceutorhynchus napi, Conoderus scalaris, Conoderus stigmosus,
Conotrachelus nenuphar, Cotinis nitida, Crioceris asparagi,
Cryptolestes ferrugineus, Cryptolestes pusillus, Cryptolestes
turcicus, Cylindrocopturus adspersus, Deporaus marginatus,
Dermestes lardarius, Dermestes maculatus, Epilachna varivestis,
Faustinus cubae, Hylobius pales, Hypera postica, Hypothenemus
hampei, Lasioderma serricorne, Leptinotarsa decemlineata, Liogenys
fuscus, Liogenys suturalis, Lissorhoptrus oryzophilus, Maecolaspis
joliveti, Melanotus communis, Meligethes aeneus, Melolontha
melolontha, Oberea brevis, Oberea linearis, Oryctes rhinoceros,
Oryzaephilus mercator, Oryzaephilus surinamensis, Oulema melanopus,
Oulema oryzae, Phyllophaga cuyabana, Popillia japonica,
Prostephanus truncatus, Rhyzopertha dominica, Sitona lineatus,
Sitophilus granarius, Sitophilus oryzae, Sitophilus zeamais,
Stegobium paniceum, Tribolium castaneum, Tribolium confusum,
Trogoderma variabile, and Zabrus tenebrioides.
[0853] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Dermaptera.
[0854] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Blattaria. A non-exhaustive list
of particular species includes, but is not limited to, Blattella
germanica, Blatta orientalis, Parcoblatta pennsylvanica,
Periplaneta americana, Periplaneta australasiae, Periplaneta
brunnea, Periplaneta fuliginosa, Pycnoscelus surinamensis, and
Supella longipalpa.
[0855] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Diptera. A non-exhaustive list
of particular genera includes, but is not limited to, Aedes spp.,
Agromyza spp., Anastrepha spp., Anopheles spp., Bactrocera spp.,
Ceratitis spp., Chrysops spp., Cochliomyia spp., Contarinia spp.,
Culex spp., Dasineura spp., Delia spp., Drosophila spp., Fannia
spp., Hylemyia spp., Liriomyza spp., Musca spp., Phorbia spp.,
Tabanus spp., and Tipula spp. A non-exhaustive list of particular
species includes, but is not limited to, Agromyza frontella,
Anastrepha suspensa, Anastrepha ludens, Anastrepha obliqa,
Bactrocera cucurbitae, Bactrocera dorsalis, Bactrocera invadens,
Bactrocera zonata, Ceratitis capitata, Dasineura brassicae, Delia
platura, Fannia canicularis, Fannia scalaris, Gasterophilus
intestinalis, Gracillia perseae, Haematobia irritans, Hypoderma
lineatum, Liriomyza brassicae, Melophagus ovinus, Musca autumnalis,
Musca domestica, Oestrus ovis, Oscinella frit, Pegomya betae, Psila
rosae, Rhagoletis cerasi, Rhagoletis pomonella, Rhagoletis mendax,
Sitodiplosis mosellana, and Stomoxys calcitrans.
[0856] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Hemiptera. A non-exhaustive list
of particular genera includes, but is not limited to, Adelges spp.,
Aulacaspis spp., Aphrophora spp., Aphis spp., Bemisia spp.,
Ceroplastes spp., Chionaspis spp., Chrysomphalus spp., Coccus spp.,
Empoasca spp., Lepidosaphes spp., Lagynotomus spp., Lygus spp.,
Macrosiphum spp., Nephotettix spp., Nezara spp., Philaenus spp.,
Phytocoris spp., Piezodorus spp., Planococcus spp., Pseudococcus
spp., Rhopalosiphum spp., Saissetia spp., Therioaphis spp.,
Toumeyella spp., Toxoptera spp., Trialeurodes spp., Triatoma spp.
and Unaspis spp. A non-exhaustive list of particular species
includes, but is not limited to, Acrosternum hilare, Acyrthosiphon
pisum, Aleyrodes proletella, Aleurodicus dispersus, Aleurothrixus
floccosus, Amrasca biguttula biguttula, Aonidiella aurantii, Aphis
gossypii, Aphis glycines, Aphis pomi, Aulacorthum solani, Bemisia
argentifolii, Bemisia tabaci, Blissus leucopterus, Brachycorynella
asparagi, Brevennia rehi, Brevicoryne brassicae, Calocoris
norvegicus, Ceroplastes rubens, Cimex hemipterus, Cimex
lectularius, Dagbertusfasciatus, Dichelops furcatus, Diuraphis
noxia, Diaphorina citri, Dysaphis plantaginea, Dysdercus
suturellus, Edessa meditabunda, Eriosoma lanigerum, Eurygaster
maura, Euschistus heros, Euschistus servus, Helopeltis antonii,
Helopeltis theivora, Icerya purchasi, Idioscopus nitidulus,
Laodelphax striatellus, Leptocorisa oratorius, Leptocorisa
varicornis, Lygus hesperus, Maconellicoccus hirsutus, Macrosiphum
euphorbiae, Macrosiphum granarium, Macrosiphum rosae, Macrosteles
quadrilineatus, Mahanarvafrimbiolata, Metopolophium dirhodum,
Mictis longicornis, Myzus persicae, Nephotettix cinctipes,
Neurocolpus longirostris, Nezara viridula, Nilaparvata lugens,
Parlatoria pergandii, Parlatoria ziziphi, Peregrinus maidis,
Phylloxera vitifoliae, Physokermes piceae, Phytocoris californicus,
Phytocoris relativus, Piezodorus guildinii, Poecilocapsus lineatus,
Psallus vaccinicola, Pseudacysta perseae, Pseudococcus brevipes,
Quadraspidiotus perniciosus, Rhopalosiphum maidis, Rhopalosiphum
padi, Saissetia oleae, Scaptocoris castanea, Schizaphis graminum,
Sitobion avenae, Sogatella furcifera, Trialeurodes vaporariorum,
Trialeurodes abutiloneus, Unaspis yanonensis, and Zulia
entrerriana.
[0857] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Hymenoptera. A non-exhaustive
list of particular genera includes, but is not limited to,
Acromyrmex spp., Atta spp., Camponotus spp., Diprion spp., Formica
spp., Monomorium spp., Neodiprion spp., Pogonomyrmex spp., Polistes
spp., Solenopsis spp., Vespula spp., and Xylocopa spp. A
non-exhaustive list of particular species includes, but is not
limited to, Athalia rosae, Atta texana, Iridomyrmex humilis,
Monomorium minimum, Monomorium pharaonis, Solenopsis invicta,
Solenopsis geminata, Solenopsis molesta, Solenopsis richtery,
Solenopsis xyloni, and Tapinoma sessile.
[0858] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Isoptera. A non-exhaustive list
of particular genera includes, but is not limited to, Coptotermes
spp., Cornitermes spp., Cryptotermes spp., Heterotermes spp.,
Kalotermes spp., Incisitermes spp., Macrotermes spp., Marginitermes
spp., Microcerotermes spp., Procornitermes spp., Reticulitermes
spp., Schedorhinotermes spp., and Zootermopsis spp. A
non-exhaustive list of particular species includes, but is not
limited to, Coptotermes curvignathus, Coptotermes frenchi,
Coptotermes formosanus, Heterotermes aureus, Microtermes obesi,
Reticulitermes banyulensis, Reticulitermes grassei, Reticulitermes
flavipes, Reticulitermes hageni, Reticulitermes hesperus,
Reticulitermes santonensis, Reticulitermes speratus, Reticulitermes
tibialis, and Reticulitermes virginicus.
[0859] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Lepidoptera. A non-exhaustive
list of particular genera includes, but is not limited to,
Adoxophyes spp., Agrotis spp., Argyrotaenia spp., Cacoecia spp.,
Caloptilia spp., Chilo spp., Chrysodeixis spp., Colias spp.,
Crambus spp., Diaphania spp., Diatraea spp., Earias spp., Ephestia
spp., Epimecis spp., Feltia spp., Gortyna spp., Helicoverpa spp.,
Heliothis spp., Indarbela spp., Lithocolletis spp., Loxagrotis
spp., Malacosoma spp., Peridroma spp., Phyllonorycter spp.,
Pseudaletia spp., Sesamia spp., Spodoptera spp., Synanthedon spp.,
and Yponomeuta spp. A non-exhaustive list of particular species
includes, but is not limited to, Achaea janata, Adoxophyes orana,
Agrotis ipsilon, Alabama argillacea, Amorbia cuneana, Amyelois
transitella, Anacamptodes defectaria, Anarsia lineatella, Anomis
sabulifera, Anticarsia gemmatalis, Archips argyrospila, Archips
rosana, Argyrotaenia citrana, Autographa gamma, Bonagota cranaodes,
Borbo cinnara, Bucculatrix thurberiella, Capua reticulana,
Carposina niponensis, Chlumetia transversa, Choristoneura
rosaceana, Cnaphalocrocis medinalis, Conopomorpha cramerella,
Cossus cossus, Cydia caryana, Cydia funebrana, Cydia molesta, Cydia
nigricana, Cydia pomonella, Darna diducta, Diatraea saccharalis,
Diatraea grandiosella, Earias insulana, Earias vittella,
Ecdytolopha aurantianum, Elasmopalpus lignosellus, Ephestia
cautella, Ephestia elutella, Ephestia kuehniella, Epinotia aporema,
Epiphyas postvittana, Erionota thrax, Eupoecilia ambiguella, Euxoa
auxiliaris, Grapholita molesta, Hedylepta indicata, Helicoverpa
armigera, Helicoverpa zea, Heliothis virescens, Hellula undalis,
Keiferia lycopersicella, Leucinodes orbonalis, Leucoptera
coffeella, Leucoptera malifoliella, Lobesia botrana, Loxagrotis
albicosta, Lymantria dispar, Lyonetia clerkella, Mahasena corbetti,
Mamestra brassicae, Maruca testulalis, Metisa plana, Mythimna
unipuncta, Neoleucinodes elegantalis, Nymphula depunctalis,
Operophtera brumata, Ostrinia nubilalis, Oxydia vesulia, Pandemis
cerasana, Pandemis heparana, Papilio demodocus, Pectinophora
gossypiella, Peridroma saucia, Perileucoptera coffeella,
Phthorimaea operculella, Phyllocnistis citrella, Pieris rapae,
Plathypena scabra, Plodia interpunctella, Plutella xylostella,
Polychrosis viteana, Prays endocarpa, Prays oleae, Pseudaletia
unipuncta, Pseudoplusia includens, Rachiplusia nu, Scirpophaga
incertulas, Sesamia inferens, Sesamia nonagrioides, Setora nitens,
Sitotroga cerealella, Sparganothis pilleriana, Spodoptera exigua,
Spodoptera frugiperda, Spodoptera eridania, Thecla basilides,
Tineola bisselliella, Trichoplusia ni, Tuta absoluta, Zeuzera
coffeae, and Zeuzera pyrina.
[0860] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Mallophaga. A non-exhaustive
list of particular genera includes, but is not limited to,
Anaticola spp., Bovicola spp., Chelopistes spp., Goniodes spp.,
Menacanthus spp., and Trichodectes spp. A non-exhaustive list of
particular species includes, but is not limited to, Bovicola bovis,
Bovicola caprae, Bovicola ovis, Chelopistes meleagridis, Goniodes
dissimilis, Goniodes gigas, Menacanthus stramineus, Menopon
gallinae, and Trichodectes canis.
[0861] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Orthoptera. A non-exhaustive
list of particular genera includes, but is not limited to,
Melanoplus spp., and Pterophylla spp. A non-exhaustive list of
particular species includes, but is not limited to, Anabrus
simplex, Gryllotalpa africana, Gryllotalpa australis, Gryllotalpa
brachyptera, Gryllotalpa hexadactyla, Locusta migratoria,
Microcentrum retinerve, Schistocerca gregaria, and
Scudderiafurcata.
[0862] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Siphonaptera. A non-exhaustive
list of particular species includes, but is not limited to,
Ceratophyllus gallinae, Ceratophyllus niger, Ctenocephalides canis,
Ctenocephalides felis, and Pulex irritans.
[0863] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Thysanoptera. A non-exhaustive
list of particular genera includes, but is not limited to,
Caliothrips spp., Frankliniella spp., Scirtothrips spp., and Thrips
spp. A non-exhaustive list of particular sp. includes, but is not
limited to, Frankliniella fusca, Frankliniella occidentalis,
Frankliniella schultzei, Frankliniella williamsi, Heliothrips
haemorrhoidalis, Rhipiphorothrips cruentatus, Scirtothrips citri,
Scirtothrips dorsalis, and Taeniothrips rhopalantennalis, Thrips
hawaiiensis, Thrips nigropilosus, Thrips orientalis, Thrips
tabaci.
[0864] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Thysanura. A non-exhaustive list
of particular genera includes, but is not limited to, Lepisma spp.
and Thermobia spp.
[0865] In another embodiment, the molecules of Formula One may be
used to control pests of the Order Acarina. A non-exhaustive list
of particular genera includes, but is not limited to, Acarus spp.,
Aculops spp., Boophilus spp., Demodex spp., Dermacentor spp.,
Epitrimerus spp., Eriophyes spp., Ixodes spp., Oligonychus spp.,
Panonychus spp., Rhizoglyphus spp., and Tetranychus spp. A
non-exhaustive list of particular species includes, but is not
limited to, Acarapis woodi, Acarus siro, Aceria mangiferae, Aculops
lycopersici, Aculus pelekassi, Aculus schlechtendali, Amblyomma
americanum, Brevipalpus obovatus, Brevipalpus phoenicis,
Dermacentor variabilis, Dermatophagoides pteronyssinus,
Eotetranychus carpini, Notoedres cati, Oligonychus coffeae,
Oligonychus ilicis, Panonychus citri, Panonychus ulmi,
Phyllocoptruta oleivora, Polyphagotarsonemus latus, Rhipicephalus
sanguineus, Sarcoptes scabiei, Tegolophus perseaflorae, Tetranychus
urticae, and Varroa destructor.
[0866] In another embodiment, the molecules of Formula One may be
used to control pest of the Order Symphyla. A non-exhaustive list
of particular sp. includes, but is not limited to, Scutigerella
immaculata.
[0867] In another embodiment, the molecules of Formula One may be
used to control pests of the Phylum Nematoda. A non-exhaustive list
of particular genera includes, but is not limited to,
Aphelenchoides spp., Belonolaimus spp., Criconemella spp.,
Ditylenchus spp., Heterodera spp., Hirschmanniella spp.,
Hoplolaimus spp., Meloidogyne spp., Pratylenchus spp., and
Radopholus spp. A non-exhaustive list of particular sp. includes,
but is not limited to, Dirofilaria immitis, Heterodera zeae,
Meloidogyne incognita, Meloidogyne javanica, Onchocerca volvulus,
Radopholus similis, and Rotylenchulus reniformis.
[0868] For additional information consult "HANDBOOK OF PEST
CONTROL--THE BEHAVIOR, LIFE HISTORY, AND CONTROL OF HOUSEHOLD
PESTS" by Arnold Mallis, 9th Edition, copyright 2004 by GIE Media
Inc.
Applications
[0869] Molecules of Formula One are generally used in amounts from
about 0.01 grams per hectare to about 5000 grams per hectare to
provide control. Amounts from about 0.1 grams per hectare to about
500 grams per hectare are generally preferred, and amounts from
about 1 gram per hectare to about 50 grams per hectare are
generally more preferred.
[0870] The area to which a molecule of Formula One is applied can
be any area inhabited (or maybe inhabited, or traversed by) a pest,
for example: where crops, trees, fruits, cereals, fodder species,
vines, turf and ornamental plants, are growing; where domesticated
animals are residing; the interior or exterior surfaces of
buildings (such as places where grains are stored), the materials
of construction used in building (such as impregnated wood), and
the soil around buildings. Particular crop areas to use a molecule
of Formula One include areas where apples, corn, sunflowers,
cotton, soybeans, canola, wheat, rice, sorghum, barley, oats,
potatoes, oranges, alfalfa, lettuce, strawberries, tomatoes,
peppers, crucifers, pears, tobacco, almonds, sugar beets, beans and
other valuable crops are growing or the seeds thereof are going to
be planted. It is also advantageous to use ammonium sulfate with a
molecule of Formula One when growing various plants.
[0871] Controlling pests generally means that pest populations,
pest activity, or both, are reduced in an area. This can come about
when: pest populations are repulsed from an area; when pests are
incapacitated in or around an area; or pests are exterminated, in
whole, or in part, in or around an area. Of course, a combination
of these results can occur. Generally, pest populations, activity,
or both are desirably reduced more than fifty percent, preferably
more than 90 percent. Generally, the area is not in or on a human;
consequently, the locus is generally a non-human area.
[0872] The molecules of Formula One may be used in mixtures,
applied simultaneously or sequentially, alone or with other
compounds to enhance plant vigor (e.g. to grow a better root
system, to better withstand stressful growing conditions). Such
other compounds are, for example, compounds that modulate plant
ethylene receptors, most notably 1-methylcyclopropene (also known
as 1-MCP). Furthermore, such molecules may be used during times
when pest activity is low, such as before the plants that are
growing begin to produce valuable agricultural commodities. Such
times include the early planting season when pest pressure is
usually low.
[0873] The molecules of Formula One can be applied to the foliar
and fruiting portions of plants to control pests. The molecules
will either come in direct contact with the pest, or the pest will
consume the pesticide when eating leaf, fruit mass, or extracting
sap, that contains the pesticide. The molecules of Formula One can
also be applied to the soil, and when applied in this manner, root
and stem feeding pests can be controlled. The roots can absorb a
molecule taking it up into the foliar portions of the plant to
control above ground chewing and sap feeding pests.
[0874] Generally, with baits, the baits are placed in the ground
where, for example, termites can come into contact with, and/or be
attracted to, the bait. Baits can also be applied to a surface of a
building, (horizontal, vertical, or slant surface) where, for
example, ants, termites, cockroaches, and flies, can come into
contact with, and/or be attracted to, the bait. Baits can comprise
a molecule of Formula One.
[0875] The molecules of Formula One can be encapsulated inside, or
placed on the surface of a capsule. The size of the capsules can
range from nanometer size (about 100-900 nanometers in diameter) to
micrometer size (about 10-900 microns in diameter).
[0876] Because of the unique ability of the eggs of some pests to
resist certain pesticides, repeated applications of the molecules
of Formula One may be desirable to control newly emerged
larvae.
[0877] Systemic movement of pesticides in plants may be utilized to
control pests on one portion of the plant by applying (for example
by spraying an area) the molecules of Formula One to a different
portion of the plant. For example, control of foliar-feeding
insects can be achieved by drip irrigation or furrow application,
by treating the soil with for example pre- or post-planting soil
drench, or by treating the seeds of a plant before planting.
[0878] Seed treatment can be applied to all types of seeds,
including those from which plants genetically modified to express
specialized traits will germinate. Representative examples include
those expressing proteins toxic to invertebrate pests, such as
Bacillus thuringiensis or other insecticidal toxins, those
expressing herbicide resistance, such as "Roundup Ready" seed, or
those with "stacked" foreign genes expressing insecticidal toxins,
herbicide resistance, nutrition-enhancement, drought resistance, or
any other beneficial traits. Furthermore, such seed treatments with
the molecules of Formula One may further enhance the ability of a
plant to better withstand stressful growing conditions. This
results in a healthier, more vigorous plant, which can lead to
higher yields at harvest time. Generally, about 1 gram of the
molecules of Formula One to about 500 grams per 100,000 seeds is
expected to provide good benefits, amounts from about 10 grams to
about 100 grams per 100,000 seeds is expected to provide better
benefits, and amounts from about 25 grams to about 75 grams per
100,000 seeds is expected to provide even better benefits.
[0879] It should be readily apparent that the molecules of Formula
One may be used on, in, or around plants genetically modified to
express specialized traits, such as Bacillus thuringiensis or other
insecticidal toxins, or those expressing herbicide resistance, or
those with "stacked" foreign genes expressing insecticidal toxins,
herbicide resistance, nutrition-enhancement, or any other
beneficial traits.
[0880] The molecules of Formula One may be used for controlling
endoparasites and ectoparasites in the veterinary medicine sector
or in the field of non-human animal keeping. The molecules of
Formula One are applied, such as by oral administration in the form
of, for example, tablets, capsules, drinks, granules, by dermal
application in the form of, for example, dipping, spraying, pouring
on, spotting on, and dusting, and by parenteral administration in
the form of, for example, an injection.
[0881] The molecules of Formula One may also be employed
advantageously in livestock keeping, for example, cattle, sheep,
pigs, chickens, and geese. They may also be employed advantageously
in pets such as, horses, dogs, and cats. Particular pests to
control would be fleas and ticks that are bothersome to such
animals. Suitable formulations are administered orally to the
animals with the drinking water or feed. The dosages and
formulations that are suitable depend on the species.
[0882] The molecules of Formula One may also be used for
controlling parasitic worms, especially of the intestine, in the
animals listed above.
[0883] The molecules of Formula One may also be employed in
therapeutic methods for human health care. Such methods include,
but are limited to, oral administration in the form of, for
example, tablets, capsules, drinks, granules, and by dermal
application.
[0884] Pests around the world have been migrating to new
environments (for such pest) and thereafter becoming a new invasive
species in such new environment. The molecules of Formula One may
also be used on such new invasive species to control them in such
new environment.
[0885] The molecules of Formula One may also be used in an area
where plants, such as crops, are growing (e.g. pre-planting,
planting, pre-harvesting) and where there are low levels (even no
actual presence) of pests that can commercially damage such plants.
The use of such molecules in such area is to benefit the plants
being grown in the area. Such benefits, may include, but are not
limited to, improving the health of a plant, improving the yield of
a plant (e.g. increased biomass and/or increased content of
valuable ingredients), improving the vigor of a plant (e.g.
improved plant growth and/or greener leaves), improving the quality
of a plant (e.g. improved content or composition of certain
ingredients), and improving the tolerance to abiotic and/or biotic
stress of the plant.
[0886] Before a pesticide can be used or sold commercially, such
pesticide undergoes lengthy evaluation processes by various
governmental authorities (local, regional, state, national, and
international). Voluminous data requirements are specified by
regulatory authorities and must be addressed through data
generation and submission by the product registrant or by a third
party on the product registrant's behalf, often using a computer
with a connection to the World Wide Web. These governmental
authorities then review such data and if a determination of safety
is concluded, provide the potential user or seller with product
registration approval. Thereafter, in that locality where the
product registration is granted and supported, such user or seller
may use or sell such pesticide.
[0887] A molecule according to Formula One can be tested to
determine its efficacy against pests. Furthermore, mode of action
studies can be conducted to determine if said molecule has a
different mode of action than other pesticides. Thereafter, such
acquired data can be disseminated, such as by the internet, to
third parties.
[0888] The headings in this document are for convenience only and
must not be used to interpret any portion hereof.
TABLE-US-00001 Lengthy table referenced here
US20160159766A9-20160609-T00001 Please refer to the end of the
specification for access instructions.
TABLE-US-00002 Lengthy table referenced here
US20160159766A9-20160609-T00002 Please refer to the end of the
specification for access instructions.
TABLE-US-00003 Lengthy table referenced here
US20160159766A9-20160609-T00003 Please refer to the end of the
specification for access instructions.
TABLE-US-00004 Lengthy table referenced here
US20160159766A9-20160609-T00004 Please refer to the end of the
specification for access instructions.
TABLE-US-LTS-00001 LENGTHY TABLES The patent application contains a
lengthy table section. A copy of the table is available in
electronic form from the USPTO web site
(http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20160159766A9).
An electronic copy of the table will also be available from the
USPTO upon request and payment of the fee set forth in 37 CFR
1.19(b)(3).
* * * * *
References